"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,DE,A1,DE 3711247 A1,025-346-558-994-768,1987-10-08,1987,DE 3711247 A,1987-04-03,US 84840986 A,1986-04-04,STARTHILFE FUER KLEINVERBRENNUNGSMOTOREN,,TILLOTSON LTD,SCOTT WILLIAM ARTHUR;;DULL CARL,,https://lens.org/025-346-558-994-768,Patent Application,no,0,0,13,14,0,F02M1/02;;F02M1/00;;F02M1/02,F02M1/02,,0,0,,,,DISCONTINUED
2,GB,A,GB 2188679 A,094-531-665-192-311,1987-10-07,1987,GB 8706623 A,1987-03-20,US 84840986 A,1986-04-04,STARTING AID FOR SMALL INTERNAL COMBUSTION ENGINES,,TILLOTSON LTD,SCOTT WILLIAM ARTHUR;;DULL CARL,,https://lens.org/094-531-665-192-311,Patent Application,no,0,1,13,14,0,F02M1/02;;F02M1/00;;F02M1/02,F02M1/02,F1H HCC           CC;;F1H HDA           DA;;F1H H1105         DA;;F1H H1107         DA;;F1H H1108         DA;;F1H H141          CC;;F1H H701          CC;;F1H H704          CC;;F1H H707          CC;;F1H H711          CC;;F1H H72X          CC,0,0,,,,EXPIRED
3,CA,C,CA 1279796 C,027-460-437-377-44X,1991-02-05,1991,CA 533117 A,1987-03-26,US 84840986 A,1986-04-04,STARTING AID FOR SMALL INTERNAL COMBUSTION ENGINES,"A choke assembly or starting aid for small internal combustion engines is disclosed. An inertia valve is resiliently biased in the bore of the engine, The inertia valve is responsive to vibration of the internal combustion engine for providing a controlled amount of combustion air into the carburetor of the internal combustion engine.",TILLOTSON LTD,SCOTT WILLIAM A;;DULL CARL,,https://lens.org/027-460-437-377-44X,Granted Patent,no,0,0,13,14,0,F02M1/02;;F02M1/00;;F02M1/02,F02M1/02,D41230062    M,0,0,,,,EXPIRED
4,US,A,US 4711744 A,081-269-961-458-409,1987-12-08,1987,US 84840986 A,1986-04-04,US 84840986 A,1986-04-04,Starting aid for small internal combustion engines,A choke assembly or starting aid for small internal combustion engines is disclosed. An inertia valve is resiliently biased in the bore of the engine. The inertia valve is responsive to vibration of the internal combustion engine for providing a controlled amount of combustion air into the carburetor of the internal combustion engine.,TILLOTSON LTD,SCOTT WILLIAM A;;DULL CARL,TILLOTSON LTD (1986-04-03),https://lens.org/081-269-961-458-409,Granted Patent,yes,18,9,13,14,0,F02M1/02;;F02M1/00;;F02M1/02,F02M1/02,261/64.4;;261/64.6;;X123179G,0,0,,,,EXPIRED
5,GB,B,GB 2188679 B,140-412-882-066-746,1990-01-10,1990,GB 8706623 A,1987-03-20,US 84840986 A,1986-04-04,CHOKE ASSEMBLY FOR SMALL INTERNAL COMBUSTION ENGINES,,TILLOTSON LTD,SCOTT WILLIAM ARTHUR;;DULL CARL,,https://lens.org/140-412-882-066-746,Granted Patent,no,0,0,13,14,0,F02M1/02;;F02M1/00;;F02M1/02,F02M1/02,F1H HCC           CC;;F1H HDA           DA;;F1H H1105         DA;;F1H H1107         DA;;F1H H1108         DA;;F1H H141          CC;;F1H H701          CC;;F1H H704          CC;;F1H H707          CC;;F1H H711          CC;;F1H H72X          CC,0,0,,,,EXPIRED
6,IT,B,IT 1216913 B,147-617-991-613-466,1990-03-14,1990,IT 1995187 A,1987-04-02,US 84840986 A,1986-04-04,DISPOSITIVO DI AUSILIO PERL'AVVIAMENTO DI PICCOLI MOTORI ACOMBUSTIONE INTERNA.,,TILLOTSON LTD,SCOTT WILLIAM ARTHUR;;DULL CARL,,https://lens.org/147-617-991-613-466,Granted Patent,no,0,0,13,14,0,F02M1/02;;F02M1/00;;F02M1/02,F02M1/02,,0,0,,,,EXPIRED
7,MX,A,MX 160818 A,123-879-324-635-038,1990-05-30,1990,MX 589287 A,1987-04-03,US 84840986 A,1986-04-04,ESTRANGULADOR MEJORADO PARA MOTORES PEQUENOS DE COMBUSTION INTERNA,,TILLOTSON LTD,SCOTT WILLIAM ARTHUR;;DULL CARL,,https://lens.org/123-879-324-635-038,Granted Patent,no,0,0,13,14,0,F02M1/02;;F02M1/00;;F02M1/02,F02M1/02,,0,0,,,,EXPIRED
8,IT,A0,IT 8719951 A0,171-858-835-364-047,1987-04-02,1987,IT 1995187 A,1987-04-02,US 84840986 A,1986-04-04,DISPOSITIVO DI AUSILIO PERL'AVVIAMENTO DI PICCOLI MOTORI ACOMBUSTIONE INTERNA.,,TILLOTSON LTD,SCOTT WILLIAM ARTHUR;;DULL CARL,,https://lens.org/171-858-835-364-047,Patent Application,no,0,0,13,14,0,F02M1/02;;F02M1/00;;F02M1/02,F02M1/02,,0,0,,,,EXPIRED
9,BR,A,BR 8701546 A,048-697-382-199-179,1988-01-26,1988,BR 8701546 A,1987-04-03,US 84840986 A,1986-04-04,AFOGADOR E APARELHO AUXILIAR DE ARRANQUE PARA PEQUENOS MOTORES DE EXPLOSAO,,TILLOTSON LTD,SCOTT WILLIAM ARTHUR;;DULL CARL,,https://lens.org/048-697-382-199-179,Patent Application,no,0,0,13,14,0,F02M1/02;;F02M1/00;;F02M1/02,F02M1/02,,0,0,,,,DISCONTINUED
10,US,A,US 4820454 A,169-423-823-274-39X,1989-04-11,1989,US 10848987 A,1987-10-14,US 10848987 A;;US 84840986 A,1986-04-04,Starting aid for small internal combustion engines,A choke assembly or starting aid for small internal combustion engines is disclosed. An inertia valve is resiliently biased in the bore of the engine. The inertia valve is responsive to vibration of the internal combustion engine for providing a controlled amount of combustion air into the carburetor of the internal combustion engine.,TILLOTSON LTD,SCOTT WILLIAM A;;DULL CARL,,https://lens.org/169-423-823-274-39X,Granted Patent,yes,24,3,1,14,0,F02M1/02;;F02M1/02,F02M1/02,261/64.4;;261/64.6;;X123179G,0,0,,,,EXPIRED
11,DE,D1,DE 69535131 D1,184-195-574-299-116,2006-09-07,2006,DE 69535131 T,1995-12-28,US 36497795 A;;US 36497895 A;;US 36497995 A;;US 9517034 W,1995-01-06,PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ZUR VORBEUGUNG UND BEHANDLUNG VON STÖRUNGEN DES ZENTRALNERVENSYSTEMS,"Patients susceptible to or suffering from central nervous system disorders (e.g., Tourette's syndrome, attention deficit disorder or schizophrenia) are treated by administering an effective amount of an aryl substituted aliphatic compound, an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-N-methyl-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-N-methyl-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (Z)-metanicotine, (E)-metanicotine, N-methyl-(3-pyridinyl)-butane-1-amine, N-methyl-4-(3-pyridinyl)-3-butyne-1-amine and (E)-N-methyl-4-[3-(6-methylpyridin)yl]-3-butene-1-amine.",TARGACEPT INC,BENCHERIF MEROUANE;;LIPPIELLO MICHAEL;;CALDWELL SCOTT;;DULL MAURICE,,https://lens.org/184-195-574-299-116,Granted Patent,no,0,0,10,15,0,A61K31/44;;A61K31/4406;;A61K31/505;;C07D213/65;;C07D239/26;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28,C07D247/02;;A61K31/44;;A61K31/4406;;A61K31/465;;A61K31/505;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28;;C07D213/65;;C07D239/26,,0,0,,,,EXPIRED
12,DE,T2,DE 69535131 T2,142-615-343-296-000,2007-03-01,2007,DE 69535131 T,1995-12-28,US 36497795 A;;US 36497895 A;;US 36497995 A;;US 9517034 W,1995-01-06,PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ZUR VORBEUGUNG UND BEHANDLUNG VON STÖRUNGEN DES ZENTRALNERVENSYSTEMS,"Patients susceptible to or suffering from central nervous system disorders (e.g., Tourette's syndrome, attention deficit disorder or schizophrenia) are treated by administering an effective amount of an aryl substituted aliphatic compound, an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-N-methyl-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-N-methyl-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (Z)-metanicotine, (E)-metanicotine, N-methyl-(3-pyridinyl)-butane-1-amine, N-methyl-4-(3-pyridinyl)-3-butyne-1-amine and (E)-N-methyl-4-[3-(6-methylpyridin)yl]-3-butene-1-amine.",TARGACEPT INC,BENCHERIF MEROUANE;;LIPPIELLO MICHAEL;;CALDWELL SCOTT;;DULL MAURICE,,https://lens.org/142-615-343-296-000,Granted Patent,no,0,0,10,15,0,A61K31/44;;A61K31/4406;;A61K31/505;;C07D213/65;;C07D239/26;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28,C07D247/02;;A61K31/44;;A61K31/4406;;A61K31/465;;A61K31/505;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28;;C07D213/65;;C07D239/26,,0,0,,,,EXPIRED
13,AU,A,AU 1997/027332 A,039-351-746-750-108,1997-11-12,1997,AU 1997/027332 A,1997-04-16,US 63176196 A;;US 9706398 W,1996-04-23,Pharmaceutical compositions for prevention and treatment of central nervous system disorders,,TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;DOBSON GRAYLAND PAGE,"TARGACEPT, INC. (2001-07-26)",https://lens.org/039-351-746-750-108,Patent Application,no,0,0,25,25,0,C07D213/38;;A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38,C07D239/42;;A61K31/00;;A61K31/44;;A61K31/505;;A61P25/00;;C07D213/38,,0,0,,,,EXPIRED
14,ES,T3,ES 2318856 T3,142-110-730-133-70X,2009-05-01,2009,ES 97921232 T,1997-04-16,US 63176196 A,1996-04-23,COMPOSICIONES FARMACEUTICAS PARA LA PREVENCION Y EL TRATAMIENTO DE TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL.,"Patients susceptible to or suffering from central nervous system disorders are treated by administering effective amounts of aryl substituted aliphatic amine compounds, aryl substituted olefinic amine compounds or aryl substituted acetylenic amine compounds. A representative compound is (E)-N-methyl-5-(3-pyridinyl)-4-penten-2-amine.",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;DOBSON GRAYLAND PAGE,,https://lens.org/142-110-730-133-70X,Granted Patent,no,0,0,25,25,0,C07D213/38;;A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38,C07D213/38;;C07D239/42;;A61K31/00;;A61K31/44;;A61K31/505;;A61P25/00,,0,0,,,,EXPIRED
15,DE,D1,DE 69739142 D1,007-964-518-024-527,2009-01-15,2009,DE 69739142 T,1997-04-16,US 63176196 A;;US 9706398 W,1996-04-23,PHARMAZEUTISCHE ZUSAMMENSTELLUNGEN ZUR PRÄVENTION UND BEHANDLUNG VON ZNS-ERKRANKUNGEN,"Patients susceptible to or suffering from central nervous system disorders are treated by administering effective amounts of aryl substituted aliphatic amine compounds, aryl substituted olefinic amine compounds or aryl substituted acetylenic amine compounds. A representative compound is (E)-N-methyl-5-(3-pyridinyl)-4-penten-2-amine.",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;DOBSON GRAYLAND PAGE,,https://lens.org/007-964-518-024-527,Granted Patent,no,0,0,25,25,0,C07D213/38;;A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38,C07D213/38;;C07D239/42;;A61K31/00;;A61K31/44;;A61K31/505;;A61P25/00,,0,0,,,,EXPIRED
16,CA,A1,CA 2252515 A1,160-908-872-150-017,1997-10-30,1997,CA 2252515 A,1997-04-16,US 63176196 A;;US 9706398 W,1996-04-23,PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS,"Patients susceptible to or suffering from central nervous system disorders are treated by administering effective amounts of aryl substituted aliphatic amine compounds, aryl substituted olefinic amine compounds or aryl substituted acetylenic amine compounds. A representative compound is (E)-N-methyl-5-(3-pyridinyl)-4-penten-2-amine.",REYNOLDS TOBACCO CO R,DOBSON GRAYLAND PAGE;;DULL GARY MAURICE;;CALDWELL WILLIAM SCOTT,,https://lens.org/160-908-872-150-017,Patent Application,no,0,0,25,25,0,C07D213/38;;A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38,C07D239/42;;A61K31/00;;A61K31/44;;A61K31/505;;A61P25/00;;C07D213/38,,0,0,,,,EXPIRED
17,WO,A1,WO 1997/040011 A1,098-306-997-102-444,1997-10-30,1997,US 9706398 W,1997-04-16,US 63176196 A,1996-04-23,PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS,"Patients susceptible to or suffering from central nervous system disorders are treated by administering effective amounts of aryl substituted aliphatic amine compounds, aryl substituted olefinic amine compounds or aryl substituted acetylenic amine compounds. A representative compound is (E)-N-methyl-5-(3-pyridinyl)-4-penten-2-amine.",REYNOLDS TOBACCO CO R;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;DOBSON GRAYLAND PAGE,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;DOBSON GRAYLAND PAGE,,https://lens.org/098-306-997-102-444,Patent Application,yes,4,34,25,25,0,C07D213/38;;A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38,C07D239/42;;A61K31/00;;A61K31/44;;A61K31/505;;A61P25/00;;C07D213/38,,1,1,085-848-917-863-417,2754709;;10.1021/jm00128a026,"R.W. GUTHRIE ET AL.: ""Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 32, no. 8, 1989, WASHINGTON US, pages 1820 - 1835, XP002037072",PATENTED
18,JP,A,JP 2008247903 A,151-137-457-141-691,2008-10-16,2008,JP 2008060649 A,2008-03-11,US 63176196 A,1996-04-23,PHARMACEUTICAL FORMULATION FOR PREVENTING AND TREATING CENTRAL NERVOUS SYSTEM DISORDER,"<P>PROBLEM TO BE SOLVED: To direct a compound useful for preventing and treating central nervous system disorders and to provide a method for treating patients with a central nervous system disorder or patients highly susceptible to a central nervous system disorder, especially a method for treating patients with a central nervous system disorder associated with neurotransmitter dysfunction. <P>SOLUTION: A patient highly susceptible to a central nervous system disorder or a patient already suffering from such disorder is treated by administration of an effective amount of an aryl-substituted aliphatic amine compound, an aryl-substituted olefinic amine compound, or an aryl-substituted acetylenic amine compound. A representative compound among them is (E)-N-methyl-5-(3-pyridinyl)-4-pentene-2-amine. <P>COPYRIGHT: (C)2009,JPO&INPIT",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;DOBSON GRAYLAND PAGE,,https://lens.org/151-137-457-141-691,Patent Application,no,3,0,25,25,0,C07D213/38;;A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38,C07D213/38;;C07D239/42;;A61K31/00;;A61K31/44;;A61K31/505;;A61P25/00;;A61P25/02;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28,,0,0,,,,PENDING
19,ES,T4,ES 2318856 T4,087-048-854-090-847,2010-03-03,2010,ES 97921232 T,1997-04-16,US 63176196 A,1996-04-23,COMPOSICIONES FARMACEUTICAS PARA LA PREVENCION Y EL TRATAMIENTO DE TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL.,"Patients susceptible to or suffering from central nervous system disorders are treated by administering effective amounts of aryl substituted aliphatic amine compounds, aryl substituted olefinic amine compounds or aryl substituted acetylenic amine compounds. A representative compound is (E)-N-methyl-5-(3-pyridinyl)-4-penten-2-amine.",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;DOBSON GRAYLAND PAGE,,https://lens.org/087-048-854-090-847,Granted Patent,no,0,0,25,25,0,C07D213/38;;A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38,C07D213/38;;C07D239/42;;A61K31/00;;A61K31/44;;A61K31/505;;A61P25/00,,0,0,,,,EXPIRED
20,DK,T3,DK 0900200 T3,000-459-916-933-361,2009-03-30,2009,DK 97921232 T,1997-04-16,US 63176196 A;;US 9706398 W,1996-04-23,Farmaceutiske sammensætninger til forebyggelse og behandling af sygdom i centralnervesystemet,"Patients susceptible to or suffering from central nervous system disorders are treated by administering effective amounts of aryl substituted aliphatic amine compounds, aryl substituted olefinic amine compounds or aryl substituted acetylenic amine compounds. A representative compound is (E)-N-methyl-5-(3-pyridinyl)-4-penten-2-amine.",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;DOBSON GRAYLAND PAGE,,https://lens.org/000-459-916-933-361,Granted Patent,no,0,0,25,25,0,C07D213/38;;A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38,C07D213/38;;C07D239/42;;A61K31/00;;A61K31/44;;A61K31/505;;A61P25/00,,0,0,,,,EXPIRED
21,KR,A,KR 20000010596 A,000-782-943-557-63X,2000-02-15,2000,KR 19980708472 A,1998-10-22,KR 19980708472 A,1998-10-22,PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS,"PURPOSE: A pharmaceutical composition is provided which is safe and effective in preventing and treating central nervous system disorders. CONSTITUTION: The pharmaceutical composition relates to an aliphatic amine compound substituted with aryl group, an olefin amine compound substituted with aryl group and an acetylene amine compound substituted with aryl group which have a structure of formula I where X is nitrogen or carbon bonded to a substituent species; n is 1, 2, 3, 4, 5, 6 or 7; z' and z'' individually represent hydrogen, C1-C5 alkyl; A, A' and A'' individually represent hydrogen, C1-C7 alkyl or halo; the dashed line in the structure represents a C-C single bond, a C-C double bond or a C-C triple bond; m is 0 or 1 when dashed line represents a C-C single bond or a C-C double bond and m is 0 when dashed line represents a C-C triple bond; p is 0 or 1 when dashed line represents a C-C single bond or a C-C double bond, and p is 0 when dashed line represents a C-C triple bond; the wavy line is a cis(Z) or trans(E) form of the compound when dashed line is C-C double bond; and E and E' individually represents hydrogen, C1-C5 alkyl or halo-substituted C1-C5 alkyl.",REYNOLDS TOBACCO CO R,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;DOBSON GRAYLAND PAGE,,https://lens.org/000-782-943-557-63X,Patent Application,no,0,0,2,2,0,C07D213/38;;C07D213/38;;C07D213/38,C07D239/42;;A61K31/00;;A61K31/44;;A61K31/505;;A61P25/00;;C07D213/38,,0,0,,,,EXPIRED
22,BR,A,BR 9708815 A,000-520-805-296-240,2000-01-04,2000,BR 9708815 A,1997-04-16,US 63176196 A;;US 9706398 W,1996-04-23,Composições farmacêuticas para prevenção e tratamento de desordens do sistema nervoso central.,"Patients susceptible to or suffering from central nervous system disorders are treated by administering effective amounts of aryl substituted aliphatic amine compounds, aryl substituted olefinic amine compounds or aryl substituted acetylenic amine compounds. A representative compound is (E)-N-methyl-5-(3-pyridinyl)-4-penten-2-amine.",REYNOLDS TOBACCO CO R,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;DOBSON GRAYLAND PAGE,,https://lens.org/000-520-805-296-240,Patent Application,no,0,0,25,25,0,C07D213/38;;A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38,C07D239/42;;A61K31/00;;A61K31/44;;A61K31/505;;A61P25/00;;C07D213/38,,0,0,,,,EXPIRED
23,BR,B1,BR 9708815 B1,084-679-571-229-070,2009-01-13,2009,BR 9708815 A,1997-04-16,US 63176196 A;;US 9706398 W,1996-04-23,compostos úteis para prevenção e tratamento de desordens do sistema nervoso central.,"Patients susceptible to or suffering from central nervous system disorders are treated by administering effective amounts of aryl substituted aliphatic amine compounds, aryl substituted olefinic amine compounds or aryl substituted acetylenic amine compounds. A representative compound is (E)-N-methyl-5-(3-pyridinyl)-4-penten-2-amine.",,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;DOBSON GRAYLAND PAGE,,https://lens.org/084-679-571-229-070,Granted Patent,no,0,0,25,25,0,C07D213/38;;A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38,C07D213/38;;C07D239/42;;A61K31/00;;A61K31/44;;A61K31/505;;A61P25/00,,0,0,,,,EXPIRED
24,AU,B2,AU 727976 B2,139-225-652-899-399,2001-01-04,2001,AU 1997/027332 A,1997-04-16,US 63176196 A;;US 9706398 W,1996-04-23,Pharmaceutical compositions for prevention and treatment of central nervous system disorders,"Patients susceptible to or suffering from central nervous system disorders are treated by administering effective amounts of aryl substituted aliphatic amine compounds, aryl substituted olefinic amine compounds or aryl substituted acetylenic amine compounds. A representative compound is (E)-N-methyl-5-(3-pyridinyl)-4-penten-2-amine.",REYNOLDS TOBACCO CO R,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;DOBSON GRAYLAND PAGE,"TARGACEPT, INC. (2001-07-26)",https://lens.org/139-225-652-899-399,Granted Patent,no,0,0,25,25,0,C07D213/38;;A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38,C07D239/42;;A61K31/00;;A61K31/44;;A61K31/505;;A61P25/00;;C07D213/38,,1,1,085-848-917-863-417,2754709;;10.1021/jm00128a026,"J. MED. CHEM. 1989, 32, 1820-1835.",EXPIRED
25,US,B2,US 6555684 B2,189-816-457-604-207,2003-04-29,2003,US 97341901 A,2001-10-09,US 97341901 A;;US 63176196 A,1996-04-23,Pyrimidinyl compounds for treatment of central nervous system disorders,"
    Patients susceptible to or suffering from central nervous system disorders are treated by administering effective amounts of aryl substituted aliphatic amine compounds, aryl substituted olefinic amine compounds or aryl substituted acetylenic amine compounds. A representative compound is (E)-N-methyl-5-(3-pyridinyl)-4-penten-2-amine. 
",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;DOBSON GRAYLAND PAGE,,https://lens.org/189-816-457-604-207,Granted Patent,yes,9,22,25,25,0,C07D213/38;;A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38,C07D239/42;;A61K31/00;;A61K31/44;;A61K31/505;;A61P25/00;;C07D213/38,544/242;;544/334,20,10,043-091-711-667-642;;045-674-999-105-805;;174-507-030-434-145;;114-695-843-875-364;;061-556-297-543-520;;056-184-684-713-117;;085-848-917-863-417;;142-350-433-703-027;;105-959-091-465-070;;077-658-197-676-56X,10.1002/bms.1200221006;;8218423;;10.1002/cber.189402701216;;10.1021/ja01396a022;;10.1002/cber.19090420378;;10.1021/jo00409a002;;10.1021/jo00148a033;;2754709;;10.1021/jm00128a026;;1263119;;10.1016/0306-4522(94)00410-7;;7700528;;10.1002/ddr.430310112,"Cooper et al., ""Femtogram On-column Detection of Nicotine by Isotope Dilution Gas Chromatography/Negative Ion Detection Mass Spectrometry,"" Biological Mass Spectrometry, vol. 22 (1993).;;Pinner, A., ""Ueber Nicotin (Metanicotin),"" Chem. Ber., pp. 1053-1061, (1894).;;Pinner, A., ""Ueber Nicotin,"" Chem. Ber., pp. 2861-2870 (1894).;;LaForge, F.B., ""The Preparation and Properties of Some New Derivatives of Pyridine,"" J. Am. Chem. Soc., vol. 50, pp. 2477-2483 (1928).;;Acheson, et al., ""Transformations involving the Pyrrolidine Ring of Nictone,"" J. Chem. Soc., Perking Trans. 1, vol. 2, pp. 579-585 (1980).;;Loffler et al., Chem. Ber., Vo. 42, pp. 3431-3438 (1909).;;Joyce, et al., ""The Formation of 1-Methyl-3-Nicotinoylpyrrolidine from Nicotine-1'-Oxide,"" Heterocycles, vol. 29, No. 7, pp. 1335-1342 (1989).;;Frank, et al., ""Palladium-Catalyzed Vinylic Substitution Reactions with Heterocyclic Bromides,"" J. Org. Chem., vol. 43, No. 15. pp. 2947-2949 (1978).;;Malek, et al., ""Palladium-Catalyzed Synthesis of Cinnamylamines,"" J. Org. Chem., vol. 47, pp. 5395-5397 (1982).;;Sprouse, et al., ""Isomers of metanicotine and the Pinner-Etard reaction,"" In Abstracts of Papers, Coresta/TCRC, pp. 32-33 (1972).;;Guthrie, R.W., et al., Chem Abstract 110:212619 (1989).;;Guthrie, R.W., et al., J. Med. Chem. 32:1820-1935 (1989).;;Tomcufcik et al., Chem. Abstract 108:37830 (1988).;;Tilley et al., Chem. Abstract 106:12535 (1987).;;Seeman et al., Chem. Abstract 103:142236 (1985).;;Wilson, K.L., Jr., et al., Nicotine-Like Actions of CIS Metanicotine and trans-Metanicotine, Journal of Pharmacology and Experimental Therapeutics, 196:685-696 (1976).;;Perry, E. K., et al., Alteration in Nicotine Binding Sites in Parkinson's Disease, Lewy Body Dementia and Alzheimer's Disease: Possible Index of Early Neuropathology, Neuroscience, 64(2):385-395 (1995).;;Sahakian, B. J., et al., Nicotine and Tetrahydroaminoacradine: Evidence for Improved Attention in Patients with Dementia of the Alzheimer Type, Drug Development Research, 31:80-88 (1994).;;Arneric, S. P., et al., Nicotinic Agonists in Alzheimer's Disease: Does the Molecular Diversity of Nicotine Receptors Offer the Opportunity for Developing CNS-Selective Cholinergic Channel Activators? Int. Acad. Biomed. Drug Res. 7:58-70 (1994).;;Bencherif, M., et al., Metanicotine: A Nicotinic Agonist with CNS Selectivity: In Vivo Characterization, Society for Neuroscience Abstracts, 21:605 (1995).",EXPIRED
26,EP,A1,EP 1997806 A1,192-427-496-070-737,2008-12-03,2008,EP 08014695 A,1997-04-16,EP 97921232 A;;US 63176196 A,1996-04-23,Pahrmaceutical compositions for prevention and treatment of central nervous system disorders,"Patients susceptible to or suffering from central nervous system disorders are treated by administering effective amounts of aryl substituted aliphatic amine compounds, aryl substituted olefinic amine compounds or aryl substituted acetylenic amine compounds. A representative compound is (E)-N-methyl-5-(3-pyridinyl)-4-penten-2-amine.",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;DOBSON GRAYLAND PAGE,,https://lens.org/192-427-496-070-737,Patent Application,yes,9,0,25,25,0,C07D213/38;;A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38,C07D213/38;;C07D239/42;;A61K31/00;;A61K31/44;;A61K31/505;;A61P25/00,,88,64,021-137-985-293-708;;038-238-087-951-57X;;051-814-877-475-516;;116-715-331-598-066;;105-506-224-571-95X;;148-957-521-420-43X;;115-451-707-484-452;;068-063-053-003-076;;143-217-942-947-189;;006-641-363-044-503;;071-994-906-730-368;;003-961-737-556-233;;000-123-414-169-456;;026-925-467-091-419;;115-409-843-187-701;;017-510-618-626-839;;126-412-656-895-936;;093-377-286-425-032;;075-056-023-131-809;;059-442-869-656-153;;118-260-956-021-157;;022-483-915-548-216;;148-957-521-420-43X;;076-850-144-943-517;;076-187-514-882-208;;003-451-124-907-862;;123-054-424-610-835;;094-167-042-973-375;;043-709-369-760-068;;023-913-706-643-069;;011-079-540-338-760;;075-354-305-937-70X;;010-424-747-994-894;;077-450-904-605-806;;072-642-229-453-523;;020-870-110-885-423;;145-071-460-101-117;;114-695-843-875-364;;102-292-233-862-978;;149-929-583-255-570;;061-556-297-543-520;;056-184-684-713-117;;061-556-297-543-520;;041-887-169-139-065;;174-553-740-689-588;;127-449-372-530-885;;160-102-028-768-345;;020-725-670-386-904;;050-320-015-840-544;;031-200-500-000-244;;026-735-553-245-755;;010-934-187-404-293;;086-987-570-534-476;;127-449-372-530-885;;085-544-277-828-062;;047-807-682-518-619;;095-719-226-739-312;;028-189-130-689-554;;019-531-252-128-872;;047-807-682-518-619;;081-522-687-660-570;;011-933-502-771-010;;150-294-822-638-894;;055-326-310-965-736,10.1093/oxfordjournals.bmb.a072100;;3513895;;10.1126/science.351808;;351808;;2079716;;10.1002/jnr.490270416;;10.1212/wnl.36.11.1490;;3531917;;6887012;;6149266;;10.1111/j.1471-4159.1984.tb06083.x;;10.1002/hup.470080303;;2597885;;10.1192/bjp.154.6.797;;2572781;;1859921;;10.1111/j.1360-0443.1991.tb01810.x;;1817466;;10.1176/ajp.148.6.793;;10.1111/j.1360-0443.1991.tb01801.x;;1677596;;1643197;;10.1016/0006-3223(92)90315-q;;8032506;;10.1001/archfami.3.5.445;;8031743;;pmc1188589;;8018786;;10.1016/0006-3223(94)90006-x;;8255409;;10.1159/000118998;;8100644;;10.1093/schbul/19.2.371;;8465868;;10.1176/ajp.150.4.546;;10.3928/0048-5713-19930401-05;;10.1016/0006-3223(92)90073-9;;1450287;;10.1016/0006-8993(93)90091-z;;8252404;;6149266;;10.1111/j.1471-4159.1984.tb06083.x;;10.1111/j.1471-4159.1988.tb10582.x;;3346670;;1817734;;10.1016/0006-8993(91)90810-i;;10.1111/j.1476-5381.1973.tb08203.x;;4723798;;pmc1776061;;10.1016/0006-2952(72)90179-7;;4646185;;1352387;;10.1007/bf00966669;;8265684;;10.1016/0091-3057(93)90357-y;;10.1111/j.1471-4159.1992.tb08874.x;;1351932;;1977478;;10.1016/0006-3223(90)90483-i;;10.1016/0306-4603(84)90018-2;;6496202;;8289578;;10.1016/0024-3205(94)00588-5;;7909396;;10.1016/0165-6147(94)90104-x;;10.1021/cr00002a004;;948991;;10.1271/bbb1961.27.684;;10.1002/cber.19090420378;;906829;;10.1248/cpb.38.2446;;2285975;;10.1021/jo00409a002;;10.1021/jo00148a033;;10.1021/jo00409a002;;1447735;;10.1021/jm00101a011;;10.1016/s0040-4039(00)91620-4;;10.1021/jm00307a001;;5637185;;10.1016/0006-2952(73)90196-2;;4202581;;10.1021/jo00288a014;;14907713;;10.1016/s0021-9258(19)52451-6;;10.1126/science.7433991;;7433991;;3534542;;10.1016/0024-3205(90)90095-9;;2329919;;6088694;;10.1111/j.1471-4159.1984.tb12851.x;;10.1021/jm00307a001;;5637185;;10.1093/carcin/10.5.899;;2650908;;2571716;;10.1523/jneurosci.09-03-01082.1989;;pmc6569985;;2564429;;2469352;;10.1016/0003-2697(88)90380-6;;10.1038/327515a0;;2438558;;2571716;;1542648;;pmc48494;;10.1073/pnas.89.5.1572;;19912783;;10.1016/1044-7431(91)90039-q;;1646330;;10.1006/abio.1976.9999;;942051;;10.1016/0003-2697(76)90527-3,"JONES ET AL., INTERN. J. NEUROSCI., vol. 50, 1990, pages 147;;PERRY, BR. MED. BULL., vol. 42, 1986, pages 63;;SITARAM ET AL., SCIENCE, vol. 201, 1978, pages 274;;GIACOBINI, J, NEUROSCI. RES., vol. 27, 1990, pages 548;;BARON, NEUROLOGV, vol. 36, 1986, pages 1490;;ROWELL, ADV. BEHAV. BIOL., vol. 31, 1987, pages 191;;MARKS, J. PHARMACOL. EXP. THER., vol. 226, 1983, pages 817;;ROWELL ET AL., J. NEUROCHEM., vol. 43, 1984, pages 1593;;SHERWOOD, HUMAN PSYCHOPHARM., vol. 8, 1993, pages 155 - 184;;HODGES; LIPPIELLO ET AL.: ""Bio. pf Nic."", 1991, pages: 157;;SAHAKIAN ET AL., BR. J. PSVCH., vol. 154, 1989, pages 797;;RINNE ET AL., BRAIN RES., vol. 54, 1991, pages 167 - 170;;CLARK ET AL., SR. J. PHARML, vol. 85, 1985, pages 827 - 835;;SMITH ET AL., REV. NEUROSCI., vol. 3, no. 1, 1982, pages 25 - 43;;CALDERON-GONZALEZ ET AL., INTERN. PEDIAT., vol. 8, no. 2, 1993, pages 176 - 188;;""Oxford Textbook of Medicine"", vol. 218, 1987;;DEVOR ET AL., THE LANCET., vol. 8670, 1989, pages 1046;;JARVIK, BRITISH J. OF ADDICTION., vol. 86, 1991, pages 571 - 575;;MCCONVILLE, AM. J. PSYCHIATRY., vol. 148, no. 6, 1991, pages 793 - 794;;NEWHOUSE ET AL., BRIT. J. ADDIC., vol. 86, 1991, pages 521 - 526;;MCCONVILLE ET AL., BIOL. PSVCHIATRV., vol. 31, 1992, pages 832 - 840;;SANBERG ET AL., PROCEEDINGS FROM INTL. SVMP. NIC., 1994, pages 39;;VINSON, RCH. FAM. MED., vol. 3, no. 5, 1994, pages 445 - 451;;HECHTMAN, J. PSYCHIATRY NEUROSCI., vol. 19, no. 3, 1994, pages 193 - 201;;FARAONE ET AL., BIOL. PAVCHIATRV., vol. 35, no. 6, 1994, pages 398 - 402;;MALONE ET AL., J. CHILD NEUROL., vol. 9, no. 2, 1994, pages 161 - 169;;WARBURTON ET AL.: ""Cholinergic control of cognitive resources Neuropsychobiology"", 1993, pages: 43 - 46;;LIEBERMAN ET AL., SEHIZOPHR. BULL., vol. 19, 1993, pages 371 - 429;;GLASSMAN, AMER. Y. PSYCHIATRY., vol. 150, 1993, pages 546 - 553;;MERRIAM ET AL., PSYCHIATR. ANNALS, vol. 23, 1993, pages 171 - 178;;ADLER ET AL., BIOL. PSYCHIATRY., vol. 32, 1992, pages 607 - 616;;SJAK-SHIE ET AL., BRAIN RES., vol. 624, 1993, pages 295 - 298;;ROWELL ET AL., J. NEUROCHEM., vol. 43, 1984, pages 1593 - 1598;;RAPIER ET AL., J. NEUROCHEM., vol. 50, 1988, pages 1123 - 1130;;SANDOR ET AL., BRAIN RES., vol. 567, 1991, pages 313 - 316;;VIZI, BR. J. PHARMACOL., vol. 47, 1973, pages 765 - 777;;HALL ET AL., BIOCHEM. PHARMACOL., vol. 21, 1972, pages 1829 - 1838;;HERY ET AL., ARCH. INT. PHARMACODYN. THER., vol. 296, 1977, pages 91 - 97;;TOTH ET AL., NEUROCHEM RES., vol. 17, 1992, pages 265 - 271;;SANBERG ET AL., PHARMACOL. BIOCHEM. & BEHAVIOR, vol. 46, 1993, pages 303 - 307;;HARSING ET AL., J. NEUROCHEM., vol. 59, 1993, pages 48 - 54;;HUGHES, PROCEEDINGS FROM INTL. SYMP. NIC., 1994, pages 40;;DECINA ET AL., BIOL. PSYCHIATRV., vol. 28, 1990, pages 502 - 508;;WAGNER ET AL., PHARMACOASYCHIATRY, vol. 21, 1988, pages 301 - 303;;POMERLEAU ET AL., ADDICTIVE BEHAVIORS, vol. 9, 1984, pages 265;;ONAIVI ET AL., LIFE SCI., vol. 54, no. 3, 1994, pages 193 - 202;;HAMON, TRENDS, IN PHARMACOL. RES., vol. 15, pages 36 - 39;;HANSCH ET AL., CHERN. REV., vol. 91, 1991, pages 165 - 195;;RONDAHL, ACTA PHARM. SUEC., vol. 13, 1976, pages 229 - 234;;KAMIMURA ET AL., AGR. BIOL. CHEM., vol. 27, no. 10, 1963, pages 684 - 688;;LÖFFLER ET AL., CHEM..BER., vol. 42, 1909, pages 3431 - 3438;;LAFORGE, J.A.C.S., vol. 50, 1928, pages 2477;;ACHESON ET AL., J. CHEM. SOC.. PERKIN TRANS. 1., vol. 2, 1980, pages 579 - 585;;RONDAHL, ACTA PHARM. SUEC., vol. 14, 1977, pages 113 - 118;;ACHESON ET AL., J. CHEM. SOC. PERKIN TRANS. 1, vol. 2, 1980, pages 579 - 585;;ASHIMORI ET AL., CHEM. PHARM. BULL, vol. 38, no. 9, 1990, pages 2446 - 2458;;FRANK ET AL., J. ORG. CHEM., vol. 43, no. 15, 1978, pages 2947 - 2949;;MALEK ET AL., J. ORG. CHEM., vol. 47, 1982, pages 5395 - 5397;;FRANK ET AL., J. ORG. CHEM., vol. 43, 1978, pages 2947 - 2949;;DECOSTA ET AL., J. ORQ. CHEM., vol. 35, 1992, pages 4334 - 4343;;KUBOTA ET AL., TETRAHEDRON LETTERS, vol. 33, no. 10, 1992, pages 1351 - 1354;;ISHIHARA ET AL., TETRAHEDRON LETTERS, vol. 34, no. 56, 1993, pages 5777 - 5780;;HANSCH ET AL., J. MED. CHEM., vol. 11, 1968, pages 1;;CHENG ET AL., BIOCHEM. PHARMACOL., vol. 22, 1973, pages 3099 - 3108;;COMINS ET AL., J. ORG. CHEM., vol. 55, 1990, pages 69 - 73;;LOWRY ET AL., J. BIOL. CHEM., vol. 193, 1951, pages 265 - 275;;ROMANO ET AL., SCIENCE, vol. 210, 1980, pages 647 - 650;;MARKS ET AL., MOL. PHARMACOL., vol. 30, 1986, pages 427 - 436;;ROMM ET AL., LIFE SCI., vol. 46, 1990, pages 935 - 943;;NAGY ET AL., NEUROCHEM., vol. 43, 1984, pages 1114 - 1123;;HANSCH ET AL., J. MED. CHEM., vol. 11, 1968, pages 1;;HOPFINGER: ""Conformational Properties of Macromolecules"", 1973, ACADEMIC PRESS;;STRATTON ET AL., CARCINOGEN., vol. 10, 1989, pages 899 - 905;;LUKAS, J. PHARMACOL. EXP. THER., vol. 251, 1989, pages 175 - 182;;OSWALD ET AL., HEUROSCI., LETT., vol. 9, no. 6, 1989, pages 207 - 212;;LUTHER ET AL., J. NEUROSCI., vol. 9, 1989, pages 1082 - 1096;;LUKAS ET AL., ANAL. BIOCHEM, vol. 175, 1988, pages 212 - 218;;WHITING ET AL., NATURE, vol. 327, 1987, pages 515 - 518;;LUKAS, J. BHARMACOL. EXP. TIER., vol. 251, 1989, pages 175 - 182;;WHITING ET AL., MOL. BRAIN RES., vol. 10, 1990, pages 61 - 70;;LUKAS ET AL., INTERNATL. REVIEW NEUROBIOL., vol. 34, 1992, pages 25 - 130;;PORNASARI ET AL., NEUROSCI. LETT., vol. 111, 1990, pages 351 - 356;;CHINI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 1572 - 1576;;BENCHERIF ET AL., MOL. CELL. NEUROSCI., vol. 2, 1991, pages 52 - 65;;BENCHERIF ET AL., J. PHARMACOL. EXP., THER., vol. 257, 1991, pages 946 - 953;;BRADFORD, ANAL. BIOCHEM., vol. 72, 1976, pages 248 - 254;;LUKAS ET AL., ANAL. BIOCHEM., vol. 175, 1988, pages 212 - 218;;MARKS ET AL., J. PHARMACOL. EXP. THER., vol. 264, 1993, pages 427 - 436",DISCONTINUED
27,EP,B9,EP 0900200 B9,152-239-959-164-459,2009-10-21,2009,EP 97921232 A,1997-04-16,US 9706398 W;;US 63176196 A,1996-04-23,PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS,"Patients susceptible to or suffering from central nervous system disorders are treated by administering effective amounts of aryl substituted aliphatic amine compounds, aryl substituted olefinic amine compounds or aryl substituted acetylenic amine compounds. A representative compound is (E)-N-methyl-5-(3-pyridinyl)-4-penten-2-amine.",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;DOBSON GRAYLAND PAGE,"TARGACEPT, INC., US (2013-12-13);;TARGACEPT, INC. (2003-01-02)",https://lens.org/152-239-959-164-459,Amended Patent,yes,4,0,25,25,0,C07D213/38;;A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38,C07D213/38;;C07D239/42;;A61K31/00;;A61K31/44;;A61K31/505;;A61P25/00,,1,0,,,"JOURNAL OF MEDICINAL CHEMISTRY, vol. 32, no. 8, 1989, WASHINGTON US, pages 1820-1835, XP002037072 R.W. GUTHRIE ET AL.: ""Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor""",EXPIRED
28,PT,E,PT 900200 E,006-621-862-735-837,2009-02-26,2009,PT 97921232 T,1997-04-16,US 63176196 A,1996-04-23,PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS,"Patients susceptible to or suffering from central nervous system disorders are treated by administering effective amounts of aryl substituted aliphatic amine compounds, aryl substituted olefinic amine compounds or aryl substituted acetylenic amine compounds. A representative compound is (E)-N-methyl-5-(3-pyridinyl)-4-penten-2-amine.",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;DOBSON GRAYLAND PAGE,,https://lens.org/006-621-862-735-837,Granted Patent,no,0,0,25,25,0,C07D213/38;;A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38,C07D213/38;;C07D239/42;;A61K31/00;;A61K31/44;;A61K31/505;;A61P25/00;;C07D213/00;;C07D239/00,,0,0,,,,EXPIRED
29,US,B1,US 6603011 B1,028-134-653-571-75X,2003-08-05,2003,US 64235100 A,2000-08-21,US 64235100 A;;US 63176196 A,1996-04-23,3-pyridinyl compounds,"
    Patients susceptible to or suffering from central nervous system disorders are treated by administering effective amounts of aryl substituted aliphatic amine compounds, aryl substituted olefinic amine compounds or aryl substituted acetylenic amine compounds. A representative compound is (E)-N-methyl-5-(3-pyridinyl)-4-penten-2-amine. 
",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;DOBSON GRAYLAND PAGE,,https://lens.org/028-134-653-571-75X,Granted Patent,yes,9,38,25,25,0,C07D213/38;;A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38,C07D239/42;;A61K31/00;;A61K31/44;;A61K31/505;;A61P25/00;;C07D213/38,546/329;;546/286;;546/290;;546/294;;546/297;;546/298;;546/300,20,10,085-848-917-863-417;;043-091-711-667-642;;045-674-999-105-805;;174-507-030-434-145;;114-695-843-875-364;;061-556-297-543-520;;056-184-684-713-117;;105-959-091-465-070;;077-658-197-676-56X;;142-350-433-703-027,2754709;;10.1021/jm00128a026;;10.1002/bms.1200221006;;8218423;;10.1002/cber.189402701216;;10.1021/ja01396a022;;10.1002/cber.19090420378;;10.1021/jo00409a002;;10.1021/jo00148a033;;10.1016/0306-4522(94)00410-7;;7700528;;10.1002/ddr.430310112;;1263119,"Guthrie, R.W., et al., Chem. Abstract 110:212619 (1989).;;Guthrie, R.W., et al., J. Med. Chem. 32:1820-1935 (1989).;;Tomcufcik et al., Chem. Abstract 108:37830 (1988).;;Tilley et al., Chem. Abstract 106:12535 (1987).;;Seeman et al., Chem. Abstract 103:142236 (1985).;;Cooper et al., ""Femtogram On-column Detection of Nicotine by Isotope Dilution Gas Chromatography/Negative Ion Detection Mass Spectrometry,"" Biological Mass Spectrometry, vol. 22 (1993).;;Pinner, A., ""Ueber Nicotin (Metanicotin),"" Chem. Ber., pp. 1053-1061, (1894).;;Pinner, A., ""Ueber Nicotin,"" Chem. Ber., pp. 2861-2870 (1894).;;LaForge, F.B., ""The Preparation and Properties of Some New Derivatives of Pyridine,"" J. Am. Chem. Soc., vol. 50, pp. 2477-2483 (1928).;;Acheson, et al., ""Transformations involving the Pyrrolidine Ring of Nictone,"" J. Chem. Soc., Perking Trans. 1, vol. 2, pp. 579-585 (1980).;;Loffler et al., Chem. Ber., vo. 42, pp. 3431-3438 (1909).;;Joyce, et al., ""The Formation of 1-Methyl-3-Nicotinoylpyrrolidine from Nicotine-1'-Oxide,"" Heterocycles, vol. 29, No. 7, pp. 1335-13342 (1989).;;Frank, et al., ""Palladium-Catalyzed Vinylic Substitution Reactions with Heterocyclic Bromides,"" J. Org. Chem., vol. 43, No. 15, pp. 2947-2949 (1978).;;Malek, et al., ""Palladium-Catalyzed Synthesis of Cinnamylamines,"" J. Org. Chem., vol. 47, pp. 5395-5397 (1982).;;Sprouse, et al., ""Isomers of metanicotine and the Pinner-Etard reaction,"" In Abstracts of Papers, Coresta/TCRC, pp. 32-33 (1972).;;S. Arneric & M. Williams, ""Nicotinic Agonists in Alzheimer's Disease: Does the Molecular Diversity of Nicotine Receptors Offer the Opportunity for Developing CNS-Selective Cholinergic Channel Activators?"" Int. Acad. Biomed. Drug Res., 7: 58-70 (1994).;;Bencherif et al., ""Metanicotine: A Nicotinic Agonist with CNS Selectivity-In Vitro Characterization,"" Society for Neuroscience Abstracts, 21(1-3): 605 (1995).;;Perry et al., ""Alteration in Nicotine Binding Sites in Parkinson's Disease, Lewy Body Dementia and Alzheimer's Disease: Possible Index of Early Neuropathology,"" Elsevier Science Ltd., 64(2): 385-395 (1995).;;B. Sahakian & J. Coull, ""Nicotine and Tetrahydroaminoacradine: Evidence for Improved Attention in Patients with Dementia of the Alzheimer Type,"" Drug Development Research, 31: 80-88 (1994).;;Wilson Jr. et al., ""Nicotine-Like Actions of cis-Metanicotine and trans-Metanicotine,"" The Journal of Pharmacology and Experimental Therapeutics, 196(3): 685-696 (1976).",EXPIRED
30,EP,A1,EP 0900200 A1,120-151-924-140-564,1999-03-10,1999,EP 97921232 A,1997-04-16,US 9706398 W;;US 63176196 A,1996-04-23,PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS,"Patients susceptible to or suffering from central nervous system disorders are treated by administering effective amounts of aryl substituted aliphatic amine compounds, aryl substituted olefinic amine compounds or aryl substituted acetylenic amine compounds. A representative compound is (E)-N-methyl-5-(3-pyridinyl)-4-penten-2-amine.",REYNOLDS TOBACCO CO R,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;DOBSON GRAYLAND PAGE,"TARGACEPT, INC., US (2013-12-13);;TARGACEPT, INC. (2003-01-02)",https://lens.org/120-151-924-140-564,Patent Application,yes,0,0,25,25,0,C07D213/38;;A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38,C07D239/42;;A61K31/00;;A61K31/44;;A61K31/505;;A61P25/00;;C07D213/38,,0,0,,,,EXPIRED
31,CA,C,CA 2252515 C,163-253-269-359-910,2006-11-07,2006,CA 2252515 A,1997-04-16,US 63176196 A;;US 9706398 W,1996-04-23,PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS,"Patients susceptible to or suffering from central nervous system disorders a re treated by administering effective amounts of aryl substituted aliphatic amine compounds, aryl substituted olefinic amine compounds or aryl substituted acetylenic amine compounds. A representative compound is (E)-N-methyl-5-(3-pyridinyl)-4-penten-2-amine.</S DOAB>",REYNOLDS TOBACCO CO R,DOBSON GRAYLAND PAGE;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE,,https://lens.org/163-253-269-359-910,Granted Patent,no,0,0,25,25,0,C07D213/38;;A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38,C07D213/38;;C07D239/42;;A61K31/00;;A61K31/44;;A61K31/505;;A61P25/00;;C07D213/61;;C07D239/26;;C07D239/30,,0,0,,,,EXPIRED
32,EP,B1,EP 0900200 B1,158-216-425-345-147,2008-12-03,2008,EP 97921232 A,1997-04-16,US 9706398 W;;US 63176196 A,1996-04-23,PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS,"Patients susceptible to or suffering from central nervous system disorders are treated by administering effective amounts of aryl substituted aliphatic amine compounds, aryl substituted olefinic amine compounds or aryl substituted acetylenic amine compounds. A representative compound is (E)-N-methyl-5-(3-pyridinyl)-4-penten-2-amine.",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;DOBSON GRAYLAND PAGE,"TARGACEPT, INC., US (2013-12-13);;TARGACEPT, INC. (2003-01-02)",https://lens.org/158-216-425-345-147,Granted Patent,yes,4,0,25,25,0,C07D213/38;;A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38,C07D213/38;;C07D239/42;;A61K31/00;;A61K31/44;;A61K31/505;;A61P25/00,,1,0,,,"JOURNAL OF MEDICINAL CHEMISTRY, vol. 32, no. 8, 1989, WASHINGTON US, pages 1820-1835, XP002037072 R.W. GUTHRIE ET AL.: ""Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor""",EXPIRED
33,EP,B9,EP 0900200 B9,048-448-000-760-77X,2009-04-29,2009,EP 97921232 A,1997-04-16,US 9706398 W;;US 63176196 A,1996-04-23,PHARMAZEUTISCHE ZUSAMMENSTELLUNGEN ZUR PRÄVENTION UND BEHANDLUNG VON ZNS-ERKRANKUNGEN,"Patients susceptible to or suffering from central nervous system disorders are treated by administering effective amounts of aryl substituted aliphatic amine compounds, aryl substituted olefinic amine compounds or aryl substituted acetylenic amine compounds. A representative compound is (E)-N-methyl-5-(3-pyridinyl)-4-penten-2-amine.",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;DOBSON GRAYLAND PAGE,"TARGACEPT, INC., US (2013-12-13);;TARGACEPT, INC. (2003-01-02)",https://lens.org/048-448-000-760-77X,Amended Patent,yes,4,0,25,25,0,C07D213/38;;A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38,C07D213/38;;C07D239/42;;A61K31/00;;A61K31/44;;A61K31/505;;A61P25/00,,1,0,,,"JOURNAL OF MEDICINAL CHEMISTRY, vol. 32, no. 8, 1989, WASHINGTON US, pages 1820-1835, XP002037072 R.W. GUTHRIE ET AL.: ""Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor""",EXPIRED
34,US,A1,US 2002/0032206 A1,078-212-199-339-444,2002-03-14,2002,US 97341901 A,2001-10-09,US 97341901 A;;US 63176196 A,1996-04-23,Pharmaceutical compositions for prevention and treatment of central nervous system disorders,"
   Patients susceptible to or suffering from central nervous system disorders are treated by administering effective amounts of aryl substituted aliphatic amine compounds, aryl substituted olefinic amine compounds or aryl substituted acetylenic amine compounds. A representative compound is (E)-N-methyl-5-(3-pyridinyl)-4-penten-2-amine. 
",CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;DOBSON GARYLAND PAGE,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;DOBSON GARYLAND PAGE,,https://lens.org/078-212-199-339-444,Patent Application,yes,0,13,25,25,0,C07D213/38;;A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38,C07D239/42;;A61K31/00;;A61K31/44;;A61K31/505;;A61P25/00;;C07D213/38,514/256;;514/352;;544/323;;546/304,0,0,,,,EXPIRED
35,DK,T5,DK 0900200 T5,159-434-214-082-350,2010-01-11,2010,DK 97921232 T,1997-04-16,US 63176196 A;;US 9706398 W,1996-04-23,Farmaceutiske sammensætninger til forebyggelse og behandling af sygdom i centralnervesystemet,"Patients susceptible to or suffering from central nervous system disorders are treated by administering effective amounts of aryl substituted aliphatic amine compounds, aryl substituted olefinic amine compounds or aryl substituted acetylenic amine compounds. A representative compound is (E)-N-methyl-5-(3-pyridinyl)-4-penten-2-amine.",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;DOBSON GRAYLAND PAGE,,https://lens.org/159-434-214-082-350,Amended Patent,no,0,0,25,25,0,C07D213/38;;A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38,C07D213/38;;C07D239/42;;A61K31/00;;A61K31/44;;A61K31/505;;A61P25/00,,0,0,,,,EXPIRED
36,DE,D1,DE 69532687 D1,180-024-875-322-277,2004-04-15,2004,DE 69532687 T,1995-12-27,US 36498095 A;;US 9516901 W,1995-01-06,PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ZUR VORBEUGUNG UND BEHANDLUNG DER ULZERATIVEN KOLITIS,"Patients suffering from or susceptible to an idiopathic chronic inflammatory bowel disease (e.g., ulcerative colitis) are treated with pharmaceutical compositions. Those patients are treated by administration of an effective amount of aryl substituted aliphatic compound, an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-N-methyl-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-N-methyl-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-metanicotine, (Z)-metanicotine, N-methyl-(3-pyridinyl)-butane-1-amine, N-methyl-4-(3-pyridinyl)-3-butyne-1-amine and (E)-N-methyl-4 -[3-(6-methylpyrindin)yl]-3-butone-1-amine.",TARGACEPT INC,SMITH JOSEPH;;LIPPIELLO MICHAEL;;BENCHERIF MEROUANE;;CALDWELL SCOTT;;DULL MAURICE,,https://lens.org/180-024-875-322-277,Granted Patent,no,0,0,13,13,0,A61K31/44;;A61K31/4406;;A61K31/505;;A61P1/00;;A61P1/04;;A61P29/00;;A61K31/44;;A61K31/4406;;A61K31/505,A61K31/44;;A61K31/4406;;A61K31/505;;A61P1/00;;A61P29/00,,0,0,,,,EXPIRED
37,DE,T2,DE 69532687 T2,186-879-811-924-297,2005-03-03,2005,DE 69532687 T,1995-12-27,US 36498095 A;;US 9516901 W,1995-01-06,PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ZUR VORBEUGUNG UND BEHANDLUNG DER ULZERATIVEN KOLITIS,"Patients suffering from or susceptible to an idiopathic chronic inflammatory bowel disease (e.g., ulcerative colitis) are treated with pharmaceutical compositions. Those patients are treated by administration of an effective amount of aryl substituted aliphatic compound, an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-N-methyl-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-N-methyl-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-metanicotine, (Z)-metanicotine, N-methyl-(3-pyridinyl)-butane-1-amine, N-methyl-4-(3-pyridinyl)-3-butyne-1-amine and (E)-N-methyl-4 -[3-(6-methylpyrindin)yl]-3-butone-1-amine.",TARGACEPT INC,SMITH JOSEPH;;LIPPIELLO MICHAEL;;BENCHERIF MEROUANE;;CALDWELL SCOTT;;DULL MAURICE,,https://lens.org/186-879-811-924-297,Granted Patent,no,0,0,13,13,0,A61K31/44;;A61K31/4406;;A61K31/505;;A61P1/00;;A61P1/04;;A61P29/00;;A61K31/44;;A61K31/4406;;A61K31/505,A61K31/44;;A61K31/4406;;A61K31/505;;A61P1/00;;A61P29/00,,0,0,,,,EXPIRED
38,US,A,US 5861423 A,023-324-513-528-878,1999-01-19,1999,US 80424897 A,1997-02-21,US 80424897 A,1997-02-21,Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds,"Patients susceptible to or suffering from central nervous system disorders (e.g., Alzheimer's disease, Parkinson's disease, Tourette's syndrome, attention deficit disorder or schizophrenia) are treated by administering an effective amount of an aryl substituted olefinic amine compound. Exemplary compounds include (E)-N-methyl-4-�3-(5-benzyloxypyridin)yl!-3-buten-1-amine, (E)-N-methyl-4-�3-(5-phenoxypyridin)yl!-3-buten-1-amine, and (E)-N-methyl-4-�3-(5-phenylpyridin)yl!-3-buten-1-amine.",CALDWELL; WILLIAM SCOTT;;DULL; GARY MAURICE;;BENCHERIF; MEROUANE;;LIPPIELLO; PATRICK MICHAEL,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BENCHERIF MEROUANE;;LIPPIELLO PATRICK MICHAEL,TARGACEPT INC. A CORPORATION OF DELAWARE (1999-04-09);;R.J. REYNOLDS TOBACCO COMPANY (1997-05-08),https://lens.org/023-324-513-528-878,Granted Patent,yes,9,118,2,19,0,C07D213/38;;C07D213/61;;C07D213/64;;C07D213/64;;C07D213/38;;C07D213/61,C07D213/38;;C07D213/61;;C07D213/64,514/351;;514/345;;514/357,28,26,018-809-595-981-768;;087-436-730-206-398;;142-350-433-703-027;;116-715-331-598-066;;011-079-540-338-760;;017-510-618-626-839;;123-054-424-610-835;;077-450-904-605-806;;023-913-706-643-069;;003-961-737-556-233;;010-424-747-994-894;;075-354-305-937-70X;;076-850-144-943-517;;037-488-093-058-206;;148-957-521-420-43X;;076-187-514-882-208;;115-451-707-484-452;;022-483-915-548-216;;094-167-042-973-375;;003-451-124-907-862;;086-301-895-292-306;;073-981-318-375-830;;184-367-294-782-70X;;085-676-249-744-157;;007-021-281-307-399;;061-556-297-543-520,6541274;;8831772;;10.1021/jm960058h;;1263119;;10.1212/wnl.36.11.1490;;3531917;;1977478;;10.1016/0006-3223(90)90483-i;;8018786;;10.1016/0006-3223(94)90006-x;;10.1016/0006-2952(72)90179-7;;4646185;;7909396;;10.1016/0165-6147(94)90104-x;;10.1111/j.1471-4159.1992.tb08874.x;;1351932;;10.1111/j.1360-0443.1991.tb01801.x;;1677596;;8289578;;10.1016/0024-3205(94)00588-5;;10.1016/0306-4603(84)90018-2;;6496202;;10.1111/j.1471-4159.1988.tb10582.x;;3346670;;10.1007/978-1-4613-1911-5_13;;6149266;;10.1111/j.1471-4159.1984.tb06083.x;;1817734;;10.1016/0006-8993(91)90810-i;;10.1002/hup.470080303;;10.1016/0006-8993(93)90091-z;;8252404;;1352387;;10.1007/bf00966669;;10.1111/j.1476-5381.1973.tb08203.x;;4723798;;pmc1776061;;2907632;;10.1055/s-2007-1016985;;8968367;;8968366;;834319;;10.1007/bf00508459;;10.1056/nejm199403243301202;;8114833;;10.1021/jo00409a002,"Henrich et al.; Microcirculatory Effects of Nicotine and Related Alkaloids ; Klin Wochenchr, 62(II):92 100 (1984).;;Gibson et al.; Principal Components Describing Biological Activities and Molecular Diversity of Heterocyclic Aromatic Ring Fragments ; J. Med. Chem., 39:4065 4072 (1996).;;Wilson, Jr. et al.; Nicotine Like Actions of cis Metanicotine and trans Metanicotine ; J. of Pharmacology and Exper. Therapeutics, 196(3):685 696 (1976).;;Baron; Cigarette smoking and Parkinson s Disease ; Neurology, 36:1490 1496 (1986).;;Decina et al.; Cigarette Smoking and Neuroleptic Induced Parkinsonism ; Biol. Psychiatry, 28(6):502 508 (1990).;;Faraone et al.; An Exploratory Study of ADHD among Second Degree Relatives of ADHD Children ; Biol. Psychiatry, 35(6):398 402 (1994).;;Giacobini; Pharmacotherapy of Alzheimer s Disease: New Drugs and Novel Strategies ; Therapeutics, 61:529 538 (1993).;;Hall et al.; Effects of Nicotine on the Release of 3 H Noradrenaline from the Hypothalamus ; Biochemical Pharmacology, 21:1829 1838 (1972).;;Hamon: Neuropharmacology of anxiety: perspectives and prospects ; TiPS, 15:36 39 (1994).;;Harsing, Jr. et al.; Dopamine Efflux from Striatum After Chronic Nicotine: Evidence for Autoreceptor Desensitization ; J. of Neurochemistry, 59(1):48 54 (1992).;;Newhouse et al.; The role of nicotine and nicotinic mechanisms in neuropsychiatric disease ; British J. of Addiction, 86:521 526 (1991).;;Onaivi et al.; Chronic Nicotine Reverses Age Associated Increases in Tail Flick Latency and Anxiety in Rats ; Life Sciences, 54(3):193 202 (1994).;;Pomerleau et al.; The Effects of Cigarette Smoking on Pain and Anxiety ; Addictive Behaviors, 9:265 271 (1984).;;Rapier et al.; Stereoselective Nicotine Induced Release of Dopamine from Striatal Synaptosomes: Concentration Dependence and Repetitive Stimulation ; J. Neurochem., 50(4):1123 1130 (1988).;;Rowell; Current Concepts on the Effects of Nicotine on Neurotransmitter Release in the Central Nervous System ; Adv. Behav. Biol., 31:191 208 (1987).;;Rowell et al.; Nicotinic Stimulation of 3 H Acetylcholine Release from Mouse Cerebral Cortical Synaptosomes ; J. Neurochem., 43(6):1593 1598 (1984).;;Sandor et al.; Effect of Nicotine on dopaminergic cholinergic interaction in the striatum ; Brain Res., 567:313 316 (1991).;;Sherwood; Effects of Nicotine on Human Psychomoter Performance ; Human Psychopharmacology, 8:155 184 (1993).;;Sjak Shie et al.; Effects of chronic nicotine and pilocarpine administration on neocortocal neuronal density and 3 H GABA uptake in nucleus basalis lesioned rats ; Brain Res., 624:295 298 (1993).;;Toth et al.; Effect of Nicotine of Extracellular Levels of Neurotransmitters Assessed by Microdialysis in Various Brain Regions ; Neurochem. Res., 17(3):265 271 (1992).;;Vizi; Acetylcholine release from guinea pig ileum by parasymathetic ganglion stimulants and gastrin like polypeptides ; Br. J. Pharmac., 47:765 777 (1973).;;Wagner et al.; Does Smoking Reduce the Risk of Neuroleptic Parkinsonoids ; Pharmacopsychiat., 21:302 303 (1988).;;Lippiello et al.; RJR 2403: A Nicotinic Agonist with CNS Selectivity II. In Vivo Characterization ; J. Pharmacol. Exper. Therapeutics, 279(3):1422 1429 (1996).;;Bencherif et al.; RJR 2403: A Nicotinic Agonsist with CNS Selectivity I: In Vitro Characterization ; J. Pharmacol. Exper. Therapeutics, 279(3):1413 1421 (1996).;;H e ry et al.; Control of the Release of Newly Synthetized 3H 5 Hydroxytryptamine by Nicotinic and Muscarinic Receptors in Rat Hypothalamic Slices ; Naunyn Schmiedeberg s Arch. Pharmacol., 296:91 97 (1977).;;Pullan et al.; Transdermal Nicotine for Active Ulcerative Colitis ; New England J. Med., 330(12):811 815 (1994).;;Frank et al.; Palladium Catalyzed Vinylic Substitution Reactions with Heterocyclic Bromides ; J. Org. Chem., 43(15):2947 2949 (1978).;;Abstract S39: Sanberg et al.; Beneficial Effects of Nicotine in Tourette s Syndrome ; Int l Symposium on Nicotine: The Effects of Nicotine on Biological Systems II, Montreal Canada, Jul. 21 24, 1994 .",EXPIRED
39,US,A,US 5731314 A,070-611-353-898-082,1998-03-24,1998,US 36497895 A,1995-01-06,US 36497895 A,1995-01-06,Pharamceutical compositions for prevention and treatment of tourette's syndrome,"Patients susceptible to or suffering from Tourette's syndrome are treated by administering an effective amount of an aryl substituted aliphatic compound, an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-4-�3-(5-methoxypyridin)yl!-3-butene-1-amine, (E)-N-methyl-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-N-methyl-4-�3-(5-methoxypyrindin)yl!-3-butene-1-amine, (Z)-metanicotine, (E)-metanicotine, N-methyl-(3-pyridinyl)-butane-1-amine, N-methyl-4-(3-pyridinyl)-3-butyne-1-amine and (E)-N-methyl-4-�3-(6-methylpyrindin)yl!-3-butene-1-amine.",BENCHERIF; MEROUANE;;LIPPIELLO; PATRICK MICHAEL;;CALDWELL; WILLIAM SCOTT;;DULL; GARY MAURICE,BENCHERIF MEROUANE;;LIPPIELLO PATRICK MICHAEL;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE,TARGACEPT INC. A CORPORATION OF DELAWARE (1999-04-09);;R. J. REYNOLDS TOBACCO COMPANY (1995-02-14),https://lens.org/070-611-353-898-082,Granted Patent,yes,6,30,3,15,0,A61K31/44;;A61K31/44;;A61K31/4406;;A61K31/4406;;A61K31/505;;A61K31/505;;C07D239/26;;C07D239/26;;C07D213/65;;C07D213/65,A61K31/44;;A61K31/4406;;A61K31/505;;C07D213/65;;C07D239/26,514/256;;514/277;;514/344;;514/357,43,32,118-260-956-021-157;;011-079-540-338-760;;143-217-942-947-189;;017-510-618-626-839;;075-056-023-131-809;;123-054-424-610-835;;023-913-706-643-069;;085-676-249-744-157;;006-641-363-044-503;;093-377-286-425-032;;019-636-446-749-969;;071-994-906-730-368;;000-123-414-169-456;;003-961-737-556-233;;010-424-747-994-894;;021-137-985-293-708;;076-850-144-943-517;;148-957-521-420-43X;;043-709-369-760-068;;076-187-514-882-208;;038-238-087-951-57X;;022-483-915-548-216;;094-167-042-973-375;;003-451-124-907-862;;015-171-920-682-341;;115-409-843-187-701;;059-442-869-656-153;;075-354-305-937-70X;;026-925-467-091-419;;086-301-895-292-306;;126-412-656-895-936;;014-704-698-899-293,10.1016/0006-3223(92)90073-9;;1450287;;1977478;;10.1016/0006-3223(90)90483-i;;2572781;;8018786;;10.1016/0006-3223(94)90006-x;;8465868;;10.1176/ajp.150.4.546;;10.1016/0006-2952(72)90179-7;;4646185;;10.1111/j.1471-4159.1992.tb08874.x;;1351932;;834319;;10.1007/bf00508459;;1859921;;10.1111/j.1360-0443.1991.tb01810.x;;8100644;;10.1093/schbul/19.2.371;;10.1177/088307389400900216;;8006372;;1817466;;10.1176/ajp.148.6.793;;1643197;;10.1016/0006-3223(92)90315-q;;10.1111/j.1360-0443.1991.tb01801.x;;1677596;;8289578;;10.1016/0024-3205(94)00588-5;;10.1093/oxfordjournals.bmb.a072100;;3513895;;10.1111/j.1471-4159.1988.tb10582.x;;3346670;;6149266;;10.1111/j.1471-4159.1984.tb06083.x;;8265684;;10.1016/0091-3057(93)90357-y;;1817734;;10.1016/0006-8993(91)90810-i;;10.1126/science.351808;;351808;;10.1016/0006-8993(93)90091-z;;8252404;;1352387;;10.1007/bf00966669;;10.1111/j.1476-5381.1973.tb08203.x;;4723798;;pmc1776061;;10.1201/noe0849320057.ch12;;8031743;;pmc1188589;;10.3928/0048-5713-19930401-05;;10.1016/0306-4603(84)90018-2;;6496202;;8032506;;10.1001/archfami.3.5.445;;2907632;;10.1055/s-2007-1016985;;8255409;;10.1159/000118998;;3778556,"Adler, L. et al., Normalization by Nicotine of Deficient Auditory Sensory Gating in the Relative Schizophrenics , Biol. Psychiatry, vol. 32, pp. 607 616 (1992).;;Calderon Gonzalez R., Tourette Syndrome , Intern. Pediat., vol. 8(2), pp. 176 188 (1993).;;Decina, P. et al., Cigarette Smoking and Neuroleptic Induced Parkinsonism , Biol. Psychiatry, 28, pp. 502 508 (1990).;;Devor, E. et al., Nicotine and Tourette s Syndrome , The Lancet, vol. 8670, pp. 1046 (1989).;;Faraone, S. et al., An Exploratory Study of ADHD among Second Degree Relatives of ADHD Children , Biol. Psychiatry, vol. 35(6), pp. 398 402 (1994).;;Glassman, A., Cigarette Smoking: Implications for Psychiatric Illness , Am J Psychiatry, vol. pp. 546 553 (1993).;;Hall, G. et al., Effects of Nicotine on the Release of 3 H Noradrenaline form the Hypothalamus Biochemical Pharmacology, vol. 21, pp. 1829 1838 (1972).;;Harsing, L. et al., Dopamine Efflux from Striatum After Chronic Nicotine: Evidence for Autore Desensitization , Journal of Neurochemistry, vol. 59, pp. 48 54 (1993).;;Hery, F. et al., Control of the Release of Newly Synthetized 3 H 5 Hydroxytryptamine by Nicoti and Muscarinic Receptors in Rat Hypothalamic Slices , Arch. Int. Pharmacodyn. Ther., vol. 29 91 97 (1977).;;Jarvik, M. Beneficial effects of nicotine , British Journal of Addiction, vol. 86, pp. 571 575 (1991).;;Lieberman, J. et al., Neurochemistry and Neuronendocrinology of Schizophrenia: A Selective Review , Schizophr. Bull., vol. 19, pp. 371 429 (1993).;;Malone, M. et al., Hemispheric Processing and Methylphenidate Effects in Attention Deficit Hyperactivity Disorder , J. Child Neurol., vol. 9(2), pp. 181 189 (1994).;;Hughes, Proceedings from Intl. Symp. Nic. , S40 (1994).;;McConville, B. et al., Nicotine Potentiation of Haloperidol in Reducing Tic Frequency in Tourette s Disorder , Am. J. Psychiatry, vol. 148, pp. 793 794 (1991).;;McConville, B. et al., The Effects of Nicotine Plus Haloperidol Compared to Nicotine Only and Placebo Nicotine Only in Reducing Tic Severity and Frequency in Tourette s Disorder , Biol. Psychiatry, vol. 31, pp. 832 840 (1992).;;Newhouse, P. et al., The role of nicotine and nicotinic mechanisms in neuropsychiatric disease , British Journal of Addiction, vol. 86, pp. 521 526 (1991).;;Onaivi, E. et al., Chronic Nicotine Reverses Age Associated Increases in Tail Flick Latency and Anxiety in Rats , Life Sciences, vol. 54, pp. 193 202 (1994).;;Perry E., The Cholinergic Hypothesis Ten Years On , British Medical Bulletin, vol. 42, pp. 63 69 (1986).;;Rapier, C. et al., Stereoselective Nicotine Induced Release of Dopamine from Striatal Synaptosomes: Concentration Dependence and Repetitive Stimulation , Journal of Neurochemistry, vol. 50, pp. 1123 1130 (1988).;;Rowell, P. et al., Nicotinic Stimulation of 3 H Acetylcholine Release from Mouse Cerebral Cortical Synaptosomes , Journal of Neurochemistry, vol. 43, pp. 1593 1598 (1984).;;Sanberg, P. et al., Nicotine Potentiation of Haloperidol Induced Catalepsy: Striatal Mechanisms , Pharmacology Biochemistry and Behavior, vol. 46, pp. 303 307 (1993).;;Sandor, N. et al., Effect of nicotine on dopaminergic cholinergic interaction in the striatum , Brain Research, vol. 567, pp. 313 316 (1991).;;Sitaram, N. et al., Human Serial Learning: Enhancement with Arecholine and Choline and Impairment with Scopolamine , Science, vol. 201, pp. 274 276 (1978).;;Sjak Shie, N. et al., Effects of chronic nicotine and pilocarpine administration on neocortical neuronal density and 3 H GABA uptake in nucleus basalis lesioned rats , Brain Research, vol. 624, pp. 295 298 (1993).;;Toth, E. et al., Effect of Nicotine on Extracellular Levels of Neurotransmitters Assessed by Microdialysis in Various Brain Regions: Role of Glutamic Acid , Neurochemical Research, vol. 17(3), pp. 265 271 (1992).;;Vizi, E., Acetylcholine release from guinea pig ileum by parasympathetic ganglion stimulants and gastrin like polypeptides , British Journal Pharmacology, vol. 47, pp. 765 777 (1973).;;Physicians Desk Reference, 48 Edition, p. 410 411 (1994), Cylert .;;Physicians Desk Reference, 48 Edition, p. 520 523 (1994), Prolixin .;;Physicians Desk Reference, 48 Edition, p. 612 614 (1994), Catapres .;;Physicians Desk Reference, 48 Edition, p. 835 836 (1994), Ritalin .;;Physicians Desk Reference, 48 Edition, p. 977 979 (1994), Orap .;;Physicians Desk Reference, 48 Edition, p. 1357 1359 (1994), Haldol .;;Physicians Desk Reference, 48 Edition, p. 1935 1936 (1994), Klonopin .;;Physicians Desk Reference, 48 Edition, p. 2248 2250 (1994), Dexedrine .;;Hechtman, L., Genetic and Neurobiological Aspects of Attention Deficit Hyperactive Disorder: A Review , J. Psychiatry Neurosci., vol. 19(3), pp. 193 201 (1994).;;Merriam, et al., Schizophrenia as a Neurobehavioral Disorder , Psychiatr. Annals., vol. 23, p. 178 (1993).;;Pomerleau, et al., The Effects of Cigarette Smoking on Pain and Anxiety , Addictive Behavi 9, p. 265 (1984).;;Sanberg, et al., Proceedings from Intl. Symp. Nic., S39 (1994).;;Vinson, D., Therapy for Attention Deficit Hyperactivity Disorder , Arch. Fam. Med., vol. 3(5), 445 451 (1994).;;Wagner, et al., Does Smoking Reduce the Risk of Neuroleptic Parkinsolnoids , Pharmacopsychiatry, vol. 21, pp. 301 303 (1988).;;Warburton, et al., Cholinergic control of cognitive resources , Neuropsychobiology, Eds. Mendlewicz, et al., pp. 43 46 (1993).;;Freedman, R. et al., Proceedings from Intl. Symp. Nic., S41 (1994).;;Repond et al, Arzneim. Forsch./Drug Research 36(II), No. 8 (1986), pp. 1191 1194.",EXPIRED
40,US,B1,US 6274606 B1,070-235-367-095-25X,2001-08-14,2001,US 16986198 A,1998-10-12,US 16986198 A;;US 80424897 A,1997-02-21,Methods of treating central nervous system disorders with aryl substituted olefinic amine compounds,"Patients susceptible to or suffering from central nervous system disorders (e.g., Alzheimer's disease, Parkinson's disease, Tourette's syndrome, attention deficit disorder or schizophrenia) are treated by administering an effective amount of an aryl substituted olefinic amine compound. Exemplary compounds include, (E)-N-methyl-4-[3-(5-isopropoxypyridin)yl]-3-buten-1-amine, and (E)-N-methyl-4-[3-(5-methoxymethylpyridin)yl]-3-buten-1-amine.",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BENCHERIF MEROUANE;;LIPPIELLO PATRICK MICHAEL,,https://lens.org/070-235-367-095-25X,Granted Patent,yes,14,41,2,19,0,C07D213/38;;C07D213/61;;C07D213/64;;C07D213/64;;C07D213/38;;C07D213/61,C07D213/38;;C07D213/61;;C07D213/64,514/345;;514/351;;514/357,29,26,018-809-595-981-768;;087-436-730-206-398;;116-715-331-598-066;;142-350-433-703-027;;011-079-540-338-760;;017-510-618-626-839;;123-054-424-610-835;;077-450-904-605-806;;023-913-706-643-069;;003-961-737-556-233;;010-424-747-994-894;;075-354-305-937-70X;;076-850-144-943-517;;037-488-093-058-206;;148-957-521-420-43X;;076-187-514-882-208;;115-451-707-484-452;;022-483-915-548-216;;094-167-042-973-375;;003-451-124-907-862;;086-301-895-292-306;;073-981-318-375-830;;184-367-294-782-70X;;085-676-249-744-157;;007-021-281-307-399;;061-556-297-543-520,6541274;;8831772;;10.1021/jm960058h;;10.1212/wnl.36.11.1490;;3531917;;1263119;;1977478;;10.1016/0006-3223(90)90483-i;;8018786;;10.1016/0006-3223(94)90006-x;;10.1016/0006-2952(72)90179-7;;4646185;;7909396;;10.1016/0165-6147(94)90104-x;;10.1111/j.1471-4159.1992.tb08874.x;;1351932;;10.1111/j.1360-0443.1991.tb01801.x;;1677596;;8289578;;10.1016/0024-3205(94)00588-5;;10.1016/0306-4603(84)90018-2;;6496202;;10.1111/j.1471-4159.1988.tb10582.x;;3346670;;10.1007/978-1-4613-1911-5_13;;6149266;;10.1111/j.1471-4159.1984.tb06083.x;;1817734;;10.1016/0006-8993(91)90810-i;;10.1002/hup.470080303;;10.1016/0006-8993(93)90091-z;;8252404;;1352387;;10.1007/bf00966669;;10.1111/j.1476-5381.1973.tb08203.x;;4723798;;pmc1776061;;2907632;;10.1055/s-2007-1016985;;8968367;;8968366;;834319;;10.1007/bf00508459;;10.1056/nejm199403243301202;;8114833;;10.1021/jo00409a002,"Henrich et al.; ""Microcirculatory Effects of Nicotine and Related Alkaloids""; Klin Wochenchr, 62(II):92-100 (1984).;;Gibson et al.; ""Principal Components Describing Biological Activities and Molecular Diversity of Heterocyclic Aromatic Ring Fragments""; J. Med. Chem.,39:4065-4072 (1996).;;Baron; ""Cigarette smoking and Parkinson's Disease""; Neurology,36:1490-1496 (1986).;;Wilson, Jr. et al.; ""Nicotine-Like Actions of cis-Metanicotine and trans-Metanicotine""; J. of Pharmacology and Exper. Therapeutics, 196(3):685-696 (1976).;;Decina et al.; ""Cigarette Smoking and Neuroleptic-Induced Parkinsonism""; Biol. Psychiatry, 28(6):502-508 (1990).;;Faraone et al.; ""An Exploratory Study of ADHD among Second-Degree Relatives of ADHD Children""; Biol. Psychiatry, 35(6):398-402 (1994).;;Giacobini; ""Pharmacotherapy of Alzheimer's Disease: New Drugs and Novel Strategies""; Therapeutics, 61:529-538 (1993).;;Hall et al.; ""Effects of Nicotine on the Release of3 H-Noradrenaline from the Hypothalamus""; Biochemical Pharmacology, 21:1829-1838 (1972).;;Hamon; ""Neuropharmacology of anxiety: perspectives and prospects""; TiPS, 1536-39 (1994).;;Harsing, Jr. et al.; ""Dopamine Efflux from Striatum After Chronic Nicotine: Evidence for Autoreceptor Desensitization""; J. of Neurochemistry, 59(1):48-54 (1992).;;Newhouse et al.; ""The role of nicotine and nicotinic mechanisms in neuropsychiatric disease""; British J. of Addiction, 86:521-526 (1991).;;Onaivi et al.; ""Chronic Nicotine Reverses Age-Associated Increases in Tail-Flick Latency and Anxiety in Rats""; Life Sciences, 54(3):193-202 (1994).;;Pomerleau et al.; ""The Effects of Cigarette Smoking on Pain and Anxiety""; Addictive Behaviors, 9:265-271 (1984).;;Rapier et al.; ""Stereoselective Nicotine-Induced Release of Dopamine from Striatal Synaptosomes: Concentration Dependence and Repetitive Stimulation""; J. Neurochem., 50(4):1123-1130 (1988).;;Rowell; ""Current Concepts on the Effects of Nicotine on Neurotransmitter Release in the Central Nervous System""; Adv. Behav. Biol.,31:191-208 (1987).;;Rowell et al.; ""Nicotinic Stimulation of [3H] Acetylcholine Release from Mouse Cerebral Cortical Synaptosomes""; J. Neurochem., 43(6):1593-1598 (1984).;;Sandor et al.; ""Effect of Nicotine on dopaminergic-cholinergic interaction in the striatum""; Brain Res., 567:313-316 (1991).;;Sherwood; ""Effects of Nicotine on Human Psychomoter Performance ""; Human Psychopharmacology, 8:155-184 (1993).;;Sjak-Shie et al.; ""Effects of chronic nicotine and pilocarpine administration on neocortocal neuronal density and [3H]GABA uptake in nucleus basalis lesioned rats""; Brain Res., 624:295-298 (1993).;;Toth et al.; ""Effect of Nicotine of Extracellular Levels of Neurotransmitters Assessed by Microdialysis in Various Brain Regions""; Neurochem. Res., 17(3):265-271 (1992).;;Vizi; ""Acetylcholine release from guinea-pig ileum by parasymathetic ganglion stimulants and gastrinlike polypeptides""; Br. J. Pharmac.,47:765-777 (1973).;;Wagner et al.; ""Does Smoking Reduce the Risk of Neuroleptic Parkinsonoids?""; Pharmacopsychiat.,21:302-303 (1988).;;Lippiello et al.; ""RJR-2403: A Nicotinic Agonist with CNS Selectivity II. In Vivo Characterization""; J. Pharmacol. Exper. Therapeutics, 279(3):1422-1429 (1996).;;Bencherif et al.; ""RJR-2403: A Nicotinic Agonsist with CNS Selectivity I: In Vitro Characterization""; J. Pharmacol. Exper. Therapeutics, 279(3):1413-1421 (1996).;;Héry et al.; ""Control of the Release of Newly Synthetized 3H-5-Hydroxytryptamine by Nicotinic and Muscarinic Receptors in Rat Hypothalamic Slices""; Naunyn-Schmiedeberg's Arch. Pharmacol., 296:91-97 (1977).;;Pullan et al.; ""Transdermal Nicotine for Active Ulcerative Colitis""; New England J. Med., 330(12):811-815 (1994).;;Frank et al.; ""Palladium-Catalyzed Vinylic Substitution Reactions with Heterocyclic Bromides""; J. Org. Chem.,43(15):2947-2949 (1978).;;ABSTRACT S39: Sanberg et al.; ""Beneficial Effects of Nicotine in Tourette's Syndrome""; Int'l Symposium on Nicotine: The Effects of Nicotine on Biological Systems II, Montreal Canada, Jul. 21-24, 1994.;;International Search Report, PCT/US98/03091, 06/04/98.",EXPIRED
41,US,A,US 6100269 A,047-920-720-383-503,2000-08-08,2000,US 30649799 A,1999-05-06,US 30649799 A;;US 70844596 A;;US 43715395 A,1995-05-17,Pharmaceutical compositions for prevention and treatment of central nervous system disorders,"Patients susceptible to or suffering from central nervous system disorders (e.g., neurodegenerative diseases including presenile dementia, senile dementia of the Alzheimer's type, and Parkinsonism including Parkinson's disease, and other CNS disorders including attention deficit disorder, schizophrenia and Tourette's syndrome) are treated by administering an effective amount of 2-azabicyclo [2.2.1] heptane and 2-azabicyclo [2.2.2] octane compounds.",BENCHERIF; MEROUANE;;CALDWELL; WILLIAM SCOTT;;DULL; GARY MAURICE;;LIPPIELLO; PATRICK MICHAEL,BENCHERIF MEROUANE;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;LIPPIELLO PATRICK MICHAEL,,https://lens.org/047-920-720-383-503,Granted Patent,yes,20,5,3,5,0,C07D401/04;;C07D401/04;;C07D453/06;;C07D453/06,C07D401/04;;C07D453/06,514/256;;514/299,91,57,072-429-806-476-723;;166-476-258-760-757;;079-116-610-276-006;;109-321-006-804-780;;116-715-331-598-066;;000-474-373-080-168;;090-386-965-436-396;;011-079-540-338-760;;051-814-877-475-516;;123-054-424-610-835;;023-913-706-643-069;;085-676-249-744-157;;046-339-281-278-65X;;006-641-363-044-503;;161-022-205-991-350;;105-506-224-571-95X;;066-977-238-396-37X;;008-912-139-594-599;;010-424-747-994-894;;021-137-985-293-708;;154-025-112-153-26X;;076-850-144-943-517;;061-200-895-479-648;;148-957-521-420-43X;;068-063-053-003-076;;043-709-369-760-068;;076-187-514-882-208;;115-451-707-484-452;;022-483-915-548-216;;094-167-042-973-375;;116-479-210-421-043;;003-451-124-907-862;;075-354-305-937-70X;;086-301-895-292-306;;118-260-956-021-157;;143-217-942-947-189;;017-510-618-626-839;;075-056-023-131-809;;093-377-286-425-032;;019-636-446-749-969;;071-994-906-730-368;;000-123-414-169-456;;003-961-737-556-233;;038-238-087-951-57X;;015-171-920-682-341;;115-409-843-187-701;;059-442-869-656-153;;026-925-467-091-419;;126-412-656-895-936;;127-547-110-034-08X;;061-556-297-543-520;;174-507-030-434-145;;056-184-684-713-117;;102-292-233-862-978;;020-870-110-885-423;;149-929-583-255-570;;077-450-904-605-806,10.1016/s0040-4039(00)73702-6;;10.1016/s0031-9422(00)97265-0;;10.1139/v88-074;;10.1021/ac00170a027;;3239791;;10.1212/wnl.36.11.1490;;3531917;;10.1111/j.1471-4159.1988.tb10600.x;;3346676;;10.1111/j.1476-5381.1985.tb11081.x;;pmc1916681;;4041681;;1977478;;10.1016/0006-3223(90)90483-i;;2079716;;10.1002/jnr.490270416;;10.1016/0006-2952(72)90179-7;;4646185;;10.1111/j.1471-4159.1992.tb08874.x;;1351932;;834319;;10.1007/bf00508459;;2587746;;10.1016/s0079-6123(08)62485-1;;1859921;;10.1111/j.1360-0443.1991.tb01810.x;;2265894;;10.3109/00207459008987168;;6887012;;10.1007/bf00174504;;3137593;;2685906;;10.1016/s0079-6123(08)62495-4;;8289578;;10.1016/0024-3205(94)00588-5;;10.1093/oxfordjournals.bmb.a072100;;3513895;;10.1007/bf03323906;;2095855;;10.1111/j.1471-4159.1988.tb10582.x;;3346670;;10.1016/0006-8993(91)90588-m;;6149266;;10.1111/j.1471-4159.1984.tb06083.x;;2597885;;10.1192/bjp.154.6.797;;8265684;;10.1016/0091-3057(93)90357-y;;1817734;;10.1016/0006-8993(91)90810-i;;10.1002/hup.470080303;;10.1016/0006-8993(93)90091-z;;8252404;;1352387;;10.1007/bf00966669;;1855016;;10.1136/bmj.302.6791.1491;;pmc1670208;;10.1111/j.1476-5381.1973.tb08203.x;;4723798;;pmc1776061;;10.1016/0306-4603(84)90018-2;;6496202;;2907632;;10.1055/s-2007-1016985;;10.1016/0006-3223(92)90073-9;;1450287;;2572781;;8018786;;10.1016/0006-3223(94)90006-x;;8465868;;10.1176/ajp.150.4.546;;8100644;;10.1093/schbul/19.2.371;;10.1177/088307389400900216;;8006372;;1817466;;10.1176/ajp.148.6.793;;1643197;;10.1016/0006-3223(92)90315-q;;10.1111/j.1360-0443.1991.tb01801.x;;1677596;;10.1126/science.351808;;351808;;10.1201/noe0849320057.ch12;;8031743;;pmc1188589;;10.3928/0048-5713-19930401-05;;8032506;;10.1001/archfami.3.5.445;;8255409;;10.1159/000118998;;10.3891/acta.chem.scand.17-1717;;10.1021/jo00409a002;;10.1021/ja01396a022;;10.1021/jo00148a033;;906829;;948991;;10.1248/cpb.38.2446;;2285975;;7909396;;10.1016/0165-6147(94)90104-x,"Kelly, T. et al., Maxonine: Structure Correction and Synthesis , Tetrahedron Letters, vol. 34, No. 39, pp. 6173 6176 (1993).;;Leete, E. et al. Formation of 5 Fluoronicotine from 5 Fluoronicotinic Acid in Nicotiana Tabacum* , Phytochemistry, 1971, vol. 10, pp. 2687 2692.;;Lynch, B. et al. Pyrazolo 3,4 b pyridines: Syntheses, reactions, and nuclear magnetic resonance spectra , Can. J. Chem. 66, 420 (1988).;;Rubtsov M. et al., Translated from Zhurnal Obshchei Khimii, Hofmann Cleavage of 6,9 diazoniadispiro 5.2.5.2 hexadecane dichloride with methanolic potassium hydroxide , vol. 35, No. 4, pp. 621 628 (Apr. 1965).;;Sadikov, A. et al., Translated from Zhurnal Obshichei Khimii, Syntheses Based on Anabasine , vol. 33, No. 10, pp. 3717 3420 (Oct. 1963).;;Seeman, J. et al., Anal. Chem., Enantiomeric Resolution and Chiral Recognition of Racemic Nicotine and Nicotine Analogues by Cyclodextrin Complexation. Structure Enantiomeric Resolution Relationships in Host Guest Interactions , 60, 2120 2127 (1988).;;Baron, J., Cigarette smoking and Parkinson s disease , Neurology, vol. 36, pp. 1490 1496 (1986).;;Benwell, M. et al., Evidence that Tobacco Smoking Increases the Density of ( ) 3 H Nicotine Binding Sites in Human Brain , Journal of Neurochemistry, vol. 50, pp. 1243 1247 (1988).;;Clark, P. et al., Electrophysiological actions of nicotine on substantia nigra single units , Br. J. Pharm., vol. 85, pp. 827 835 (1985).;;Decina, P. et al., Cigarette Smoking and Neuroleptic Induced Parkinsonism , Biol. Psychiatry, vol. 28, pp. 502 508 (1990).;;Giacobini, E., Pharmacotherapy of Alzheimer s Disease: New Drugs and Novel Strategies , Alzheimer s Disease: Advances in Clinical and Basic Research, S61, pp. 529 538 (1993).;;Giacobini, E., New Cholinesterase Inhibitors for Treatment of Alzheimer s Disease , Alzheimer s Disease: Basic Mechanisms, Diagnosis and Therapeutic Strategies, S80, pp. 627 631 (1991).;;Giacobini, E., Cholinergic Receptors in Human Brain: Effects of Aging and Alzheimer s Disease , Journal of Neuroscience Research, vol. 27, pp. 548 560 (1990).;;Giacobini, E., The Second Generation of Cholinesterasse Inhibitors: Pharmacological Aspects , Pharmacological Basis of Cholinergic Therapy of Alz. Dis., Eds., Becker, R. et al. Boxton:Birkhauser (1991).;;Giacobini, E. et al., Toward a Third Generation of Cholinesterase Inhibitors , Pharmacological Basis of Cholinergic Therapy of Alz. Dis., Eds., Becker, R. et al., Boxton:Birkhauser, (1991).;;Hall, G. et al., Effects of Nicotine on the Release of 3 H Noradrenaline from the Hypothalamus , Biochemical Pharmacology, vol. 21, pp. 1829 1838 (1972).;;Harsing, L. et al., Dopamine Efflux from Striatum After Chronic Nicotine: Evidence for Autoreceptor Desensitization , Journal of Neurochemistry, vol. 59, pp. 48 54 (1993).;;Hery, F. et al., Control of the Release of Newly Synthetized 3 H 5 Hydroxytryptamine by Nicotinic and Muscarinic Receptors in Rat hypothalamic Slices , Arch. Int. Pharmacodyn. Ther., vol. 296, pp. 91 97 (1977).;;Janson, A. et al., Protective effects of chronic nicotine treatment on lesioned nigrostriatal dopa neurons in the male rat , Progress in Brain Research, vol. 79, pp. 257 265 (1989).;;Jarvik, M. Beneficial effects of nicotine , British Journal of Addiction, vol. 86, pp. 571 575 (1991).;;Jones, A. et al., Alzheimer s Disease: Clinical and Pathological Characteristics , Intern. J. Neuroscience, vol. 50, pp. 147 168 (1990).;;Marks, M. et al., Effects of Chronic Nicotine Infusion on Tolerance Development and Nicotinic Receptors , The Journal of Pharmacology and Experimental Therapeutics, vol. 226, pp. 817 825 (1983).;;Hughes, Proceedings from Intl. Symp. Nic. , S40 (1994).;;Newhouse, P. et al., Intravenous nicotine in Alzheimer s disease: a pilot study , Psychopharmacology, vol. 95, pp. 171 175 (1988).;;Nordberg, A. et al., The role of nicotinic receptors in the pathophysiology of Alzheimer s disease , Progress in Brain Research, vol. 79, pp. 353 362 (1989).;;Onaivi, E. et al., Chronic Nicotine Reverses Age Associated Increases in Tall Flick Latency and Anxiety in Rats , Life Sciences, vol. 54, pp. 193 202 (1994).;;Perry E., The Cholinergic Hypothesis Ten Years On , British Medical Bulletin, vol. 42, pp. 63 69 (1986).;;Pomponi, M. et al., Present state and future development of the therapy of Alzheimer disease , Aging, vol. 2(2), pp. 125 153 (1990).;;Rapier, C. et al., Stereoselective Nicotine Induced Release of Dopamine from Striatal Synaptosomes: Concentration Dependence and Repetitive Stimulation , Journal of Neurochemistry, vol. 50, pp. 1123 1130 (1988).;;Rinne, J. et al., A postmortem study of brain nicotinic receptors in Parkinson s and Alzheimer s disease , Brain Research, vol. 547, pp. 167 170 (1991).;;Rowell, P., Current Concepts on the Effects of Nicotine on Neurotransmitter Release in the Central Nervous System , Adv. Behav. Biol., vol. 31, pp. 191 208 (1987).;;Rowell, P. et al., Nicotinic Stimulation of 3 H Acetylcholine Release from Mouse Cerebral Cortical Synaptosomes , Journal of Neurochemistry, vol. 43, pp. 1593 1598 (1984).;;Sahakian, B. et al., The Effects of Nicotine on Attention, Information Processing, and Short Term Memory in Patients with Dementia of the Alzheimer Type , British Journal of Psychiatry, vol. 154, pp. 797 800 (1989).;;Sanberg, P. et al., Nicotine Potentiation of Haloperidol Induced Catalepsy: Striatal Mechanisms , Pharmacology Biochemistry and Behavior, vol. 46, pp. 303 307 (1993).;;Sandor, N. et al., Effect of nicotine on dopaminergic cholinergic interaction in the striatum , Brian Research, vol. 567, pp. 313 316 (1991).;;Sherwood, Human Psychopharm., vol. 8, pp. 155 184 (1993).;;Sjak Shie, N. et al., Effects of chronic nicotine and pilocarpine administration on neocortical neuronal density and 3 H GABA uptake in nucleus basalis lesioned rats , Brain Research, vol. 624, pp. 295 298 (1993).;;Smith, C. et al., Nicotine, Parkinson s and Alzheimer s Disease , Rev. in Neuroscience, vol. 3, pp. 25 43 (1992).;;Toth, E. et al., Effect of Nicotine on Extracellular Levels of Neurotransmitters Assessed by Microdialysis in Various Brain Regions: Role of Glutamic Acid , Neurochemical Research, vol. 17(3), pp. 265 271 (1992).;;van Duijan, C. et al., Relation between nicotine intake and Alzheimer s disease , BMJ, vol. 302, pp. 1491 1494 (1991).;;Vizi, E., Acetylcholine release from guinea pig ileum by parasympathetic ganglion stimulants and gastrin like polypeptides , British Journal Pharmacology, vol. 47, pp. 765 777 (1973).;;Physicians Desk Reference, 48 Edition, pp. 899 903 (1994), Sinemet .;;Physicians Desk Reference, 48 Edition, pp. 2067 2069 (1994), Parlodel .;;Physicians Desk Reference, 48 Edition, pp. 2309 2311 (1994), Eldepryl .;;Hodges, H. et al., Nicotine as a Tool to Characterize the Role of the Forebrain Cholinergic Pr System in Cognition , Biology of Nicotine, pp. 157 182(1991).;;Pomerleau, et al., The Effects of Cigarette Smoking on Pain and Anxiety , Addictive Behavior 9, pp. 265 271 (1984).;;Wagner, et al., Does Smoking Reduce the Risk of Neuroleptic Parkinsonoids , Pharmacopsychiatry, vol. 21, pp. 302 303 (1988).;;Baron, J., Proceedings from Intl. Symp. Nic. , S42 (1994).;;Janson, A. et al., Proceedings from Intl. Symp. Nic. , S43 (1994).;;Levin, E. et al., Proceedings from Intl. Symp. Nic. , S44 (1994).;;Joseph M. et al., Proceedings from Intl. Symp. Nic. , S45 (1994).;;Newhouse, P. et al., Proceedings from Intl. Symp. Nic. , S46 (1994).;;Adler, L. et al., Normalization by Nicotine of Deficient Auditory Sensory Gating in the Relatives Schizophrenics , Biol. Psychiatry, vol. 32, pp. 607 616 (1992).;;Calderon Gonzalez R., Tourette Syndrome , Intern. Pediat., vol. 8(2), pp. 176 188 (1993).;;Devor, E. et al., Nicotine and Tourette s Syndrome , The Lancet, vol. 8670, p. 1046 (1989).;;Faraone, S. et al., An Exploratory Study of ADHD among Second Degree Relatives of ADHD Children , Biol. Psychiatry, vol. 35(6), pp. 398 402 (1994).;;Glassman, A., Cigarette Smoking: Implications for Psychiatric Illness , Am J Psychiatry, vol. 1 546 553 (1993).;;Lieberman, J. et al., Neurochemistry and Neuroendocrinology of Schizophrenia: A Selective Review , Schizophr. Bull., vol. 19, pp. 371 429 (1993).;;Malone, M. et al., Hemispheric Processing and Methylphenidate Effects in Attention Deficit Hyperactivity Disorder , J. Child Neurol., vol. 9(2), pp. 181 189 (1994).;;McConville, B. et al., Nicotine Potentiation of Haloperidol in Reducing Tic Frequency in Tourette s Disorder , Am. J. Psychiatry, vol. 148, pp. 793 794 (1991).;;McConville, B. et al., The Effects of Nicotine Plus Haloperidol Compared to Nicotine Only and Placebo Nicotine Only in Reducing Tic Severity and Frequency in Tourette s Disorder , Biol. Psychiatry, vol. 31, pp. 832 840 (1992).;;Newhouse, P. et al., The role of Nicotine and nicotinic mechanisms in neuropsychiatric disease , British Journal of Addiction, vol. 86, pp. 521 526 (1991).;;Sitaram, N. et al., Human Serial Learning: Enhancement with Arecholine and Choline and Impairment with Scopolamine , Science, vol. 201, pp. 274 276 (1978).;;Physicians Desk Reference, 48 Edition, p. 410 411 (1994), Cylert .;;Physicians Desk Reference, 48 Edition, p. 520 523 (1994), Prolixin .;;Physicians Desk Reference, 48 Edition, p. 612 614 (1994), Catapres .;;Physicians Desk Reference, 48 Edition, p. 835 836 (1994), Ritalin .;;Physicians Desk Reference, 48 Edition, p. 977 979 (1994), Orap .;;Physicians Desk Reference, 48 Edition, p. 1357 1359 (1994), Haldol .;;Physicians Desk Reference, 48 Edition, p. 1935 1936 (1994), Klonopin .;;Physicians Desk Reference, 48 Edition, p. 2248 2250 (1994), Dexedrine .;;Hechtman, L., Genetic and Neurobiological Aspects of Attention Deficit Hyperactive Disorder: A Review , J. Psychiatry Neurosci., vol. 19(3), pp. 193 201 (1994).;;Merriam, et al., Schizophrenia as a Neurobehavioral Disorder , Psychiatr. Annals., vol. 23, p. 178 (1993).;;Sanberg, et al., Proceedings from Intl. Symp. Nic., S39 (1994).;;Vinson, D., Therapy for Attention Deficit Hyperactivity Disorder , Arch. Fam. Med., vol. 3(5), p. 451 (1994).;;Warburton, et al., Cholinergic control of cognitive resources , Neuropsychobiology, Eds. Mendl et al., pp. 43 46 (1993).;;Freedman, R. et al., Proceedings from Intl. Symp. Nic., S41 (1994).;;Acheson, R. et al., J. Chem. Soc. Perkin Trans., vol. 2, pp. 579 585 (1980).;;Erdtman, H. et al., Acta Chem. Scand., vol. 17, pp. 1717 1726 (1963).;;Frank, W. et al., J. Org. Chem., vol. 43(15), pp. 2947 2949 (1978).;;Gol dfarb, Y. et al., J. Gen. Chem., USSR(Engl. Transl.), vol. 39, pp. 1071 1075 (1969).;;Kamimura, H. et al., Agr. Biol. Chem., vol. 27, No. 10, pp. 684 688 (1963).;;LaForge, F., JACS , vol. 50, pp. 2477 2483 (1928).;;Loffler, K. et al., Chem. Ber., vol. 42, pp. 3431 3428 (1909).;;Malek, N. et al., J. Org. Chem., vol. 47, pp. 5395 5397 (1982).;;Pinner, A., Chem. Ber., pp. 2861 2870 (1894).;;Rondahl, L., Acta Pharm. Suec., vol. 14, No. 2, pp. 113 118 (1977).;;Rondahl, L., Acta Pharm. Suec., vol. 13, pp. 229 234 (1976).;;Sprouse, C. et al., Abstracts of Papers, p. 32, Coresta/TCRC, Joint Conference (1972).;;Ashimori, A. et al., Chem. Pharm. Bull. vol. 38(9), pp. 2446 2458 (1990).;;Hamon, Trends in Pharmacol. Res., vol. 15, pp. 36 39 (1994).",EXPIRED
42,EP,A1,EP 0801527 A1,119-692-291-753-219,1997-10-22,1997,EP 95944268 A,1995-12-28,US 9517034 W;;US 36497795 A;;US 36497895 A;;US 36497995 A,1995-01-06,PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS,"Patients susceptible to or suffering from central nervous system disorders (e.g., Tourette's syndrome, attention deficit disorder or schizophrenia) are treated by administering an effective amount of an aryl substituted aliphatic compound, an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-N-methyl-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-N-methyl-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (Z)-metanicotine, (E)-metanicotine, N-methyl-(3-pyridinyl)-butane-1-amine, N-methyl-4-(3-pyridinyl)-3-butyne-1-amine and (E)-N-methyl-4-[3-(6-methylpyridin)yl]-3-butene-1-amine.",REYNOLDS TOBACCO CO R,BENCHERIF MEROUANE;;LIPPIELLO PATRICK MICHAEL;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE,"TARGACEPT, INC. (2002-12-11)",https://lens.org/119-692-291-753-219,Patent Application,yes,0,0,10,15,0,A61K31/44;;A61K31/4406;;A61K31/505;;C07D213/65;;C07D239/26;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28,C07D247/02;;A61K31/44;;A61K31/4406;;A61K31/465;;A61K31/505;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28;;C07D213/65;;C07D239/26,,0,0,,,,EXPIRED
43,WO,A1,WO 1996/020600 A1,009-171-503-665-56X,1996-07-11,1996,US 9517034 W,1995-12-28,US 36497995 A;;US 36497795 A;;US 36497895 A,1995-01-06,PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS,"Patients susceptible to or suffering from central nervous system disorders (e.g., Tourette's syndrome, attention deficit disorder or schizophrenia) are treated by administering an effective amount of an aryl substituted aliphatic compound, an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-N-methyl-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-N-methyl-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (Z)-metanicotine, (E)-metanicotine, N-methyl-(3-pyridinyl)-butane-1-amine, N-methyl-4-(3-pyridinyl)-3-butyne-1-amine and (E)-N-methyl-4-[3-(6-methylpyridin)yl]-3-butene-1-amine.",REYNOLDS TOBACCO CO R;;BENCHERIF MEROUANE;;LIPPIELLO PATRICK MICHAEL;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE,BENCHERIF MEROUANE;;LIPPIELLO PATRICK MICHAEL;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE,,https://lens.org/009-171-503-665-56X,Patent Application,yes,2,28,10,15,0,A61K31/44;;A61K31/4406;;A61K31/505;;C07D213/65;;C07D239/26;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28,A61K31/44;;A61K31/4406;;A61K31/465;;A61K31/505;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28;;C07D213/65;;C07D239/26,,0,0,,,,PATENTED
44,EP,B1,EP 0801527 B1,089-684-233-597-178,2006-07-26,2006,EP 95944268 A,1995-12-28,US 9517034 W;;US 36497795 A;;US 36497895 A;;US 36497995 A,1995-01-06,PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS,"Patients susceptible to or suffering from central nervous system disorders (e.g., Tourette's syndrome, attention deficit disorder or schizophrenia) are treated by administering an effective amount of an aryl substituted aliphatic compound, an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-N-methyl-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-N-methyl-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (Z)-metanicotine, (E)-metanicotine, N-methyl-(3-pyridinyl)-butane-1-amine, N-methyl-4-(3-pyridinyl)-3-butyne-1-amine and (E)-N-methyl-4-[3-(6-methylpyridin)yl]-3-butene-1-amine.",TARGACEPT INC,BENCHERIF MEROUANE;;LIPPIELLO PATRICK MICHAEL;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE,"TARGACEPT, INC. (2002-12-11)",https://lens.org/089-684-233-597-178,Granted Patent,yes,2,0,10,15,0,A61K31/44;;A61K31/4406;;A61K31/505;;C07D213/65;;C07D239/26;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28,C07D247/02;;A61K31/44;;A61K31/4406;;A61K31/465;;A61K31/505;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28;;C07D213/65;;C07D239/26,,5,0,,,"WILSON K L JR ET AL: ""NICOTINE-LIKE ACTIONS OF CIS METANICOTINE AND TRANS METANICOTINE"" JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 196, no. 3, 1976, pages 685-696, XP001007225 ISSN: 0022-3565;;PERRY EK ET AL.: ""Alterationn in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's Disease: Possible index of early neuropathology"" NEUROSCIENCE, vol. 64, no. 2, 1995, pages 385-395, XP001005329;;SAHAKIAN BJ, COULL JT: ""Nicotine and Tetrahydroaminoacradine : Evidence for improved attention in patients with dementia of the Alzheimer type"" DRUG DEVELOPMENT RESEARCH, vol. 31, 1994, pages 80-88, XP002087142;;ARNERIC, STEPHEN P. ET AL: ""Nicotinic agonists in Alzheimer 's disease: does the molecular diversity of nicotine receptors offer the opportunity for developing CNS-selective cholinergic channel activators??"" INT. ACAD. BIOMED. DRUG RES. (1994), 7(RECENT ADVANCES IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND COGNITIVE DYSFUNCTION), 58-70, vol. 7, 1994, pages 58-70, XP001000103;;LIPPIELLO P M ET AL: ""Metanicotine: A nicotinic agonist with CNS selectivity: In vivo characterization."" SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 21, no. 1-3, 1995, page 605 XP001000967 25th Annual Meeting of the Society for Neuroscience;San Diego, California, USA; November 11-16, 1995 ISSN: 0190-5295",EXPIRED
45,US,B1,US 6489349 B1,096-169-773-331-941,2002-12-03,2002,US 65628400 A,2000-09-06,US 65628400 A;;US 29518199 A;;US 63176196 A,1996-04-23,Pharmaceutical compositions for inhibition of cytokine production and secretion,"
    Pharmaceutical compositions incorporate compounds that affect cytokine production and/or secretion. Such compounds include aryl substituted olefinic amine compounds, pyridyloxylalkylamines and phenoxyalkylamines, and aryl substituted amine compounds, such as 3-aminophenyl amine compounds. Such pharmaceutical compositions can be used for treating a wide variety of conditions, diseases and disorders, and particularly those associated with dysfunction of cytokine production and/or secretion. Of particular interest are pharmaceutical compositions useful for preventing and treating conditions, diseases and disorders associated with undesirably high levels of cytokine production and/or secretion. Such pharmaceutical compositions are useful for treating the effects of inflammatory bowel disease, inflammation, arthritis, cachexia in neoplastics diseases or associated with AIDS, and autoimmune diseases. 
",TARGACEPT INC,BENCHERIF MEROUANE;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;DOBSON GRAYLAND PAGE,,https://lens.org/096-169-773-331-941,Granted Patent,yes,14,29,19,21,0,A61K31/4406;;C07D213/38;;A61P1/04;;A61P1/14;;A61P17/02;;A61P29/00;;A61P29/02;;A61P3/00;;A61P31/00;;A61P31/18;;A61P33/06;;A61P35/00;;A61P37/02;;A61P37/06;;A61P43/00;;Y02A50/30;;A61K31/505;;C07D213/38;;A61K31/4406;;Y02A50/30,C07D213/38;;A61K31/00;;A61K31/138;;A61K31/435;;A61K31/4406;;A61K31/4412;;A61K31/505;;A61K31/513;;A61P1/04;;A61P1/14;;A61P3/00;;A61P17/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/18;;A61P33/06;;A61P35/00;;A61P37/02;;A61P37/06;;A61P43/00;;C07D213/65,514/357,18,15,007-021-281-307-399;;024-149-639-017-29X;;022-987-999-830-954;;050-499-477-195-79X;;018-221-009-163-942;;090-464-055-816-104;;002-742-921-254-853;;008-490-079-308-847;;003-942-043-974-568;;010-707-329-211-594;;027-019-301-544-635;;017-172-189-391-146;;067-089-418-999-208;;069-259-644-432-666;;011-630-091-061-613,10.1056/nejm199403243301202;;8114833;;8340813;;10.1523/jneurosci.13-08-03368.1993;;pmc6576518;;10.1097/00042737-199610000-00016;;8930570;;8913794;;10.1016/0162-3109(96)00122-1;;8366415;;10.1902/jop.1993.64.7.658;;9305473;;10.1046/j.1365-2036.1997.00208.x;;8307477;;10.1136/gut.35.2.247;;pmc1374502;;8678464;;pmc2502541;;8170192;;10.1016/s0025-6196(12)61637-1;;pmc2398677;;10.1136/pgmj.72.854.714;;9015463;;9106250;;10.1016/s0197-0186(96)00071-x;;9290087;;10.1016/s0899-9007(97)00185-8;;7504358;;10.1016/0166-2236(93)90011-a;;9083252;;9304801;;10.1016/s1357-2725(96)00159-8,"Pullan et al. ""Transdermal Nicotine for Active Ulcerative Colitis,"" The New England Journal of Medicine, vol. 330, No. 12, Mar. 24, 1994, pp. 811-815.;;International Search Report, PCT/US00/10551, Dec. 20, 2000.;;Van Dijk, Jeanette P.M. et al., European Journal of Pharmacology, 278, R11-R12 (1995).;;Hanisch, Uwe-Karsten et al., The Journal of Neuroscience, vol. 13 (8), pp. 3368-3374 (1993).;;Madretsma, Stanley et al., European Journal of Gastroenterology & Hepatology, vol. 8, No. 10, pp. 1017-1020 (1996).;;Madretsma, G. S. et al., Immunopharmacology, 35, pp. 47-51 (1996).;;Peacock, Mark E. et al., J. Periodontal, vol. 64, No. 7, pp. 658-665 (1993).;;Sandborn, W. J. et al., Ailment Pharmacol Ther., 11, pp. 663-671 (1997).;;Zijlstra, F. J. et al., Gut, 35, pp. 247-251 (1994).;;Pullan, Robert D., Ann R. Coll. Surg. Engl., 78, pp. 85-91 (1996).;;Silverstein, Marc D., M.D. et al., Mayo Clin. Proc., vol. 69, pp. 425-429 (1994).;;Birtwistle, Jon, Postgrad Med. J., vol. 72, pp. 714-718 (1996).;;Ebadi, M. et al., Neurochem. Int., vol. 30, Nos. 4/5, pp. 347-374 (1997).;;Matthys, Patrick Ph.D. et al, Nutrition, vol. 13, pp. 763-770 (1997).;;Jonakait, G. Miller, TINS, vol. 16, No. 10, pp. 419-423 (1993).;;Wallace, John L. et al., Proc. Soc. Exp. Biol. Med., vol. 214, pp. 192-203 (1997).;;Barnes, Peter J., Int. J. Biochem. Cell Ciol., vol. 29, No. 6, pp. 867-870 (1997).;;Sartor, R. Balfour M.D., The American Journal of Gastroenterology, vol. 92, No. 12 (1997).",EXPIRED
46,US,A,US 6107298 A,079-703-347-431-414,2000-08-22,2000,US 26755399 A,1999-03-12,US 26755399 A;;US 2304098 A;;US 36497895 A,1995-01-06,Methods for prevention and treatment of Tourette's syndrome and schizophrenia,"Patients susceptible to or suffering from Tourette's syndrome or schizophrenia are treated by administering an effective amount of an aryl substituted aliphatic compound, an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-N-methyly-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-N-methyl-4-[3-(5-methoxypyrindin)yl]-3-butene-1-amine, (Z)-metanicotine, (E)-metanicotine, N-methyl-(3-pyridinyl)-butane-1-amine, N-methyl-4-(3-pyridinyl)-3-butyne-1-amine and (E)-N-methyl-4-[3-(6-methylpyrindin)yl]-3-butene-1-amine.",BENCHERIF; MEROUANE;;LIPPIELLO; PATRICK MICHAEL;;CALDWELL; WILLIAM SCOTT;;DULL; GARY MAURICE,BENCHERIF MEROUANE;;LIPPIELLO PATRICK MICHAEL;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE,,https://lens.org/079-703-347-431-414,Granted Patent,yes,6,13,3,15,0,A61K31/44;;A61K31/44;;A61K31/4406;;A61K31/4406;;A61K31/505;;A61K31/505;;C07D239/26;;C07D239/26;;C07D213/65;;C07D213/65,A61K31/44;;A61K31/4406;;A61K31/505;;C07D213/65;;C07D239/26,514/256;;514/277;;514/344;;514/357,43,32,118-260-956-021-157;;011-079-540-338-760;;143-217-942-947-189;;017-510-618-626-839;;075-056-023-131-809;;123-054-424-610-835;;023-913-706-643-069;;085-676-249-744-157;;006-641-363-044-503;;093-377-286-425-032;;019-636-446-749-969;;071-994-906-730-368;;000-123-414-169-456;;003-961-737-556-233;;010-424-747-994-894;;021-137-985-293-708;;076-850-144-943-517;;148-957-521-420-43X;;043-709-369-760-068;;076-187-514-882-208;;038-238-087-951-57X;;022-483-915-548-216;;094-167-042-973-375;;003-451-124-907-862;;015-171-920-682-341;;115-409-843-187-701;;059-442-869-656-153;;075-354-305-937-70X;;026-925-467-091-419;;086-301-895-292-306;;126-412-656-895-936;;014-704-698-899-293,10.1016/0006-3223(92)90073-9;;1450287;;1977478;;10.1016/0006-3223(90)90483-i;;2572781;;8018786;;10.1016/0006-3223(94)90006-x;;8465868;;10.1176/ajp.150.4.546;;10.1016/0006-2952(72)90179-7;;4646185;;10.1111/j.1471-4159.1992.tb08874.x;;1351932;;834319;;10.1007/bf00508459;;1859921;;10.1111/j.1360-0443.1991.tb01810.x;;8100644;;10.1093/schbul/19.2.371;;10.1177/088307389400900216;;8006372;;1817466;;10.1176/ajp.148.6.793;;1643197;;10.1016/0006-3223(92)90315-q;;10.1111/j.1360-0443.1991.tb01801.x;;1677596;;8289578;;10.1016/0024-3205(94)00588-5;;10.1093/oxfordjournals.bmb.a072100;;3513895;;10.1111/j.1471-4159.1988.tb10582.x;;3346670;;6149266;;10.1111/j.1471-4159.1984.tb06083.x;;8265684;;10.1016/0091-3057(93)90357-y;;1817734;;10.1016/0006-8993(91)90810-i;;10.1126/science.351808;;351808;;10.1016/0006-8993(93)90091-z;;8252404;;1352387;;10.1007/bf00966669;;10.1111/j.1476-5381.1973.tb08203.x;;4723798;;pmc1776061;;10.1201/noe0849320057.ch12;;8031743;;pmc1188589;;10.3928/0048-5713-19930401-05;;10.1016/0306-4603(84)90018-2;;6496202;;8032506;;10.1001/archfami.3.5.445;;2907632;;10.1055/s-2007-1016985;;8255409;;10.1159/000118998;;3778556,"Adler, L. et al., Normalization by Nicotine of Deficient Auditory Sensory Gating in the Relative Schizophrenics , Biol. Psychiatry, vol. 32, pp. 607 616 (1992).;;Calderon Gonzalez R., Tourette Syndrome , Intern. Pediat., vol. 8(2), pp. 176 188 (1993).;;Decina, P. et al., Cigarette Smoking and Neuroleptic Induced Parkinsonism , Biol. Psychiatry, 28, pp. 502 508 (1990).;;Devor, E. et al., Nicotine and Tourette s Syndrome , The Lancet, vol. 8670, pp. 1046 (1989).;;Faraone, S. et al., An Exploratory Study of ADHD among Second Degree Relatives of ADHD Children , Biol. Psychiatry, vol. 35(6), pp. 398 402 (1994).;;Glassman, A., Cigarette Smoking: Implications for Psychiatric Illness , Am J Psychiatry, vol. pp. 546 553 (1993).;;Hall, G. et al., Effects of Nicotine on the Release of 3 H Noradrenaline from the Hypothalamus Biochemical Pharmacology, vol. 21, pp. 1829 1838 (1972).;;Harsing, L. et al., Dopamine Efflux from Striatum After Chronic Nicotine: Evidence for Autore Desensitization , Journal of Neurochemistry, vol. 59, pp. 48 54 (1993).;;Hery, F. et al., Control of the Release of Newly Synthetized 3 H 5 Hydroxytryptamine by Nicoli and Muscarinic Receptors in Rat Hypothalamic Slices , Arch. Int. Pharmacodyn. Ther., vol. 29 91 97 (1977).;;Jarvik, M. Beneficial effects of nicotine , British Journal of Addiction, vol. 86, pp. 571 575 (1991).;;Lieberman, J. et al., Neurochemistry and Neuroendocrinology of Schizophrenia: A Selective Review , Schizophr. Bull., vol. 19, pp. 371 429 (1993).;;Malone, M. et al., Hemispheric Processing and Methylphenidate Effects in Attention Deficit Hyperactivity Disorder , J. Child Neurol., vol. 9(2), pp. 181 189 (1994).;;Hughes, Proceedings from Intl. Symp. Nic. , S40 (1994).;;McConville, B. et al., Nicotine Potentiation of Haloperidol in Reducing Tic Frequency in Tourette s Disorder , Am. J. Psychiatry, vol. 148, pp. 793 794 (1991).;;McConville, B. et al., The Effects of Nicotine Plus Haloperidol Compared to Nicotine Only and Placebo Nicotine Only in Reducing Tic Severity and Frequency in Tourette s Disorder , Biol. Psychiatry, vol. 31, pp. 832 840 (1992).;;Newhouse, P. et al., The role of nicotine and nicotinic mechanisms in neuropsychiatric disease , British Journal of Addiction, vol. 86, pp. 521 526 (1991).;;Onaivi, E. et al., Chronic Nicotine Reverses Age Associated Increases in Tail Flick Latency and Anxiety in Rats , Life Sciences, vol. 54, pp. 193 202 (1994).;;Perry E., The Cholinergic Hypothesis Ten Years On , British Medical Bulletin, vol. 42, pp. 63 69 (1986).;;Rapier, C. et al., Stereoselective Nicotine Induced Release of Dopamine from Striatal Synaptosomes: Concentration Dependence and Repetitive Stimulation , Journal of Neurochemistry, vol. 50, pp. 1123 1130 (1988).;;Rowell, P. et al., Nicotinic Stimulation of 3 H Acetylcholine Release from Mouse Cerebral Cortical Synaptosomes , Journal of Neurochemistry, vol. 43, pp. 1593 1598 (1984).;;Sanberg, P. et al., Nicotine Potentiation of Haloperidol Induced Catalepsy: Striatal Mechanisms , Pharmacology Biochemistry and Behavior, vol. 46, pp. 303 307 (1993).;;Sandor, N. et al., Effect of nicotine on dopaminergic cholinergic interaction in the striatum , Brain Research, vol. 567, pp. 313 316 (1991).;;Sltaram, N. et al., Human Serial Learning: Enhancement with Arecholine and Choline and Impairment with Scopolamine , Science, vol. 201, pp. 274 276 (1978).;;Sjak Shie, N. et al., Effects of chronic nicotine and pilocarpine administration on neocortical neuronal density and 3 H GABA uptake in nucleus basalis lesioned rats , Brain Research, vol. 624, pp. 295 298 (1993).;;Toth, E. et al., Effect of Nicotine on Extracellular Levels of Neurotransmitters Assessed by Microdialysis in Various Brain Regions: Role of Glutamic Acid , Neurochemical Research, vol. 17(3), pp. 265 271 (1992).;;Vizi, E., Acetylcholine release from guinea pig ileum by parasympathetic ganglion stimulants and gastrin like polypeptides , British Journal Pharmacology, vol. 47, pp. 765 777 (1973).;;Physicians Desk Reference, 48 Edition, p. 410 411 (1994), Cylert .;;Physicians Desk Reference, 48 Edition, p. 520 523 (1994), Prolixin .;;Physicians Desk Reference, 48 Edition, p. 612 614 (1994), Catapres .;;Physicians Desk Reference, 48 Edition, p. 835 836 (1994), Ritalin .;;Physicians Desk Reference, 48 Edition, p. 977 979 (1994), Orap .;;Physicians Desk Reference, 48 Edition, p. 1357 1359 (1994), Haldol .;;Physicians Desk Reference, 48 Edition, p. 1935 1936 (1994), Klonopin .;;Physicians Desk Reference, 48 Edition, p. 2248 2250 (1994), Dexedrine .;;Hechtman, L., Genetic and Neurobiological Aspects of Attention Deficit Hyperactive Disorder: A Review , J. Psychiatry Neurosci., vol. 19(3), pp. 193 201 (1994).;;Merriam, et al., Schizophrenia as a Neurobehavioral Disorder , Psychiatr. Annals., vol. 23, p. 178 (1993).;;Pomerieau, et al., The Effects of Cigarette Smoking on Pain and Anxiety , Addictive Behavi 9, p. 265 (1984).;;Sanberg, et al., Proceedings from Intl. Symp. Nic., S39 (1994).;;Vinson, D., Therapy for Attention Deficit Hyperactivity Disorder , Arch. Fam. Med., vol. 3(5), 445 451 (1994).;;Wagner, et al., Does Smoking Reduce the Risk of Neuroleptic Parkinsolnoids , Pharmacopsychiatry, vol. 21, pp. 301 303 (1988).;;Warburton, et al., Cholinergic control of cognitive resources , Neuropsychobiology, Eds. Mendlewicz, et al., pp. 43 46 (1993).;;Freedman, R. et al., Proceedings from Intl. Symp. Nic., S41 (1994).;;Repond, C. et al, Arzneim. Forsch./Drug Research, vol. 36(II), No. 8, pp. 1191 1194 (1986).",EXPIRED
47,US,A,US 5885998 A,049-996-188-916-038,1999-03-23,1999,US 2304098 A,1998-02-12,US 2304098 A;;US 36497895 A,1995-01-06,Methods for prevention and treatment of attention deficit disorder,"Patients susceptible to or suffering from attention deficit disorder are treated by administering an effective amount of an aryl subsistituted aliphatic compound, an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-4-�3-(5-methoxypyridin)yl!-3-butene-1-amine, (E)-N-methyl-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-N-methyl-4-�3-(5-methoxypyrindin)yl!-3-butene-1-amine, (Z)-metanicotine, (E)-metanicotine, N-methyl-(3-pyridinyl)-butane-1-amine, N-methyl-4-(3-pyridinyl)-3-butyne-1-amine and (E)-N-methyl-4-�3-(6-methylpyrindin)yl!-3-butene-1-amine.",BENCHERIF; MEROUANE;;LIPPIELLO; PATRICK MICHAEL;;CALDWELL; WILLIAM SCOTT;;DULL; GARY MAURICE,BENCHERIF MEROUANE;;LIPPIELLO PATRICK MICHAEL;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE,TARGACEPT INC. A CORPORATION OF DELAWARE (1999-04-09),https://lens.org/049-996-188-916-038,Granted Patent,yes,6,28,3,15,0,A61K31/44;;A61K31/44;;A61K31/4406;;A61K31/4406;;A61K31/505;;A61K31/505;;C07D239/26;;C07D239/26;;C07D213/65;;C07D213/65,A61K31/44;;A61K31/4406;;A61K31/505;;C07D213/65;;C07D239/26,514/256;;514/277;;514/344;;514/357,42,30,118-260-956-021-157;;011-079-540-338-760;;143-217-942-947-189;;017-510-618-626-839;;075-056-023-131-809;;123-054-424-610-835;;023-913-706-643-069;;085-676-249-744-157;;006-641-363-044-503;;093-377-286-425-032;;019-636-446-749-969;;071-994-906-730-368;;000-123-414-169-456;;003-961-737-556-233;;010-424-747-994-894;;021-137-985-293-708;;076-850-144-943-517;;148-957-521-420-43X;;043-709-369-760-068;;076-187-514-882-208;;038-238-087-951-57X;;022-483-915-548-216;;094-167-042-973-375;;003-451-124-907-862;;115-409-843-187-701;;059-442-869-656-153;;075-354-305-937-70X;;026-925-467-091-419;;086-301-895-292-306;;126-412-656-895-936,10.1016/0006-3223(92)90073-9;;1450287;;1977478;;10.1016/0006-3223(90)90483-i;;2572781;;8018786;;10.1016/0006-3223(94)90006-x;;8465868;;10.1176/ajp.150.4.546;;10.1016/0006-2952(72)90179-7;;4646185;;10.1111/j.1471-4159.1992.tb08874.x;;1351932;;834319;;10.1007/bf00508459;;1859921;;10.1111/j.1360-0443.1991.tb01810.x;;8100644;;10.1093/schbul/19.2.371;;10.1177/088307389400900216;;8006372;;1817466;;10.1176/ajp.148.6.793;;1643197;;10.1016/0006-3223(92)90315-q;;10.1111/j.1360-0443.1991.tb01801.x;;1677596;;8289578;;10.1016/0024-3205(94)00588-5;;10.1093/oxfordjournals.bmb.a072100;;3513895;;10.1111/j.1471-4159.1988.tb10582.x;;3346670;;6149266;;10.1111/j.1471-4159.1984.tb06083.x;;8265684;;10.1016/0091-3057(93)90357-y;;1817734;;10.1016/0006-8993(91)90810-i;;10.1126/science.351808;;351808;;10.1016/0006-8993(93)90091-z;;8252404;;1352387;;10.1007/bf00966669;;10.1111/j.1476-5381.1973.tb08203.x;;4723798;;pmc1776061;;8031743;;pmc1188589;;10.3928/0048-5713-19930401-05;;10.1016/0306-4603(84)90018-2;;6496202;;8032506;;10.1001/archfami.3.5.445;;2907632;;10.1055/s-2007-1016985;;8255409;;10.1159/000118998,"Adler, L. et al., Normalization by Nicotine of Deficient Auditory Sensory Gating in the Relative Schizophrenics , Biol. Psychiatry, vol. 32, pp. 607 616 (1992).;;Calderon Gonzalez R., Tourette Syndrome , Intern. Pediat., vol. 8(2), pp. 176 188 (1993).;;Decina, P. et al., Cigarette Smoking and Neuroleptic Induced Parkinsonism , Biol. Psychiatry, 28, pp. 502 508 (1990).;;Devor, E. et al., Nicotine and Tourette s Syndrome , The Lancet, vol. 8670, p. 1046 (1989).;;Faraone, S. et al., An Exploratory Study of ADHD among Second Degree Relatives of ADHD Children , Biol. Psychiatry, vol. 35(6), pp. 398 402 (1994).;;Glassman, A., Cigarette Smoking: Implications for Psychiatric Illness , Am J Psychiatry, vol. pp. 546 553 (1993).;;Hall, G. et al., Effects of Nicotine on the Release of 3 H Noradrenaline from the Hypothalamus Biochemical Pharmacology, vol. 21, pp. 1829 1838 (1972).;;Harsing, L. et al., Dopamine Efflux from Striatum After Chronic Nicotine: Evidence for Autore Desensitization , Journal of Neurochemistry, vol. 59, pp. 48 54 (1993).;;Hery, F. et al., Control of the Release of Newly Synthesized 3 H 5 Hydroxytryptamine by Nicotine and Muscarinic Receptors in Rat Hypothalamic Slices , Arch. Int. Pharmacodyn. Ther., vol. 29, 91 97 (1977).;;Jarvik, M. Beneficial effects of nicotine , British Journal of Addiction, vol. 86, pp. 571 575 (1991).;;Lieberman, J. et al., Neurochemistry and Neuroendocrinology of Schizophrenia: A Selective Review , Schizophr. Bull., vol. 19, pp. 371 429 (1993).;;Malone, M. et al., Hemispheric Processing and Methylphenidate Effects in Attention Deficit Hyperactivity Disorder , J. Child Neurol., vol. 9(2), pp. 181 189 (1994).;;Hughes, Proceedings from Intl. Symp. Nic. , S40 (1994).;;McConville, B. et al., Nicotine Potentiation of Haloperidol in Reducing Tic Frequency in Tourette s Disorder , Am. J. Psychiatry, vol. 148, pp. 793 794 (1991).;;McConville, B. et al., The Effects of Nicotine Plus Haloperidol Compared to Nicotine Only and Placebo Nicotine Only in Reducing Tic Severity and Frequency in Tourette s Disorder , Biol. Psychiatry, vol. 31, pp. 832 840 (1992).;;Newhouse, P. et al., The role of nicotine and nicotinic mechanisms in neuropsychiatric disease , British Journal of Addiction, vol. 86, pp. 521 526 (1991).;;Onaivi, E. et al., Chronic Nicotine Reverses Age Associated Increases in Tail Flick Latency and Anxiety in Rats , Life Sciences, vol. 54, pp. 193 202 (1994).;;Perry, E., The Cholinergic Hypothesis Ten Years On , British Medical Bulletin, vol. 42, pp. 63 69 (1986).;;Rapier, C. et al., Stereoselective Nicotine Induced Release of Dopamine from Striatal Synaptosomes: Concentration Dependence and Repetitive Stimualtion , Journal of Neurochemistry, vol. 50, pp. 1123 1130 (1988).;;Rowell, P. et al., Nicotinic Stimulation of 3 H Acetylcholine Release from Mouse Cerebral Cortical Synaptosomes , Journal of Neurochemistry, vol. 43, pp. 1593 1598 (1984).;;Sanberg, P. et al., Nicotine Potentiation of Haloperidol Induced Catalepsy: Striatal Mechanisms , Pharmacology Biochemistry and Behavior, vol. 46, pp. 303 307 (1993).;;Sandor, N. et al., Effect of nicotine on dopaminergic cholinergic interaction in the striatum , Brain Research, vol. 567, pp. 313 316 (1991).;;Sitaram, N. et al., Human Serial Learning: Enhancement with Arecholine and Choline and Impairment with Scopolamine , Science, vol. 201, pp. 274 276 (1978).;;Sjak Shie, N. et al., Effects of chronic nicotine and pilocarpine administration on neocortical neuronal density and 3 H GABA uptake in nucleus basalis lesioned rats , Brain Research, vol. 624, pp. 295 298 (1993).;;Toth, E. et al., Effect of Nicotine on Extracellular Levels of Neurotransmitters Assessed by Microdialysis in Various Brain Regions: Role of Glutamic Acid , Neurochemical Research, vol. 17(3), pp. 265 271 (1992).;;Vizi, E., Acetylcholine release from guinea pig ileum by parasympathetic ganglion stimulants and gastrin like polypeptides , British Journal Pharmacology, vol. 47, pp. 765 777 (1973).;;Physicians Desk Reference, 48 Edition, pp. 410 411 (1994), Cylert .;;Physicians Desk Reference, 48 Edition, pp. 520 523 (1994), Prolixin .;;Physicians Desk Reference, 48 Edition, pp. 612 614 (1994), Catapres .;;Physicians Desk Reference, 48 Edition, pp. 835 836 (1994), Ritalin .;;Physicians Desk Reference, 48 Edition, pp. 977 979 (1994), Orap .;;Physicians Desk Reference, 48 Edition, pp. 1357 1359 (1994), Haldol .;;Physicians Desk Reference, 48 Edition, pp. 1935 1936 (1994), Klonopin .;;Physicians Desk Reference, 48 Edition, pp. 2248 2250 (1994), Dexedrine .;;Hechtman, L., Genetic and Neurobiological Aspects of Attention Deficit Hyperactive Disorder: A Review , J. Psychiatry Neurosci., vol. 19(3), pp. 193 201 (1994).;;Merriam, et al., Schizophrenia as a Neurobehavioral Disorder , Psychiatr. Annals., vol. 23 p. 178 (1993).;;Pomerfeau, et al., The Effects of Cigarette Smoking on Pain and Anxiety , Addictive Behavior, 9, p. 265 (1984).;;Sanberg, et al., Proceedings from Intl. Symp. Nic., S39 (1994).;;Vinson, D., Therapy for Attention Deficit Hyperactivity Disorder , Arch. Fam. Med., vol. 3(5), 445 451 (1994).;;Wagner, et al., Does Smoking Reduce the Risk of Neuroleptic Parkinsolnoids , Pharmacopsychiatry, vol. 21, pp. 301 303 (1988).;;Warburton, et al., Cholinergic control of cognitive resources , Neuropsychobiology, Eds. Mendlewicz, et al., pp. 43 46 (1993).;;Freedman, R. et al., Proceedings from Intl. Symp. Nic., S41 (1994).",EXPIRED
48,US,A,US 5922723 A,070-157-412-424-825,1999-07-13,1999,US 70844596 A,1996-09-05,US 70844596 A;;US 43715395 A,1995-05-17,Pharmaceutical compositions for prevention and treatment of central nervous system disorders,"Patients susceptible to or suffering from central nervous system disorders (e.g., neurodegenerative diseases including presenile dementia, senile dementia of the Alzheimer's type, and Parkinsonism including Parkinson's disease, and other CNS disorders including attention deficit disorder, schizophrenia and Tourette's syndrome) are treated by administering an effective amount of 2-azabicyclo �2.2.1! hept-5-ene and 2-azabicyclo �2.2.2! oct-5-ene compounds.",BENCHERIF; MEROUANE;;CALDWELL; WILLIAM SCOTT;;DULL; GARY MAURICE;;LIPPIELLO; PATRICK MICHAEL,BENCHERIF MEROUANE;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;LIPPIELLO PATRICK MICHAEL,,https://lens.org/070-157-412-424-825,Granted Patent,yes,20,9,3,5,0,C07D401/04;;C07D401/04;;C07D453/06;;C07D453/06,C07D401/04;;C07D453/06,514/256;;514/299,91,57,116-715-331-598-066;;000-474-373-080-168;;090-386-965-436-396;;011-079-540-338-760;;051-814-877-475-516;;123-054-424-610-835;;023-913-706-643-069;;085-676-249-744-157;;046-339-281-278-65X;;006-641-363-044-503;;161-022-205-991-350;;105-506-224-571-95X;;066-977-238-396-37X;;008-912-139-594-599;;010-424-747-994-894;;021-137-985-293-708;;154-025-112-153-26X;;076-850-144-943-517;;061-200-895-479-648;;148-957-521-420-43X;;068-063-053-003-076;;043-709-369-760-068;;076-187-514-882-208;;115-451-707-484-452;;022-483-915-548-216;;094-167-042-973-375;;116-479-210-421-043;;003-451-124-907-862;;075-354-305-937-70X;;086-301-895-292-306;;118-260-956-021-157;;143-217-942-947-189;;017-510-618-626-839;;075-056-023-131-809;;093-377-286-425-032;;019-636-446-749-969;;071-994-906-730-368;;000-123-414-169-456;;003-961-737-556-233;;038-238-087-951-57X;;015-171-920-682-341;;115-409-843-187-701;;059-442-869-656-153;;026-925-467-091-419;;126-412-656-895-936;;127-547-110-034-08X;;061-556-297-543-520;;174-507-030-434-145;;056-184-684-713-117;;102-292-233-862-978;;020-870-110-885-423;;149-929-583-255-570;;077-450-904-605-806;;072-429-806-476-723;;166-476-258-760-757;;079-116-610-276-006;;109-321-006-804-780,10.1212/wnl.36.11.1490;;3531917;;10.1111/j.1471-4159.1988.tb10600.x;;3346676;;10.1111/j.1476-5381.1985.tb11081.x;;pmc1916681;;4041681;;1977478;;10.1016/0006-3223(90)90483-i;;2079716;;10.1002/jnr.490270416;;10.1016/0006-2952(72)90179-7;;4646185;;10.1111/j.1471-4159.1992.tb08874.x;;1351932;;834319;;10.1007/bf00508459;;2587746;;10.1016/s0079-6123(08)62485-1;;1859921;;10.1111/j.1360-0443.1991.tb01810.x;;2265894;;10.3109/00207459008987168;;6887012;;10.1007/bf00174504;;3137593;;2685906;;10.1016/s0079-6123(08)62495-4;;8289578;;10.1016/0024-3205(94)00588-5;;10.1093/oxfordjournals.bmb.a072100;;3513895;;10.1007/bf03323906;;2095855;;10.1111/j.1471-4159.1988.tb10582.x;;3346670;;10.1016/0006-8993(91)90588-m;;6149266;;10.1111/j.1471-4159.1984.tb06083.x;;2597885;;10.1192/bjp.154.6.797;;8265684;;10.1016/0091-3057(93)90357-y;;1817734;;10.1016/0006-8993(91)90810-i;;10.1002/hup.470080303;;10.1016/0006-8993(93)90091-z;;8252404;;1352387;;10.1007/bf00966669;;1855016;;10.1136/bmj.302.6791.1491;;pmc1670208;;10.1111/j.1476-5381.1973.tb08203.x;;4723798;;pmc1776061;;10.1016/0306-4603(84)90018-2;;6496202;;2907632;;10.1055/s-2007-1016985;;10.1016/0006-3223(92)90073-9;;1450287;;2572781;;8018786;;10.1016/0006-3223(94)90006-x;;8465868;;10.1176/ajp.150.4.546;;8100644;;10.1093/schbul/19.2.371;;10.1177/088307389400900216;;8006372;;1817466;;10.1176/ajp.148.6.793;;1643197;;10.1016/0006-3223(92)90315-q;;10.1111/j.1360-0443.1991.tb01801.x;;1677596;;10.1126/science.351808;;351808;;10.1201/noe0849320057.ch12;;8031743;;pmc1188589;;10.3928/0048-5713-19930401-05;;8032506;;10.1001/archfami.3.5.445;;8255409;;10.1159/000118998;;10.3891/acta.chem.scand.17-1717;;10.1021/jo00409a002;;10.1021/ja01396a022;;10.1021/jo00148a033;;906829;;948991;;10.1248/cpb.38.2446;;2285975;;7909396;;10.1016/0165-6147(94)90104-x;;10.1016/s0040-4039(00)73702-6;;10.1016/s0031-9422(00)97265-0;;10.1139/v88-074;;10.1021/ac00170a027;;3239791,"Baron, J., Cigarette smoking and Parkinson s disease , Neurology, vol. 36, pp. 1490 1496 (1986).;;Benwell, M. et al., Evidence that Tobacco Smoking Increases the Density of ( ) 3 H Nicotine Binding Sites in Human Brain , Journal of Neurochemistry, vol. 50, pp. 1243 1247 (1988).;;Clark, P. et al., Electrophysiological actions of nicotine on substantia nigra units , Br. J. Pharm., vol. 85, pp. 827 835 (1985).;;Decina, P. et al., Cigarette Smoking and Neuroleptic Induced Parkinsonism , Biol. Psychiatry, vol. 28, pp. 502 508 (1990).;;Giacobini, E., Pharmacotherapy of Alzheimer s Disease: New Drugs and Novel Strategies , Alzheimer s Disease: Advances in Clinical and Basic Research, S61, pp. 529 538 (1993).;;Giacobini, E., New Cholinesterase Inhibitors for Treatment of Alzheimer s Disease , Alzheimer s Disease: Basic Mechanisms, Diagnosis and Therapeutic Strategies , S80, pp.627 631 (1991).;;Giacobini, E., Cholinergic Receptors in Human Brain: Effects of Aging and Alzheimer s Disease , Journal of Neuroscience Research, vol. 27, pp. 548 560 (1990).;;Giacobini, E. The Second Generation of Cholinesterasse Inhibitors: Pharmacological Aspects , Pharmacological Basis of Cholinergic Therapy of Alz. Dis., Eds., Becker, R. et al. Boxton:Birkhauser (1991).;;Giacobini, E. et al., Toward a Third Generation of Cholinesterase Inhibtors , Pharmacological Basis of Cholinergic Therapy of Alz. Dis., Eds., Becker, R. et al., Boxton:Birkhauser, (1991).;;Hall, G. et al., Effects of Nicotine on the Release of 3 H Noradrenaline from the Hypothalmus , Biochemical Pharmacology, vol. 21, pp. 1829 1838 (1972).;;Harsing, L. et al., Dopamine Efflux from Striatum After Chronic Nicotine: Evidence for Autoreceptor Desensitization , Journal of Neurochemistry, vol. 59, pp. 48 54 (1993).;;Hery, F. et al., Control of the Release of Newly Synthetized 3 H 5 Hydroxytryptamine by Nicotinic and Muscarinic Receptors in Rat hypothalamic Slices , Arch. Int. Pharmacodyn. Ther., vol. 296, pp. 91 97 (1977).;;Janson, A. et al., Protective effects of chronic nicotine treatment on lesioned nigrostriatal dopa neurons in the male rat , Progress in Brain Research, vol. 79, pp. 257 265 (1989).;;Jarvik, M. Beneficial effects of nicotine , British Journal of Addiction, vol. 86, pp. 571 575 (1991).;;Jones, A. et al., Alzheimer s Disease: Clinical and Pathological Characteristics , Intern. J. Neuroscience, vol. 50, pp. 147 168 (1990).;;Marks, M. et al., Effects of Chronic Nicotine Infusion on Tolerance Development and Nicotinic Receptors , The Journal of Pharmacology and Experimental Therapeutics, vol. 226, pp. 817 825 (1993).;;Hughes, Proceedings from Intl. Symp. Nic. , S40 (1994).;;Newhouse, P. et al., Intravenous nicotine in Alzheimer s disease: a pilot study , Psychopharmacology, vol. 95, pp. 171 175 (1988).;;Nordberg, A. et al., The role of nicotinic receptors in the pathophysiology of Alzheimer s disease Progress in Brain Research, vol. 79, pp. 353 362 (1989).;;Onaivi, E. et al., Chronic Nicotine Reverses Age Associated Increases in Tail Flick Latency and Anxiety in Rats , Life Sciences, vol. 54, pp. 193 202 (1994).;;Perry, E., The Cholinergic Hypothesis Ten Years On , British Medical Bulletin, vol. 42, pp. 63 69 (1986).;;Pomponi, M. et al., Present state and future development of the therapy of Alzheimer disease , Aging, vol. 2(2), pp. 125 153 (1990).;;Rapier, C. et al., Stereoselective Nicotine Induced Release of Dopamine from Striatal Synaptosomes: Concentration Dependence and Repetitive Stimulation , Journal of Neurochemistry, vol. 50, pp. 1123 1130 (1988).;;Rinne, J. et al., A postmortem study of brain nicotinic receptors in Parkinson s and Alzheimer s disease , Brain Research, vol. 547, pp. 167 170 (1991).;;Rowell, P., Current Concepts on the Effects of Nicotine on Neurotransmitter Release in the Central Nervous System , Adv. Behav. Biol., vol. 31, pp. 191, 208 (1987).;;Rowell, P. et al., Nicotinic Stimulation of 3 H Acetylcholine Release from Mouse Cerebral Cortical Snyaptosomes , Journal of Neurochemistry, vol. 43, pp. 1593 1598 (1984).;;Sahakian, B. et al., The Effects of Nicotine on Attention, Information Processing, and Short Term Memory in Patients with Dementia of the Alzheimer Type , British Journal of Psychiatry, vol. 154, pp. 797 800 (1989).;;Sanberg, P. et al., Nicotine Potentiation of Haloperidol Induced Catalepsy: Striatal Mechanisme , Pharmacology Biochemistry and Behavior, vol. 46, pp. 303 307 (1993).;;Sandor, N. et al., Effect of nicotine on dopaminergic cholinergic interaction in the striatum , Brain Research, vol. 567, pp. 313 316 (1991).;;Sherwood, Human Psychopharm., vol. 8, pp. 155 184 (1993).;;Sjak Shie, N. et al., Effects of chronic nicotine and pilocarpine administration on neocortical neuronal density and 3 H GABA uptake in nucleus basalis lesioned rats , Brain Research, vol. 624, pp. 295 298 (1993).;;Smith, C. et al., Nicotine, Parkinson s and Alzheimer s Disease , Rev. in Neuroscience, vol. 3, pp. 25 43 (1992).;;Toth, E. et al., Effect of Nicotine on Extracellular Levels of Neurotransmitters Assessed by Microdialysis in Various Brain Regions: Role of Glutamic Acid , Neurochemical Research, vol. 17(3), pp. 265 271 (1992).;;van Duijan, C. et al., Relation between nicotine intake and Alzheimer s disease , BMJ, vol. 302, pp. 1491 1494 (1991).;;Vizi, E., Acetylcholine release from guinea pig ileum by parasympathetic ganglion stimulants and gastrin like polypeptides , British Journal Pharmacology, vol. 47, pp. 765 777 (1973).;;Physicians Desk Reference, 48 Edition, p. 899 903 (1994), Sinemet .;;Physicians Desk Reference, 48 Edition, p. 2067 2069 (1994), Parlodel .;;Physicians Desk Reference, 48 Edition, p. 2309 2311 (1994), Eldepryl .;;Hodges, H. et al., Nicotine as a Tool to Characterize the Role of the Forebrain Cholinergid Pr System in Cognition , Biology of Nicotine, pp. 157 182(1991).;;Pomerleau, et al., The Effects of Cigarette Smoking on Pain and Anxiety , Addictive Behavior 9, p. 265 271 (1984).;;Wagner, et al., Does Smoking Reduce the Risk of Neuroleptic Parkinsonoids , Pharmacopsychiatry, vol. 21, pp. 302 303 (1988).;;Baron, J., Proceedings from Intl. Symp. Nic. , S42 (1994).;;Janson, A. et al., Proceedings from Intl. Symp. Nic. , S43 (1994).;;Levin, E. et al., Proceedings from Intl. Symp. Nic. , S44 (1994).;;Joseph M. et al., Proceedings from Intl. Symp. Nic. , S45 (1994).;;Newhouse, P. et al., Proceedings from Intl. Symp. Nic. , S46 (1994).;;Adler, L. et al., Normalization by Nicotine of Deficient Auditory Sensory Gating in the Relatives Schizophrenics , Biol. Psychiatry, vol. 32, pp. 607 616 (1992).;;Calderon Gonzalez R., Tourette Syndrome , Intern. Pediat., vol. 8(2), pp. 176 188 (1993).;;Devor, E. et al., Nicotine and Tourette s Syndrome , The Lancet, vol. 8670, pp. 1046 (1989).;;Faraone, S. et al., An Exploratory Study of ADHD among Second Degree Relatives of ADHD Children , Biol. Psychiatry, vol. 35(6), pp. 398 402 (1994).;;Glassman, A., Cigarette Smoking: Implications for Psychiatric Illness , Am J Psychiatry, vol. 1 546 553 (1993).;;Lieberman, J. et al., Neurochemistry and Neuroendocrinology of Schizophrenia: A Selective Review , Schizophr. Bull., vol. 19, pp. 371 429 (1993).;;Malone, M. et al., Hemispheric Processing and Methylphenidate Effects in Attention Deficit Hyperactivity Disorder , J. Child Neurol., vol. 9(2), pp. 181 189 (1994).;;McConville, B. et al., Nicotine Potentiation of Haloperidol in Reducing Tic Frequency in Tourette s Disorder , Am.J. Psychiatry, vol. 148, pp. 793 794 (1991).;;McConville, B. et al., The Effects of Nicotine Plus Haloperidol Compared to Nicotine Only and Placebo Nicotine Only in Reducing Tic Severity and Frequency in Tourette s Disorder , Biol. Psychiatry, vol. 31, pp. 832 840 (1992).;;Newhouse, P. et al., The role of nicotine and nicotinic mechanisms in neuropsychiatric disease , British Journal of Addiction, vol. 86, pp. 521 526 (1991).;;Sitaram, N. et al., Human Serial Learning: Enhancement with Arecholine and Choline and Impairment with Scopolamine , Science, vol. 201, pp. 274 276 (1978).;;Physicians Desk Reference, 48 Edition, p. 410 411 (1994) Cylert .;;Physicians Desk Reference, 48 Edition, p. 520 523 (1994), Prolixin .;;Physicians Desk Reference, 48 Edition, p. 612 614 (1994), Catapres .;;Physicians Desk Reference, 48 Edition, p. 835 836 (1994), Ritalin .;;Physicians Desk Reference, 48 Edition, p. 977 979 (1994), Orap .;;Physicians Desk Reference, 48 Edition, p. 1357 1359 (1994), Haldol .;;Physicians Desk Reference, 48 Edition, p. 1935 1936 (1994), Klonopin .;;Physicians Desk Reference, 48 Edition, p. 2248 2250 (1994), Dexedrine .;;Hechtman, L., Genetic and Neurobiological Aspects of Attention Deficit Hyperactive Disorder: A Review , J. Psychiatry Neurosci., vol. 19(3), pp. 193 201 (1994).;;Merriam, et al., Schizophrenia as a Neurobehavioral Disorder , Psychiatr. Annals., vol. 23, pp. 178 (1993).;;Sanberg, et al., Proceedings fron Intl. Symp. Nic., S39 (1994).;;Vinson, D., Therapy for Attention Deficit Hyperactivity Disorder , Arch. Fam. Med., vol. 3(5), pp. 451 (1994).;;Warburton, et al., Cholinergic control of cognitive resources , Neuropsychobiology, Eds. Mendl et al., pp. 43 46 (1993).;;Freedman, R. et al., Proceedings from Intl. Symp. Nic., S41 (1994).;;Acheson, R. et al., J. Chem. Soc. Perkin Trans., vol. 2, pp. 579 585 (1980).;;Erdtman, H. et al., Acta Chem. Scand., vol. 17, pp. 1717 1726 (1963).;;Frank, W. et al., J. Org. Chem., vol. 43(15), pp. 2947 2949 (1978).;;Gol dfarb, Y. et al., J. Gen. Chem., USSR(Eng. Transl.), vol. 39, pp. 1071 1075 (1969).;;Kamimura, H. et al., Agr. Biol. Chem., vol. 27, No. 10, pp. 684 688 (1963).;;LaForge, F., JACS, vol. 50, pp. 2477 2483 (1928).;;Loffler, K. et al., Chem. Berl., vol. 42, pp. 3431 3428 (1909).;;Malek, N. et al., J. Org. Chem., vol. 47, pp. 5395 5397 (1982).;;Pinner, A., Chem. Ber., pp. 2861 2870 (1894).;;Rondahl, L., Acta Pharm. Suec., vol. 14, No. 2, pp. 113 118 (1977).;;Rondahl, L., Acta Pharm. Suec., vol. 13, pp. 229 234 (1976).;;Sprouse, C. et al., Abstracts of Papers, p. 32, Coresta/TCRC, Joint Conference (1972).;;Ashimori, A. et al., Chem. Pharm. Bull. vol. 38(9), pp. 2446 2458 (1990).;;Hamon, Trends in Pharmacol. Res., vol. 15, pp. 36 39 (1994).;;Kelly, T. et al., Maxonine: Structure Correction and Synthesis , Tetrahedron Letters, vol. 34, No. 39, pp. 6173 6176 (1993).;;Leete, E. et al. Formation of 5 Fluoronicotine from 5 Fluoronicotinic Acid in Nicotiana Tabacum* , Phytochemistry, 1971, vol. 10, pp. 2687 2692.;;Lynch, B. et al. Pyrazolo 3,4 b pyridines: Syntheses, reactions, and nuclear magnetic resonance spectra , Can. J. Chem. 66, 420 (1988).;;Rubtsov M. et al., Translated from Zhurnal Obshchei Khimii, Hofmann Cleavage of 6,9 diazoniadispiro 5.2.5.2 hexadecane dichloride with methanolic potassium hydroxide , vol. 35, No. 4, pp. 621 628 (Apr. 1965).;;Sadikov, A. et al., Translated from Zhurnal Obshchei Khimii, Syntheses Based on Anabasine , vol. 33, No. 10, pp. 3417 3420 (Oct. 1963).;;Seeman, J. et al., Anal. Chem., Enantiomeric Resolution and Chiral Recognition of Racemic Nicotine and Nicotine Analogues by Cyclodextrin Complexation. Structure Enantiomeric Resolution Relationships in Host Guest Interactions , 60, 2120 2127 (1988).",EXPIRED
49,AU,A,AU 1996/046108 A,080-127-102-657-872,1996-07-24,1996,AU 1996/046108 A,1995-12-28,US 36497795 A;;US 36497895 A;;US 36497995 A;;US 9517034 W,1995-01-06,Pharmaceutical compositions for prevention and treatment of central nervous system disorders,"Patients susceptible to or suffering from central nervous system disorders (e.g., Tourette's syndrome, attention deficit disorder or schizophrenia) are treated by administering an effective amount of an aryl substituted aliphatic compound, an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-N-methyl-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-N-methyl-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (Z)-metanicotine, (E)-metanicotine, N-methyl-(3-pyridinyl)-butane-1-amine, N-methyl-4-(3-pyridinyl)-3-butyne-1-amine and (E)-N-methyl-4-[3-(6-methylpyridin)yl]-3-butene-1-amine.",REYNOLDS TOBACCO CO R,BENCHERIF MEROUANE;;LIPPIELLO PATRICK MICHAEL;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE,,https://lens.org/080-127-102-657-872,Patent Application,no,0,0,10,15,0,A61K31/44;;A61K31/4406;;A61K31/505;;C07D213/65;;C07D239/26;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28,A61K31/44;;A61K31/4406;;A61K31/465;;A61K31/505;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28;;C07D213/65;;C07D239/26,,0,0,,,,PENDING
50,US,A,US 5824692 A,195-832-467-091-617,1998-10-20,1998,US 36497795 A,1995-01-06,US 36497795 A,1995-01-06,Pharmaceutical compositions for prevention and treatment of central nervous system disorders,"Patients susceptible to or suffering from central nervous system disorders (e.g., neurodegenerative diseases including presenile dementia, senile dementia of the Alzeimer's type, and Parkinsonism including Parkinson's disease) are treated by administering an effective amount of an aryl substituted aliphatic compound, an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-4-�3-(5-methoxypyridin)yl!-3-butene-1-amine, (E)-N-methyl-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-N-methyl-4-�3-(5-methoxypyrindin)yl!-3-butene-1-amine, (Z)-metanicotine, N-methyl-(3-pyridinyl)-butane-1-amine, N-methyl-4-(3-pyridinyl)-3-butyne-1-amine and (E)-N-methyl-4-�3-(6-methylpyrindin)yl!-3-butene-1-amine.",LIPPIELLO; PATRICK MICHAEL;;BENCHERIF; MEROUANE;;CALDWELL; WILLIAM SCOTT;;DULL; GARY MAURICE,LIPPIELLO PATRICK MICHAEL;;BENCHERIF MEROUANE;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE,R. J. REYNOLDS TOBACCO COMPANY (1995-02-14);;TARGACEPT INC (1999-04-09),https://lens.org/195-832-467-091-617,Granted Patent,yes,10,68,1,15,0,A61K31/44;;A61K31/44;;A61K31/4406;;A61K31/4406;;A61K31/505;;A61K31/505;;C07D239/26;;C07D239/26;;C07D213/65;;C07D213/65,A61K31/44;;A61K31/4406;;A61K31/505;;C07D213/65;;C07D239/26,514/343,46,30,116-715-331-598-066;;000-474-373-080-168;;090-386-965-436-396;;011-079-540-338-760;;051-814-877-475-516;;123-054-424-610-835;;023-913-706-643-069;;085-676-249-744-157;;046-339-281-278-65X;;006-641-363-044-503;;161-022-205-991-350;;105-506-224-571-95X;;066-977-238-396-37X;;008-912-139-594-599;;010-424-747-994-894;;021-137-985-293-708;;154-025-112-153-26X;;076-850-144-943-517;;061-200-895-479-648;;148-957-521-420-43X;;068-063-053-003-076;;043-709-369-760-068;;076-187-514-882-208;;115-451-707-484-452;;022-483-915-548-216;;094-167-042-973-375;;116-479-210-421-043;;003-451-124-907-862;;075-354-305-937-70X;;086-301-895-292-306,10.1212/wnl.36.11.1490;;3531917;;10.1111/j.1471-4159.1988.tb10600.x;;3346676;;10.1111/j.1476-5381.1985.tb11081.x;;pmc1916681;;4041681;;1977478;;10.1016/0006-3223(90)90483-i;;2079716;;10.1002/jnr.490270416;;10.1016/0006-2952(72)90179-7;;4646185;;10.1111/j.1471-4159.1992.tb08874.x;;1351932;;834319;;10.1007/bf00508459;;2587746;;10.1016/s0079-6123(08)62485-1;;1859921;;10.1111/j.1360-0443.1991.tb01810.x;;2265894;;10.3109/00207459008987168;;6887012;;10.1007/bf00174504;;3137593;;2685906;;10.1016/s0079-6123(08)62495-4;;8289578;;10.1016/0024-3205(94)00588-5;;10.1093/oxfordjournals.bmb.a072100;;3513895;;10.1007/bf03323906;;2095855;;10.1111/j.1471-4159.1988.tb10582.x;;3346670;;10.1016/0006-8993(91)90588-m;;6149266;;10.1111/j.1471-4159.1984.tb06083.x;;2597885;;10.1192/bjp.154.6.797;;8265684;;10.1016/0091-3057(93)90357-y;;1817734;;10.1016/0006-8993(91)90810-i;;10.1002/hup.470080303;;10.1016/0006-8993(93)90091-z;;8252404;;1352387;;10.1007/bf00966669;;1855016;;10.1136/bmj.302.6791.1491;;pmc1670208;;10.1111/j.1476-5381.1973.tb08203.x;;4723798;;pmc1776061;;10.1016/0306-4603(84)90018-2;;6496202;;2907632;;10.1055/s-2007-1016985,"Baron, J., Cigarette smoking and Parkinson s disease , Neurology, vol. 36, pp. 1490 1496 (1986).;;Benwell, M. et al., Evidence that Tobacco Smoking Increses the Density of ( ) 3 H Nicotine Binding Sites in Human Brain , Journal of Neurochemistry, vol. 50, pp. 1243 1247 (1988).;;Clark, P. et al., Electrophysiological actions of nicotine on substantia nigra single units , Br. J. Pharm., vol. 85, pp. 827 835 (1985).;;Decina, P. et al., Cigarette Smoking and Neuroleptic Induced Parkinsonism , Biol. Psychiatry, vol. 28, pp. 502 508 (1990).;;Giacobini, E., Pharmacotherapy of Alzheimer s Disease: New Drugs and Novel Strategies , Alzheimer s Disease: Advances in Clinical and Basic Research, S61, pp. 529 538 (1993).;;Giacobini, E., New Cholinesterase Inhibitors for Treatment of Alzheimer s Disease , Alzheimer s Disease: Basic Mechanisms, Diagnosis and Therapeutic Strategies, S80, pp. 627 631 (1991).;;Giacobini, E., Cholinergic Receptors in Human Brain: Effects of Aging and Alzheimer s Disease , Journal of Neuroscience Research, vol. 27, pp. 548 560 (1990).;;Giacobini, E., The Second Generation of Cholinesterasse Inhibitors: Pharmacological Aspects , Pharmacological Basis of Cholinergic Therapy of Alz. Dis., Eds., Becker, R. et al. Boxton:Birkhauser (1991).;;Giacobini, E. et al., Toward a Third Generation of Cholinesterase Inhibitors , Pharmacological Basis of Cholinergic Therapy of Alz. Dis., Eds., Becker, R. et al., Boxton:Birkhauser (1991).;;Hall, G. et al., Effects of Nicotine on the Release of 3 H Noradrenaline from the Hypothalamus , Biochemical Pharmacology, vol. 21, pp. 1829 1838 (1972).;;Harsing, L. et al., Dopamine Efflux from Striatum After Chronic Nicotine: Evidence for Autoreceptor Desensitization , Journal of Neurochemistry, vol. 59, pp. 48 54 (1993).;;Hery, F. et al., Control of the Release of Newly Synthetized 3 H 5 Hydroxytryptamine by Nicotinic and Muscarinic Receptors in Rat hypothalamic Slices , Arch. Int. Pharmacodyn. Ther., vol. 296, pp. 91 97 (1977).;;Janson, A. et al., Protective effects of chronic nicotine treatment on lesioned nigrostriatal dop neurons in the male rat , Progress in Brain Research, vol. 79, pp. 257 265 (1989).;;Jarvik, M. Beneficial effects of nicotine , British Journal of Addition, vol. 86, pp. 571 575 (1991).;;Jones, A. et al., Alzheimer s Disease: Clinical and Pathological Characteristics , Intern. J. Neuroscience, vol. 50, pp. 147 168 (1990).;;Marks, M. et al., Effects on Chronic Nicotine Infusion on Tolerance Development and Nicotinic Receptors , The Journal of Pharmacology and Experimental Therapeutics, vol. 226, pp. 817 825 (1983).;;Hughes, Proceedings from Intl. Symp. Nic. , S40 (1994).;;Newhouse, P. et al., Intravenous nicotine in Alzheimer s disease: a pilot study , Psychopharmacology, vol. 95, pp. 171 175 (1988).;;Nordberg, A. et al., The role of nicotinic receptors in the pathophysiology of Alzheimer s disease , Progress in Brain Research, vol. 79, pp. 353 362 (1989).;;Onaivi, E. et al., Chronic Nicotine Reverses Age Associated Increases in Tail Flick Latency and Anxiety in Rats , Life Sciences, vol. 54, pp. 193 202 (1994).;;Perry E., The Cholinergic Hypothesis Ten Years On , British Medical Bulletin, vol. 42, pp. 63 69 (1986).;;Pomponi, M. et al., Present state and future development of the therapy of Alzheimer disease , Aging , vol. 2(2), pp. 125 153 (1990).;;Rapier, C. et al., Stereoselective Nicotine Induced Release of Dopamine from Striatal Synaptosomes: Concentration Dependence and Repetitive Stimulation , Journal of Neurochemistry, vol. 50, pp. 1123 1130 (1988).;;Rinne, J. et al., A postmortem study of brain nicotinic receptors in Parkinson s and Alzheimer s disease , Brain Research, vol. 547, pp. 167 170 (1991).;;Rowell, P., Current Concepts on the Effects of Nicotine on Neurotransmitter Release in the Central Nervous System , Adv. Behav. Biol., vol. 31, pp. 191 208 (1987).;;Rowell, P. et al., Nicotinic Stimulation of 3 H Acetylcholine Release form Mouse Cerebral Cortical Synaptosomes , Journal of Neurochemistry, vol. 43, pp. 1593 1598 (1984).;;Sahakian, B. et al., The Effects of Nicotine on Attention, Information Processing, and Short Term Memory in Patients with Dementia of the Alzheimer Type , British Journal of Psychiatry, vol. 154, pp. 797 800 (1989).;;Sanberg, P. et al., Nicotine Potentiation of Haloperidol Induced Catalepsy: Striatal Mechanisms , Pharmacology Biochemistry and Behavior, vol. 46, pp. 303 307 (1993).;;Sandor, N. et al., Effect of nicotine on dopaminergic cholinergic interaction in the striatum , Brain Research, vol. 567, pp. 313 316 (1991).;;Sherwood, Human Psychopharm., vol. 8, pp. 155 184 (1993).;;Sjak Shie, N. et al., Effects of chronic nicotine and pilocarpine administration on neocortical neuronal density and 3 H GABA uptake in nucleus basalis lesioned rats , Brain Research, vol. 624, pp. 295 298 (1993).;;Smith, C. et al., Nicotine, Parkinson s and Alzheimer s Disease , Rev. in Neuroscience, vol. 3, pp. 25 43 (1992).;;Toth, E. et al., Effect of Nicotine on Extracellular Levels of Neurotransmitters Assessed by Microdialysis in Various Brain Regions: Role of Glutamic Acid , Neurochemical Research, vol. 17(3), pp. 265 271 (1992).;;van Duijan, C. et al., Relation between nicotine intake and Alzheimer s disease , BMJ, vol. 302, pp. 1491 1494 (1991).;;Vizi, E., Acetylcholine release from guinea pig ileum by parasympathetic ganglion stimulants and gastrin like polypeptides , British Journal Pharmacology, vol. 47, pp. 765 777 (1973).;;Physicians Desk Reference, 48 Edition, pp. 899 903 (1994), Sinemet .;;Physicians Desk Reference, 48 Edition, pp. 2067 2069 (1994), Parlodel .;;Physicians Desk Reference, 48 Edition, pp. 2309 2311 (1994), Eldepryl .;;Hodges, H. et al., Nicotine as a Tool to Characterize the Role of the Forebrain Cholinergic Projection System in Cognition , Biology of Nicotine, pp. 157 182(1991).;;Pomerleau, et al., The Effects of Cigarette Smoking on Pain and Anxiety , Addictive Behavi 9, pp. 265 271 (1984).;;Wagner, et al., Does Smoking Reduce the Risk of Neuroleptic Parkinsonoids , Pharmacopsychiatry, vol. 21, pp. 302 303 (1988).;;Baron, J. Proceedings from Intl. Symp. Nic. , S42 (1994).;;Janson, A. et al., Proceedings from Intl. Symp. Nic. , S43 (1994).;;Levin, E. et al., Proceedings from Intl. Symp. Nic. , S44 (1994).;;Joseph M. et al., Proceedings from Intl. Symp. Nic. , S45 (1994).;;Newhouse, P. et al., Proceedings from Intl. Symp. Nic. , S46 (1994).",EXPIRED
51,EP,A4,EP 0801527 A4,030-596-987-297-226,2001-09-05,2001,EP 95944268 A,1995-12-28,US 9517034 W;;US 36497795 A;;US 36497895 A;;US 36497995 A,1995-01-06,PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS,"Patients susceptible to or suffering from central nervous system disorders (e.g., Tourette's syndrome, attention deficit disorder or schizophrenia) are treated by administering an effective amount of an aryl substituted aliphatic compound, an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-N-methyl-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-N-methyl-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (Z)-metanicotine, (E)-metanicotine, N-methyl-(3-pyridinyl)-butane-1-amine, N-methyl-4-(3-pyridinyl)-3-butyne-1-amine and (E)-N-methyl-4-[3-(6-methylpyridin)yl]-3-butene-1-amine.",REYNOLDS TOBACCO CO R,BENCHERIF MEROUANE;;LIPPIELLO PATRICK MICHAEL;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE,"TARGACEPT, INC. (2002-12-11)",https://lens.org/030-596-987-297-226,Search Report,no,0,0,10,15,0,A61K31/44;;A61K31/4406;;A61K31/505;;C07D213/65;;C07D239/26;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28,A61K31/44;;A61K31/4406;;A61K31/465;;A61K31/505;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28;;C07D213/65;;C07D239/26,,5,3,142-350-433-703-027;;105-959-091-465-070;;077-658-197-676-56X,1263119;;10.1016/0306-4522(94)00410-7;;7700528;;10.1002/ddr.430310112,"WILSON K L JR ET AL: ""NICOTINE-LIKE ACTIONS OF CIS METANICOTINE AND TRANS METANICOTINE"", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 196, no. 3, 1976, pages 685 - 696, XP001007225, ISSN: 0022-3565;;PERRY EK ET AL.: ""Alterationn in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's Disease: Possible index of early neuropathology"", NEUROSCIENCE, vol. 64, no. 2, 1995, pages 385 - 395, XP001005329;;SAHAKIAN BJ, COULL JT: ""Nicotine and Tetrahydroaminoacradine : Evidence for improved attention in patients with dementia of the Alzheimer type"", DRUG DEVELOPMENT RESEARCH, vol. 31, 1994, pages 80 - 88, XP002087142;;ARNERIC, STEPHEN P. ET AL: ""Nicotinic agonists in Alzheimer 's disease: does the molecular diversity of nicotine receptors offer the opportunity for developing CNS-selective cholinergic channel activators??"", INT. ACAD. BIOMED. DRUG RES. (1994), 7(RECENT ADVANCES IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND COGNITIVE DYSFUNCTION), 58-70, vol. 7, 1994, pages 58 - 70, XP001000103;;LIPPIELLO P M ET AL: ""Metanicotine: A nicotinic agonist with CNS selectivity: In vivo characterization."", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 21, no. 1-3, 1995, 25th Annual Meeting of the Society for Neuroscience;San Diego, California, USA; November 11-16, 1995, pages 605, XP001000967, ISSN: 0190-5295",EXPIRED
52,AT,T1,AT E334120 T1,097-796-045-619-401,2006-08-15,2006,AT 95944268 T,1995-12-28,US 36497795 A;;US 36497895 A;;US 36497995 A,1995-01-06,PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ZUR VORBEUGUNG UND BEHANDLUNG VON STÖRUNGEN DES ZENTRALNERVENSYSTEMS,"Patients susceptible to or suffering from central nervous system disorders (e.g., Tourette's syndrome, attention deficit disorder or schizophrenia) are treated by administering an effective amount of an aryl substituted aliphatic compound, an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-N-methyl-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-N-methyl-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (Z)-metanicotine, (E)-metanicotine, N-methyl-(3-pyridinyl)-butane-1-amine, N-methyl-4-(3-pyridinyl)-3-butyne-1-amine and (E)-N-methyl-4-[3-(6-methylpyridin)yl]-3-butene-1-amine.",TARGACEPT INC,BENCHERIF MEROUANE;;LIPPIELLO PATRICK MICHAEL;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE,,https://lens.org/097-796-045-619-401,Granted Patent,no,0,0,10,15,0,A61K31/44;;A61K31/4406;;A61K31/505;;C07D213/65;;C07D239/26;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28,A61K31/44;;A61K31/4406;;A61K31/465;;A61K31/505;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28;;C07D213/65;;C07D239/26,,0,0,,,,EXPIRED
53,US,B1,US 6232316 B1,166-481-647-001-304,2001-05-15,2001,US 9813398 A,1998-06-16,US 9813398 A,1998-06-16,Methods for treatment of CNS disorders,"Pharmaceutical compositions incorporate aryl substituted olefinic amine compounds. Representative compounds are (4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-pyrimidinyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-methoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(6-amino-5-methyl-3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-bromo-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-ethoxy-3-pyridyl)-4-penten-2-amine, (2S)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine and (2S)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine.",TARGACEPT INC,DULL GARY MAURICE;;CALDWELL WILLIAM SCOTT;;LIPPIELLO PATRICK MICHAEL;;BENCHERIF MEROUANE,TARGACEPT INC. A CORP. OF DELAWARE (1999-04-09);;R.J. REYNOLDS TOBACCO COMPANY (1998-09-01),https://lens.org/166-481-647-001-304,Granted Patent,yes,14,47,2,42,0,A61K31/44;;A61K31/4406;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26;;C07D213/73;;C07D239/26;;C07D213/65;;C07D213/38;;A61K31/4406;;C07D213/61;;A61K31/44;;A61K31/505,A61K31/44;;A61K31/4406;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26,514/256,13,6,114-695-843-875-364;;174-507-030-434-145;;056-184-684-713-117;;061-556-297-543-520;;073-981-318-375-830;;184-367-294-782-70X,10.1002/cber.19090420378;;10.1021/ja01396a022;;10.1021/jo00148a033;;10.1021/jo00409a002;;8968367;;8968366,"Cooper, Donald A. et al., Biological Mass Spectrometry, vol. 22, (1993).;;Loffler, Karl et al., Chem. Ber., vol. 42, pp. 3431-3438 (1909).;;LaForge, F. B., J. Am. Chem. Soc., vol. 50, pp. 2477-2483 (1928).;;Pinner, A., Chem. Ber., pp. 2861-2870 (1894).;;Malek, N. et al., J. Org. Chem., vol. 47, pp. 5395-5397 (1982).;;Joyce, N. J. et al., Heterocycles, vol. 29, No. 7, pp. 2947-2949 (1978).;;Frank, W. et al., J. Org. Chem., vol. 43(15), pp. 2947-2949 (1978).;;Sprouse, C. et al., Abstracts of Papers, p. 32, Coresta/TCRC, Joint Conference (1972).;;Pinner, A., Chem. Ber., pp. 1053-1061 (1894).;;Acheson, R. et al., J. Chem. Soc. Perkin Trans., vol. 2, pp. 579-585 (1980).;;Bleicher, Leo et al., Synlett, pp. 1115-1116 (1995).;;Lippiello, P. et al., JPET, vol. 279, No. 3, pp. 1422-1429 (1996).;;Bencherif, M. et al., JPET, vol. 279, pp. 1413-1421 (1996).",EXPIRED
54,US,B1,US 6531606 B1,118-206-591-275-244,2003-03-11,2003,US 80425097 A,1997-02-21,US 80425097 A,1997-02-21,Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds,"
    Patients susceptible to or suffering from central nervous system disorders (e.g., Alzheimer's disease, Parkinson's disease, Tourette's syndrome, attention deficit disorder or schizophrenia) are treated by administering an effective amount of an aryl substituted olefinic amine compound. Exemplary compounds include (E)-N-methyl-4-3-(5-benzyloxypyridin)yl-3-buten-1-amine, (E)-N-methyl-4-3-(5-phenoxypyridin)yl-3-buten-1-amine, (E)-N-methyl-4-3-(5-isopropoxypyridin)yl-3-buten-1-amine, (E)-N-methyl-4-3-(5-methoxymethylpyridin)yl-3-buten-1-amine, and (E)-N-methyl-4-3-(5-phenylpyridin)yl-3-buten-1-amine. 
",TARGACEPT INC,DULL GARY MAURICE;;CALDWELL WILLIAM SCOTT;;DOBSON GRAYLAND PAGE;;MILLER CRAIG HARRISON,TARGACEPT INC. A CORPORATION OF DELAWARE (1999-04-09);;R. J. REYNOLDS TOBACCO COMPANY (1997-05-08),https://lens.org/118-206-591-275-244,Granted Patent,yes,16,22,1,19,0,C07D213/38;;C07D213/61;;C07D213/64;;C07D213/64;;C07D213/61;;C07D213/38,C07D213/38;;C07D213/61;;C07D213/64,546/300;;546/329;;514/256;;514/277;;514/357;;544/242,43,33,174-507-030-434-145;;114-695-843-875-364;;061-556-297-543-520;;056-184-684-713-117;;184-367-294-782-70X;;073-981-318-375-830;;116-715-331-598-066;;184-367-294-782-70X;;011-079-540-338-760;;017-510-618-626-839;;061-556-297-543-520;;087-436-730-206-398;;123-054-424-610-835;;077-450-904-605-806;;023-913-706-643-069;;018-809-595-981-768;;085-676-249-744-157;;033-155-761-065-997;;073-981-318-375-830;;003-961-737-556-233;;010-424-747-994-894;;075-354-305-937-70X;;007-021-281-307-399;;076-850-144-943-517;;148-957-521-420-43X;;037-488-093-058-206;;076-187-514-882-208;;115-451-707-484-452;;022-483-915-548-216;;094-167-042-973-375;;003-451-124-907-862;;086-301-895-292-306;;142-350-433-703-027,10.1021/ja01396a022;;10.1002/cber.19090420378;;10.1021/jo00409a002;;10.1021/jo00148a033;;8968366;;8968367;;10.1212/wnl.36.11.1490;;3531917;;8968366;;1977478;;10.1016/0006-3223(90)90483-i;;8018786;;10.1016/0006-3223(94)90006-x;;10.1021/jo00409a002;;8831772;;10.1021/jm960058h;;10.1016/0006-2952(72)90179-7;;4646185;;7909396;;10.1016/0165-6147(94)90104-x;;10.1111/j.1471-4159.1992.tb08874.x;;1351932;;6541274;;834319;;10.1007/bf00508459;;10.1152/jappl.1994.76.4.1651;;8045845;;8968367;;10.1111/j.1360-0443.1991.tb01801.x;;1677596;;8289578;;10.1016/0024-3205(94)00588-5;;10.1016/0306-4603(84)90018-2;;6496202;;10.1056/nejm199403243301202;;8114833;;10.1111/j.1471-4159.1988.tb10582.x;;3346670;;6149266;;10.1111/j.1471-4159.1984.tb06083.x;;10.1007/978-1-4613-1911-5_13;;1817734;;10.1016/0006-8993(91)90810-i;;10.1002/hup.470080303;;10.1016/0006-8993(93)90091-z;;8252404;;1352387;;10.1007/bf00966669;;10.1111/j.1476-5381.1973.tb08203.x;;4723798;;pmc1776061;;2907632;;10.1055/s-2007-1016985;;1263119,"Cooper, Donald A. et al., Biological Mass Spectrometry, vol. 22, (1993).;;Pinner, A., Chem. Ber., pp. 1053-1061 (1894).;;Pinner, A., Chem. Ber., pp. 2861-2870 (1894).;;LaForge, F., JACS, vol. 50, pp. 2477-2483 (1928).;;Acheson, R. et al., J. Chem. Soc. Perkin Trans., vol. 2, pp. 579-585 (1980).;;Loffler, K. et al., Chem. Ber., vol. 42, pp. 3431-3438 (1909).;;Joyce, N. J. et al., Heterocycles, vol. 29, No. 7, pp. 1335-1342 (1978).;;Frank, W. et al., J. Org. Chem., vol. 43(15), pp. 2947-2949 (1978).;;Malek, N. et al., J. Org. Chem., vol. 47, pp. 5395-5397 (1982).;;Miyaura, N. et al., Synthetic Communications, vol. 11(7), pp. 513-519 (1982).;;Sprouse, C. et al., Abstracts of Papers, p. 32, Coresta/TCRC, Joint Conference (1972).;;Bencherif, M. et al., JPET, vol. 279, No. 3, pp. 1413-1421 (1996).;;Lippiello P. et al., JPET, vol. 279, No. 3, pp. 1422-1429 (1996).;;Baron, J.A., ""Cigarette smoking and Parkinson's Disease,"" Neurology, 36:1490-1496 (1986).;;Bencherif, M., et al., ""RJR-2403: A Nicotinic Agonsist with CNS Selectivity I: In Vitro Characterization,"" J. Pharmacol. Exper. Therapeutics, 279(3):1413-1421 (1996).;;Decina, P. et al., ""Cigarette Smoking and Neuroleptic-Induced Parkinsonism,"" Biol. Psychiatry, 28(6):502-508 (1990).;;Faraone, S.V., et al., ""An Exploratory Study of ADHD among Second-Degree Relatives of ADHD Children,"" Biol. Psychiatry, 35(6):398-402 (1994).;;Frank, W.C. et al., ""Palladium-Catalyzed Vinylic Substitution Reactions with Heterocyclic Bromides,"" J. Org. Chem., 43(15):2947-2949 (1978).;;Giacobini, E., ""Pharmacotherapy of Alzheimer's Disease: New Drugs and Novel Strategies,"" Chapter 61, pp. 529-538 in Alzheimer's Disease: Advances in Clinical and Basic Research, Ed. Corain, B., et al., John Wiley & Sons Ltd, (1993).;;Gibson, S. et al., ""Principal Components Describing Biological Activities and Molecular Diversity of Heterocyclic Aromatic Ring Fragments,"" J. Med. Chem., 39:4065-4072 (1996).;;Hall, G.H. and D.M. Turner, ""Effects of Nicotine on the Release of 3H-Noradrenaline from the Hypothalamus,"" Biochemical Pharmacology, 21:1829-1838 (1972).;;Hamon, M., ""Neuropharmacology of anxiety: perspectives and prospects""; TiPS, 15:1536-1539 (1994).;;Harsing, Jr., L.G., et al., ""Dopamine Efflux from Striatum After Chronic Nicotine: Evidence for Autoreceptor Desensitization,"" J. Neurochem., 59:48-54 (1992).;;Henrich, H., et al., ""Microcirculatory Effects of Nicotine and Related Alkaloids,"" Klin Wochenschr 62(Supp. II):92-100 (1984).;;Hery, F., et al., ""Control of the Release of Newly Synthetized 3H-5-Hydroxytryptamine by Nicotinic and Muscarinic Receptors in Rat Hypothalamic Slices,"" Naunyn-Schmiedeberg's Arch. Pharmacol., 296:91-97 (1977).;;Jinno, S., et al., ""Nicotine and acetylcholine induce release of calcitonin gene-related peptide from rat trachea,"" J. Appl. Physiol., 76(4):1651-1656 (1994).;;Kontos, H.A., ""Vascular diseases of the limbs,"" Chapter 46, pp. 346-349 in Cardiovascular Diseases.;;Lippiello, P.M., et al., ""RJR-2403: A Nicotinic Agonist with CNS Selectivity II. In Vivo Characterization,"" J. Pharmacol. Exper. Therapeutics, 279(3):1422-1429 (1996).;;Newhouse, P.A. and J.R. Hughes, ""The role of nicotine and nicotinic mechanisms in neuropsychiatric disease,"" British J. of Addiction, 86:521-526 (1991).;;Onaivi, E.S., et al., ""Chronic Nicotine Reverses Age-Associated Increases in Tail-Flick Latency and Anxiety in Rats,"" Life Sciences, 54(3):193-202 (1994).;;Pomerlau, O.F., et al.; ""The Effects of Cigarette Smoking on Pain and Anxiety""; Addictive Behaviors, 9:265-271 (1984).;;Pullan, R.D. et al., ""Transdermal Nicotine for Active Ulcerative Colitis,"" New England J. Med., 330(12):811-815 (1994).;;Rapier, C., et al., ""Stereoselective Nicotine-Induced Release of Dopamine from Striatal Synaptosomes: Concentration Dependence and Repetitive Stimulation,"" J. Neurochem., 50(4):1123-1130 (1988).;;Rowell, P.P. and D.L. Winkler, ""Nicotinic Stimulation of [3H] Acetylcholine Release from Mouse Cerebral Cortical Synaptosomes,"" J. Neurochem., 43(6):1593-1598 (1984).;;Rowell, P.P., ""Current Concepts on the Effects of Nicotine on Neurotransmitter Release in the Central Nervous System,"" Adv. Behav. Biol., 31:191-208 (1987).;;Sanberg, P.R. and A.A. Silver, ""Beneficial Effects of Nicotine in Tourette's Syndrome""; ABSTRACT S39, Int'l Symposium on Nicotine: The Effects of Nicotine on Biological Systems II, Montreal Canada, Jul. 21-24, 1994.;;Sandor, N.T., et al. ""Effect of Nicotine on dopaminergic-cholinergic interaction in the striatum,"" Brain Res., 567:313-316 (1991).;;Sherwood, N., ""Effects of Nicotine on Human Psychomoter Performance,"" Human Psychopharmacology, 8:155-184 (1993).;;Sjak-Shie, N.N. and E.M. Meyer, ""Effects of chronic nicotine and pilocarpine administration on neocortocal neuronal density and [3H]GABA uptake in nucleus basalis lesioned rats,"" Brain Res., 624:295-298 (1993).;;Toth, E., et al., ""Effect of Nicotine of Extracellular Levels of Neurotransmitters Assessed by Microdialysis in Various Brain Regions: Role of Glutamic Acid,"" Neurochem. Res., 17(3):265-271 (1992).;;Vizi, E.S., ""Acetylcholine release from guinea-pig ileum by parasympathetic ganglion stimulants and gastrin-like polypeptides,"" Br. J. Pharmac., 47:765-777 (1973).;;Wagner, B., et al., ""Does Smoking Reduce the Risk of Neuroleptic Parkinsonoids?,"" Pharmacopsychiat., 21:302-303 (1988).;;Wilson, Jr., K.L., et al.; ""Nicotine-Like Actions of cis-Metanicotine and trans-Metanicotine,"" J. Pharmacol. and Exp. Ther., 196(3):685-696 (1976).",EXPIRED
55,EP,A4,EP 0801646 A4,136-902-159-799-884,1998-03-25,1998,EP 95944395 A,1995-12-27,US 9516903 W;;US 36497695 A,1995-01-06,PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS,,REYNOLDS TOBACCO CO R;;UNIV KENTUCKY RES FOUND,CROOKS PETER ANTHONY;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALDWINDER SINGH,"THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (2002-12-18);;TARGACEPT, INC. (2002-12-18)",https://lens.org/136-902-159-799-884,Search Report,no,1,0,7,7,0,A61P25/00;;C07D239/26;;C07D239/26;;C07D213/38;;C07D213/38;;C07D213/65;;C07D213/65,A61K31/44;;A61P25/00;;C07D213/38;;C07D213/65;;C07D239/26,,1,0,,,See also references of WO 9620929A1,DISCONTINUED
56,DE,D1,DE 69825879 D1,103-796-418-157-71X,2004-09-30,2004,DE 69825879 T,1998-02-19,US 80425097 A;;US 80424897 A;;US 9803091 W,1997-02-21,PHARMAZEUTISCHE ZUSAMMENSETZUNGEN WELCHE ARYL-SUBSTITUIERTE OLEFINISCHE AMIN-VERBINDUNGEN ENTHALTEN,"Patients susceptible to or suffering from central nervous system disorders (e.g., Alzheimer's disease, Parkinson's disease, Tourette's syndrome, attention deficit disorder or schizophrenia) are treated by administering an effective amount of an aryl substituted olefinic amine compound of Formula (I): wherein X is C-R', C-OR', C-CH2-OR' wherein R' is selected from the group consisting of H, C1-C5 alkyl, an aromatic group containing species and alkyl-, halo-, or amino-substituted aromatic group containing species; E' is hydrogen or C1-C5 alkyl or halo substituted C1-C5 alkyl; E'' is C1-C5 alkyl or halo substituted C1-C5 alkyl; Z' and Z'' are each individually selected from the group consisting of hydrogen, C1-C5 alkyl, aryl rings, and can form a ring structure (a), A, A' and A'' are each individually selected from the group consisting of hydrogen, C1-C7 alkyl, and halo; m is 0 or 1; p is 0 or 1 with the proviso that when m or p is 0 then that E'' is hydrogen; and the wavy line in the structure represents a cis (Z) or trans (E) form of the compound. Exemplary compounds include (E)-N-methyl-4-[3-(benzyloxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-phenoxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-isopropoxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-methoxymethylpyridin)yl]-3-buten-1-amine, and (E)-N-methyl-4-[3-(5-phenylpyridin)yl]-3-buten-1-amine.",TARGACEPT INC,CALDWELL SCOTT;;DULL MAURICE;;DOBSON PAGE;;MILLER HARRISON;;BENCHERIF MEROUANE;;LIPPIELLO MICHAEL,,https://lens.org/103-796-418-157-71X,Granted Patent,no,0,0,16,19,0,C07D213/38;;C07D213/61;;C07D213/64;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28;;A61P43/00;;C07D213/64;;C07D213/61;;C07D213/38;;C07D239/30;;C07D239/26,C07D213/65;;A61K31/44;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28;;A61P43/00;;C07D213/38;;C07D213/61;;C07D213/64,,0,0,,,,EXPIRED
57,US,B1,US 6492399 B1,096-856-864-832-869,2002-12-10,2002,US 32777499 A,1999-06-07,US 32777499 A;;US 9813398 A,1998-06-16,Pharmaceutical compositions and methods for use,"
    Pharmaceutical compositions incorporate aryl substituted olefinic amine compounds. Representative compounds are (3E)-N-methyl-4-3-(5-nitro-6-aminopyridin)yl-3-buten-1-amine, (3E)-N-methyl-4-3-(5-(N-benzylcarboxamido)pyridin)yl-3-buten-1-amine, (4E)-N-methyl-5-5-(2-aminopyrimidin)yl-4-penten-2-amine, (4E)-N-methyl-5-(3-(5-aminopyridin)yl)-4-penten-2-amine, (3E)-N-methyl-4-(3-(5-isobutoxypyridin)yl)-3-buten-1-amine, (3E)-N-methyl-4-(3-(1-oxopyridin)yl)-3-buten-1-amine, (3E)-N-methyl-4-(3-(5-ethylthiopyridin)yl)-3-buten-1-amine, (4E)-N-methyl-5-(3-(5-trifluoromethylpyridin)yl)-4-penten-2-amine and (4E)-N-methyl-5-(3-(5-hydroxypyridin)yl)-4-penten-2-amine. 
",TARGACEPT INC,DULL GARY MAURICE;;MILLER CRAIG HARRISON;;CALDWELL WILLIAM SCOTT;;HADIMANI SRISHAILKUMAR BASAWAN,TARGACEPT INC (1999-08-10),https://lens.org/096-856-864-832-869,Granted Patent,yes,38,109,2,42,0,A61K31/44;;A61K31/4406;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26;;C07D213/73;;C07D239/26;;C07D213/65;;C07D213/38;;A61K31/4406;;C07D213/61;;A61K31/44;;A61K31/505,A61K31/44;;A61K31/4406;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26,514/345;;514/740;;514/744,22,7,080-173-777-134-292;;001-410-478-176-952;;085-848-917-863-417;;072-642-229-453-523;;080-173-777-134-292;;073-981-318-375-830;;098-645-664-739-486,10.1021/jm00400a005;;2966246;;2903032;;2754709;;10.1021/jm00128a026;;10.1021/cr00002a004;;10.1021/jm00400a005;;2966246;;8968367;;3339617;;10.1021/jm00397a034,"Hogberg et al., ""Homallylic Amines Related to Zimeldine. A Comparative Study on Neuronal Serotonin and Norepinephrine Reuptake Based on Conformational Analysis,"" J. Med. Chem. 31:5 913-919 (1988).;;International Search Report; Nov. 26, 1999; R.J. Reynolds Tobacco Company et al.; PCT/US99/12340; file ref:627-311. WO.;;Caplus AN 1974:535967, RN 54127-22-9.;;Caplus AN 1985:560530, RN 6021-23-4.;;Caplus AN 1987:84609 RN 6021-23-4.;;Caplus AN 1989:2314447, RN 319690-13-2.;;Caplus AN 1991:408582, RN 134162-95-1.;;Caplus AN 1992:197012, RN 140681-92-1.;;Caplus AN 1998: 618370, RN 1129-68-6.;;Cashman, et al., ""Stereoselective N-Oxygenation of Zimeldine and Homozimeldine by the Flavin-containing Monooxygenase,"", Drug Metab. Dispos., 16(4): 616-622 (1988) (Abstract).;;Gold'faarb, et al., ""Strength of Some Nicotine Series Base,""Izv. Acad. Nauk SSR. Ser. Khim., (8):1883-1885 (1970) (Abstract).;;Guthrie, et al, ""Pentadienyl Carboxamide Derivatives as Antagonists of Platelet Activating Factor,"", J. Med. Chem., 32(8): 1820-1835 (1989) (Guthrie).;;Hansch, et al., ""A Survey of Hammett Substituent Constants and Resonance and Field Parameters"", Chem. Rev., 91:165-195 (1991).;;Högberg, et al., ""Homoallylic Amines Related to Zimeldine, Comparative Study on Neuronal Serotonin and Norepinephrine Reuptake Based on Conformational Analysis,""J. Med. Chem., 31(5):913-919 (1988).;;International Search Report, PCT/US00/15560, Nov. 7, 2000.;;Lippiello, et al., ""RJR-2403: A Nicotinic Agonist with CNS Selectivity. II. In Vivo Characterization,""J. Pharmacol. Exp. Ther., 279(3): 1422-1429 (1996).;;Stoyanovich, et al, ""Action of Potassium Amide on 5-Bromo-2(or 6)-Amino-3-(4-Methylaminobutyl)pyridine,"", Azv. Akad. Nauk SSSR.,. Ser. Khim., 11:2585-2590 (1970) (Abstract).;;Tilley, et al., ""Pyrido[2,1-b]quinazolinecarboxamide Derivatives as Platelet Activating Factor Antagonists,"", J. Med. Chem., 31(2):466-472 (1988) (Abstract).;;Uspatfull AN 89:92535, RN 112102-59-7.;;Uspatfull 89:67281, RN 126427-28-9.;;Uspatfull AN 89:74192, RN 112860-50-1/;;Yamamoto et al., ""Nicotinoids as an Insecticide. VII. Cholinesterase Inhibition by Nicotinoids and Pyridylakylamines, Its Significance to Mode of Action,""Agr. Biol. Chem. , (Tokyo), 32(11): 1341-1348.",EXPIRED
58,AU,A,AU 1996/046455 A,079-643-720-266-727,1996-07-24,1996,AU 1996/046455 A,1995-12-27,US 36497695 A;;US 9516903 W,1995-01-06,Pharmaceutical compositions for prevention and treatment of central nervous system disorders,,REYNOLDS TOBACCO CO R;;UNIV KENTUCKY RES FOUND,CROOKS PETER ANTHONY;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALDWINDER SINGH,,https://lens.org/079-643-720-266-727,Patent Application,no,0,0,7,7,0,A61P25/00;;C07D239/26;;C07D239/26;;C07D213/38;;C07D213/38;;C07D213/65;;C07D213/65,A61K31/44;;A61P25/00;;C07D213/38;;C07D213/65;;C07D239/26,,0,0,,,,PENDING
59,DE,T2,DE 69825879 T2,152-031-532-677-498,2005-09-01,2005,DE 69825879 T,1998-02-19,US 80425097 A;;US 80424897 A;;US 9803091 W,1997-02-21,PHARMAZEUTISCHE ZUSAMMENSETZUNGEN WELCHE ARYL-SUBSTITUIERTE OLEFINISCHE AMIN-VERBINDUNGEN ENTHALTEN,"Patients susceptible to or suffering from central nervous system disorders (e.g., Alzheimer's disease, Parkinson's disease, Tourette's syndrome, attention deficit disorder or schizophrenia) are treated by administering an effective amount of an aryl substituted olefinic amine compound of Formula (I): wherein X is C-R', C-OR', C-CH2-OR' wherein R' is selected from the group consisting of H, C1-C5 alkyl, an aromatic group containing species and alkyl-, halo-, or amino-substituted aromatic group containing species; E' is hydrogen or C1-C5 alkyl or halo substituted C1-C5 alkyl; E'' is C1-C5 alkyl or halo substituted C1-C5 alkyl; Z' and Z'' are each individually selected from the group consisting of hydrogen, C1-C5 alkyl, aryl rings, and can form a ring structure (a), A, A' and A'' are each individually selected from the group consisting of hydrogen, C1-C7 alkyl, and halo; m is 0 or 1; p is 0 or 1 with the proviso that when m or p is 0 then that E'' is hydrogen; and the wavy line in the structure represents a cis (Z) or trans (E) form of the compound. Exemplary compounds include (E)-N-methyl-4-[3-(benzyloxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-phenoxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-isopropoxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-methoxymethylpyridin)yl]-3-buten-1-amine, and (E)-N-methyl-4-[3-(5-phenylpyridin)yl]-3-buten-1-amine.",TARGACEPT INC,CALDWELL SCOTT;;DULL MAURICE;;DOBSON PAGE;;MILLER HARRISON;;BENCHERIF MEROUANE;;LIPPIELLO MICHAEL,,https://lens.org/152-031-532-677-498,Granted Patent,no,0,0,16,19,0,C07D213/38;;C07D213/61;;C07D213/64;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28;;A61P43/00;;C07D213/64;;C07D213/61;;C07D213/38;;C07D239/30;;C07D239/26,C07D213/65;;A61K31/44;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28;;A61P43/00;;C07D213/38;;C07D213/61;;C07D213/64,,0,0,,,,EXPIRED
60,EP,A1,EP 0801646 A1,034-945-833-165-78X,1997-10-22,1997,EP 95944395 A,1995-12-27,US 9516903 W;;US 36497695 A,1995-01-06,PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS,,REYNOLDS TOBACCO CO R;;UNIV KENTUCKY RES FOUND,CROOKS PETER ANTHONY;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALDWINDER SINGH,"THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (2002-12-18);;TARGACEPT, INC. (2002-12-18)",https://lens.org/034-945-833-165-78X,Patent Application,yes,0,0,7,7,0,A61P25/00;;C07D239/26;;C07D239/26;;C07D213/38;;C07D213/38;;C07D213/65;;C07D213/65,A61K31/44;;A61P25/00;;C07D213/38;;C07D213/65;;C07D239/26,,0,0,,,,DISCONTINUED
61,WO,A1,WO 1996/020929 A1,004-306-426-030-264,1996-07-11,1996,US 9516903 W,1995-12-27,US 36497695 A,1995-01-06,PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS,Patients susceptible to or suffering from central nervous system disorders are treated by administering an effective amount of an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-N-methyl-4-[3-(6-methylpyrindin)yl]-3-butene-1-amine and N-methyl-4-(3-pyridinyl)-3-butyne-1-amine.,REYNOLDS TOBACCO CO R;;UNIV KENTUCKY RES FOUND;;CROOKS PETER ANTHONY;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALDWINDER SINGH,CROOKS PETER ANTHONY;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALDWINDER SINGH,,https://lens.org/004-306-426-030-264,Patent Application,yes,1,15,7,7,0,A61P25/00;;C07D239/26;;C07D239/26;;C07D213/38;;C07D213/38;;C07D213/65;;C07D213/65,A61K31/44;;A61P25/00;;C07D213/38;;C07D213/65;;C07D239/26,,3,0,,,"CHEMICAL ABSTRACTS, Volume 109, Number 25, issued 19 December 1988, KURBANOV et al., ""Aminomethylation of 2-Methyl-5-Ethynyl Pyridine by Dimethyl- and Diethyl Amines"", page 834, Abstract 230750t; & UZB. KIM. ZH., 1988, (2), pages 31-33.;;CHEMICAL ABSTRACTS, Volume 71, Number 16, issued 20 October 1969, KOTLYAREVSKII et al., ""Synthesis and Some Reactions of beta-Ethynylpyridine"", page 368, Abstract 81101z; & SER. KHIM. NAUK., 1969, (2), pages 111-115.;;See also references of EP 0801646A4",PENDING
62,WO,A1,WO 2000/075110 A1,138-432-532-979-752,2000-12-14,2000,US 0015560 W,2000-06-06,US 32714199 A;;US 32777499 A,1999-06-07,PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE,"Pharmaceutical compositions incorporate aryl substituted olefinic amine compounds. Representative compounds are (2S)-(4E)-N-methyl-5-[3-(5-isopropoxy-1-oxopyridin)yl)]-4-penten-2-amine, (3E)-N-methyl-4-(3-(1-oxopyridin)yl)-3-buten-1-amine, (4E)-N-methyl-5-(3-(1-oxopyridin)yl)-4-penten-2-amine, (4E)-N-methyl-5-(3-(5-((carboxymethyl)oxy)pyridin)yl)-4-penten-2-amine, (3E)-N-methyl-4-[3-(5-nitro-6-aminopyridin)yl]-3-buten-1-amine, (3E)-N-methyl-4-[3-(5-(N-benzylcarboxamido)pyridin)yl]-3-buten-1-amine(4E)-N-methyl-5-[5-(2-aminopyrimidin)yl]-4-penten-2-amine, (4E)-N-methyl-5-(3-(5-aminopyridin)yl)-4-penten-2-amine (3E)-N-methyl-4-(3-(5-isobutoxypyridin)yl)-3-buten-1-amine, (3E)-N-methyl-4-(3-(5-ethylthiopyridin)yl)-3-buten-1-amine, (4E)-N-methyl-5-(3-(5-trifluoromethylpyridin)yl)-4-penten-2-amine, (4E)-5-(3-(5-isopropoxypyridin)yl)-4-penten-2-amine, and (4E)-5-(3-(5-isopropoxypyridin)yl)-4-penten-2-amine.",TARGACEPT INC;;DULL MAURICE DULL;;MILLER CRAIG HARRISON;;CALDWELL WILLIAM SCOTT;;LYNM DWO;;BHATTI BALWINDER SINGH;;SCHMITT JEFFREY DANIEL;;BYRD GARY DWIGHT;;HADIMANI SRISHAILKUMAR BASAWAN,DULL MAURICE DULL;;MILLER CRAIG HARRISON;;CALDWELL WILLIAM SCOTT;;LYNM DWO;;BHATTI BALWINDER SINGH;;SCHMITT JEFFREY DANIEL;;BYRD GARY DWIGHT;;HADIMANI SRISHAILKUMAR BASAWAN,,https://lens.org/138-432-532-979-752,Patent Application,yes,27,50,5,6,0,A61P25/04;;A61P25/08;;A61P25/14;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D213/70;;C07D213/38;;C07D213/65;;C07D213/73;;C07D213/74;;C07D213/82;;C07D213/89,A61K31/44;;A61K31/4406;;A61K31/455;;A61P25/04;;A61P25/08;;A61P25/14;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D213/38;;C07D213/65;;C07D213/70;;C07D213/73;;C07D213/74;;C07D213/82;;C07D213/89,,14,5,080-173-777-134-292;;098-645-664-739-486;;080-173-777-134-292;;001-410-478-176-952;;072-642-229-453-523,10.1021/jm00400a005;;2966246;;3339617;;10.1021/jm00397a034;;10.1021/jm00400a005;;2966246;;2903032;;10.1021/cr00002a004,"HOEGBERG T ET AL: ""HOMOALLYLIC AMINES RELATED TO ZIMELDINE A COMPARATIVE STUDY ON NEURONAL SEROTONIN AND NOREPINEPHRINE REUPTAKE BASED ON CONFORMATIONAL ANALYSIS"", JOURNAL OF MEDICINAL CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 31, no. 5, 1 May 1988 (1988-05-01), pages 913 - 919, XP000608983, ISSN: 0022-2623;;DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; TILLEY, JEFFERSON W. ET AL: ""Pyrido[2,1-b]quinazolinecarboxamide derivatives as platelet activating factor antagonists"", XP002148166, retrieved from STN Database accession no. 108:75343;;DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; GUTHRIE, ROBERT W. ET AL: ""Pentadienyl carboxamide derivatives as antagonists of platelet activating factor"", XP002148167, retrieved from STN Database accession no. 111:232526;;DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; YAMAMOTO, IZURU ET AL: ""Nicotinoids as an insecticide. VII. Cholinesterase inhibition by nicotinoids and pyridylalkylamines, its significance to mode of action"", XP002148168, retrieved from STN Database accession no. 70:19156;;DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; GOL'DFARB, YA. L. ET AL: ""Strength of some nicotine series bases"", XP002148169, retrieved from STN Database accession no. 74:31877;;DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; STOYANOVICH, F. M. ET AL: ""Action of potassium amide on 5-bromo-2(or 6)-amino-3-(4- methylaminobutyl)pyridine"", XP002148170, retrieved from STN Database accession no. 74:111870;;DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; HOEGBERG, THOMAS ET AL: ""Homoallylic amines related to zimeldine. Comparative study on neuronal serotonin and norepinephrine reuptake based on conformational analysis"", XP002148171, retrieved from STN Database accession no. 108:167263;;DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; LIPPIELLO, P. M. ET AL: ""RJR-2403: A nicotinic agonist with CNS selectivity. II. In vivo characterization"", XP002148172, retrieved from STN Database accession no. 126:99173;;DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; LIPPIELLO, P. M. ET AL: ""Metanicotine: A nicotinic agonist with central nervous system selectivity-in vitro and in vivo characterization"", XP002148173, retrieved from STN Database accession no. 126:126801;;DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; YAMAMOTO, IZURU ET AL: ""Nicotinoids as an insecticide. VII. Cholinesterase inhibition by nicotinoids and pyridylalkylamines, its significance to mode of action"", XP002148174, retrieved from STN Database accession no. 70:19156;;DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; CASHMAN, JOHN R. ET AL: ""Stereoselective N-oxygenation of zimeldine and homozimeldine by the flavin-containing monooxygenase"", XP002148175, retrieved from STN Database accession no. 109:141972;;DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KISAKI, TAKURO ET AL: ""Tobacco flavorant"", XP002148176, retrieved from STN Database accession no. 91:53030;;DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KISAKI, TAKURO ET AL: ""Pseudooxynicotine"", XP002148177, retrieved from STN Database accession no. 88:168512;;C. HANSCH ET AL., CHEM. REV., vol. 91, 1991, pages 165 - 195, XP002147860",PENDING
63,AU,A,AU 2000/053261 A,067-864-279-767-638,2000-12-28,2000,AU 2000/053261 A,2000-06-06,US 32714199 A;;US 32777499 A;;US 0015560 W,1999-06-07,Pharmaceutical compositions and methods for use,,TARGACEPT INC,DULL MAURICE DULL;;MILLER CRAIG HARRISON;;CALDWELL WILLIAM SCOTT;;LYNM DWO;;BHATTI BALWINDER SINGH;;SCHMITT JEFFREY DANIEL;;BYRD GARY DWIGHT;;HADIMANI SRISHAILKUMAR BASAWAN,,https://lens.org/067-864-279-767-638,Patent Application,no,0,0,5,6,0,A61P25/04;;A61P25/08;;A61P25/14;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D213/70;;C07D213/38;;C07D213/65;;C07D213/73;;C07D213/74;;C07D213/82;;C07D213/89,A61K31/44;;A61K31/4406;;A61K31/455;;A61P25/04;;A61P25/08;;A61P25/14;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D213/38;;C07D213/65;;C07D213/70;;C07D213/73;;C07D213/74;;C07D213/82;;C07D213/89,,0,0,,,,DISCONTINUED
64,US,B1,US 6525065 B1,109-096-469-354-044,2003-02-25,2003,US 88539797 A,1997-06-30,US 88539797 A,1997-06-30,Pharmaceutical compositions and methods for effecting dopamine release,"
    Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia) are treated by administering an endo or exo form of a 1-aza-2-(3-pyridyl)bicyclo2.2.1heptane, a 1-aza-2-(3-pyridyl)bicyclo2.2.2octane, a 1-aza-2-(3-pyridyl)bicyclo3.2.2nonane, a 1-aza-7-(3-pyridyl)bicyclo2.2.1heptane, a 1-aza-3-(3-pyridyl)bicyclo3.2.2nonane, or a 1-aza-7-(3-pyridyl)bicyclo3.2.2nonane. 
",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;BENCHERIF MEROUANE;;DULL GARY MAURICE;;CROOKS PETER ANTHONY;;LIPPIELLO PATRICK MICHAEL,KENTUCKY UNIVERSITY OF (1998-01-16);;KENTUCKY RESEARCH FOUNDATION UNIVERSITY OF (1998-05-15);;R. J. REYNOLDS TOBACCO COMPANY (1998-01-13);;TARGACEPT INC (1999-03-17),https://lens.org/109-096-469-354-044,Granted Patent,yes,11,15,1,15,0,C07D453/02;;C07D487/08;;C07D487/08;;C07D453/02,C07D453/02;;C07D487/08,514/305;;514/299;;514/300;;514/277;;514/256;;546/137,2,0,,,"Sadikov et al., ""Syntheses Based on Anabasine,"" pp. 3345-3347 (1962).;;Rubtsov et al., ""Hofmann Cleavage of 6, 9-Diazoniadispiro-(5.2.5.2) Hexadecan Dichlorid with Methanolic Potassium Hydroxide,"" pp. 624-630 (1964).",EXPIRED
65,EP,B1,EP 0873050 B1,015-029-827-130-051,2004-03-10,2004,EP 95943979 A,1995-12-27,US 9516901 W;;US 36498095 A,1995-01-06,PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF ULCERATIVE COLITIS,"Patients suffering from or susceptible to an idiopathic chronic inflammatory bowel disease (e.g., ulcerative colitis) are treated with pharmaceutical compositions. Those patients are treated by administration of an effective amount of aryl substituted aliphatic compound, an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-N-methyl-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-N-methyl-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-metanicotine, (Z)-metanicotine, N-methyl-(3-pyridinyl)-butane-1-amine, N-methyl-4-(3-pyridinyl)-3-butyne-1-amine and (E)-N-methyl-4 -[3-(6-methylpyrindin)yl]-3-butone-1-amine.",TARGACEPT INC,SMITH CARR JOSEPH;;LIPPIELLO PATRICK MICHAEL;;BENCHERIF MEROUANE;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE,"TARGACEPT, INC. (2002-12-11)",https://lens.org/015-029-827-130-051,Granted Patent,yes,3,0,13,13,0,A61K31/44;;A61K31/4406;;A61K31/505;;A61P1/00;;A61P1/04;;A61P29/00;;A61K31/44;;A61K31/4406;;A61K31/505,A61K31/44;;A61K31/4406;;A61K31/505;;A61P1/00;;A61P29/00,,7,0,,,"DATABASE WPI Section Ch, Week 9345 Derwent Publications Ltd., London, GB; Class B03, AN 93-357175 XP002110678 & JP 05 262747 A (MORISHITA ROUSSEL KK), 12 October 1993 (1993-10-12);;DATABASE WPI Section Ch, Week 9113 Derwent Publications Ltd., London, GB; Class A96, AN 91-090638 XP002110679 & JP 03 034929 A (TEIKOKU SEIYAKU KK), 14 February 1991 (1991-02-14);;LASHNER B.A., ET AL.: ""Testing nicotine gum for ulcerative colitis patients. Experience with single-patients trials."" DIGESTIVE DISEASES AND SCIENCES, vol. 35, no. 7, 1990, pages 827-832, XP000600385;;COMPREHENSIVE THERAPY, Volume 18, Number 8, issued 1992, B. LASHNER, ""Conspectus: Inflammatory Bowel Disease, Family Patterns and Risk Factors"", pages 2-4.;;HUMAN TOXICOLOGY, Volume 8, issued November 1989, SRIVASTAVA et al., ""Effect of Nicotine and Cotinine on the Production of Oxygen Free Radicals by Neutrophils in Smokers and Non-Smokers"", pages 461-463.;;JOURNAL OF CLINICAL GASTROENTEROLOGY, Volume 18, Number 4, issued 1994, M. GUSLANDI et al., ""Steroid-Sparing Effect of Transdermal Nicotine in Ulcerative Colitis"", pages 347-348.;;NEW ENGLAND JOURNAL OF MEDICINE, Volume 330, Number 12, issued 24 March 1994, R.D. PULLAN et al., ""Transdermal Nicotine for Active Ulcerative Colitis"", pages 811-815.",EXPIRED
66,EP,A1,EP 0873050 A1,109-989-677-130-609,1998-10-28,1998,EP 95943979 A,1995-12-27,US 9516901 W;;US 36498095 A,1995-01-06,PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF ULCERATIVE COLITIS,"Patients suffering from or susceptible to an idiopathic chronic inflammatory bowel disease (e.g., ulcerative colitis) are treated with pharmaceutical compositions. Those patients are treated by administration of an effective amount of aryl substituted aliphatic compound, an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-N-methyl-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-N-methyl-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-metanicotine, (Z)-metanicotine, N-methyl-(3-pyridinyl)-butane-1-amine, N-methyl-4-(3-pyridinyl)-3-butyne-1-amine and (E)-N-methyl-4 -[3-(6-methylpyrindin)yl]-3-butone-1-amine.",REYNOLDS TOBACCO CO R,SMITH CARR JOSEPH;;LIPPIELLO PATRICK MICHAEL;;BENCHERIF MEROUANE;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE,"TARGACEPT, INC. (2002-12-11)",https://lens.org/109-989-677-130-609,Patent Application,yes,0,0,13,13,0,A61K31/44;;A61K31/4406;;A61K31/505;;A61P1/00;;A61P1/04;;A61P29/00;;A61K31/44;;A61K31/4406;;A61K31/505,A61K31/44;;A61K31/4406;;A61K31/505;;A61P1/00;;A61P29/00,,0,0,,,,EXPIRED
67,ES,T3,ES 2220946 T3,162-314-077-091-120,2004-12-16,2004,ES 95943979 T,1995-12-27,US 36498095 A,1995-01-06,COMPOSICIONES FARMACEUTICAS PARA LA PREVENCION Y TRATAMIENTO DE COLITIS ULCEROSA.,"Patients suffering from or susceptible to an idiopathic chronic inflammatory bowel disease (e.g., ulcerative colitis) are treated with pharmaceutical compositions. Those patients are treated by administration of an effective amount of aryl substituted aliphatic compound, an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-N-methyl-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-N-methyl-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-metanicotine, (Z)-metanicotine, N-methyl-(3-pyridinyl)-butane-1-amine, N-methyl-4-(3-pyridinyl)-3-butyne-1-amine and (E)-N-methyl-4 -[3-(6-methylpyrindin)yl]-3-butone-1-amine.",TARGACEPT INC,SMITH CARR JOSEPH;;LIPPIELLO PATRICK MICHAEL;;BENCHERIF MEROUANE;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE,,https://lens.org/162-314-077-091-120,Granted Patent,no,0,0,13,13,0,A61K31/44;;A61K31/4406;;A61K31/505;;A61P1/00;;A61P1/04;;A61P29/00;;A61K31/44;;A61K31/4406;;A61K31/505,A61K31/44;;A61K31/4406;;A61K31/505;;A61P1/00;;A61P29/00,,0,0,,,,EXPIRED
68,DK,T3,DK 0873050 T3,109-132-746-645-612,2004-05-03,2004,DK 95943979 T,1995-12-27,US 36498095 A;;US 9516901 W,1995-01-06,Farmaceutiske sammensætninger til forebyggelse og behandling af colitis ulcerosa,"Patients suffering from or susceptible to an idiopathic chronic inflammatory bowel disease (e.g., ulcerative colitis) are treated with pharmaceutical compositions. Those patients are treated by administration of an effective amount of aryl substituted aliphatic compound, an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-N-methyl-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-N-methyl-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-metanicotine, (Z)-metanicotine, N-methyl-(3-pyridinyl)-butane-1-amine, N-methyl-4-(3-pyridinyl)-3-butyne-1-amine and (E)-N-methyl-4 -[3-(6-methylpyrindin)yl]-3-butone-1-amine.",TARGACEPT INC,SMITH CARR JOSEPH;;LIPPIELLO PATRICK MICHAEL;;BENCHERIF MEROUANE;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE,,https://lens.org/109-132-746-645-612,Granted Patent,no,0,0,13,13,0,A61K31/44;;A61K31/4406;;A61K31/505;;A61P1/00;;A61P1/04;;A61P29/00;;A61K31/44;;A61K31/4406;;A61K31/505,A61K31/44;;A61K31/4406;;A61K31/505;;A61P1/00;;A61P29/00,,0,0,,,,EXPIRED
69,WO,A1,WO 1996/020599 A1,121-965-774-536-65X,1996-07-11,1996,US 9516901 W,1995-12-27,US 36498095 A,1995-01-06,PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF ULCERATIVE COLITIS,"Patients suffering from or susceptible to an idiopathic chronic inflammatory bowel disease (e.g., ulcerative colitis) are treated with pharmaceutical compositions. Those patients are treated by administration of an effective amount of aryl substituted aliphatic compound, an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-N-methyl-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-N-methyl-4-[3-(5-methoxypyrindin)yl]-3-butene-1-amine, (E)-metanicotine, (Z)-metanicotine, N-methyl-(3-pyridinyl)-butane-1-amine, N-methyl-4-(3-pyridinyl)-3-butyne-1-amine and (E)-N-methyl-4-[3-(6-methylpyrindin)yl]-3-butene-1-amine.",REYNOLDS TOBACCO CO R;;SMITH CARR JOSEPH;;LIPPIELLO PATRICK MICHAEL;;BENCHERIF MEROUANE;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE,SMITH CARR JOSEPH;;LIPPIELLO PATRICK MICHAEL;;BENCHERIF MEROUANE;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE,,https://lens.org/121-965-774-536-65X,Patent Application,yes,0,3,13,13,0,A61K31/44;;A61K31/4406;;A61K31/505;;A61P1/00;;A61P1/04;;A61P29/00;;A61K31/44;;A61K31/4406;;A61K31/505,A61K31/44;;A61K31/4406;;A61K31/505;;A61P1/00;;A61P29/00,,4,4,139-275-726-226-599;;027-765-780-589-703;;068-631-826-770-086;;007-021-281-307-399,1424531;;2591986;;10.1177/096032718900800605;;8071525;;10.1097/00004836-199406000-00019;;10.1056/nejm199403243301202;;8114833,"COMPREHENSIVE THERAPY, Volume 18, Number 8, issued 1992, B. LASHNER, ""Conspectus: Inflammatory Bowel Disease, Family Patterns and Risk Factors"", pages 2-4.;;HUMAN TOXICOLOGY, Volume 8, issued November 1989, SRIVASTAVA et al., ""Effect of Nicotine and Cotinine on the Production of Oxygen Free Radicals by Neutrophils in Smokers and Non-Smokers"", pages 461-463.;;JOURNAL OF CLINICAL GASTROENTEROLOGY, Volume 18, Number 4, issued 1994, M. GUSLANDI et al., ""Steroid-Sparing Effect of Transdermal Nicotine in Ulcerative Colitis"", pages 347-348.;;NEW ENGLAND JOURNAL OF MEDICINE, Volume 330, Number 12, issued 24 March 1994, R.D. PULLAN et al., ""Transdermal Nicotine for Active Ulcerative Colitis"", pages 811-815.",PATENTED
70,AU,A,AU 2001/057449 A,051-827-805-727-094,2001-11-12,2001,AU 2001/057449 A,2001-05-01,US 56248500 A;;US 0113950 W,2000-05-01,Imaging of nicotinic acetylcholine receptor subtypes,,TARGACEPT INC,BENCHERIF MEROUANE;;MILLER CRAIG HARRISON;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;CALDWELL WILLIAM SCOTT,,https://lens.org/051-827-805-727-094,Patent Application,no,0,0,3,3,0,A61K51/0455;;A61K51/0459,A61K51/04,,0,0,,,,PENDING
71,DE,D1,DE 69907894 D1,188-946-548-050-958,2003-06-18,2003,DE 69907894 T,1999-03-03,US 5393798 A;;US 5417598 A;;US 9904728 W,1998-04-02,AZATRICYCLO[3.3.1.1]DECANDERIVATE UND DIESE ENTHALTENDE PHRMAZEUTISCHE ZUBEREITUNGEN,"A pharmaceutical composition incorporating a nicotinic antagonist is provided. The composition is an effective amount of a compound of formula (I), wherein X' is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; X is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; A, A' and A"" are individually substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; Z' is a substituent other than hydrogen; j is an integer from 0 to 5; and the wavy line in the structure indicates that the compound can exist in the form of an enantiomer or a diasteromer; Z"" is hydrogen or a substituent other than hydrogen; Y is C=O, C(OH)R' or C-A, where R' is hydrogen or lower alkyl.",TARGACEPT INC,BENCHERIF MEROUANE;;LIPPIELLO MICHAEL;;CROOKS ANTHONY;;PARK HAEIL;;BHATTI SINGH;;CALDWELL SCOTT;;DULL MAURICE,,https://lens.org/188-946-548-050-958,Granted Patent,no,0,0,16,19,0,A61K31/439;;A61K31/444;;A61P25/00;;A61P43/00;;C07D471/18;;A61K31/439;;A61K31/444,C07D471/18;;A61K31/439;;A61K31/444;;A61P25/00;;A61P43/00,,0,0,,,,EXPIRED
72,WO,A3,WO 2001/082978 A3,043-517-739-684-132,2002-08-01,2002,US 0113950 W,2001-05-01,US 56248500 A,2000-05-01,IMAGING OF NICOTINIC ACETYLCHOLINE RECEPTOR SUBTYPES,"Compounds useful as probes for determining the relative number and/or function of specific receptor subtypes. Of particular interest are nicotinic agonists and antagonists (e.g., metanicotine-type compounds and azaadamantane-type compounds) that are selective to certain nicotinic receptor subtypes. Those compounds are labeled with a radioactive isotopic moiety such as ?11C, 18F, 76Br, 123I or 125¿I. Central nervous system disorders are diagnosed by administering to a patient a detectably labeled compound, and detecting the binding of that compound to selected nicotinic receptor subtypes (e.g., alpha 7 and/or alpha 4 beta 2 receptor subtypes). The compounds that have been administered are detected using methods such as position emission topography (PET) and single-photon emission computed tomography (SPECT). The present invention is useful in the diagnosis of a wide variety of CNS diseases and disorders, including Alzheimer's disease, Parkinson's disease and schizophrenia.",TARGACEPT INC;;BENCHERIF MEROUANE;;MILLER CRAIG HARRISON;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;CALDWELL WILLIAM SCOTT,BENCHERIF MEROUANE;;MILLER CRAIG HARRISON;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;CALDWELL WILLIAM SCOTT,,https://lens.org/043-517-739-684-132,Search Report,yes,4,0,3,3,0,A61K51/0455;;A61K51/0459,A61K51/04,,4,4,010-224-187-590-683;;084-626-181-114-180;;080-183-663-251-406;;110-580-572-585-238,10.1016/s0969-8051(00)00091-3;;10938478;;10.1016/s0969-8051(98)00031-6;;9804040;;10.1016/s0969-8051(98)00070-5;;10096514;;10.1002/(sici)1098-2299(199607/08)38:3/4<169::aid-ddr5>3.0.co;2-k,"BROWN-PROCTOR C. ET AL: ""Synthesis and in vivo evaluation of (E)-N-[ 11C ]Methyl-4-(3-pyridinyl)-3-butene-1-amine ([ 11C ] metanicotine ) as a nicotinic receptor radioligand."", JOURNAL OF INORGANIC BIOCHEMISTRY, (29 FEB 2000) 78/3 (415-418)., XP001076828;;HORTI A G ET AL: ""2-[F]fluoro-A-85380, an in vivo tracer for the nicotinic acetylcholine receptors - In vitro pharmacological properties of a novel, high affinity alpha4beta2 nicotinic acethylcholine receptor ligand"", NUCLEAR MEDICINE AND BIOLOGY, ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY, US, vol. 25, no. 7, October 1998 (1998-10-01), pages 599 - 603, XP004149429, ISSN: 0969-8051;;DING Y-S ET AL: ""Comparative studies of epibatidine derivatives [F]NFEP and [F]N-Methyl-NFEP: kinetics, nicotine effect, and toxicity - Preclinical assessment of acute toxicity"", NUCLEAR MEDICINE AND BIOLOGY, ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY, US, vol. 26, no. 1, January 1999 (1999-01-01), pages 139 - 148, XP004151313, ISSN: 0969-8051;;LIPPIELLO P M ET AL: ""METANICOTINE: A NICOTINIC AGONIST WITH CENTRAL NERVOUS SYSTEM SELECTIVITY-IN VITRO AND IN VIVO CHARACTERIZATION"", DRUG DEVELOPMENT RESEARCH, NEW YORK, NY, US, vol. 38, no. 3/4, July 1996 (1996-07-01), pages 169 - 176, XP008000891, ISSN: 0272-4391",PENDING
73,US,B1,US 6417359 B1,049-670-610-713-587,2002-07-09,2002,US 56042100 A,2000-04-27,US 56042100 A;;US 5393798 A,1998-04-02,Pharmaceutical compositions and methods for use,"
    A compound having the formula: 

    wherein X is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; X is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0, but not equal to 0; A, A and A are individually substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; Z is a substituent other than hydrogen; j is an integer from 0 to 5; and the wavy line in the structure indicates that the compound can exist in the form of an enantiomer or a diasteromer; Z is hydrogen or a substituent other than hydrogen; Y is CO, C(OH)R or CA, where R is hydrogen or lower alkyl. 
",TARGACEPT INC,CROOKS PETER ANTHONY;;PARK HAEIL;;BHATTI BALWINDER SINGH;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE,,https://lens.org/049-670-610-713-587,Granted Patent,yes,7,28,2,19,0,A61K31/439;;A61K31/444;;A61K31/439;;A61K31/444,A61K31/439;;A61K31/444,544/298;;544/299;;544/309;;544/317;;544/323;;544/326;;544/330;;544/332,6,3,011-094-348-909-418;;075-115-600-469-760;;134-944-492-720-212,10.1021/ja00151a005;;9435889;;10.1021/jm970377o;;10.1021/jo00330a020,"Becker et al., Synthesis, vol. 11, pp. 1080-1082, (Nov. 1992).;;Fernanded et al., J. Hetercycl. Chem., vol. 26, pp. 349-353.;;Lau et al., J. Amer. Chem. Soc., 117, pp. 11421-11425 (1995).;;Speckamp et al., Hetercycles, 2, pp. 293-296 (1974).;;Holladay et al., J. Med. Chem., vol. 40, No. 26, pp. 4169-4194.;;Henkel et al., J. Org. Chem., 46, pp. 3483-3486 (1981).",EXPIRED
74,WO,A2,WO 2001/082978 A2,098-863-057-301-621,2001-11-08,2001,US 0113950 W,2001-05-01,US 56248500 A,2000-05-01,IMAGING OF NICOTINIC ACETYLCHOLINE RECEPTOR SUBTYPES,"Compounds useful as probes for determining the relative number and/or function of specific receptor subtypes. Of particular interest are nicotinic agonists and antagonists (e.g., metanicotine-type compounds and azaadamantane-type compounds) that are selective to certain nicotinic receptor subtypes. Those compounds are labeled with a radioactive isotopic moiety such as ?11C, 18F, 76Br, 123I or 125¿I. Central nervous system disorders are diagnosed by administering to a patient a detectably labeled compound, and detecting the binding of that compound to selected nicotinic receptor subtypes (e.g., alpha 7 and/or alpha 4 beta 2 receptor subtypes). The compounds that have been administered are detected using methods such as position emission topography (PET) and single-photon emission computed tomography (SPECT). The present invention is useful in the diagnosis of a wide variety of CNS diseases and disorders, including Alzheimer's disease, Parkinson's disease and schizophrenia.",TARGACEPT INC;;BENCHERIF MEROUANE;;MILLER CRAIG HARRISON;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;CALDWELL WILLIAM SCOTT,BENCHERIF MEROUANE;;MILLER CRAIG HARRISON;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;CALDWELL WILLIAM SCOTT,,https://lens.org/098-863-057-301-621,Patent Application,yes,0,14,3,3,0,A61K51/0455;;A61K51/0459,A61K51/04,,0,0,,,,PENDING
75,AT,T1,AT E261244 T1,031-446-263-702-292,2004-03-15,2004,AT 95943979 T,1995-12-27,US 36498095 A;;US 9516901 W,1995-01-06,PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ZUR VORBEUGUNG UND BEHANDLUNG DER ULZERATIVEN KOLITIS,"Patients suffering from or susceptible to an idiopathic chronic inflammatory bowel disease (e.g., ulcerative colitis) are treated with pharmaceutical compositions. Those patients are treated by administration of an effective amount of aryl substituted aliphatic compound, an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-N-methyl-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-N-methyl-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-metanicotine, (Z)-metanicotine, N-methyl-(3-pyridinyl)-butane-1-amine, N-methyl-4-(3-pyridinyl)-3-butyne-1-amine and (E)-N-methyl-4 -[3-(6-methylpyrindin)yl]-3-butone-1-amine.",TARGACEPT INC,SMITH CARR JOSEPH;;LIPPIELLO PATRICK MICHAEL;;BENCHERIF MEROUANE;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE,,https://lens.org/031-446-263-702-292,Granted Patent,no,0,0,13,13,0,A61K31/44;;A61K31/4406;;A61K31/505;;A61P1/00;;A61P1/04;;A61P29/00;;A61K31/44;;A61K31/4406;;A61K31/505,A61K31/44;;A61K31/4406;;A61K31/505;;A61P1/00;;A61P29/00,,0,0,,,,DISCONTINUED
76,EP,A4,EP 0873050 A4,075-241-451-955-198,1999-09-22,1999,EP 95943979 A,1995-12-27,US 9516901 W;;US 36498095 A,1995-01-06,PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF ULCERATIVE COLITIS,"Patients suffering from or susceptible to an idiopathic chronic inflammatory bowel disease (e.g., ulcerative colitis) are treated with pharmaceutical compositions. Those patients are treated by administration of an effective amount of aryl substituted aliphatic compound, an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-N-methyl-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-N-methyl-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-metanicotine, (Z)-metanicotine, N-methyl-(3-pyridinyl)-butane-1-amine, N-methyl-4-(3-pyridinyl)-3-butyne-1-amine and (E)-N-methyl-4 -[3-(6-methylpyrindin)yl]-3-butone-1-amine.",REYNOLDS TOBACCO CO R,SMITH CARR JOSEPH;;LIPPIELLO PATRICK MICHAEL;;BENCHERIF MEROUANE;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE,"TARGACEPT, INC. (2002-12-11)",https://lens.org/075-241-451-955-198,Search Report,no,3,0,13,13,0,A61K31/44;;A61K31/4406;;A61K31/505;;A61P1/00;;A61P1/04;;A61P29/00;;A61K31/44;;A61K31/4406;;A61K31/505,A61K31/44;;A61K31/4406;;A61K31/505;;A61P1/00;;A61P29/00,,3,1,056-398-240-111-901,2194767;;10.1007/bf01536795,"DATABASE WPI Section Ch Week 9345, Derwent World Patents Index; Class B03, AN 93-357175, XP002110678;;DATABASE WPI Section Ch Week 9113, Derwent World Patents Index; Class A96, AN 91-090638, XP002110679;;LASHNER B.A., ET AL.: ""Testing nicotine gum for ulcerative colitis patients. Experience with single-patients trials."", DIGESTIVE DISEASES AND SCIENCES, vol. 35, no. 7, 1990, pages 827 - 832, XP000600385",EXPIRED
77,DE,T2,DE 69907894 T2,092-404-024-542-313,2004-03-11,2004,DE 69907894 T,1999-03-03,US 5393798 A;;US 5417598 A;;US 9904728 W,1998-04-02,AZATRICYCLO[3.3.1.1]DECANDERIVATE UND DIESE ENTHALTENDE PHRMAZEUTISCHE ZUBEREITUNGEN,"A pharmaceutical composition incorporating a nicotinic antagonist is provided. The composition is an effective amount of a compound of formula (I), wherein X' is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; X is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; A, A' and A"" are individually substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; Z' is a substituent other than hydrogen; j is an integer from 0 to 5; and the wavy line in the structure indicates that the compound can exist in the form of an enantiomer or a diasteromer; Z"" is hydrogen or a substituent other than hydrogen; Y is C=O, C(OH)R' or C-A, where R' is hydrogen or lower alkyl.",TARGACEPT INC,BENCHERIF MEROUANE;;LIPPIELLO MICHAEL;;CROOKS ANTHONY;;PARK HAEIL;;BHATTI SINGH;;CALDWELL SCOTT;;DULL MAURICE,,https://lens.org/092-404-024-542-313,Granted Patent,no,0,0,16,19,0,A61K31/439;;A61K31/444;;A61P25/00;;A61P43/00;;C07D471/18;;A61K31/439;;A61K31/444,C07D471/18;;A61K31/439;;A61K31/444;;A61P25/00;;A61P43/00,,0,0,,,,EXPIRED
78,PT,E,PT 873050 E,163-952-497-124-833,2004-06-30,2004,PT 95943979 T,1995-12-27,US 36498095 A,1995-01-06,COMPOSICOES FARMACEUTICAS PARA A PREVENCAO E TRATAMENTO DA COLITE ULCERATIVA,"Patients suffering from or susceptible to an idiopathic chronic inflammatory bowel disease (e.g., ulcerative colitis) are treated with pharmaceutical compositions. Those patients are treated by administration of an effective amount of aryl substituted aliphatic compound, an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-N-methyl-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-N-methyl-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-metanicotine, (Z)-metanicotine, N-methyl-(3-pyridinyl)-butane-1-amine, N-methyl-4-(3-pyridinyl)-3-butyne-1-amine and (E)-N-methyl-4 -[3-(6-methylpyrindin)yl]-3-butone-1-amine.",TARGACEPT INC,LIPPIELLO PATRICK MICHAEL;;SMITH CARR JOSEPH;;BENCHERIF MEROUANE;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE,,https://lens.org/163-952-497-124-833,Granted Patent,no,0,0,13,13,0,A61K31/44;;A61K31/4406;;A61K31/505;;A61P1/00;;A61P1/04;;A61P29/00;;A61K31/44;;A61K31/4406;;A61K31/505,A61K31/44;;A61K31/4406;;A61K31/505;;A61P1/00;;A61P29/00,,0,0,,,,EXPIRED
79,US,A,US 6057446 A,011-934-229-061-302,2000-05-02,2000,US 5393798 A,1998-04-02,US 5393798 A,1998-04-02,"Certain 1-aza-tricyclo [3.3.1-13,7] decane compounds","A compound having the formula: ##STR1## wherein X' is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; X is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0, but not equal to 0; A, A' and A"" are individually substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; Z' is a substituent other than hydrogen; j is an integer from 0 to 5; and the wavy line in the structure indicates that the compound can exist in the form of an enantiomer or a diasteromer; Z"" is hydrogen or a substituent other than hydrogen; Y is C.dbd.O, C(OH)R' or C--A, where R' is hydrogen or lower alkyl.",CROOKS; PETER ANTHONY;;PARK; HAEIL;;BHATTI; BALWINDER SINGH;;CALDWELL; WILLIAM SCOTT;;DULL; GARY MAURICE,CROOKS PETER ANTHONY;;PARK HAEIL;;BHATTI BALWINDER SINGH;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE,TARGACEPT INC. A CORPORATION OF DELAWARE (1999-04-09);;R.J. REYNOLDS TOBACCO COMPANY (1998-06-10);;UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION THE (1998-06-08);;TARGACEPT INC (1999-03-17),https://lens.org/011-934-229-061-302,Granted Patent,yes,7,20,2,19,0,A61K31/439;;A61K31/444;;A61K31/439;;A61K31/444,A61K31/439;;A61K31/444,546/97;;552/1;;546/97,6,3,011-094-348-909-418;;075-115-600-469-760;;134-944-492-720-212,10.1021/ja00151a005;;9435889;;10.1021/jm970377o;;10.1021/jo00330a020,"Becker et al., Synthesis, vol. 11, pp. 1080 1082 (Nov. 1992).;;Fernandez et al., J. Heterocycl. Chem., vol. 26, pp. 349 353 (1989).;;Lau et al., J. Amer. Chem. Soc., 117, pp. 11421 11425 (1995).;;Speckamp et al., Hetercycles, 2, pp. 293 296 (1974).;;Holladay et al., J. Med. Chem., vol. 40, No. 26, pp. 4169 4194 (1997).;;Henkel et al., J. Org. Chem., 46, pp. 3483 3486 (1981).",EXPIRED
80,AU,A,AU 1996/045295 A,183-388-737-565-816,1996-07-24,1996,AU 1996/045295 A,1995-12-27,US 36498095 A;;US 9516901 W,1995-01-06,Pharmaceutical compositions for prevention and treatment of ulcerative colitis,"Patients suffering from or susceptible to an idiopathic chronic inflammatory bowel disease (e.g., ulcerative colitis) are treated with pharmaceutical compositions. Those patients are treated by administration of an effective amount of aryl substituted aliphatic compound, an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-N-methyl-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-N-methyl-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-metanicotine, (Z)-metanicotine, N-methyl-(3-pyridinyl)-butane-1-amine, N-methyl-4-(3-pyridinyl)-3-butyne-1-amine and (E)-N-methyl-4 -[3-(6-methylpyrindin)yl]-3-butone-1-amine.",REYNOLDS TOBACCO CO R,SMITH CARR JOSEPH;;LIPPIELLO PATRICK MICHAEL;;BENCHERIF MEROUANE;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE,,https://lens.org/183-388-737-565-816,Patent Application,no,0,0,13,13,0,A61K31/44;;A61K31/4406;;A61K31/505;;A61P1/00;;A61P1/04;;A61P29/00;;A61K31/44;;A61K31/4406;;A61K31/505,A61K31/44;;A61K31/4406;;A61K31/505;;A61P1/00;;A61P29/00,,0,0,,,,PENDING
81,DE,D1,DE 69822300 D1,037-160-395-909-433,2004-04-15,2004,DE 69822300 T,1998-04-22,US 88539797 A;;US 88576897 A;;US 9808145 W,1997-06-30,3-PYRIDYL-1-AZABICYCLOALKAN-DERIVATE ZUR BEHANDLUNG VON ZNS-ERKRANKUNGEN,"Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia) are treated by administering an <u>endo</u> or <u>exo</u> form of a 1-aza-2-(3-pyridyl)bicyclo[2.2.1]heptane, a 1-aza-2-(3-pyridyl)bicyclo[2.2.2] octane, a 1-aza-2-(3-pyridyl)bicyclo[3.2.2]nonane, a 1-aza-7-(3-pyridyl) bicyclo[2.2.1]heptane, a 1-aza-3-(3-pyridyl)bicyclo[3.2.2]nonane, or a 1-aza-7-(3-pyridyl)bicyclo[3.2.2]nonane.",TARGACEPT INC;;UNIV KENTUCKY RES FOUNDATION L,CALDWELL SCOTT;;BENCHERIF MEROUANE;;DULL MAURICE;;CROOKS ANTHONY;;LIPPIELLO MICHAEL;;BHATTI SINGH;;DEO MADHUKAR;;RAVARD ALAIN,"TARGACEPT, INC., WINSTON-SALEM, N.C., US (2004-07-01)",https://lens.org/037-160-395-909-433,Granted Patent,no,0,0,13,15,0,C07D453/02;;C07D487/08;;A61P25/00;;A61P25/16;;A61P25/28,A61K31/407;;A61K31/439;;A61K31/55;;A61P25/00;;A61P25/16;;A61P25/28;;C07D453/02;;C07D471/08;;C07D487/08,,0,0,,,,EXPIRED
82,DE,T2,DE 69822300 T2,148-886-554-731-378,2005-03-10,2005,DE 69822300 T,1998-04-22,US 88539797 A;;US 88576897 A;;US 9808145 W,1997-06-30,3-PYRIDYL-1-AZABICYCLOALKAN-DERIVATE ZUR BEHANDLUNG VON ZNS-ERKRANKUNGEN,"Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia) are treated by administering an <u>endo</u> or <u>exo</u> form of a 1-aza-2-(3-pyridyl)bicyclo[2.2.1]heptane, a 1-aza-2-(3-pyridyl)bicyclo[2.2.2] octane, a 1-aza-2-(3-pyridyl)bicyclo[3.2.2]nonane, a 1-aza-7-(3-pyridyl) bicyclo[2.2.1]heptane, a 1-aza-3-(3-pyridyl)bicyclo[3.2.2]nonane, or a 1-aza-7-(3-pyridyl)bicyclo[3.2.2]nonane.",TARGACEPT INC,CALDWELL SCOTT;;BENCHERIF MEROUANE;;DULL MAURICE;;CROOKS ANTHONY;;LIPPIELLO MICHAEL;;BHATTI SINGH;;DEO MADHUKAR;;RAVARD ALAIN,"TARGACEPT, INC., WINSTON-SALEM, N.C., US (2004-07-01)",https://lens.org/148-886-554-731-378,Granted Patent,no,0,0,13,15,0,C07D453/02;;C07D487/08;;A61P25/00;;A61P25/16;;A61P25/28,A61K31/407;;A61K31/439;;A61K31/55;;A61P25/00;;A61P25/16;;A61P25/28;;C07D453/02;;C07D471/08;;C07D487/08,,0,0,,,,EXPIRED
83,US,A,US 5726316 A,153-124-191-787-726,1998-03-10,1998,US 78461597 A,1997-01-21,US 78461597 A;;US 36497695 A,1995-01-06,Pharmaceutical compositions for prevention and treatment of central nervous system disorders,Patients susceptible to or suffering from central nervous system disorders are treated by administering an effective amount of an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-N-methyl-4-�3-(6-methylpyrindin)yl!-3-butene-1-amine and N-methyl-4-(3-pyridinyl)-3-butyne-1-amine.,CROOKS; PETER ANTHONY;;CALDWELL; WILLIAM SCOTT;;DULL; GARY MAURICE;;BHATTI; BALWINDER SINGH;;DEO; NIRANJAN MADHUKAR;;RAVARD; ALAIN,CROOKS PETER ANTHONY;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;DEO NIRANJAN MADHUKAR;;RAVARD ALAIN,TARGACEPT INC (1999-04-09),https://lens.org/153-124-191-787-726,Granted Patent,yes,4,81,7,7,0,A61P25/00;;C07D239/26;;C07D239/26;;C07D213/38;;C07D213/38;;C07D213/65;;C07D213/65,A61K31/44;;A61P25/00;;C07D213/38;;C07D213/65;;C07D239/26,546/311;;546/329,13,7,127-547-110-034-08X;;061-556-297-543-520;;174-507-030-434-145;;056-184-684-713-117;;102-292-233-862-978;;020-870-110-885-423;;149-929-583-255-570,10.3891/acta.chem.scand.17-1717;;10.1021/jo00409a002;;10.1021/ja01396a022;;10.1021/jo00148a033;;906829;;948991;;10.1248/cpb.38.2446;;2285975,"Chemical Abstracts, vol. 71, No. 81, 101z, Oct. 20, 1969, p. 368.;;Acheson, R. et al., J. Chem. Soc. Perkin Trans. , vol. 2, pp. 579 585 (1980).;;Erdtman, H. et al., Acta Chem. Scand. , vol. 17, pp. 1717 1726 (1963).;;Frank, W. et al., J. Org. Chem. , vol. 43(15), pp. 2947 2949 (1978).;;Gol dfarb, Y. et al., J. Gen. Chem. , USSR(Engl. Transl.), vol. 39, pp. 1070 1075 (1969).;;Kamimura, H. et al., Agr. Biol. Chem. , vol. 27, No. 10, pp. 684 688 (1963).;;LaForge, F., JACS , vol. 50, pp. 2477 2483 (1928).;;Malek, N. et al., J. Org. Chem. , vol. 47, pp. 5395 5397 (1982).;;Pinner, A., Chem. Ber. , pp. 2861 2870 (1894).;;Rondahl, L., Acta Pharm. Suec. , vol. 14, No. 2, pp. 113 118 (1977).;;Rondahl, L., Acta Pharm. Suec. , vol. 13, pp. 229 234 (1976).;;Sprouse, C. et al., Abstracts of Papers, p. 32, Coresta/TCRC, Joint Conference (1972)..;;Ashimori, A. et al., Chem. Pharm. Bull. , vol. 38(9), pp. 2446 2458 (1990).",EXPIRED
84,PT,E,PT 973743 E,153-757-139-663-996,2004-11-30,2004,PT 98905108 T,1998-02-19,US 80424897 A;;US 80425097 A,1997-02-21,COMPOSICOES FARMACEUTICAS QUE INCORPORAM COMPOSTOS OLEFINICOS DE AMINA SUBSTITUIDOS COM ARILO,"Patients susceptible to or suffering from central nervous system disorders (e.g., Alzheimer's disease, Parkinson's disease, Tourette's syndrome, attention deficit disorder or schizophrenia) are treated by administering an effective amount of an aryl substituted olefinic amine compound of Formula (I): wherein X is C-R', C-OR', C-CH2-OR' wherein R' is selected from the group consisting of H, C1-C5 alkyl, an aromatic group containing species and alkyl-, halo-, or amino-substituted aromatic group containing species; E' is hydrogen or C1-C5 alkyl or halo substituted C1-C5 alkyl; E'' is C1-C5 alkyl or halo substituted C1-C5 alkyl; Z' and Z'' are each individually selected from the group consisting of hydrogen, C1-C5 alkyl, aryl rings, and can form a ring structure (a), A, A' and A'' are each individually selected from the group consisting of hydrogen, C1-C7 alkyl, and halo; m is 0 or 1; p is 0 or 1 with the proviso that when m or p is 0 then that E'' is hydrogen; and the wavy line in the structure represents a cis (Z) or trans (E) form of the compound. Exemplary compounds include (E)-N-methyl-4-[3-(benzyloxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-phenoxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-isopropoxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-methoxymethylpyridin)yl]-3-buten-1-amine, and (E)-N-methyl-4-[3-(5-phenylpyridin)yl]-3-buten-1-amine.",TARGACEPT INC,LIPPIELLO PATRICK MICHAEL;;DULL GARY MAURICE;;BENCHERIF MEROUANE;;CALDWELL WILLIAM SCOTT;;DOBSON GRAYLAND PAGE;;MILLER CRAIG HARRISON,,https://lens.org/153-757-139-663-996,Granted Patent,no,0,0,16,19,0,C07D213/38;;C07D213/61;;C07D213/64;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28;;A61P43/00;;C07D213/64;;C07D213/61;;C07D213/38;;C07D239/30;;C07D239/26,A61K31/44;;A61P25/00;;A61P25/16;;A61P25/18;;C07D213/65;;A61P25/28;;A61P43/00;;C07D213/38;;C07D213/61;;C07D213/64,,0,0,,,,EXPIRED
85,ES,T3,ES 2214707 T3,014-436-983-267-377,2004-09-16,2004,ES 98918598 T,1998-04-22,US 88539797 A;;US 88576897 A,1997-06-30,DERIVADOS DE 3-PIRIDIL-1-AZABICICLOALCANO PARA LA PREVENCION Y TRATAMIENTO DE TRASTORNOS DEL SNC.,"Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia) are treated by administering an <u>endo</u> or <u>exo</u> form of a 1-aza-2-(3-pyridyl)bicyclo[2.2.1]heptane, a 1-aza-2-(3-pyridyl)bicyclo[2.2.2] octane, a 1-aza-2-(3-pyridyl)bicyclo[3.2.2]nonane, a 1-aza-7-(3-pyridyl) bicyclo[2.2.1]heptane, a 1-aza-3-(3-pyridyl)bicyclo[3.2.2]nonane, or a 1-aza-7-(3-pyridyl)bicyclo[3.2.2]nonane.",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;BENCHERIF MEROUANE;;DULL GARY MAURICE;;CROOKS PETER ANTHONY;;LIPPIELLO PATRICK MICHAEL;;BHATTI BALWINDER SINGH,,https://lens.org/014-436-983-267-377,Granted Patent,no,0,0,13,15,0,C07D453/02;;C07D487/08;;A61P25/00;;A61P25/16;;A61P25/28,A61K31/407;;A61K31/439;;A61K31/55;;A61P25/00;;A61P25/16;;A61P25/28;;C07D453/02;;C07D471/08;;C07D487/08,,0,0,,,,EXPIRED
86,BR,A,BR 9807262 A,116-146-744-217-543,2000-05-23,2000,BR 9807262 A,1998-02-19,US 80424897 A;;US 80425097 A;;US 9803091 W,1997-02-21,Composições farmacêuticas incorporando compostos de amina olefìnica substituìda com arila,"Patients susceptible to or suffering from central nervous system disorders (e.g., Alzheimer's disease, Parkinson's disease, Tourette's syndrome, attention deficit disorder or schizophrenia) are treated by administering an effective amount of an aryl substituted olefinic amine compound of Formula (I): wherein X is C-R', C-OR', C-CH2-OR' wherein R' is selected from the group consisting of H, C1-C5 alkyl, an aromatic group containing species and alkyl-, halo-, or amino-substituted aromatic group containing species; E' is hydrogen or C1-C5 alkyl or halo substituted C1-C5 alkyl; E'' is C1-C5 alkyl or halo substituted C1-C5 alkyl; Z' and Z'' are each individually selected from the group consisting of hydrogen, C1-C5 alkyl, aryl rings, and can form a ring structure (a), A, A' and A'' are each individually selected from the group consisting of hydrogen, C1-C7 alkyl, and halo; m is 0 or 1; p is 0 or 1 with the proviso that when m or p is 0 then that E'' is hydrogen; and the wavy line in the structure represents a cis (Z) or trans (E) form of the compound. Exemplary compounds include (E)-N-methyl-4-[3-(benzyloxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-phenoxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-isopropoxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-methoxymethylpyridin)yl]-3-buten-1-amine, and (E)-N-methyl-4-[3-(5-phenylpyridin)yl]-3-buten-1-amine.",REYNOLDS TOBACCO CO R,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;DOBSON GRAYLAND PAGE;;MILLER CRAIG HARRISON;;BENCHERIF MEROUANE;;LIPPIELLO PATRICK MICHAEL,,https://lens.org/116-146-744-217-543,Patent Application,no,0,0,16,19,0,C07D213/38;;C07D213/61;;C07D213/64;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28;;A61P43/00;;C07D213/64;;C07D213/61;;C07D213/38;;C07D239/30;;C07D239/26,C07D213/65;;A61K31/44;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28;;A61P43/00;;C07D213/38;;C07D213/61;;C07D213/64,,0,0,,,,DISCONTINUED
87,CA,A1,CA 2281564 A1,194-727-551-016-993,1998-08-27,1998,CA 2281564 A,1998-02-19,US 80425097 A;;US 80424897 A;;US 9803091 W,1997-02-21,PHARMACEUTICAL COMPOSITIONS INCORPORATING ARYL SUBSTITUTED OLEFINIC AMINE COMPOUNDS,"Patients susceptible to or suffering from central nervous system disorders (e.g., Alzheimer's disease, Parkinson's disease, Tourette's syndrome, attention deficit disorder or schizophrenia) are treated by administering an effective amount of an aryl substituted olefinic amine compound of Formula (I): wherein X is C-R', C-OR', C-CH2-OR' wherein R' is selected from the group consisting of H, C1-C5 alkyl, an aromatic group containing species and alkyl-, halo-, or amino-substituted aromatic group containing species; E' is hydrogen or C1-C5 alkyl or halo substituted C1-C5 alkyl; E'' is C1-C5 alkyl or halo substituted C1-C5 alkyl; Z' and Z'' are each individually selected from the group consisting of hydrogen, C1-C5 alkyl, aryl rings, and can form a ring structure (a), A, A' and A'' are each individually selected from the group consisting of hydrogen, C1-C7 alkyl, and halo; m is 0 or 1; p is 0 or 1 with the proviso that when m or p is 0 then that E'' is hydrogen; and the wavy line in the structure represents a cis (Z) or trans (E) form of the compound. Exemplary compounds include (E)-N-methyl-4-¢3-(benzyloxypyridin)yl!-3-buten-1-amine, (E)-N-methyl-4-¢3-(5-phenoxypyridin)yl!-3-buten-1-amine, (E)-N-methyl-4-¢3-(5-isopropoxypyridin)yl!-3-buten-1-amine, (E)-N-methyl-4-¢3-(5-methoxymethylpyridin)yl!-3-buten-1-amine, and (E)-N-methyl-4-¢3-(5-phenylpyridin)yl!-3-buten-1-amine.",REYNOLDS TOBACCO CO R,LIPPIELLO PATRICK MICHAEL;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BENCHERIF MEROUANE;;DOBSON GRAYLAND PAGE;;MILLER CRAIG HARRISON,,https://lens.org/194-727-551-016-993,Patent Application,no,0,0,16,19,0,C07D213/38;;C07D213/61;;C07D213/64;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28;;A61P43/00;;C07D213/64;;C07D213/61;;C07D213/38;;C07D239/30;;C07D239/26,C07D213/65;;A61K31/44;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28;;A61P43/00;;C07D213/38;;C07D213/61;;C07D213/64,,0,0,,,,DISCONTINUED
88,US,B1,US 6624173 B1,086-812-548-074-851,2003-09-23,2003,US 88576897 A,1997-06-30,US 88576897 A,1997-06-30,Pharmaceutical compositions for treating and/or preventing CNS disorders,"
    Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia) are treated by administering an endo or exo form of a 1-aza-2-(3-pyridyl)bicyclo2.2.1heptane, a 1-aza-2-(3-pyridyl)bicyclo 2.2.2octane, a 1-aza-2-(3-pyridyl)bicyclo3.2.2nonane, a 1-aza-7-(3-pyridyl) bicyclo2.2.1heptane, a 1-aza-3-(3-pyridyl)bicyclo3.2.2nonane, or a 1-aza-7-(3-pyridyl)bicyclo3.2.2nonane. 
",TARGACEPT INC,CROOKS PETER ANTHONY;;DULL GARY MAURICE;;CALDWELL WILLIAM SCOTT;;BHATTI BALWINDER SINGH;;DEO NIRANJAN MADHUKAR;;RAVARD ALAIN,KENTUCKY UNIVERSITY OF (1998-01-21);;KENTUCKY UNVERSITY OF (1998-01-16);;KENTUCKY RESEARCH FOUNDATION UNIVERSITY OF (1998-05-15);;TARGACEPT INC. A CORPORATION OF DELAWARE (1999-03-17);;R.J. REYNOLDS TOBACCO COMPANY (1998-01-13);;TARGACEPT INC (1999-04-09),https://lens.org/086-812-548-074-851,Granted Patent,yes,12,39,1,15,0,C07D453/02;;C07D487/08;;C07D487/08;;C07D453/02,C07D453/02;;C07D487/08,514/305;;514/256;;514/277;;514/299;;546/133;;546/137,6,1,032-799-637-729-036,7853341;;10.1021/jm00003a011,"Nilsson et al.; J. Med. Chem. (1995), 38, 473-487.*;;Sadykov et al., (CA 60: 5455c).;;Baker et al., (CA 115:8590, abstract of EP 412,798).;;Bencherif et al., (CA 125:26293, abstract of WO 9607410).;;Piotrowski et al., (CA 122:265,358, abstract of WO 9503306).;;Lotti et al., (CA 117:198529, abstract of CA 2058249).",EXPIRED
89,WO,A1,WO 1998/037071 A1,155-644-213-646-257,1998-08-27,1998,US 9803091 W,1998-02-19,US 80425097 A;;US 80424897 A,1997-02-21,PHARMACEUTICAL COMPOSITIONS INCORPORATING ARYL SUBSTITUTED OLEFINIC AMINE COMPOUNDS,"Patients susceptible to or suffering from central nervous system disorders (e.g., Alzheimer's disease, Parkinson's disease, Tourette's syndrome, attention deficit disorder or schizophrenia) are treated by administering an effective amount of an aryl substituted olefinic amine compound of Formula (I): wherein X is C-R', C-OR', C-CH2-OR' wherein R' is selected from the group consisting of H, C1-C5 alkyl, an aromatic group containing species and alkyl-, halo-, or amino-substituted aromatic group containing species; E' is hydrogen or C1-C5 alkyl or halo substituted C1-C5 alkyl; E'' is C1-C5 alkyl or halo substituted C1-C5 alkyl; Z' and Z'' are each individually selected from the group consisting of hydrogen, C1-C5 alkyl, aryl rings, and can form a ring structure (a), A, A' and A'' are each individually selected from the group consisting of hydrogen, C1-C7 alkyl, and halo; m is 0 or 1; p is 0 or 1 with the proviso that when m or p is 0 then that E'' is hydrogen; and the wavy line in the structure represents a cis (Z) or trans (E) form of the compound. Exemplary compounds include (E)-N-methyl-4-[3-(benzyloxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-phenoxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-isopropoxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-methoxymethylpyridin)yl]-3-buten-1-amine, and (E)-N-methyl-4-[3-(5-phenylpyridin)yl]-3-buten-1-amine.",REYNOLDS TOBACCO CO R;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;DOBSON GRAYLAND PAGE;;MILLER CRAIG HARRISON;;BENCHERIF MEROUANE;;LIPPIELLO PATRICK MICHAEL,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;DOBSON GRAYLAND PAGE;;MILLER CRAIG HARRISON;;BENCHERIF MEROUANE;;LIPPIELLO PATRICK MICHAEL,,https://lens.org/155-644-213-646-257,Patent Application,yes,4,12,16,19,0,C07D213/38;;C07D213/61;;C07D213/64;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28;;A61P43/00;;C07D213/64;;C07D213/61;;C07D213/38;;C07D239/30;;C07D239/26,A61K31/44;;A61P25/00;;A61P25/16;;A61P25/18;;C07D213/65;;A61P25/28;;A61P43/00;;C07D213/38;;C07D213/61;;C07D213/64,,0,0,,,,PATENTED
90,ES,T3,ES 2228054 T3,146-372-180-063-078,2005-04-01,2005,ES 99926152 T,1999-06-03,US 9828598 A;;US 9813398 A,1998-06-16,AMINAS OLEFINICAS SUSTITUIDAS CON ARILO Y SU USO COMO AGONISTAS DE RECEPTORES COLINERGICOS.,"Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5- (3-pyridyl) -4-penten-2-amine, (4E) -N-methyl-5- (5-pyrimidinyl) -4-penten-2-amine, (4E)-N-methyl-5-( 5-methoxy-3-pyridyl) -4-penten-2-amine, (4E)-N- methyl-5- (6-amino-5-methyl -3-pyridyl)-4-penten -2-amine, (2R)-(4E) -N-methyl-5-(3-pyridyl) -4-penten-2-amine, (2R)-(4E)-N- methyl-5-(5- isopropoxy-3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-bromo-3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-ethoxy-3- pyridyl)-4-penten- 2-amine, (2S)-(4E)-N- methyl-5-(3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-isopropoxy-3- pyridyl)-4- penten-2-amine and (2S)-(4E)-N-methyl -5-(5-isopropoxy -3-pyridyl) -4-penten-2-amine.",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR B;;PARK HAEIL;;WAGNER JARED MILLER,,https://lens.org/146-372-180-063-078,Granted Patent,no,0,0,25,42,0,A61K31/44;;A61K31/4406;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26;;A61P1/04;;A61P21/00;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P43/00;;A61K31/44,A61K31/44;;A61K31/4406;;A61K31/4418;;A61K31/505;;A61P1/04;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38;;C07D213/61;;C07D213/62;;C07D213/64;;C07D213/65;;C07D213/73;;C07D239/26,,0,0,,,,EXPIRED
91,AU,B2,AU 749151 B2,004-268-525-645-622,2002-06-20,2002,AU 1998/062806 A,1998-02-19,US 80425097 A;;US 80424897 A;;US 9803091 W,1997-02-21,Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds,"Patients susceptible to or suffering from central nervous system disorders (e.g., Alzheimer's disease, Parkinson's disease, Tourette's syndrome, attention deficit disorder or schizophrenia) are treated by administering an effective amount of an aryl substituted olefinic amine compound of Formula (I): wherein X is C-R', C-OR', C-CH2-OR' wherein R' is selected from the group consisting of H, C1-C5 alkyl, an aromatic group containing species and alkyl-, halo-, or amino-substituted aromatic group containing species; E' is hydrogen or C1-C5 alkyl or halo substituted C1-C5 alkyl; E'' is C1-C5 alkyl or halo substituted C1-C5 alkyl; Z' and Z'' are each individually selected from the group consisting of hydrogen, C1-C5 alkyl, aryl rings, and can form a ring structure (a), A, A' and A'' are each individually selected from the group consisting of hydrogen, C1-C7 alkyl, and halo; m is 0 or 1; p is 0 or 1 with the proviso that when m or p is 0 then that E'' is hydrogen; and the wavy line in the structure represents a cis (Z) or trans (E) form of the compound. Exemplary compounds include (E)-N-methyl-4-[3-(benzyloxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-phenoxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-isopropoxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-methoxymethylpyridin)yl]-3-buten-1-amine, and (E)-N-methyl-4-[3-(5-phenylpyridin)yl]-3-buten-1-amine.",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;DOBSON GRAYLAND PAGE;;MILLER CRAIG HARRISON;;BENCHERIF MEROUANE;;LIPPIELLO PATRICK MICHAEL,"ON=TARGACEPT, INC.; FT=THE FORMER OWNER WAS: R.J. (2000-09-07)",https://lens.org/004-268-525-645-622,Granted Patent,no,0,0,16,19,0,C07D213/38;;C07D213/61;;C07D213/64;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28;;A61P43/00;;C07D213/64;;C07D213/61;;C07D213/38;;C07D239/30;;C07D239/26,C07D213/65;;A61K31/44;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28;;A61P43/00;;C07D213/38;;C07D213/61;;C07D213/64,,0,0,,,,EXPIRED
92,ES,T3,ES 2226095 T3,137-591-653-885-738,2005-03-16,2005,ES 98905108 T,1998-02-19,US 80425097 A;;US 80424897 A,1997-02-21,COMPOSICIONES FARMACEUTICAS QUE INCORPORAN COMPUESTOS DE AMINA OLEFINICA SUSTITUIDA CON ARILO.,"Patients susceptible to or suffering from central nervous system disorders (e.g., Alzheimer's disease, Parkinson's disease, Tourette's syndrome, attention deficit disorder or schizophrenia) are treated by administering an effective amount of an aryl substituted olefinic amine compound of Formula (I): wherein X is C-R', C-OR', C-CH2-OR' wherein R' is selected from the group consisting of H, C1-C5 alkyl, an aromatic group containing species and alkyl-, halo-, or amino-substituted aromatic group containing species; E' is hydrogen or C1-C5 alkyl or halo substituted C1-C5 alkyl; E'' is C1-C5 alkyl or halo substituted C1-C5 alkyl; Z' and Z'' are each individually selected from the group consisting of hydrogen, C1-C5 alkyl, aryl rings, and can form a ring structure (a), A, A' and A'' are each individually selected from the group consisting of hydrogen, C1-C7 alkyl, and halo; m is 0 or 1; p is 0 or 1 with the proviso that when m or p is 0 then that E'' is hydrogen; and the wavy line in the structure represents a cis (Z) or trans (E) form of the compound. Exemplary compounds include (E)-N-methyl-4-[3-(benzyloxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-phenoxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-isopropoxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-methoxymethylpyridin)yl]-3-buten-1-amine, and (E)-N-methyl-4-[3-(5-phenylpyridin)yl]-3-buten-1-amine.",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;DOBSON GRAYLAND PAGE;;MILLER CRAIG HARRISON;;BENCHERIF MEROUANE;;LIPPIELLO PATRICK MICHAEL,,https://lens.org/137-591-653-885-738,Granted Patent,no,0,0,16,19,0,C07D213/38;;C07D213/61;;C07D213/64;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28;;A61P43/00;;C07D213/64;;C07D213/61;;C07D213/38;;C07D239/30;;C07D239/26,C07D213/65;;A61K31/44;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28;;A61P43/00;;C07D213/38;;C07D213/61;;C07D213/64,,0,0,,,,EXPIRED
93,EP,A1,EP 0973743 A1,007-677-276-779-094,2000-01-26,2000,EP 98905108 A,1998-02-19,US 9803091 W;;US 80425097 A;;US 80424897 A,1997-02-21,PHARMACEUTICAL COMPOSITIONS INCORPORATING ARYL SUBSTITUTED OLEFINIC AMINE COMPOUNDS,"Patients susceptible to or suffering from central nervous system disorders (e.g., Alzheimer's disease, Parkinson's disease, Tourette's syndrome, attention deficit disorder or schizophrenia) are treated by administering an effective amount of an aryl substituted olefinic amine compound of Formula (I): wherein X is C-R', C-OR', C-CH2-OR' wherein R' is selected from the group consisting of H, C1-C5 alkyl, an aromatic group containing species and alkyl-, halo-, or amino-substituted aromatic group containing species; E' is hydrogen or C1-C5 alkyl or halo substituted C1-C5 alkyl; E'' is C1-C5 alkyl or halo substituted C1-C5 alkyl; Z' and Z'' are each individually selected from the group consisting of hydrogen, C1-C5 alkyl, aryl rings, and can form a ring structure (a), A, A' and A'' are each individually selected from the group consisting of hydrogen, C1-C7 alkyl, and halo; m is 0 or 1; p is 0 or 1 with the proviso that when m or p is 0 then that E'' is hydrogen; and the wavy line in the structure represents a cis (Z) or trans (E) form of the compound. Exemplary compounds include (E)-N-methyl-4-[3-(benzyloxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-phenoxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-isopropoxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-methoxymethylpyridin)yl]-3-buten-1-amine, and (E)-N-methyl-4-[3-(5-phenylpyridin)yl]-3-buten-1-amine.",REYNOLDS TOBACCO CO R,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;DOBSON GRAYLAND PAGE;;MILLER CRAIG HARRISON;;BENCHERIF MEROUANE;;LIPPIELLO PATRICK MICHAEL,"TARGACEPT, INC. (2002-12-18)",https://lens.org/007-677-276-779-094,Patent Application,yes,0,0,16,19,0,C07D213/38;;C07D213/61;;C07D213/64;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28;;A61P43/00;;C07D213/64;;C07D213/61;;C07D213/38;;C07D239/30;;C07D239/26,C07D213/65;;A61K31/44;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28;;A61P43/00;;C07D213/38;;C07D213/61;;C07D213/64,,0,0,,,,EXPIRED
94,DK,T3,DK 0973743 T3,140-023-429-488-941,2004-11-29,2004,DK 98905108 T,1998-02-19,EP 98905108 A;;US 80425097 A;;US 80424897 A,1997-02-21,"Farmaceutiske præparater, der inkorporerer arylsubstituerede olefiniske aminforbindelser","Patients susceptible to or suffering from central nervous system disorders (e.g., Alzheimer's disease, Parkinson's disease, Tourette's syndrome, attention deficit disorder or schizophrenia) are treated by administering an effective amount of an aryl substituted olefinic amine compound of Formula (I): wherein X is C-R', C-OR', C-CH2-OR' wherein R' is selected from the group consisting of H, C1-C5 alkyl, an aromatic group containing species and alkyl-, halo-, or amino-substituted aromatic group containing species; E' is hydrogen or C1-C5 alkyl or halo substituted C1-C5 alkyl; E'' is C1-C5 alkyl or halo substituted C1-C5 alkyl; Z' and Z'' are each individually selected from the group consisting of hydrogen, C1-C5 alkyl, aryl rings, and can form a ring structure (a), A, A' and A'' are each individually selected from the group consisting of hydrogen, C1-C7 alkyl, and halo; m is 0 or 1; p is 0 or 1 with the proviso that when m or p is 0 then that E'' is hydrogen; and the wavy line in the structure represents a cis (Z) or trans (E) form of the compound. Exemplary compounds include (E)-N-methyl-4-[3-(benzyloxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-phenoxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-isopropoxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-methoxymethylpyridin)yl]-3-buten-1-amine, and (E)-N-methyl-4-[3-(5-phenylpyridin)yl]-3-buten-1-amine.",TARGACEPT INC,DULL GARY MAURICE;;MILLER CRAIG HARRISON;;LIPPIELLO PATRICK MICHAEL;;CALDWELL WILLIAM SCOTT;;DOBSON GRAYLAND PAGE;;BENCHERIF MEROUANE,,https://lens.org/140-023-429-488-941,Granted Patent,no,0,0,16,19,0,C07D213/38;;C07D213/61;;C07D213/64;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28;;A61P43/00;;C07D213/64;;C07D213/61;;C07D213/38;;C07D239/30;;C07D239/26,C07D213/65;;A61K31/44;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28;;A61P43/00;;C07D213/38;;C07D213/61;;C07D213/64,,0,0,,,,EXPIRED
95,AT,T1,AT E274496 T1,030-715-352-172-787,2004-09-15,2004,AT 98905108 T,1998-02-19,US 80425097 A;;US 80424897 A;;US 9803091 W,1997-02-21,PHARMAZEUTISCHE ZUSAMMENSETZUNGEN WELCHE ARYL- SUBSTITUIERTE OLEFINISCHE AMIN-VERBINDUNGEN ENTHALTEN,"Patients susceptible to or suffering from central nervous system disorders (e.g., Alzheimer's disease, Parkinson's disease, Tourette's syndrome, attention deficit disorder or schizophrenia) are treated by administering an effective amount of an aryl substituted olefinic amine compound of Formula (I): wherein X is C-R', C-OR', C-CH2-OR' wherein R' is selected from the group consisting of H, C1-C5 alkyl, an aromatic group containing species and alkyl-, halo-, or amino-substituted aromatic group containing species; E' is hydrogen or C1-C5 alkyl or halo substituted C1-C5 alkyl; E'' is C1-C5 alkyl or halo substituted C1-C5 alkyl; Z' and Z'' are each individually selected from the group consisting of hydrogen, C1-C5 alkyl, aryl rings, and can form a ring structure (a), A, A' and A'' are each individually selected from the group consisting of hydrogen, C1-C7 alkyl, and halo; m is 0 or 1; p is 0 or 1 with the proviso that when m or p is 0 then that E'' is hydrogen; and the wavy line in the structure represents a cis (Z) or trans (E) form of the compound. Exemplary compounds include (E)-N-methyl-4-[3-(benzyloxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-phenoxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-isopropoxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-methoxymethylpyridin)yl]-3-buten-1-amine, and (E)-N-methyl-4-[3-(5-phenylpyridin)yl]-3-buten-1-amine.",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;DOBSON GRAYLAND PAGE;;MILLER CRAIG HARRISON;;BENCHERIF MEROUANE;;LIPPIELLO PATRICK MICHAEL,,https://lens.org/030-715-352-172-787,Granted Patent,no,0,0,16,19,0,C07D213/38;;C07D213/61;;C07D213/64;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28;;A61P43/00;;C07D213/64;;C07D213/61;;C07D213/38;;C07D239/30;;C07D239/26,C07D213/65;;A61K31/44;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28;;A61P43/00;;C07D213/38;;C07D213/61;;C07D213/64,,0,0,,,,PENDING
96,EP,B1,EP 0973743 B1,027-646-907-811-550,2004-08-25,2004,EP 98905108 A,1998-02-19,US 9803091 W;;US 80425097 A;;US 80424897 A,1997-02-21,PHARMACEUTICAL COMPOSITIONS INCORPORATING ARYL SUBSTITUTED OLEFINIC AMINE COMPOUNDS,"Patients susceptible to or suffering from central nervous system disorders (e.g., Alzheimer's disease, Parkinson's disease, Tourette's syndrome, attention deficit disorder or schizophrenia) are treated by administering an effective amount of an aryl substituted olefinic amine compound of Formula (I): wherein X is C-R', C-OR', C-CH2-OR' wherein R' is selected from the group consisting of H, C1-C5 alkyl, an aromatic group containing species and alkyl-, halo-, or amino-substituted aromatic group containing species; E' is hydrogen or C1-C5 alkyl or halo substituted C1-C5 alkyl; E'' is C1-C5 alkyl or halo substituted C1-C5 alkyl; Z' and Z'' are each individually selected from the group consisting of hydrogen, C1-C5 alkyl, aryl rings, and can form a ring structure (a), A, A' and A'' are each individually selected from the group consisting of hydrogen, C1-C7 alkyl, and halo; m is 0 or 1; p is 0 or 1 with the proviso that when m or p is 0 then that E'' is hydrogen; and the wavy line in the structure represents a cis (Z) or trans (E) form of the compound. Exemplary compounds include (E)-N-methyl-4-[3-(benzyloxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-phenoxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-isopropoxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-methoxymethylpyridin)yl]-3-buten-1-amine, and (E)-N-methyl-4-[3-(5-phenylpyridin)yl]-3-buten-1-amine.",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;DOBSON GRAYLAND PAGE;;MILLER CRAIG HARRISON;;BENCHERIF MEROUANE;;LIPPIELLO PATRICK MICHAEL,"TARGACEPT, INC. (2002-12-18)",https://lens.org/027-646-907-811-550,Granted Patent,yes,4,0,16,19,0,C07D213/38;;C07D213/61;;C07D213/64;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28;;A61P43/00;;C07D213/64;;C07D213/61;;C07D213/38;;C07D239/30;;C07D239/26,C07D213/65;;A61K31/44;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28;;A61P43/00;;C07D213/38;;C07D213/61;;C07D213/64,,0,0,,,,EXPIRED
97,AU,A,AU 1998/062806 A,169-870-086-645-14X,1998-09-09,1998,AU 1998/062806 A,1998-02-19,US 80425097 A;;US 80424897 A;;US 9803091 W,1997-02-21,Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds,,TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;DOBSON GRAYLAND PAGE;;MILLER CRAIG HARRISON;;BENCHERIF MEROUANE;;LIPPIELLO PATRICK MICHAEL,"ON=TARGACEPT, INC.; FT=THE FORMER OWNER WAS: R.J. (2000-09-07)",https://lens.org/169-870-086-645-14X,Patent Application,no,0,0,16,19,0,C07D213/38;;C07D213/61;;C07D213/64;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28;;A61P43/00;;C07D213/64;;C07D213/61;;C07D213/38;;C07D239/30;;C07D239/26,C07D213/65;;A61K31/44;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/28;;A61P43/00;;C07D213/38;;C07D213/61;;C07D213/64,,0,0,,,,EXPIRED
98,DE,T2,DE 69919537 T2,040-827-063-723-385,2005-09-08,2005,DE 69919537 T,1999-06-03,US 9828598 A;;US 9813398 A;;US 9912340 W,1998-06-16,ARYLSUBSTITUIERTE OLEFINISCHE AMINE UND IHRE VERWENDUNG ALS CHOLINERGISCHE REZEPTORAGONISTEN,"Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5- (3-pyridyl) -4-penten-2-amine, (4E) -N-methyl-5- (5-pyrimidinyl) -4-penten-2-amine, (4E)-N-methyl-5-( 5-methoxy-3-pyridyl) -4-penten-2-amine, (4E)-N- methyl-5- (6-amino-5-methyl -3-pyridyl)-4-penten -2-amine, (2R)-(4E) -N-methyl-5-(3-pyridyl) -4-penten-2-amine, (2R)-(4E)-N- methyl-5-(5- isopropoxy-3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-bromo-3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-ethoxy-3- pyridyl)-4-penten- 2-amine, (2S)-(4E)-N- methyl-5-(3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-isopropoxy-3- pyridyl)-4- penten-2-amine and (2S)-(4E)-N-methyl -5-(5-isopropoxy -3-pyridyl) -4-penten-2-amine.",TARGACEPT INC,CALDWELL SCOTT;;DULL MAURICE;;BHATTI SINGH;;HADIMANI B;;PARK HAEIL;;WAGNER MILLER;;CROOKS ANTHONY;;LIPPIELLO MICHAEL;;BENCHERIF MEROUANE,,https://lens.org/040-827-063-723-385,Granted Patent,no,0,0,25,42,0,A61K31/44;;A61K31/4406;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26;;A61P1/04;;A61P21/00;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P43/00;;A61K31/44,A61K31/44;;A61K31/4406;;A61K31/4418;;A61K31/505;;A61P1/04;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38;;C07D213/61;;C07D213/62;;C07D213/64;;C07D213/65;;C07D213/73;;C07D239/26,,0,0,,,,EXPIRED
99,DE,D1,DE 69919537 D1,052-522-097-244-137,2004-09-23,2004,DE 69919537 T,1999-06-03,US 9828598 A;;US 9813398 A;;US 9912340 W,1998-06-16,ARYLSUBSTITUIERTE OLEFINISCHE AMINE UND IHRE VERWENDUNG ALS CHOLINERGISCHE REZEPTORAGONISTEN,"Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5- (3-pyridyl) -4-penten-2-amine, (4E) -N-methyl-5- (5-pyrimidinyl) -4-penten-2-amine, (4E)-N-methyl-5-( 5-methoxy-3-pyridyl) -4-penten-2-amine, (4E)-N- methyl-5- (6-amino-5-methyl -3-pyridyl)-4-penten -2-amine, (2R)-(4E) -N-methyl-5-(3-pyridyl) -4-penten-2-amine, (2R)-(4E)-N- methyl-5-(5- isopropoxy-3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-bromo-3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-ethoxy-3- pyridyl)-4-penten- 2-amine, (2S)-(4E)-N- methyl-5-(3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-isopropoxy-3- pyridyl)-4- penten-2-amine and (2S)-(4E)-N-methyl -5-(5-isopropoxy -3-pyridyl) -4-penten-2-amine.",TARGACEPT INC,CALDWELL SCOTT;;DULL MAURICE;;BHATTI SINGH;;HADIMANI B;;PARK HAEIL;;WAGNER MILLER;;CROOKS ANTHONY;;LIPPIELLO MICHAEL;;BENCHERIF MEROUANE,,https://lens.org/052-522-097-244-137,Granted Patent,no,0,0,25,42,0,A61K31/44;;A61K31/4406;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26;;A61P1/04;;A61P21/00;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P43/00;;A61K31/44,A61K31/44;;A61K31/4406;;A61K31/4418;;A61K31/505;;A61P1/04;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38;;C07D213/61;;C07D213/62;;C07D213/64;;C07D213/65;;C07D213/73;;C07D239/26,,0,0,,,,EXPIRED
100,AU,A,AU 1999/028929 A,009-223-055-540-633,1999-10-25,1999,AU 1999/028929 A,1999-03-03,US 5393798 A;;US 5417598 A;;US 9904728 W,1998-04-02,Azatricyclo¬3.3.1.1| decane derivatives and pharmaceutical compositions containing them,"A pharmaceutical composition incorporating a nicotinic antagonist is provided. The composition is an effective amount of a compound of formula (I), wherein X' is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; X is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; A, A' and A"" are individually substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; Z' is a substituent other than hydrogen; j is an integer from 0 to 5; and the wavy line in the structure indicates that the compound can exist in the form of an enantiomer or a diasteromer; Z"" is hydrogen or a substituent other than hydrogen; Y is C=O, C(OH)R' or C-A, where R' is hydrogen or lower alkyl.",REYNOLDS TOBACCO CO R,BENCHERIF MEROUANE;;LIPPIELLO PATRICK MICHAEL;;CROOKS PETER ANTHONY;;PARK HAEIL;;BHATTI BALWINDER SINGH;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE,,https://lens.org/009-223-055-540-633,Patent Application,no,0,0,16,19,0,A61K31/439;;A61K31/444;;A61P25/00;;A61P43/00;;C07D471/18;;A61K31/439;;A61K31/444,C07D471/18;;A61K31/439;;A61K31/444;;A61P25/00;;A61P43/00,,0,0,,,,DISCONTINUED
101,BR,A,BR 9907172 A,097-390-355-971-195,2000-10-10,2000,BR 9907172 A,1999-03-03,US 5393798 A;;US 5417598 A;;US 9904728 W,1998-04-02,Derivados de azatriciclo[3.3.1.1] decano e composições farmacêuticas contendo-os,"A pharmaceutical composition incorporating a nicotinic antagonist is provided. The composition is an effective amount of a compound of formula (I), wherein X' is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; X is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; A, A' and A"" are individually substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; Z' is a substituent other than hydrogen; j is an integer from 0 to 5; and the wavy line in the structure indicates that the compound can exist in the form of an enantiomer or a diasteromer; Z"" is hydrogen or a substituent other than hydrogen; Y is C=O, C(OH)R' or C-A, where R' is hydrogen or lower alkyl.",REYNOLDS TOBACCO CO R,BENCHERIF MEROUANE;;LIPPIELLO PATRICK MICHAEL;;CROOKS PETER ANTHONY;;PARK HAELIL;;BHATTI BALWINDER SINGH;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE,,https://lens.org/097-390-355-971-195,Patent Application,no,0,0,16,19,0,A61K31/439;;A61K31/444;;A61P25/00;;A61P43/00;;C07D471/18;;A61K31/439;;A61K31/444,C07D471/18;;A61K31/439;;A61K31/444;;A61P25/00;;A61P43/00,,0,0,,,,DISCONTINUED
102,EP,A1,EP 1068208 A1,168-796-042-461-913,2001-01-17,2001,EP 99909806 A,1999-03-03,US 9904728 W;;US 5393798 A;;US 5417598 A,1998-04-02,AZATRICYCLO[3.3.1.1] DECANE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM,"A pharmaceutical composition incorporating a nicotinic antagonist is provided. The composition is an effective amount of a compound of formula (I), wherein X' is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; X is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; A, A' and A"" are individually substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; Z' is a substituent other than hydrogen; j is an integer from 0 to 5; and the wavy line in the structure indicates that the compound can exist in the form of an enantiomer or a diasteromer; Z"" is hydrogen or a substituent other than hydrogen; Y is C=O, C(OH)R' or C-A, where R' is hydrogen or lower alkyl.",REYNOLDS TOBACCO CO R,BENCHERIF MEROUANE;;LIPPIELLO PATRICK MICHAEL;;CROOKS PETER ANTHONY;;PARK HAEIL;;BHATTI BALWINDER SINGH;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE,"TARGACEPT, INC. (2002-12-18)",https://lens.org/168-796-042-461-913,Patent Application,yes,0,0,16,19,0,A61K31/439;;A61K31/444;;A61P25/00;;A61P43/00;;C07D471/18;;A61K31/439;;A61K31/444,C07D471/18;;A61K31/439;;A61K31/444;;A61P25/00;;A61P43/00,,0,0,,,,EXPIRED
103,WO,A1,WO 1999/051602 A1,142-648-798-415-29X,1999-10-14,1999,US 9904728 W,1999-03-03,US 5393798 A;;US 5417598 A,1998-04-02,AZATRICYCLO[3.3.1.1] DECANE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM,"A pharmaceutical composition incorporating a nicotinic antagonist is provided. The composition is an effective amount of a compound of formula (I), wherein X' is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; X is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; A, A' and A' are individually substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; Z' is a substituent other than hydrogen; j is an integer from 0 to 5; and the wavy line in the structure indicates that the compound can exist in the form of an enantiomer or a diasteromer; Z' is hydrogen or a substituent other than hydrogen; Y is C=O, C(OH)R' or C-A, where R' is hydrogen or lower alkyl.",REYNOLDS TOBACCO CO R;;BENCHERIF MEROUANE;;LIPPIELLO PATRICK MICHAEL;;CROOKS PETER ANTHONY;;PARK HAEIL;;BHATTI BALWINDER SINGH;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE,BENCHERIF MEROUANE;;LIPPIELLO PATRICK MICHAEL;;CROOKS PETER ANTHONY;;PARK HAEIL;;BHATTI BALWINDER SINGH;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE,,https://lens.org/142-648-798-415-29X,Patent Application,yes,6,43,16,19,0,A61K31/439;;A61K31/444;;A61P25/00;;A61P43/00;;C07D471/18;;A61K31/439;;A61K31/444,A61K31/439;;A61K31/444;;C07D471/18;;A61P25/00;;A61P43/00,,1,0,,,"PATENT ABSTRACTS OF JAPAN vol. 97, no. 4 30 April 1997 (1997-04-30)",PATENTED
104,PT,E,PT 1068208 E,027-209-670-580-532,2003-09-30,2003,PT 99909806 T,1999-03-03,US 5393798 A;;US 5417598 A,1998-04-02,DERIVADOS DO AZATRICICLO¬3.3.1.1|DECANO E COMPOSICOES FARMACEUTICAS CONTENDO OS MESMOS,"A pharmaceutical composition incorporating a nicotinic antagonist is provided. The composition is an effective amount of a compound of formula (I), wherein X' is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; X is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; A, A' and A"" are individually substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; Z' is a substituent other than hydrogen; j is an integer from 0 to 5; and the wavy line in the structure indicates that the compound can exist in the form of an enantiomer or a diasteromer; Z"" is hydrogen or a substituent other than hydrogen; Y is C=O, C(OH)R' or C-A, where R' is hydrogen or lower alkyl.",TARGACEPT INC,BENCHERIF MEROUANE;;LIPPIELLO PATRICK MICHAEL;;CROOKS PETER ANTHONY;;PARK HAEIL;;BHATTI BALWINDER SINGH;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE,,https://lens.org/027-209-670-580-532,Granted Patent,no,0,0,16,19,0,A61K31/439;;A61K31/444;;A61P25/00;;A61P43/00;;C07D471/18;;A61K31/439;;A61K31/444,A61K31/439;;A61K31/444;;C07D471/18;;A61P25/00;;A61P43/00,,0,0,,,,EXPIRED
105,AT,T1,AT E240331 T1,080-647-243-500-069,2003-05-15,2003,AT 99909806 T,1999-03-03,US 5393798 A;;US 5417598 A;;US 9904728 W,1998-04-02,AZATRICYCLO(3.3.1.1)DECANDERIVATE UND DIESE ENTHALTENDE PHRMAZEUTISCHE ZUBEREITUNGEN,"A pharmaceutical composition incorporating a nicotinic antagonist is provided. The composition is an effective amount of a compound of formula (I), wherein X' is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; X is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; A, A' and A"" are individually substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; Z' is a substituent other than hydrogen; j is an integer from 0 to 5; and the wavy line in the structure indicates that the compound can exist in the form of an enantiomer or a diasteromer; Z"" is hydrogen or a substituent other than hydrogen; Y is C=O, C(OH)R' or C-A, where R' is hydrogen or lower alkyl.",TARGACEPT INC,BENCHERIF MEROUANE;;LIPPIELLO PATRICK MICHAEL;;CROOKS PETER ANTHONY;;PARK HAEIL;;BHATTI BALWINDER SINGH;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE,,https://lens.org/080-647-243-500-069,Granted Patent,no,0,0,16,19,0,A61K31/439;;A61K31/444;;A61P25/00;;A61P43/00;;C07D471/18;;A61K31/439;;A61K31/444,C07D471/18;;A61K31/439;;A61K31/444;;A61P25/00;;A61P43/00,,0,0,,,,DISCONTINUED
106,CL,A1,CL 2009002146 A1,135-439-588-555-337,2010-04-30,2010,CL 2009002146 A,2009-11-30,US 11888508 P,2008-12-01,"Compuesto (r)-3-((e)-2-(pirrolidin-3-il)vinil)-5-(tetrahidropiran-4-iloxi)piridina y su sal mono-l-malato; su composicion farmaceutica; y su uso para el tratamiento de un trastorno mediado por nnr tal como trastornos del snc, inflamacion, trastornos inmunes, entre otros.",Sales de (r)-3-((e)-2-(pirrolidin-3-il)vinil)-5-(tetrahidropiran-4-iloxi)piridina; composición farmacéutica que las comprende; y uso en la prevención o tratamiento de un trastorno mediado por los receptores nicotínicos neuronales.,TARGACEPT INC,SRINIVISA RAO AKIREDDY;;SCOTT R BREINING;;TIMOTHY J CUTHBERTSON;;GARY MAURICE DULL;;NIKOLAI FEDOROV;;GREGORY J GATTO;;JOHN GEN,,https://lens.org/135-439-588-555-337,Patent Application,no,0,0,54,54,0,C07D405/14;;A61K31/4439;;A61P25/00;;A61P25/04;;A61P25/18;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P31/12;;A61P37/06;;C07D207/08;;C07D405/14;;A61K31/40;;C07D405/14;;A61K31/4439,A61K31/4439;;A61P25/00;;C07D207/02;;C07D213/00;;C07D309/00;;C07D405/14,,0,0,,,,PENDING
107,EP,B1,EP 1068208 B1,180-987-615-846-367,2003-05-14,2003,EP 99909806 A,1999-03-03,US 9904728 W;;US 5393798 A;;US 5417598 A,1998-04-02,AZATRICYCLO[3.3.1.1] DECANE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM,"A pharmaceutical composition incorporating a nicotinic antagonist is provided. The composition is an effective amount of a compound of formula (I), wherein X' is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; X is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; A, A' and A"" are individually substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; Z' is a substituent other than hydrogen; j is an integer from 0 to 5; and the wavy line in the structure indicates that the compound can exist in the form of an enantiomer or a diasteromer; Z"" is hydrogen or a substituent other than hydrogen; Y is C=O, C(OH)R' or C-A, where R' is hydrogen or lower alkyl.",TARGACEPT INC,BENCHERIF MEROUANE;;LIPPIELLO PATRICK MICHAEL;;CROOKS PETER ANTHONY;;PARK HAEIL;;BHATTI BALWINDER SINGH;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE,"TARGACEPT, INC. (2002-12-18)",https://lens.org/180-987-615-846-367,Granted Patent,yes,6,0,16,19,0,A61K31/439;;A61K31/444;;A61P25/00;;A61P43/00;;C07D471/18;;A61K31/439;;A61K31/444,C07D471/18;;A61K31/439;;A61K31/444;;A61P25/00;;A61P43/00,,1,0,,,"PATENT ABSTRACTS OF JAPAN vol. 97, no. 4, 30 April 1997 (1997-04-30) & JP 08 325367 A (JAPAN TOBACCO INC.), 10 December 1996 (1996-12-10)",EXPIRED
108,CA,A1,CA 2317567 A1,181-470-665-652-899,1999-10-14,1999,CA 2317567 A,1999-03-03,US 5393798 A;;US 5417598 A;;US 9904728 W,1998-04-02,PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE,"A pharmaceutical composition incorporating a nicotinic antagonist is provided. The composition is an effective amount of a compound of formula (I), wherein X' is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; X is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; A, A' and A"" are individually substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; Z' is a substituent other than hydrogen; j is an integer from 0 to 5; and the wavy line in the structure indicates that the compound can exist in the form of an enantiomer or a diasteromer; Z"" is hydrogen or a substituent other than hydrogen; Y is C=O, C(OH)R' or C-A, where R' is hydrogen or lower alkyl.",REYNOLDS TOBACCO CO R,LIPPIELLO PATRICK MICHAEL;;BENCHERIF MEROUANE;;BHATTI BALWINDER SINGH;;CROOKS PETER ANTHONY;;PARK HAEIL;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE,,https://lens.org/181-470-665-652-899,Patent Application,no,0,0,16,19,0,A61K31/439;;A61K31/444;;A61P25/00;;A61P43/00;;C07D471/18;;A61K31/439;;A61K31/444,C07D471/18;;A61K31/439;;A61K31/444;;A61P25/00;;A61P43/00,,0,0,,,,DISCONTINUED
109,DK,T3,DK 1068208 T3,120-579-703-193-643,2003-09-01,2003,DK 99909806 T,1999-03-03,US 5393798 A;;US 5417598 A;;US 9904728 W,1998-04-02,"Azatricyclo[3.3.1.1]dekanderivater og farmaceutiske sammensætninger, der indeholder dem","A pharmaceutical composition incorporating a nicotinic antagonist is provided. The composition is an effective amount of a compound of formula (I), wherein X' is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; X is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; A, A' and A"" are individually substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; Z' is a substituent other than hydrogen; j is an integer from 0 to 5; and the wavy line in the structure indicates that the compound can exist in the form of an enantiomer or a diasteromer; Z"" is hydrogen or a substituent other than hydrogen; Y is C=O, C(OH)R' or C-A, where R' is hydrogen or lower alkyl.",TARGACEPT INC,BENCHERIF MEROUANE;;LIPPIELLO PATRICK MICHAEL;;CROOKS PETER ANTHONY;;PARK HAEIL;;BHATTI BALWINDER SINGH;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE,,https://lens.org/120-579-703-193-643,Granted Patent,no,0,0,16,19,0,A61K31/439;;A61K31/444;;A61P25/00;;A61P43/00;;C07D471/18;;A61K31/439;;A61K31/444,C07D471/18;;A61K31/439;;A61K31/444;;A61P25/00;;A61P43/00,,0,0,,,,EXPIRED
110,US,B2,US 7790757 B2,109-244-582-367-105,2010-09-07,2010,US 93289507 A,2007-10-31,US 93289507 A;;US 37944306 A;;US 18105505 A;;US 4821205 A;;US 52211700 A;;US 9828598 A,1998-06-16,Compounds capable of activating cholinergic receptors,"Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-pyrimidinyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-methoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(6-amino-5-methyl-3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-bromo-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-ethoxy-3-pyridyl)-4-penten-2-amine, (2S)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine and (2S)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine.",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR B;;PARK HAEIL;;WAGNER JARED MILLER;;CROOKS PETER ANTHONY,,https://lens.org/109-244-582-367-105,Granted Patent,yes,38,0,6,42,0,A61K31/44;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/28;;C07D239/26;;A61K31/44;;A61K31/505;;C07D213/61;;C07D213/38;;C07D213/73;;C07D213/65,A61K31/505;;A61K31/44;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/28;;C07D213/02;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26,514/345;;514/351;;546/290;;546/297;;546/300,27,16,087-248-970-933-131;;128-203-798-400-195;;094-390-180-579-79X;;043-091-711-667-642;;174-507-030-434-145;;056-184-684-713-117;;061-556-297-543-520;;052-702-054-753-554;;040-465-959-286-768;;184-367-294-782-70X;;184-367-294-782-70X;;080-173-777-134-292;;105-959-091-465-070;;077-658-197-676-56X;;142-350-433-703-027;;004-206-224-320-513,10.1007/s002130050048;;10755737;;11074159;;10.1016/s0306-4522(00)00377-8;;11207426;;10.1016/s0891-0618(00)00110-1;;10.1002/bms.1200221006;;8218423;;10.1021/ja01396a022;;10.1021/jo00148a033;;10.1021/jo00409a002;;10.1039/p19800000579;;10.1055/s-1995-5220;;8968366;;8968366;;10.1021/jm00400a005;;2966246;;10.1016/0306-4522(94)00410-7;;7700528;;10.1002/ddr.430310112;;1263119;;12683258;;10.1016/s0193-953x(02)00084-9,"Mirza et al., Psychopharmacology 148(3) : 243-250, 2000.;;Terry et al., Neuroscience 10192) : 357-368, 2000.;;Court et al., J. Chem. Neuroanat. 20(3-4) : 281-298, 2000.;;Cooper, D.A. and J.M. Moore, ""Femtogram on column detection of nicotine by isotope dilution gas chromatography/negative ion detection mass spectrometry,"" Biol. Mass. Spectrom., 22(10): 590-594 (1993).;;Loftier, K., et al., Chem. Ber., 42:3431-3488 (1909).;;LaForge, F.B., ""The preparation and properties of some new derivatives of pyridine,"" J. Am. Chem. Soc., 50: 2477-2483 (1928).;;Pinner, A., Chem. Ber., pp. 2861-2870 (1894).;;Malek, N., et al., J. Org. Chem., 47: 5395-5397 (1982).;;Joyce, N.J., et al., Heterocycles, 29(7): 2947-2949 (1978).;;Frank, W., et al., ""Palladium-Catalyzed Vinylic Substitution Reactions with Heterocyclic Bromides,"" J. Org. Chem., 43(15): 2947-2949 (1978).;;Sprouse, C., et al., Abstracts of Papers, Coresta/TCRC, Joint Conference, pp. 32 (1972).;;Pinner, A., Chem. Ber., 1053-1061 (1894).;;Acheson, R., et al., ""Transformations involving the Pyrrolidine Ring of Nicotine,"" J. Chem. Soc. Perkin Trans., 1: 579-585 (1980).;;Bleicher, L. and N.D.P. Cosford, ""Aryl- and Heteroaryl-Alkyne Coupling Reactions Catalyzed by Palladium on Carbon and CuI in an Aqueous Medium,"" Synlett, 115-1116 (1995).;;Lippiello, P., et al., ""RJR-2403: A Nicotinic Agonist with CNS Selectivity I. In Vitro Characterization,"" JPET, 279(3): 422-1429 (1996).;;Bencherif, M., et al., ""RJR-2403: A Nicotinic Agonist with CNS Selctivity II. In Vitro Characterization,"" JPET, 279(3): 1413-1421 (1996).;;Hogberg, Thomas, et al., ""Homallylic Amines Related to Zimeldine. A Comparative Study on Neuronal Seroonin and Norepinephrine Reuptake Based on Conformational Analysis,"" J. Med. Chem., 31: 913-919 (1988).;;International Search Report; Nov. 26, 1999; R.J. Reynolds Tobacco Company, et al.; PCT/US99/12340.;;Arneric, S. and M. Williams, ""Nicotinic Agonists in Alzheimer's Disease: Does the Molecular Diversity of Nicotine Receptors Offer the Opportunity for Developing CNS-Selective Cholinergic Channel Activators?,"" Int. Acad. Biomed. Drug Res., 7: 58-70 (1994).;;Bencherif, et al., ""Metanicotine: A Nicotinic Agonist with CNS Selectivity-In Vitro Characterization,"" Society for Neuroscience Abstracts, 21(1-3): 605 (1995).;;Perry, E.K., et al., ""Alteration in Nicotine Binding Sites in Parkinson's Disease, Lewy Body Dementia and Alzheimer's Disease: Possible Index of Early Neuropathology,"" Neuroscience, 64(2): 385-395 (1995).;;Sahakian, B. and J. Coull, ""Nicotine and Tetrahydroaminoacradine: Evidence for Improved Attention in Patients with Dementia of the Alzheimer Type,"" Drug Development Research, 31: 80-88 (1994).;;Wilson, K.L., Jr., et al., ""Nicotine-Like Actions of cis-Metanicotine and trans-Metanicotine,"" The Journal of Pharmacology and Experimental Therapeutics, 196(3): 685-696 (1976).;;Mirza, et al., Psychopharmacology, 148(3): 243-250 (2000).;;Terry, et al., Neuroscience, 10192: 357-368 (2000).;;Court, et al., J. Chem. Neuroanat., 20(3-4): 281-298 (2000).;;Tonmoy Sharma et al., ""Cognitive function in schizophrenia Deficits, functional consequences, and future treatment,"" Psychiatr Clin N. Am, 26 (2003): 25-40.",EXPIRED
111,US,B1,US 6455554 B1,041-783-265-324-846,2002-09-24,2002,US 57022600 A,2000-05-12,US 57022600 A;;US 32714199 A,1999-06-07,Oxopyridinyl pharmaceutical compositions and methods for use,"
    Pharmaceutical compositions incorporate aryl substituted olefinic amine compounds. Representative compounds are (2S)-(4E)-N-methyl-5-3-(5-isopropoxy-1-oxopyridin)yl)-4-penten-2-amine, (4E)-N-methyl-5-(3-(1-oxopyridin)yl)-4-penten-2-amine, (4E)-N-methyl-5-(3-(5-((carboxymethyl)oxy)pyridin)yl)-4-penten-2-amine and (4E)-N-methyl-5-(3-(1-oxopyridin)yl)-4-penten-2-amine. 
",TARGACEPT INC,DULL GARY MAURICE;;MILLER CRAIG HARRISON;;CALDWELL WILLIAM SCOTT;;LYNM DWO;;BHATTI BALWINDER SINGH;;SCHMITT JEFFREY DANIEL;;BYRD GARY DWIGHT,,https://lens.org/041-783-265-324-846,Granted Patent,yes,91,72,1,6,0,C07D213/38;;C07D213/65;;C07D213/70;;C07D213/73;;C07D213/74;;C07D213/82;;C07D213/89;;C07D239/42;;C07D213/70;;C07D213/74;;C07D213/38;;C07D239/42;;C07D213/65;;C07D213/73;;C07D213/82;;C07D213/89,C07D213/38;;C07D213/65;;C07D213/70;;C07D213/73;;C07D213/74;;C07D213/82;;C07D213/89;;C07D239/42,514/358;;514/357;;546/329;;546/347,24,8,080-173-777-134-292;;072-642-229-453-523;;098-645-664-739-486;;085-848-917-863-417;;019-495-824-205-525;;080-173-777-134-292;;073-981-318-375-830;;001-410-478-176-952,10.1021/jm00400a005;;2966246;;10.1021/cr00002a004;;3339617;;10.1021/jm00397a034;;2754709;;10.1021/jm00128a026;;10.1080/00021369.1968.10859236;;10.1021/jm00400a005;;2966246;;8968367;;2903032,"International Search Report; Nov. 26, 1999; R.J. Reynolds Tobacco Company et al.; PCT/US99/12340; file ref: 627-311.WO.;;Hoegbert et al., ""Homoallylic Amines Related to Zimeldine. A Comparative Study on Neuronal Serotonin and Norepinephrine Reuptake Based on Conformational Analysis,"" J. Med. Chem, 1988, 31, pp. 913-919.;;Hansch et al., ""A Survey of Hammett Substituent Constants and Resonance and Field Parameters,"" Chem Rev., 1991, 91, pp. 165-195.;;Tilley et al., ""Pyrido '2,1-b!quinazolinecarboxamide derivatives as platelet activating factor antagonists,"" Database accession No. 108:75343, J. Med. Chem, 1988, 31(2), pp. 466-472.;;Guthrie et al, ""Pentadienyl carboxamide derivatives as antagonists of platelet activating factor,"" Database accession No. 111:232526, J. Med. Chem, 1989, 32(8), pp. 1820-1835.;;Yamamoto et al., ""Nicotinoids as an insecticide. VII. Cholinesterase inhibition by nicotinoids and pyridylalkylamines, its significance to mode of action,"" Database accession No. 70:19156, Agr. Biol. Chem. (Tokyo), 1968, 32(11), pp. 1341-1348.;;Gol'dfarb et al., ""Strength of some nicotine series bases,"" Database accession No. 74:31877, Izv. Akad. Nauk Ssr. Ser. Khim., 1970, (8), pp. 1883-1885.;;Stoyanovich et al., ""Action of potassium amide on 5-bromo-2(or 6)-amino-3-(4-methylaminobutyl)pyridine,"" Database accession No. 74:111870, Azv. Akad. Nauk Sssr. Ser. Khim., 1970, 11, pp. 2585-2590.;;Hoegberg et al., ""Homoallylic amines related to zimeldine. Comparative study on neuronal serotonin and norepinephrine reuptake based on conformational analysis,"" Database accession No. 108:167263, J. Med. Chem, 1988, 31(5), pp. 913-919.;;Lippiello et al., ""RJR-2403: A nicotinic agonist with CNS selectivity. II. In vivo characterization,"" Database accession No. 126:99173, J. Pharmacol. Exp. Ther., 1996, 279(3), pp. 1422-1429.;;Yamamoto et al., ""Nicotinoids as an insecticide. VII. Cholinesterase inhibition by nicotinoids and pyridylalkylamines, its significance to mode of action,"" Database accession No. 70:19156, Agr. Biol. Chem (Tokyo), 1968, 32(11), pp. 1341-1348.;;Cashman et al., ""Stereoselective N-Oxygenation of zimeldine and homozimeldine by the flavin-containing monooxygenase,"" Database accession No., 109:141972, Drug Metab. Dispos., 1988, 16(4), pp. 616-622.;;Kisaki et al., ""Tobacco flavorant,"" Database accession No. 91:53030, JP 54 006639, Mar. 30, 1979.;;Kisaki et al., ""Pseudooxynicotine"", Database accession No. 88:168512, JP 52 134094, Nov. 9, 1977.;;International Search Report, PCT/US00/15560, Nov. 7, 2000.;;Caplus DN 116:190712, RN# 140681-92-1.;;Caplus AN# 1974:535967, RN#54127-22-9.;;Uspatful AN# 89:92535, RN 112101-59-7.;;Uspatful 89:67281, RN# 126427-28-9.;;Caplus AN 1998:618370, RN 1129-68-6.;;Caplus AN# 1991:408582, RN#134162-95-1.;;Caplus AN 1985:560530, RN# 6021-23-4.;;Caplus AN 1987:84609 RN# 6021-23-4.;;Uspatful AN 89:74192, RN#112860-50-1.",EXPIRED
112,US,A1,US 2003/0087915 A1,138-858-278-136-036,2003-05-08,2003,US 24469302 A,2002-09-16,US 24469302 A;;US 57022600 A,2000-05-12,Pharmaceutical compositions and methods for use,"
   Pharmaceutical compositions incorporate aryl substituted olefinic amine compounds. Representative compounds are (2S)-(4E)-N-methyl-5-3-(5-isopropoxy-1-oxopyridin)yl)-4-penten-2-amine, (4E)-N-methyl-5-(3-(1-oxopyridin)yl)4-penten-2-amine, (4E)-N-methyl-5-(3-(5-((carboxymethyl)oxy)pyridin)yl)-4-penten-2-amine and (4E)-N-methyl-5-(3-(1-oxopyridin)yl)-4-penten-2-amine. 
",DULL GARY MAURICE;;MILLER CRAIG HARRISON;;CALDWELL WILLIAM SCOTT;;LYNM DWO;;BHATTI BALWINDER SINGH;;SCHMITT JEFFREY DANIEL;;BYRD GARY DWIGHT,DULL GARY MAURICE;;MILLER CRAIG HARRISON;;CALDWELL WILLIAM SCOTT;;LYNM DWO;;BHATTI BALWINDER SINGH;;SCHMITT JEFFREY DANIEL;;BYRD GARY DWIGHT,,https://lens.org/138-858-278-136-036,Patent Application,yes,0,13,1,1,0,C07D213/38;;C07D213/65;;C07D213/70;;C07D213/73;;C07D213/82;;C07D213/89;;C07D239/42;;C07D213/70;;C07D213/82;;C07D213/65;;C07D213/73;;C07D239/42;;C07D213/89;;C07D213/38,C07D213/38;;C07D213/65;;C07D213/70;;C07D213/73;;C07D213/82;;C07D213/89;;C07D239/42,514/256;;514/252.1;;514/242;;544/182;;544/242;;544/336,0,0,,,,DISCONTINUED
113,US,A1,US 2010/0222395 A1,109-658-731-119-579,2010-09-02,2010,US 77679810 A,2010-05-10,US 77679810 A;;US 93289507 A;;US 37944306 A;;US 18105505 A;;US 4821205 A;;US 52211700 A;;US 9828598 A,1998-06-16,COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS,"Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-pyrimidinyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-methoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(6-amino-5-methyl-3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-bromo-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-ethoxy-3-pyridyl)-4-penten-2-amine, (2S)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine and (2S)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine.",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR B;;PARK HAEIL;;WAGNER JARED MILLER;;CROOKS PETER ANTHONY,,https://lens.org/109-658-731-119-579,Patent Application,yes,33,0,6,42,0,A61K31/44;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/28;;C07D239/26;;A61K31/44;;A61K31/505;;C07D213/61;;C07D213/38;;C07D213/73;;C07D213/65,A61K31/44;;A61K31/505;;A61P25/00;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26,514/345,0,0,,,,EXPIRED
114,US,A1,US 2010/0160390 A1,123-494-049-404-683,2010-06-24,2010,US 71590710 A,2010-03-02,US 71590710 A;;US 93289507 A;;US 37944306 A;;US 18105505 A;;US 4821205 A;;US 52211700 A;;US 9828598 A,1998-06-16,COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS,"Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-pyrimidinyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-methoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(6-amino-5-methyl-3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-bromo-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-ethoxy-3-pyridyl)-4-penten-2-amine, (2S)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine and (2S)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine.",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR B;;PARK HAEIL;;WAGNER JARED MILLER;;CROOKS PETER ANTHONY,,https://lens.org/123-494-049-404-683,Patent Application,yes,32,0,6,42,0,A61K31/44;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/28;;C07D239/26;;A61K31/44;;A61K31/505;;C07D213/61;;C07D213/38;;C07D213/73;;C07D213/65,A61K31/44;;A61K31/505;;A61P25/28;;C07D213/24;;C07D213/38;;C07D213/61;;C07D213/63;;C07D213/65;;C07D213/73;;C07D239/26,514/351;;546/329;;546/290;;514/357,0,0,,,,DISCONTINUED
115,US,B2,US 7060826 B2,142-440-261-754-635,2006-06-13,2006,US 18105505 A,2005-07-14,US 18105505 A;;US 4821205 A;;US 52211700 A;;US 9828598 A,1998-06-16,Compounds capable of activating cholinergic receptors,"Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-pyrimidinyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-methoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(6-amino-5-methyl-3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-bromo-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-ethoxy-3-pyridyl)-4-penten-2-amine, (2S)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine and (2S)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine.",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR B;;PARK HAEIL;;WAGNER JARED MILLER;;CROOKS PETER ANTHONY,,https://lens.org/142-440-261-754-635,Granted Patent,yes,33,10,6,42,0,A61K31/44;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/24;;C07D239/26;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/28;;A61K31/44;;A61K31/505;;C07D239/26;;C07D213/38;;C07D213/61;;C07D213/73;;C07D239/24;;C07D213/65,C07D239/24;;A61K31/44;;A61K31/505;;A61K31/506;;A61P25/28;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26,544/301;;514/256,23,15,087-248-970-933-131;;128-203-798-400-195;;094-390-180-579-79X;;043-091-711-667-642;;174-507-030-434-145;;056-184-684-713-117;;061-556-297-543-520;;052-702-054-753-554;;040-465-959-286-768;;184-367-294-782-70X;;184-367-294-782-70X;;080-173-777-134-292;;105-959-091-465-070;;077-658-197-676-56X;;142-350-433-703-027,10.1007/s002130050048;;10755737;;11074159;;10.1016/s0306-4522(00)00377-8;;11207426;;10.1016/s0891-0618(00)00110-1;;10.1002/bms.1200221006;;8218423;;10.1021/ja01396a022;;10.1021/jo00148a033;;10.1021/jo00409a002;;10.1039/p19800000579;;10.1055/s-1995-5220;;8968366;;8968366;;10.1021/jm00400a005;;2966246;;10.1016/0306-4522(94)00410-7;;7700528;;10.1002/ddr.430310112;;1263119,"Mirza et al., Psychopharmacology 148(3): 243-250, 2000.;;Terry et al., Neuroscience 10192): 357-368, 2000.;;Court et al., J. Chem. Neuroanat. 20(3-4): 281-298, 2000.;;Cooper, D.A. and J.M. Moore, ""Femtogram on column detection of nicotine by isotope dilution gas chromatography/negative ion detection mass spectrometry,"" Biol. Mass. Spectrom., 22(10): 590-594 (1993).;;Loffler, K., et al., Chem. Ber., 42:3431-3488 (1909).;;LaForge, F.B., ""The preparation and properties of some new derivatives of pyridine,"" J. Am. Chem. Soc., 50: 2477-2483 (1928).;;Pinner, A., Chem. Ber., pp. 2861-2870 (1894).;;Malek, N., et al., J. Org. Chem., 47: 5395-5397 (1982).;;Joyce, N.J., et al., Heterocycles, 29(7): 2947-2949 (1978).;;Frank, W., et al., ""Palladium-Catalyzed Vinylic Substitution Reactions with Heterocyclic Bromides,"" J. Org. Chem., 43(15): 2947-2949 (1978).;;Sprouse, C., et al., Abstracts of Papers, Coresta/TCRC, Joint Conference, pp. 32 (1972).;;Pinner, A., Chem. Ber., 1053-1061 (1894).;;Acheson, R., et al., ""Transformations involving the Pyrrolidine Ring of Nicotine,"" J. Chem. Soc. Perkin Trans., 1: 579-585 (1980).;;Bleicher, L. and N.D.P. Cosford, ""Aryl-and Heteroaryl-Alkyne Coupling Reactions Catalyzed by Palladium on Carbon and CuI in an Aqueous Medium,"" Synlett, 115-1116 (1995).;;Lippiello, P., et al., ""RJR-2403: A Nicotinic Agonist with CNS Selectivity I. In Vitro Characterization,"" JPET, 279(3): 422-1429 (1996).;;Bencherif, M., et al., ""RJR-2403: A Nicotinic Agonist with CNS Selctivity II. In Vitro Characterization,"" JPET, 279(3): 1413-1421 (1996).;;Hogberg, Thomas, et al., ""Homallylic Amines Related to Zimeldine. A Comparative Study on Neuronal Seroonin and Norepinephrine Reuptake Based on Conformational Analysis,"" J. Med. Chem., 31: 913-919 (1988).;;International Search Report; Nov. 26, 1999; R.J. Reynolds Tobacco Company, et al.; PCT/US99/12340.;;Arneric, S. and M. Williams, ""Nicotinic Agonists in Alzheimer's Disease: Does the Molecular Diversity of Nicotine Receptors Offer the Opportunity for Developing CNS-Selective Cholinergic Channel Activators?,"" Int. Acad. Biomed. Drug Res., 7: 58-70 (1994).;;Bencherif, et al., ""Metanicotine: A Nicotinic Agonist with CNS Selectivity-In Vitro Characterization,"" Society for Neuroscience Abstracts, 21(1-3): 605 (1995).;;Perry, E.K., et al., ""Alteration in Nicotine Binding Sites in Parkinson's Disease, Lewy Body Dementia and Alzheimer's Disease: Possible Index of Early Neuropathology,"" Neuroscience, 64(2): 385-395 (1995).;;Sahakian, B. and J. Coull, ""Nicotine and Tetrahydroaminoacradine: Evidence for Improved Attention in Patients with Dementia of the Alzheimer Type,"" Drug Development Research, 31: 80-88 (1994).;;Wilson, K.L., Jr., et al., ""Nicotine-Like Actions of cis-Metanicotine and trans-Metanicotine,"" The Journal of Pharmacology and Experimental Therapeutics, 196(3): 685-696 (1976).",EXPIRED
116,US,A1,US 2008/0214628 A1,002-622-540-277-510,2008-09-04,2008,US 93289507 A,2007-10-31,US 93289507 A;;US 37944306 A;;US 18105505 A;;US 4821205 A;;US 52211700 A;;US 9828598 A,1998-06-16,Compounds Capable of Activating Cholinergic Receptors,"Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-pyrimidinyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-methoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(6-amino-5-methyl-3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-bromo-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-ethoxy-3-pyridyl)-4-penten-2-amine, (2S)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine and (2S)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine.",CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR B;;PARK HAEIL;;WAGNER JARED MILLER;;CROOKS PETER ANTHONY,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR B;;PARK HAEIL;;WAGNER JARED MILLER;;CROOKS PETER ANTHONY,,https://lens.org/002-622-540-277-510,Patent Application,yes,31,0,6,42,0,A61K31/44;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/28;;C07D239/26;;A61K31/44;;A61K31/505;;C07D213/61;;C07D213/38;;C07D213/73;;C07D213/65,A61K31/44;;A61K31/505;;A61P25/00;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26,514/357,0,0,,,,EXPIRED
117,US,A1,US 2002/0052497 A1,147-726-889-835-970,2002-05-02,2002,US 97341101 A,2001-10-09,US 97341101 A;;US 52211700 A,2000-03-09,Compounds capable of activating cholinergic receptors,"
   Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-pyrimidinyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-methoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(6-amino-5-methyl-3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-bromo-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-ethoxy-3-pyridyl)-4-penten-2-amine, (2S)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine and (2S)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine. 
",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR B;;PARK HAEIL;;WAGNER JARED MILLER;;CROOKS PETER ANTHONY,TARGACEPT INC (2001-12-18),https://lens.org/147-726-889-835-970,Patent Application,yes,0,31,3,42,0,A61K31/44;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26;;A61P25/28;;C07D213/73;;C07D213/65;;A61K31/44;;C07D213/38;;A61K31/505;;C07D213/61;;C07D239/26,A61K31/44;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26,544/309;;544/311;;544/315,0,0,,,,DISCONTINUED
118,US,B2,US 8288420 B2,146-590-131-502-893,2012-10-16,2012,US 77679810 A,2010-05-10,US 77679810 A;;US 93289507 A;;US 37944306 A;;US 18105505 A;;US 4821205 A;;US 52211700 A;;US 9828598 A,1998-06-16,Compounds capable of activating cholinergic receptors,"Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-pyrimidinyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-methoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(6-amino-5-methyl-3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-bromo-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-ethoxy-3-pyridyl)-4-penten-2-amine, (2S)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine and (2S)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine.",CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAKUMAR BASAWANNAPPA;;PARK HAEIL;;WAGNER JARED MILLER;;CROOKS PETER A;;TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAKUMAR BASAWANNAPPA;;PARK HAEIL;;WAGNER JARED MILLER;;CROOKS PETER A,,https://lens.org/146-590-131-502-893,Granted Patent,yes,46,0,6,42,0,A61K31/44;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/28;;C07D239/26;;A61K31/44;;A61K31/505;;C07D213/61;;C07D213/38;;C07D213/73;;C07D213/65,A61K31/44;;A61K31/505;;A61P25/00;;C07D213/02;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26,514/345;;514/351;;544/301,25,17,052-702-054-753-554;;184-367-294-782-70X;;040-465-959-286-768;;043-091-711-667-642;;094-390-180-579-79X;;061-556-297-543-520;;080-173-777-134-292;;174-507-030-434-145;;184-367-294-782-70X;;056-184-684-713-117;;087-248-970-933-131;;105-959-091-465-070;;077-658-197-676-56X;;128-203-798-400-195;;004-206-224-320-513;;142-350-433-703-027;;026-929-019-093-929,10.1039/p19800000579;;8968366;;10.1055/s-1995-5220;;10.1002/bms.1200221006;;8218423;;11207426;;10.1016/s0891-0618(00)00110-1;;10.1021/jo00409a002;;10.1021/jm00400a005;;2966246;;10.1021/ja01396a022;;8968366;;10.1021/jo00148a033;;10.1007/s002130050048;;10755737;;10.1016/0306-4522(94)00410-7;;7700528;;10.1002/ddr.430310112;;11074159;;10.1016/s0306-4522(00)00377-8;;12683258;;10.1016/s0193-953x(02)00084-9;;1263119;;pmc6741718;;15179444;;10.1111/j.1527-3458.2004.tb00010.x,"Acheson, R., et al., ""Transformations involving the Pyrrolidine Ring of Nicotine,"" J Chem. Soc. Perkin Trans., 1: 579-585 (1980).;;Arneric, S. and M. Williams, ""Nicotinic Agonists in Alzheimer's Disease: Does the Molecular Diversity of Nicotine Receptors Offer the Opportunity for Developing CNSSelective Cholinergic Channel Activators?,"" Int. Acad. Biomed. Drug Res., 7: 58-70 (1994).;;Bencherif, et al., ""Metanicotine: A Nicotinic Agonist with CNS Selectivity-In Vitro Characterization,"" Society for Neuroscience Abstracts, 21(1-3): 605 (1995).;;Bencherif, M., et al., ""RJR-2403: A Nicotinic Agonist with CNS Selctivity II. In Vitro Characterization,"" JPET, 279(3): 1413-1421 (1996).;;Bleicher, L. and N.D.P. Cosford, ""Aryl-and Heteroaryl-Alkyne Coupling Reactions Catalyzed by Palladium on Carbon and Cul in an Aqueous Medium,"" Synlett, 115-1116 (1995).;;Cooper, D.A. and J.M. Moore, ""Femtogram on column detection of nicotine by isotope dilution gas chromatography/negative ion detection mass spectrometry,"" Biol. Mass. Spectrom., 22(10): 590-594 (1993).;;Court et al., J. Chem. Neuroanat. 20(3-4) : 281-298, 2000.;;Frank, W., et al., ""Palladium-Catalyzed Vinylic Substitution Reactions with Heterocyclic Bromides,"" I Org. Chem., 43(15): 2947-2949 (1978).;;Hogberg, Thomas, et al., ""Homallylic Amines Related to Zimeldine. A Comparative Study on Neuronal Seroonin and Norepinephrine Reuptake Based on Conformational Analysis,"" J. Med. Chem., 31: 913-919 (1988).;;International Search Report; Nov. 26, 1999; R.J. Reynolds Tobacco Company, et al.; PCT/US99/12340.;;Joyce, N.J., et al., Heterocycles, 29(7): 2947-2949 (1978).;;LaForge, F.B., ""The preparation and properties of some new derivatives of pyridine,"" J. Am. Chem. Soc., 50: 2477-2483 (1928).;;Lippiello, P., et al., ""RJR-2403: A Nicotinic Agonist with CNS Selectivity I. In Vitro Characterization,"" JPET, 279(3): 422-1429 (1996).;;Loffler, K., et al., Chem. Ber., 42:3431-3488 (1909).;;Malek, N., et al., I Org. Chem., 47: 5395-5397 (1982).;;Mirza et al., Psychopharmacology 148(3) : 243-250, 2000.;;Perry, E.K., et al., ""Alteration in Nicotine Binding Sites in Parkinson's Disease, Lewy Body Dementia and Alzheimer's Disease: Possible Index of Early Neuropathology,"" Neuroscience, 64(2): 385-395 (1995).;;Pinner, A., Chem. Ber., 1053-1061 (1894).;;Pinner, A., Chem. Ber., pp. 2861-2870 (1894).;;Sahakian, B. and J. Coull, ""Nicotine and Tetrahydroaminoacradine: Evidence for Improved Attention in Patients with Dementia of the Alzheimer Type,"" Drug Development Research, 31: 80-88 (1994).;;Sprouse, C., et al., Abstracts of Papers, Coresta/TCRC, Joint Conference, pp. 32 (1972).;;Terry et al., Neuroscience 10192) : 357-368, 2000.;;Tonmoy Sharma et al., ""Cognitive function in schizophrenia Deficits, functional consequences, and future treatment,"" Psychiatr Clin N. Am, 26 (2003): 25-40.;;Wilson, K.L., Jr., et al., ""Nicotine-Like Actions of cis-Metanicotine and trans-Metanicotine,"" The Journal of Pharmacology and Experimental Therapeutics, 196(3): 685-696 (1976).;;Letchworth et al., ""TC-1734: an orally active neuronal nicotinic receptor modulator with long-lasting cognitive effects, anti-depressant effects and neuroprotective activity,"" Society for Neuroscience (2003) Abstract.",EXPIRED
119,US,B2,US 7307092 B2,171-221-379-792-399,2007-12-11,2007,US 37944306 A,2006-04-20,US 37944306 A;;US 18105505 A;;US 4821205 A;;US 52211700 A;;US 9828598 A,1998-06-16,Compounds Capable of Activating Cholinergic Receptors,"Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-pyrimidinyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-methoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(6-amino-5-methyl-3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-bromo-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-ethoxy-3-pyridyl)-4-penten-2-amine, (2S)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine and (2S)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine.",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR B;;PARK HAEIL;;WAGNER JARED MILLER;;CROOKS PETER ANTHONY,,https://lens.org/171-221-379-792-399,Granted Patent,yes,34,9,6,42,0,A61K31/44;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/24;;C07D239/26;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/28;;A61K31/44;;A61K31/505;;C07D239/26;;C07D213/38;;C07D213/61;;C07D213/73;;C07D239/24;;C07D213/65,A61K31/44;;A61K31/505;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/28;;C07D213/02;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26,514/345;;514/351;;546/290;;546/297;;546/300,23,15,087-248-970-933-131;;128-203-798-400-195;;094-390-180-579-79X;;043-091-711-667-642;;174-507-030-434-145;;056-184-684-713-117;;061-556-297-543-520;;052-702-054-753-554;;040-465-959-286-768;;184-367-294-782-70X;;184-367-294-782-70X;;080-173-777-134-292;;105-959-091-465-070;;077-658-197-676-56X;;142-350-433-703-027,10.1007/s002130050048;;10755737;;11074159;;10.1016/s0306-4522(00)00377-8;;11207426;;10.1016/s0891-0618(00)00110-1;;10.1002/bms.1200221006;;8218423;;10.1021/ja01396a022;;10.1021/jo00148a033;;10.1021/jo00409a002;;10.1039/p19800000579;;10.1055/s-1995-5220;;8968366;;8968366;;10.1021/jm00400a005;;2966246;;10.1016/0306-4522(94)00410-7;;7700528;;10.1002/ddr.430310112;;1263119,"Mirza et al., Psychopharmacology 148(3) : 243-250, 2000.;;Terry et al., Neuroscience 10192) : 357-368, 2000.;;Court et al., J. Chem. Neuroanat. 20(3-4) : 281-298, 2000.;;Cooper, D.A. and J.M. Moore, ""Femtogram on column detection of nicotine by isotope dilution gas chromatography/negative ion detection mass spectrometry,"" Biol. Mass. Spectrom., 22(10): 590-594 (1993).;;Loffler, K., et al., Chem. Ber., 42:3431-3488 (1909).;;LaForge, F.B., ""The preparation and properties of some new derivatives of pyridine,"" J. Am. Chem. Soc., 50: 2477-2483 (1928).;;Pinner, A., Chem. Ber., pp. 2861-2870 (1894).;;Malek, N., et al., J. Org. Chem., 47: 5395-5397 (1982).;;Joyce, N.J., et al., Heterocycles, 29(7): 2947-2949 (1978).;;Frank, W., et al., ""Palladium-Catalyzed Vinylic Substitution Reactions with Heterocyclic Bromides,"" J. Org. Chem., 43(15): 2947-2949 (1978).;;Sprouse, C., et al., Abstracts of Papers, Coresta/TCRC, Joint Conference, pp. 32 (1972).;;Pinner, A., Chem. Ber., 1053-1061 (1894).;;Acheson, R., et al., ""Transformations involving the Pyrrolidine Ring of Nicotine,"" J. Chem. Soc. Perkin Trans., 1: 579-585 (1980).;;Bleicher, L. and N.D.P. Cosford, ""Aryl-and Heteroaryl-Alkyne Coupling Reactions Catalyzed by Palladium on Carbon and CuI in an Aqueous Medium,"" Synlett, 115-1116 (1995).;;Lippiello, P., et al., ""RJR-2403: A Nicotinic Agonist with CNS Selectivity I. In Vitro Characterization,"" JPET, 279(3): 422-1429 (1996).;;Bencherif, M., et al., ""RJR-2403: A Nicotinic Agonist with CNS Selectivity II. In Vitro Characterization,"" JPET, 279(3): 1413-1421 (1996).;;Hogberg, Thomas, et al., ""Homallylic Amines Related to Zimeldine. A Comparative Study on Neuronal Seroonin and Norepinephrine Reuptake Based on Conformational Analysis,"" J. Med. Chem., 31: 913-919 (1988).;;International Search Report; Nov. 26, 1999; R.J. Reynolds Tobacco Company, et al.; PCT/US99/12340.;;Arneric, S. and M. Williams, ""Nicotinic Agonists in Alzheimer's Disease: Does the Molecular Diversity of Nicotine Receptors Offer the Opportunity for Developing CNS-Selective Cholinergic Channel Activators?,"" Int. Acad. Biomed. Drug Res., 7: 58-70 (1994).;;Bencherif, et al., ""Metanicotine: A Nicotinic Agonist with CNS Selectivity-In Vitro Characterization,"" Society for Neuroscience Abstracts, 21(1-3): 605 (1995).;;Perry, E.K., et al., ""Alteration in Nicotine Binding Sites in Parkinson's Disease, Lewy Body Dementia and Alzheimer's Disease: Possible Index of Early Neuropathology,"" Neuroscience, 64(2): 385-395 (1995).;;Sahakian, B. and J. Coull, ""Nicotine and Tetrahydroaminoacradine: Evidence for Improved Attention in Patients with Dementia of the Alzheimer Type,"" Drug Development Research, 31: 80-88 (1994).;;Wilson, K.L., Jr., et al., ""Nicotine-Like Actions of cis-Metanicotine and trans-Metanicotine,"" The Journal of Pharmacology and Experimental Therapeutics, 196(3): 685-696 (1976).",EXPIRED
120,US,A1,US 2008/0139809 A1,080-022-136-607-792,2008-06-12,2008,US 93287307 A,2007-10-31,US 93287307 A;;US 37944306 A;;US 18105505 A;;US 4821205 A;;US 52211700 A;;US 9828598 A,1998-06-16,Compounds Capable of Activating Cholinergic Receptors,"Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-pyrimidinyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-methoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(6-amino-5-methyl-3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-bromo-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-ethoxy-3-pyridyl)-4-penten-2-amine, (2S)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine and (2S)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine.",CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR B;;PARK HAEIL;;WAGNER JARED MILLER;;CROOKS PETER ANTHONY,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR B;;PARK HAEIL;;WAGNER JARED MILLER;;CROOKS PETER ANTHONY,,https://lens.org/080-022-136-607-792,Patent Application,yes,28,0,6,42,0,A61K31/44;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/24;;C07D239/26;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/28;;A61K31/44;;A61K31/505;;C07D239/26;;C07D213/38;;C07D213/61;;C07D213/73;;C07D239/24;;C07D213/65,C07D239/24;;A61K31/44;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26,544/242,0,0,,,,DISCONTINUED
121,US,B2,US 6958399 B2,026-752-474-703-521,2005-10-25,2005,US 85360204 A,2004-05-25,US 85360204 A;;US 97341101 A;;US 52211700 A;;US 9828598 A,1998-06-16,Compounds capable of activating cholinergic receptors,"Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-pyrimidinyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-methoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(6-amino-5-methyl-3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-bromo-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-ethoxy-3-pyridyl)-4-penten-2-amine, (2S)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine and (2S)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine.",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR B;;PARK HAEIL;;WAGNER JARED MILLER;;CROOKS PETER ANTHONY,,https://lens.org/026-752-474-703-521,Granted Patent,yes,29,28,3,42,0,A61K31/44;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26;;A61P25/28;;C07D213/73;;C07D213/65;;A61K31/44;;C07D213/38;;A61K31/505;;C07D213/61;;C07D239/26,A61K31/44;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26,546/290;;546/297;;514/351,20,12,043-091-711-667-642;;174-507-030-434-145;;056-184-684-713-117;;061-556-297-543-520;;052-702-054-753-554;;040-465-959-286-768;;184-367-294-782-70X;;184-367-294-782-70X;;080-173-777-134-292;;105-959-091-465-070;;077-658-197-676-56X;;142-350-433-703-027,10.1002/bms.1200221006;;8218423;;10.1021/ja01396a022;;10.1021/jo00148a033;;10.1021/jo00409a002;;10.1039/p19800000579;;10.1055/s-1995-5220;;8968366;;8968366;;10.1021/jm00400a005;;2966246;;10.1016/0306-4522(94)00410-7;;7700528;;10.1002/ddr.430310112;;1263119,"Cooper, D.A. and J.M. Moore, ""Femtogram on column detection of nicotine by isotope dilution gas chromatography/negative ion detection mass spectrometry,"" Biol. Mass. Spectrom., 22(10): 590-594 (1993).;;Loffler, K., et al., Chem. Ber., 42:3431-3488 (1909).;;LaForge, F.B., ""The preparation and properties of some new derivatives of pyridine,"" J. Am. Chem. Soc., 50: 2477-2483 (1928).;;Pinner, A., Chem. Ber., pp. 2861-2870 (1894).;;Malek, N., et al., J. Org. Chem., 47: 5395-5397 (1982).;;Joyce, N.J., et al., Heterocycles, 29(7): 2947-2949 (1978).;;Frank, W., et al., ""Palladium-Catalyzed Vinylic Substitution Reactions with Heterocyclic Bromides,"" J. Org. Chem., 43(15): 2947-2949 (1978).;;Sprouse, C., et al., Abstracts of Papers, Coresta/TCRC, Joint Conference, pp. 32 (1972).;;Pinner, A., Chem. Ber., 1053-1061 (1894).;;Acheson, R., et al., ""Transformations involving the Pyrrolidine Ring of Nicotine,"" J. Chem. Soc. Perkin Trans., 1: 579-585 (1980).;;Bleicher, L. and N.D.P. Cosford, ""Aryl-and Heteroaryl-Alkyne Coupling Reactions Catalyzed by Palladium on Carbon and CuI in an Aqueous Medium,"" Synlett, 115-1116 (1995).;;Lippiello, P., et al., ""RJR-2403: A Nicotinic Agonist with CNS Selectivity I. In Vitro Characterization,"" JPET, 279(3): 422-1429 (1996).;;Bencherif, M., et al., ""RJR-2403: A Nicotinic Agonist with CNS Selectivity II. In Vitro Characterization,"" JPET, 279(3): 1413-1421 (1996).;;Hogberg, Thomas, et al., ""Homallylic Amines Related to Zimeldine. A Comparative Study on Neuronal Seroonin and Norepinephrine Reuptake Based on Conformational Analysis,"" J. Med. Chem., 31: 913-919 (1988).;;International Search Report; Nov. 26, 1999; R.J. Reynolds Tobacco Company, et al.; PCT/US99/12340.;;Arneric, S. and M. Williams, ""Nicotinic Agonists in Alzheimer's Disease: Does the Molecular Diversity of Nicotine Receptors Offer the Opportunity for Developing CNS-Selective Cholinergic Channel Activators?,"" Int. Acad. Biomed. Drug Res., 7: 58-70 (1994).;;Bencherif, et al., ""Metanicotine: A Nicotinic Agonist with CNS Selectivity-In Vitro Characterization,"" Society for Neuroscience Abstracts, 21(1-3): 605 (1995).;;Perry, E.K., et al., ""Alteration in Nicotine Binding Sites in Parkinson's Disease, Lewy Body Dementia and Alzheimer's Disease: Possible Index of Early Neuropathology,"" Neuroscience, 64(2): 385-395 (1995).;;Sahakian, B. and J. Coull, ""Nicotine and Tetrahydroaminoacradine: Evidence for Improved Attention in Patients with Dementia of the Alzheimer Type,"" Drug Development Research, 31:80-88 (1994).;;Wilson, K.L., Jr., et al., ""Nicotine-Like Actions of cis-Metanicotine and trans-Metanicotine,"" The Journal of Pharmacology and Experimental Therapeutics, 196(3): 685-696 (1976).",EXPIRED
122,US,A1,US 2010/0204481 A1,003-449-901-689-044,2010-08-12,2010,US 76447410 A,2010-04-21,US 76447410 A;;US 71590710 A;;US 93289507 A;;US 37944306 A;;US 18105505 A;;US 4821205 A;;US 52211700 A;;US 9828598 A,1998-06-16,COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS,"Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-pyrimidinyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-methoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(6-amino-5-methyl-3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-bromo-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-ethoxy-3-pyridyl)-4-penten-2-amine, (2S)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine and (2S)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine.",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR B;;PARK HAEIL;;WAGNER JARED MILLER;;CROOKS PETER ANTHONY,,https://lens.org/003-449-901-689-044,Patent Application,yes,31,2,6,42,0,A61K31/44;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/28;;C07D239/26;;A61K31/44;;A61K31/505;;C07D213/61;;C07D213/38;;C07D213/73;;C07D213/65,C07D213/65;;A61K31/44;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/73;;C07D239/26,546/300,0,0,,,,DISCONTINUED
123,US,A1,US 2004/0214835 A1,151-747-258-829-408,2004-10-28,2004,US 85360204 A,2004-05-25,US 85360204 A;;US 97341101 A;;US 52211700 A;;US 9828598 A,1998-06-16,Compounds capable of activating cholinergic receptors,"
   Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-pyrimidinyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-methoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(6-amino-5-methyl-3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-bromo-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-ethoxy-3-pyridyl)-4-penten-2-amine, (2S)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine and (2S)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine. 
",CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR B.;;PARK HAEIL;;WAGNER JARED MILLER;;CROOKS PETER ANTHONY,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR B;;PARK HAEIL;;WAGNER JARED MILLER;;CROOKS PETER ANTHONY,,https://lens.org/151-747-258-829-408,Patent Application,yes,22,1,3,42,0,A61K31/44;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26;;A61P25/28;;C07D213/73;;C07D213/65;;A61K31/44;;C07D213/38;;A61K31/505;;C07D213/61;;C07D239/26,A61K31/44;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26,514/256;;514/357;;544/242;;546/326,0,0,,,,EXPIRED
124,US,B1,US 6310102 B1,067-250-365-582-529,2001-10-30,2001,US 51993700 A,2000-03-07,US 51993700 A;;US 17723198 A,1998-10-22,Pharmaceutical compositions and methods for use,"Pharmaceutical compositions aryl substituted amine compounds, and in particular, 3-aminophenyl amine compounds are provided. Representative compounds are (E)-4-(3-aminophenyl)-3-buten-1-amine, (E)-N-methyl-4-(3-aminophenyl)-3-buten-1-amine and (E)-N-methyl-5-(3-aminophenyl)-4-penten-2-amine.",TARGACEPT INC,DULL GARY MAURICE;;WAGNER JARED MILLER;;CALDWELL WILLIAM SCOTT;;MILLER CRAIG HARRISON;;SCHMITT JEFFREY DANIEL;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR BASAWAN,,https://lens.org/067-250-365-582-529,Granted Patent,yes,13,22,6,6,0,C07C211/49;;C07C211/49,C07C211/49,514/649;;564/338,2,2,018-158-099-633-493;;196-261-222-455-988,10.1021/jm00012a012;;7783144;;10.1021/jo01308a022,"Beams, Richard, M. et al., Development of a Novel Series of Trialkoxyaryl Derivatives as Specific and Competitive Antagonists of Platelet Activating Factor, J. Med. Chem. (1995), 38(12), 2130-7, XP002121846.;;Olsen, David K., et al., Preparation and stereochemistry of 4-aryl-3-butenylamines. A novel synthesis of an oxazolo 2,3-a! isoindole, J. Org. Chem., (1980), 45(20), 4049-52, XP002121847.",EXPIRED
125,AU,A,AU 2000/069122 A,175-153-955-478-343,2001-04-10,2001,AU 2000/069122 A,2000-08-17,US 39174799 A;;US 0022571 W,1999-09-08,Pharmaceutical compositions and methods for use,,TARGACEPT INC,DULL GARY MAURICE;;WAGNER JARED MILLER;;CALDWELL WILLIAM SCOTT;;MILLER CRAIG HARRISON;;SCHMITT JEFFREY DANIEL;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR BASAWAN,,https://lens.org/175-153-955-478-343,Patent Application,no,0,0,5,5,0,C07D317/58;;C07D317/58;;C07C211/29;;C07C211/29;;C07C211/49;;C07C211/49;;C07C233/43;;C07C233/43,C07C211/29;;C07C211/49;;C07C233/43;;C07D317/58,,0,0,,,,PENDING
126,US,B1,US 6337351 B1,038-268-899-706-331,2002-01-08,2002,US 39174799 A,1999-09-08,US 39174799 A;;US 17723198 A,1998-10-22,Pharmaceutical compositions and methods for use,"
    Pharmaceutical compositions aryl substituted amine compounds, and in particular, 3-aminophenyl amine compounds are provided. Representative compounds are (4E)-N-methyl-5-(3-acetamido-4-methylphenyl)-4-penten-2-amine, (4E)-N-methyl-5-(3-amino-4-methylphenyl)-4-penten-2-amine, (4E)-N-methyl-5-(3-(dimethylamino)phenyl)-4-penten-2-amine, (4E)-N-methyl-5-(4-methyl-3-nitrophenyl)-4-penten-2-amine, (4E)-N-methyl-5-(3-fluorophenyl)-4-penten-2-amine, (4E)-N-methyl-5-(3,4-dichlorophenyl)-4-penten-2-amine and (4E)-N-methyl-5-(3,4-methylenedioxyphenyl)-4-penten-2-amine. 
",TARGACEPT INC,DULL GARY MAURICE;;WAGNER JARED MILLER;;CALDWELL WILLIAM SCOTT;;MILLER CRAIG HARRISON;;SCHMITT JEFFREY DANIEL;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR BASAWAN,TARGACEPT INC (2002-05-14),https://lens.org/038-268-899-706-331,Granted Patent,yes,5,31,5,5,0,C07D317/58;;C07D317/58;;C07C211/29;;C07C211/29;;C07C211/49;;C07C211/49;;C07C233/43;;C07C233/43,C07C211/29;;C07C211/49;;C07C233/43;;C07D317/58,514/649;;514/654;;564/336;;564/374;;564/383,6,6,018-158-099-633-493;;196-261-222-455-988;;042-323-085-274-14X;;087-171-464-584-829;;067-949-874-923-415;;072-642-229-453-523,10.1021/jm00012a012;;7783144;;10.1021/jo01308a022;;10.1021/jo00328a018;;10.1016/s0040-4020(01)86320-1;;10.1039/c39750000903;;10.1021/cr00002a004,"Beams, Richard, M. et al., ""Development of a Novel Series of Trialkoxyaryl Derivatives as Specific and Competitive Antagonists of Platelet Activating Factor"", J. Med. Chem. (1995), 38(12), 2130-7, XP002121846.;;Olsen, David K., et al., Preparation and stereochemistry of 4-aryl-3-butenylamines. A novel synthesis of an oxazolo ""2,3-a! isoindole"", J. Org. Chem., (1980), 45(20), 4049-52, XP002121847.;;Taylor et al., ""Thallium in Organic Synthesis,"" J. Org. Chem., 1981, 46, pp. 3078-3081.;;Tokuda et al., ""New Total Synthesis of (+)-N-Methylanisomycin of Anodic Cyclization of delta-Alkenylamine,"" Tetrahedron, vol. 49, No. 12, 1993, pp. 2413-2426.;;Cox, Michael T., ""Benzo[4,5]cyclohepta[1,2-c]pyrrole Derivatives iva Intramolecular Cycloaddition and Solvolytic Ring Expansion,"" J.C.S. Chem. Comm., 1975, pp. 903-905.;;Hansch et al., ""A Survey of Hammett Substituent Constants and Resonance and Field Parameters,"" Chem Rev., 1991, vol. 91, pp. 165-195.",EXPIRED
127,WO,A1,WO 2000/023418 A1,188-870-341-225-53X,2000-04-27,2000,US 9918613 W,1999-08-17,US 17723198 A,1998-10-22,PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE,"Pharmaceutical compositions aryl substituted amine compounds, and in particular, 3-aminophenyl amine compounds are provided. Representative compounds are (E)-4-(3-aminophenyl)-3-buten-1-amine, (E)-N-methyl-4-(3-aminophenyl)-3-buten-1-amine and (E)-N-methyl-5-(3-aminophenyl)-4-penten-2-amine.",REYNOLDS TOBACCO CO R;;DULL GARY MAURICE;;WAGNER JARED MILLER;;CALDWELL WILLIAM SCOTT;;MILLER CRAIG HARRISON;;SCHMITT JEFFREY DANIEL;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR BASAWAN,DULL GARY MAURICE;;WAGNER JARED MILLER;;CALDWELL WILLIAM SCOTT;;MILLER CRAIG HARRISON;;SCHMITT JEFFREY DANIEL;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR BASAWAN,,https://lens.org/188-870-341-225-53X,Patent Application,yes,1,5,6,6,0,C07C211/49;;C07C211/49,C07C211/49,,2,2,018-158-099-633-493;;196-261-222-455-988,10.1021/jm00012a012;;7783144;;10.1021/jo01308a022,"BEAMS, RICHARD M. ET AL: ""Development of a Novel Series of Trialkoxyaryl Derivatives as Specific and Competitive Antagonists of Platelet Activating Factor"", J. MED. CHEM. (1995), 38(12), 2130-7, XP002121846;;OLSEN, DAVID K. ET AL: ""Preparation and stereochemistry of 4-aryl-3-butenylamines. A novel synthesis of an oxazolo[2,3-a]isoindole"", J. ORG. CHEM. (1980), 45(20), 4049-52, XP002121847",PENDING
128,CA,A1,CA 2384094 A1,101-306-709-493-695,2001-03-15,2001,CA 2384094 A,2000-08-17,US 39174799 A;;US 0022571 W,1999-09-08,PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE,"Pharmaceutical compositions aryl substituted amine compounds, and in particular, 3-aminophenyl amine compounds are provided. Representative compounds are (4E)-N-methyl-5-(3-acetamido-4-methylphenyl)-4-penten-2-amine, (4E)-N-methyl-5-(3-amino-4-methylphenyl)-4-penten-2-amine, (4E)-N-methyl-5-( 3- (dimethylamino)phenyl)-4-penten-2-amine, (4E)-N-methyl-5-(4-methyl-3- nitrophenyl)-4-penten-2-amine, (4E)-N-methyl-5-(3-fluorophenyl)-4-penten-2- amine, (4E)-N-methyl-5-(3,4-dichlorophenyl)-4-penten-2-amine and (4E)-N-meth yl- 5-(3,4-methylenedioxyphenyl)-4-penten-2-amine.",TARGACEPT INC,WAGNER JARED MILLER;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;MILLER CRAIG HARRISON;;HADIMANI SRISHAILKUMAR BASAWAN;;SCHMITT JEFFREY DANIEL;;BHATTI BALWINDER SINGH,,https://lens.org/101-306-709-493-695,Patent Application,no,0,0,5,5,0,C07D317/58;;C07D317/58;;C07C211/29;;C07C211/29;;C07C211/49;;C07C211/49;;C07C233/43;;C07C233/43,C07C211/29;;C07C211/49;;C07C233/43;;C07D317/58,,0,0,,,,DISCONTINUED
129,US,B1,US 6262124 B1,086-726-412-272-92X,2001-07-17,2001,US 17723198 A,1998-10-22,US 17723198 A,1998-10-22,Pharmaceutical compositions and methods for use,"Pharmaceutical compositions aryl substituted amine compounds, and in particular, 3-aminophenyl amine compounds are provided. Representative compounds are (E)-4-(3-aminophenyl)-3-buten-1-amine, (E)-N-methyl-4-(3-aminophenyl)-3-buten-1-amine and (E)-N-methyl-5-(3-aminophenyl)-4-penten-2-amine.",DULL GARY MAURICE;;WAGNER JARED MILLER;;CALDWELL WILLIAM SCOTT;;MILLER CRAIG HARRISON;;SCHMITT JEFFREY DANIEL;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR BASAWANNAPPA,DULL GARY MAURICE;;WAGNER JARED MILLER;;CALDWELL WILLIAM SCOTT;;MILLER CRAIG HARRISON;;SCHMITT JEFFREY DANIEL;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR BASAWAN,KENTUCKY RESEARCH FOUNDATION THE UNIVERSITY OF (1998-12-07);;TARGACEPT INC. A CORPORATION OF DELAWARE (1999-04-09);;R. J. REYNOLDS TOBACCO COMPANY (1998-12-08);;TARGACEPT INC (1999-03-17),https://lens.org/086-726-412-272-92X,Granted Patent,yes,15,22,6,6,0,C07C211/49;;C07C211/49,C07C211/49,514/649;;514/654;;564/336;;564/305,0,0,,,,EXPIRED
130,WO,A1,WO 2001/017943 A1,185-515-050-741-424,2001-03-15,2001,US 0022571 W,2000-08-17,US 39174799 A,1999-09-08,PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE,"Pharmaceutical compositions aryl substituted amine compounds, and in particular, 3-aminophenyl amine compounds are provided. Representative compounds are (4E)-N-methyl-5-(3-acetamido-4-methylphenyl)-4-penten-2-amine, (4E)-N-methyl-5-(3-amino-4-methylphenyl)-4-penten-2-amine, (4E)-N-methyl-5-(3-(dimethylamino)phenyl)-4-penten-2-amine, (4E)-N-methyl-5-(4-methyl-3-nitrophenyl)-4-penten-2-amine, (4E)-N-methyl-5-(3-fluorophenyl)-4-penten-2-amine, (4E)-N-methyl-5-(3,4-dichlorophenyl)-4-penten-2-amine and (4E)-N-methyl-5-(3,4-methylenedioxyphenyl)-4-penten-2-amine.",TARGACEPT INC,DULL GARY MAURICE;;WAGNER JARED MILLER;;CALDWELL WILLIAM SCOTT;;MILLER CRAIG HARRISON;;SCHMITT JEFFREY DANIEL;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR BASAWAN,,https://lens.org/185-515-050-741-424,Patent Application,yes,5,14,5,5,0,C07D317/58;;C07D317/58;;C07C211/29;;C07C211/29;;C07C211/49;;C07C211/49;;C07C233/43;;C07C233/43,C07C211/29;;C07C211/49;;C07C233/43;;C07D317/58,,6,6,196-261-222-455-988;;018-158-099-633-493;;042-323-085-274-14X;;087-171-464-584-829;;067-949-874-923-415;;072-642-229-453-523,10.1021/jo01308a022;;10.1021/jm00012a012;;7783144;;10.1021/jo00328a018;;10.1016/s0040-4020(01)86320-1;;10.1039/c39750000903;;10.1021/cr00002a004,"OLSEN ET AL: ""Preparation and stereochemistry of 4-aryl-3-butenylamines. A novel synthesis of an oxazolo[2,3-a]isoindole"", JOURNAL OF ORGANIC CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. EASTON, vol. 45, no. 20, 26 September 1980 (1980-09-26), pages 4049 - 4052, XP002121847, ISSN: 0022-3263;;BEAMS ET AL: ""Development of a Novel Series of Trialkoxyaryl Derivatives as Specific and Competitive Antagonists of Platelet Activating Factor"", JOURNAL OF MEDICINAL CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 38, no. 12, 9 June 1995 (1995-06-09), pages 2130 - 2137, XP002121846, ISSN: 0022-2623;;EDWARD C TAYLOR ET AL: ""Thallium in organic synthesis. 60. 2,6-Diaryl-3,7-dioxabicyclo[3.3.0] octane-4,8-dione lignans by oxidative dimerization of 4-alkoxycinnamic acids with thallium (III) triflouroacetate or cobalt (III) triflouride"", JOURNAL OF ORGANIC CHEMISTRY., vol. 46, no. 15, 1981, AMERICAN CHEMICAL SOCIETY. EASTON., US, pages 3078 - 3081, XP002154402, ISSN: 0022-3263;;MASAO TOKUDA ET AL: ""New total synthesis of (+)-N-methylanisomycin by anodic cyclization of delta-alkenylamine"", TETRAHEDRON., vol. 49, no. 12, 1993, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM., NL, pages 2413 - 2426, XP002154403, ISSN: 0040-4020;;MICHAEL T COX: ""Benzo[4,5]cyclohepta[1,2-c]pyrrole derivatives via intramolecular cycloaddition and solvolytic ring expansion"", JOURNAL OF THE CHEMICAL SOCIETY, CHEMICAL COMMUNICATIONS., - 1975, CHEMICAL SOCIETY. LETCHWORTH., GB, pages 903 - 5, XP000961228, ISSN: 0022-4936;;C HANSCH ET AL: ""A SURVEY OF HAMMETT SUBSTITUENT CONSTANTS AND RESONANCE AND FIELD PARAMETERS"", CHEMICAL REVIEWS,AMERICAN CHEMICAL SOCIETY. EASTON,US, vol. 91, 1991, pages 165 - 195, XP002147860, ISSN: 0009-2665",PENDING
131,AU,A,AU 1999/055650 A,161-419-243-678-133,2000-05-08,2000,AU 1999/055650 A,1999-08-17,US 17723198 A;;US 9918613 W,1998-10-22,Pharmaceutical compositions and methods for use,,REYNOLDS TOBACCO CO R,DULL GARY MAURICE;;WAGNER JARED MILLER;;CALDWELL WILLIAM SCOTT;;MILLER CRAIG HARRISON;;SCHMITT JEFFREY DANIEL;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR BASAWAN,,https://lens.org/161-419-243-678-133,Patent Application,no,0,0,6,6,0,C07C211/49;;C07C211/49,C07C211/49,,0,0,,,,DISCONTINUED
132,EP,A1,EP 1214288 A1,116-491-533-533-017,2002-06-19,2002,EP 00957516 A,2000-08-17,US 0022571 W;;US 39174799 A,1999-09-08,PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE,,TARGACEPT INC,DULL GARY MAURICE;;WAGNER JARED MILLER;;CALDWELL WILLIAM SCOTT;;MILLER CRAIG HARRISON;;SCHMITT JEFFREY DANIEL;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR BASAWAN,"TARGACEPT, INC. (2003-04-16)",https://lens.org/116-491-533-533-017,Patent Application,yes,0,0,5,5,0,C07D317/58;;C07D317/58;;C07C211/29;;C07C211/29;;C07C211/49;;C07C211/49;;C07C233/43;;C07C233/43,C07C211/29;;C07C211/49;;C07C233/43;;C07D317/58,,1,0,,,See references of WO 0117943A1,DISCONTINUED
133,CA,A1,CA 2317024 A1,146-931-686-656-24X,2000-04-27,2000,CA 2317024 A,1999-08-17,US 17723198 A;;US 9918613 W,1998-10-22,PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE,"Pharmaceutical compositions aryl substituted amine compounds, and in particular, 3-aminophenyl amine compounds are provided. Representative compounds are (E)-4-(3-aminophenyl)-3-buten-1-amine, (E)-N-methyl-4-(3-aminophenyl)-3-buten-1-amine and (E)-N-methyl-5-(3-aminophenyl)-4-penten-2-amine.",REYNOLDS TOBACCO CO R,CALDWELL WILLIAM SCOTT;;SCHMITT JEFFREY DANIEL;;MILLER CRAIG HARRISON;;WAGNER JARED MILLER;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR BASAWAN,,https://lens.org/146-931-686-656-24X,Patent Application,no,0,0,6,6,0,C07C211/49;;C07C211/49,C07C211/49,,0,0,,,,DISCONTINUED
134,EP,A1,EP 1042274 A1,009-382-687-887-246,2000-10-11,2000,EP 99942222 A,1999-08-17,US 9918613 W;;US 17723198 A,1998-10-22,PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE,,REYNOLDS TOBACCO CO R,DULL GARY MAURICE;;WAGNER JARED MILLER;;CALDWELL WILLIAM SCOTT;;MILLER CRAIG HARRISON;;SCHMITT JEFFREY DANIEL;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR BASAWAN,"TARGACEPT, INC. (2002-12-18)",https://lens.org/009-382-687-887-246,Patent Application,yes,0,0,6,6,0,C07C211/49;;C07C211/49,C07C211/49,,1,0,,,See references of WO 0023418A1,DISCONTINUED
135,AT,T1,AT E261443 T1,025-228-824-172-787,2004-03-15,2004,AT 98918598 T,1998-04-22,US 88539797 A;;US 88576897 A;;US 9808145 W,1997-06-30,3-PYRIDYL-1-AZABICYCLOALKAN-DERIVATE ZUR BEHANDLUNG VON ZNS-ERKRANKUNGEN,"Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia) are treated by administering an <u>endo</u> or <u>exo</u> form of a 1-aza-2-(3-pyridyl)bicyclo[2.2.1]heptane, a 1-aza-2-(3-pyridyl)bicyclo[2.2.2] octane, a 1-aza-2-(3-pyridyl)bicyclo[3.2.2]nonane, a 1-aza-7-(3-pyridyl) bicyclo[2.2.1]heptane, a 1-aza-3-(3-pyridyl)bicyclo[3.2.2]nonane, or a 1-aza-7-(3-pyridyl)bicyclo[3.2.2]nonane.",TARGACEPT INC;;UNIV KENTUCKY RES FOUND,CALDWELL WILLIAM SCOTT;;BENCHERIF MEROUANE;;DULL GARY MAURICE;;CROOKS PETER ANTHONY;;LIPPIELLO PATRICK MICHAEL;;BHATTI BALWINDER SINGH;;DEO NIRANJAN MADHUKAR;;RAVARD ALAIN,,https://lens.org/025-228-824-172-787,Granted Patent,no,0,0,13,15,0,C07D453/02;;C07D487/08;;A61P25/00;;A61P25/16;;A61P25/28,A61K31/407;;A61K31/439;;A61K31/55;;A61P25/00;;A61P25/16;;A61P25/28;;C07D453/02;;C07D471/08;;C07D487/08,,0,0,,,,DISCONTINUED
136,CA,A1,CA 2294990 A1,047-697-957-242-136,1999-01-07,1999,CA 2294990 A,1998-04-22,US 88539797 A;;US 88576897 A;;US 9808145 W,1997-06-30,PHARMACEUTICAL COMPOSITIONS AND METHODS FOR EFFECTING DOPAMINE RELEASE,"Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia) are treated by administering an endo or exo form of a 1-aza-2-(3-pyridyl)bicyclo¢2.2.1!heptane, a 1-aza-2-(3-pyridyl)bicyclo¢2.2.2! octane, a 1-aza-2-(3-pyridyl)bicyclo¢3.2.2!nonane, a 1aza-7-(3-pyridyl) bicyclo¢2.2.1!heptane, a 1-aza-3-(3-pyridyl)bicyclo¢3.2.2!nonane, or a 1-aza-7-(3-pyridyl)bicyclo¢3.2.2!nonane.",UNIV KENTUCKY RES FOUND;;REYNOLDS TOBACCO CO R,DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;CALDWELL WILLIAM SCOTT;;LIPPIELLO PATRICK MICHAEL;;CROOKS PETER ANTHONY;;DEO NIRANJAN MADHUKAR;;BENCHERIF MEROUANE;;RAVARD ALAIN,,https://lens.org/047-697-957-242-136,Patent Application,no,0,0,13,15,0,C07D453/02;;C07D487/08;;A61P25/00;;A61P25/16;;A61P25/28,A61K31/407;;A61K31/439;;A61K31/55;;A61P25/00;;A61P25/16;;A61P25/28;;C07D453/02;;C07D471/08;;C07D487/08,,0,0,,,,EXPIRED
137,DK,T3,DK 0994875 T3,070-921-764-175-392,2004-06-21,2004,DK 98918598 T,1998-04-22,US 88539797 A;;US 88576897 A,1997-06-30,3-Pyridyl-1-azabicycloalkanderivater til forhindring og behandling af afvigelser i centralnervesystemet,"Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia) are treated by administering an <u>endo</u> or <u>exo</u> form of a 1-aza-2-(3-pyridyl)bicyclo[2.2.1]heptane, a 1-aza-2-(3-pyridyl)bicyclo[2.2.2] octane, a 1-aza-2-(3-pyridyl)bicyclo[3.2.2]nonane, a 1-aza-7-(3-pyridyl) bicyclo[2.2.1]heptane, a 1-aza-3-(3-pyridyl)bicyclo[3.2.2]nonane, or a 1-aza-7-(3-pyridyl)bicyclo[3.2.2]nonane.",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;BENCHERIF MEROUANE;;DULL GARY MAURICE;;CROOKS PETER ANTHONY;;LIPPIELLO PATRICK MICHAEL;;BHATTI BALWINDER SINGH;;DEO NIRANJAN MADHUKAR;;RAVARD ALAIN,,https://lens.org/070-921-764-175-392,Granted Patent,no,0,0,13,15,0,C07D453/02;;C07D487/08;;A61P25/00;;A61P25/16;;A61P25/28,A61K31/407;;A61K31/439;;A61K31/55;;A61P25/00;;A61P25/16;;A61P25/28;;C07D453/02;;C07D471/08;;C07D487/08,,0,0,,,,EXPIRED
138,WO,A1,WO 1996/036637 A1,187-876-439-707-167,1996-11-21,1996,US 9604536 W,1996-04-03,US 43715495 A;;US 43715395 A,1995-05-17,PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS,"Patients susceptible to or suffering from central nervous system disorders (e.g., neurodegenerative diseases including presenile dementia, senile dementia of the Alzheimer's type, and Parkinsonism including Parkinsons's disease, and other CNS disorders including attention deficit disorder, schizophrenia and Tourette's syndrome) are treated by administering an effective amount of 2-azabicyclo [2.2.1] hept-5-ene and 2-azabicyclo [2.2.2] oct-5-ene compounds. Exemplary compounds are (+/-)-3-exo and (+/-)-3-endo forms of 2-methyl-3-(3-pyridyl)-2-azabicyclo[2.2.1]hept-5-ene, (+/-)-3-exo and (+/-)-3-endo forms of 2-methyl-3-(3-pyridyl)-2-azabicyclo[2.2.1]hept-5-ene, (+/-)-3-exo and (+/-)-3-endo forms of 2-benzyl-3-(3-pyridyl)-2-azabicyclo[2.2.1]hept-5-ene, (+/-)-3-exo and (+/-)-3-endo forms of 2-para-anisyl-3-(3-pyridyl)-2-azabicyclo[2.2.1]hept-5-ene, (+/-)-3-exo and (+/-)-3-endo forms of 3-(3-pyridyl)-2-azabicyclo[2.2.2]oct-5-ene, (+/-)-3-exo and (+/-)-3-endo forms of 3-(3-pyridyl)-2-azabicyclo[2.2.2.]oct-5-ene, (+/-)-3-exo and (+/-)-3-endo forms of 2-methyl-3-(3-pyridyl)-2-azabicyclo[2.2.2.]oct-5-ene, the racemic form of 3-(3-pyridyl)-2-azabicyclo[2.2.2]octane, and the racemic form of 2-methyl-3-(3-pyridyl)-2-azabicyclo[2.2.2]octane.",REYNOLDS TOBACCO CO R;;UNIV KENTUCKY RES FOUND;;BENCHERIF MEROUANE;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;LIPPIELLO PATRICK MICHAEL;;CROOKS PETER ANTHONY;;BHATTI BALWINDER SINGH;;DEO NIRANJAN MADHUKAR;;RAVARD ALAIN,BENCHERIF MEROUANE;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;LIPPIELLO PATRICK MICHAEL;;CROOKS PETER ANTHONY;;BHATTI BALWINDER SINGH;;DEO NIRANJAN MADHUKAR;;RAVARD ALAIN,,https://lens.org/187-876-439-707-167,Patent Application,yes,4,32,2,5,0,C07D401/04;;C07D453/06,C07D401/04;;C07D453/06,,0,0,,,,PENDING
139,AU,A,AU 1998/071497 A,105-194-828-784-905,1999-01-19,1999,AU 1998/071497 A,1998-04-22,US 88539797 A;;US 88576897 A;;US 9808145 W,1997-06-30,3-pyridyl-1-aza-bicyclo-alkane derivatives for prevention and treatment of cns disorders,"Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia) are treated by administering an <u>endo</u> or <u>exo</u> form of a 1-aza-2-(3-pyridyl)bicyclo[2.2.1]heptane, a 1-aza-2-(3-pyridyl)bicyclo[2.2.2] octane, a 1-aza-2-(3-pyridyl)bicyclo[3.2.2]nonane, a 1-aza-7-(3-pyridyl) bicyclo[2.2.1]heptane, a 1-aza-3-(3-pyridyl)bicyclo[3.2.2]nonane, or a 1-aza-7-(3-pyridyl)bicyclo[3.2.2]nonane.",REYNOLDS TOBACCO CO R;;UNIV KENTUCKY RES FOUND,CALDWELL WILLIAM SCOTT;;BENCHERIF MEROUANE;;DULL GARY MAURICE;;CROOKS PETER ANTHONY;;LIPPIELLO PATRICK MICHAEL;;BHATTI BALWINDER SINGH;;DEO NIRANJAN MADHUKAR;;RAVARD ALAIN,,https://lens.org/105-194-828-784-905,Patent Application,no,0,0,13,15,0,C07D453/02;;C07D487/08;;A61P25/00;;A61P25/16;;A61P25/28,A61K31/407;;A61K31/439;;A61K31/55;;A61P25/00;;A61P25/16;;A61P25/28;;C07D453/02;;C07D471/08;;C07D487/08,,0,0,,,,DISCONTINUED
140,EP,A1,EP 0994875 A1,197-980-435-386-151,2000-04-26,2000,EP 98918598 A,1998-04-22,US 9808145 W;;US 88539797 A;;US 88576897 A,1997-06-30,3-PYRIDYL-1-AZABICYCLOALKANE DERIVATIVES FOR PREVENTION AND TREATMENT OF CNS DISORDERS,"Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia) are treated by administering an <u>endo</u> or <u>exo</u> form of a 1-aza-2-(3-pyridyl)bicyclo[2.2.1]heptane, a 1-aza-2-(3-pyridyl)bicyclo[2.2.2] octane, a 1-aza-2-(3-pyridyl)bicyclo[3.2.2]nonane, a 1-aza-7-(3-pyridyl) bicyclo[2.2.1]heptane, a 1-aza-3-(3-pyridyl)bicyclo[3.2.2]nonane, or a 1-aza-7-(3-pyridyl)bicyclo[3.2.2]nonane.",REYNOLDS TOBACCO CO R;;UNIV KENTUCKY RES FOUND,CALDWELL WILLIAM SCOTT;;BENCHERIF MEROUANE;;DULL GARY MAURICE;;CROOKS PETER ANTHONY;;LIPPIELLO PATRICK MICHAEL;;BHATTI BALWINDER SINGH;;DEO NIRANJAN MADHUKAR;;RAVARD ALAIN,"THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (2002-12-18);;TARGACEPT, INC. (2004-07-01)",https://lens.org/197-980-435-386-151,Patent Application,yes,0,0,13,15,0,C07D453/02;;C07D487/08;;A61P25/00;;A61P25/16;;A61P25/28,A61K31/407;;A61K31/439;;A61K31/55;;A61P25/00;;A61P25/16;;A61P25/28;;C07D453/02;;C07D471/08;;C07D487/08,,0,0,,,,EXPIRED
141,CA,C,CA 2294990 C,038-812-041-343-265,2007-03-06,2007,CA 2294990 A,1998-04-22,US 88539797 A;;US 88576897 A;;US 9808145 W,1997-06-30,PHARMACEUTICAL COMPOSITIONS AND METHODS FOR EFFECTING DOPAMINE RELEASE,"Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia) are treated by administering an endo o r exo form of a 1-aza-2-(3-pyridyl)bicyclo[2.2.1]heptane, a I-aza-2-(3-pyridyl)bicyclo[2.2.2] octane, a 1-aza-2-(3- pyridyl)bicyclo[3.2.2]nonane, a 1-aza-7-(3-pyridyl) bicyclo[2.2.1]heptane, a 1-aza-3-(3-pyridyl)bicyclo[3.2.2]nonane, or a 1-aza-7-(3- pyridyl)bicyclo[3.2.2]nonane.",REYNOLDS TOBACCO CO R;;UNIV KENTUCKY RES FOUND,LIPPIELLO PATRICK MICHAEL;;DULL GARY MAURICE;;CALDWELL WILLIAM SCOTT;;CROOKS PETER ANTHONY;;BHATTI BALWINDER SINGH;;DEO NIRANJAN MADHUKAR;;RAVARD ALAIN;;BENCHERIF MEROUANE,,https://lens.org/038-812-041-343-265,Granted Patent,no,0,0,13,15,0,C07D453/02;;C07D487/08;;A61P25/00;;A61P25/16;;A61P25/28,C07D453/02;;A61K31/407;;A61K31/439;;A61K31/44;;A61K31/55;;A61P25/00;;A61P25/16;;A61P25/28;;C07D471/08;;C07D487/08,,0,0,,,,EXPIRED
142,EP,B1,EP 0994875 B1,109-661-127-268-604,2004-03-10,2004,EP 98918598 A,1998-04-22,US 9808145 W;;US 88539797 A;;US 88576897 A,1997-06-30,3-PYRIDYL-1-AZABICYCLOALKANE DERIVATIVES FOR PREVENTION AND TREATMENT OF CNS DISORDERS,"Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia) are treated by administering an <u>endo</u> or <u>exo</u> form of a 1-aza-2-(3-pyridyl)bicyclo[2.2.1]heptane, a 1-aza-2-(3-pyridyl)bicyclo[2.2.2] octane, a 1-aza-2-(3-pyridyl)bicyclo[3.2.2]nonane, a 1-aza-7-(3-pyridyl) bicyclo[2.2.1]heptane, a 1-aza-3-(3-pyridyl)bicyclo[3.2.2]nonane, or a 1-aza-7-(3-pyridyl)bicyclo[3.2.2]nonane.",TARGACEPT INC;;UNIV KENTUCKY RES FOUND,CALDWELL WILLIAM SCOTT;;BENCHERIF MEROUANE;;DULL GARY MAURICE;;CROOKS PETER ANTHONY;;LIPPIELLO PATRICK MICHAEL;;BHATTI BALWINDER SINGH;;DEO NIRANJAN MADHUKAR;;RAVARD ALAIN,"THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (2002-12-18);;TARGACEPT, INC. (2004-07-01)",https://lens.org/109-661-127-268-604,Granted Patent,yes,5,0,13,15,0,C07D453/02;;C07D487/08;;A61P25/00;;A61P25/16;;A61P25/28,A61K31/407;;A61K31/439;;A61K31/55;;A61P25/00;;A61P25/16;;A61P25/28;;C07D453/02;;C07D471/08;;C07D487/08,,0,0,,,,EXPIRED
143,AU,A,AU 1996/053831 A,101-154-148-303-627,1996-11-29,1996,AU 1996/053831 A,1996-04-03,US 43715395 A;;US 43715495 A;;US 9604536 W,1995-05-17,Pharmaceutical compositions for prevention and treatment of central nervous system disorders,,REYNOLDS TOBACCO CO R;;UNIV KENTUCKY RES FOUND,BENCHERIF MEROUANE;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;LIPPIELLO PATRICK MICHAEL;;CROOKS PETER ANTHONY;;BHATTI BALWINDER SINGH;;DEO NIRANJAN MADHUKAR;;RAVARD ALAIN,,https://lens.org/101-154-148-303-627,Patent Application,no,0,0,2,5,0,C07D401/04;;C07D453/06,C07D401/04;;C07D453/06,,0,0,,,,PENDING
144,PT,E,PT 994875 E,120-891-560-662-049,2004-06-30,2004,PT 98918598 T,1998-04-22,US 88539797 A;;US 88576897 A,1997-06-30,DERIVADOS DE 3-PIRIDIL-1-AZA-BICICLO-ALCANO PARA A PREVENCAO E TRATAMENTO DE DESORDENS DO SNC,"Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia) are treated by administering an <u>endo</u> or <u>exo</u> form of a 1-aza-2-(3-pyridyl)bicyclo[2.2.1]heptane, a 1-aza-2-(3-pyridyl)bicyclo[2.2.2] octane, a 1-aza-2-(3-pyridyl)bicyclo[3.2.2]nonane, a 1-aza-7-(3-pyridyl) bicyclo[2.2.1]heptane, a 1-aza-3-(3-pyridyl)bicyclo[3.2.2]nonane, or a 1-aza-7-(3-pyridyl)bicyclo[3.2.2]nonane.",TARGACEPT INC,BENCHERIF MEROUANE;;LIPPIELLO PATRICK MICHAEL;;CROOKS PETER ANTHONY;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;DEO NIRANJAN MADHUKAR;;BHATTI BALDWINDER SINGH;;RAVARD ALAIN,,https://lens.org/120-891-560-662-049,Granted Patent,no,0,0,13,15,0,C07D453/02;;C07D487/08;;A61P25/00;;A61P25/16;;A61P25/28,A61K31/407;;A61K31/439;;A61K31/55;;A61P25/00;;A61P25/16;;A61P25/28;;C07D453/02;;C07D471/08;;C07D487/08,,0,0,,,,EXPIRED
145,WO,A1,WO 1999/000385 A1,141-553-527-328-962,1999-01-07,1999,US 9808145 W,1998-04-22,US 88539797 A;;US 88576897 A,1997-06-30,3-PYRIDYL-1-AZA-BICYCLO-ALKANE DERIVATIVES FOR PREVENTION AND TREATMENT OF CNS DISORDERS,"Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia) are treated by administering an endo or exo form of a 1-aza-2-(3-pyridyl)bicyclo[2.2.1]heptane, a 1-aza-2-(3-pyridyl)bicyclo[2.2.2] octane, a 1-aza-2-(3-pyridyl)bicyclo[3.2.2]nonane, a 1-aza-7-(3-pyridyl) bicyclo[2.2.1]heptane, a 1-aza-3-(3-pyridyl)bicyclo[3.2.2]nonane, or a 1-aza-7-(3-pyridyl)bicyclo[3.2.2]nonane.",REYNOLDS TOBACCO CO R;;UNIV KENTUCKY RES FOUND;;CALDWELL WILLIAM SCOTT;;BENCHERIF MEROUANE;;DULL GARY MAURICE;;CROOKS PETER ANTHONY;;LIPPIELLO PATRICK MICHAEL;;BHATTI BALWINDER SINGH;;DEO NIRANJAN MADHUKAR;;RAVARD ALAIN,CALDWELL WILLIAM SCOTT;;BENCHERIF MEROUANE;;DULL GARY MAURICE;;CROOKS PETER ANTHONY;;LIPPIELLO PATRICK MICHAEL;;BHATTI BALWINDER SINGH;;DEO NIRANJAN MADHUKAR;;RAVARD ALAIN,,https://lens.org/141-553-527-328-962,Patent Application,yes,5,21,13,15,0,C07D453/02;;C07D487/08;;A61P25/00;;A61P25/16;;A61P25/28,A61K31/407;;A61K31/439;;A61K31/55;;A61P25/00;;A61P25/16;;A61P25/28;;C07D453/02;;C07D471/08;;C07D487/08,,0,0,,,,PATENTED
146,EP,A1,EP 1185514 A1,111-032-792-372-25X,2002-03-13,2002,EP 00938183 A,2000-06-06,US 0015560 W;;US 32714199 A;;US 32777499 A,1999-06-07,PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE,,TARGACEPT INC,DULL GARY MAURICE;;MILLER CRAIG HARRISON;;CALDWELL WILLIAM SCOTT;;LYNM DWO;;BHATTI BALWINDER SINGH;;SCHMITT JEFFREY DANIEL;;BYRD GARY DWIGHT;;HADIMANI SRISHAILKUMAR BASAWAN,,https://lens.org/111-032-792-372-25X,Patent Application,yes,0,0,5,6,0,A61P25/04;;A61P25/08;;A61P25/14;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D213/70;;C07D213/38;;C07D213/65;;C07D213/73;;C07D213/74;;C07D213/82;;C07D213/89,A61K31/44;;A61K31/4406;;A61K31/455;;A61P25/04;;A61P25/08;;A61P25/14;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D213/38;;C07D213/65;;C07D213/70;;C07D213/73;;C07D213/74;;C07D213/82;;C07D213/89,,1,0,,,See references of WO 0075110A1,DISCONTINUED
147,CA,A1,CA 2376061 A1,180-461-506-964-966,2000-12-14,2000,CA 2376061 A,2000-06-06,US 32714199 A;;US 32777499 A;;US 0015560 W,1999-06-07,PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE,"Pharmaceutical compositions incorporate aryl substituted olefinic amine compounds. Representative compounds are (2S)-(4E)-N-methyl-5-[3-(5-isopropox y- 1-oxopyridin)yl)]-4-penten-2-amine, (3E)-N-methyl-4-(3-(1-oxopyridin)yl)-3- buten-1-amine, (4E)-N-methyl-5-(3-(1-oxopyridin)yl)-4-penten-2-amine, (4E)-N - methyl-5-(3-(5-((carboxymethyl)oxy)pyridin)yl)-4-penten-2-amine, (3E)-N-meth yl- 4-[3-(5-nitro-6-aminopyridin)yl]-3-buten-1-amine, (3E)-N-methyl-4-[3-(5-(N- benzylcarboxamido)pyridin)yl]-3-buten-1-amine(4E)-N-methyl-5-[5-(2- aminopyrimidin)yl]-4-penten-2-amine, (4E)-N-methyl-5-(3-(5-aminopyridin)yl)- 4- penten-2-amine (3E)-N-methyl-4-(3-(5-isobutoxypyridin)yl)-3-buten-1-amine, (3E)-N-methyl-4-(3-(5-ethylthiopyridin)yl)-3-buten-1-amine, (4E)-N-methyl-5- (3- (5-trifluoromethylpyridin)yl)-4-penten-2-amine, (4E)-5-(3-(5- isopropoxypyridin)yl)-4-penten-2-amine, and (4E)-5-(3-(5-isopropoxypyridin)y l)- 4-penten-2-amine.",TARGACEPT INC,HADIMANI SRISHAILKUMAR BASAWAN;;SCHMITT JEFFREY DANIEL;;BHATTI BALWINDER SINGH;;LYNM DWO;;BYRD GARY DWIGHT;;CALDWELL WILLIAM SCOTT;;MILLER CRAIG HARRISON;;DULL GARY MAURICE,,https://lens.org/180-461-506-964-966,Patent Application,no,0,0,5,6,0,A61P25/04;;A61P25/08;;A61P25/14;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D213/70;;C07D213/38;;C07D213/65;;C07D213/73;;C07D213/74;;C07D213/82;;C07D213/89,A61K31/44;;A61K31/4406;;A61K31/455;;A61P25/04;;A61P25/08;;A61P25/14;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D213/38;;C07D213/65;;C07D213/70;;C07D213/73;;C07D213/74;;C07D213/82;;C07D213/89,,0,0,,,,DISCONTINUED
148,CO,A2,CO 6280577 A2,107-131-845-697-250,2011-05-20,2011,CO 10100051 A,2010-08-13,US 2119708 P,2008-01-15,"PREPARACION Y SEPARACION ENANTIOMERICA DE 7-(3-PIRIDINILO)-1,7-DIAZASPIRO[4.4]NONANO Y FORMAS NOVEDOSAS DE SAL DE LA MEZCLA RACEMICA Y ENANTIOMEROS","Una síntesis novedosa escalable para la preparación de 7-(3-piridinilo)-1,7-diazaspiro[4.4)nonano ha sido desarrollado, y sales 7-(3-piridinilo)1,7-diazaspiro[4.4jnonano han sido formadas con ácido succínico y ácido oxálico. Adicionalmente, 7-(3-piridinilo)-1,7-diazaspiro[4.4)nonano ha sido separado en sus estereoisómeros por medio de resoluciones con ácidos di-p-toluoyltartaric L y D, dando (R)- y (S)-7-(3- piridinilo)-1,7- diazaspiro[4.4)nonano de enantiómeros de alta pureza. Numerosas sales solidas de los resultantes (R)- y (S)-7-(3-piridinilo)-1,7-diazaspiro[4.4]nonano han sido preparados. Métodos para la preparación de sales racémicas y enantioméricas, composiciones farmacéuticas que componen dichas sales, y usos de las mismas son revelados. Las sales pueden ser suministradas a pacientes susceptibles de sufrir o sufriendo de condiciones y trastornos, como trastornos del sistema nervioso central, para tratar y/o prevenir dichos trastornos.",TARGACEPT INC,XIE JIANXUN;;BEAVER JESSICA;;BREINING SCOTT;;DULL GARY;;GATTO GREGORY;;GENUS JOHN;;MATHEW JACOB;;PFEIFFER INIGO;;MUNOZ JULIO A;;TOLER STEVE;;WAMSLEY JAMES,,https://lens.org/107-131-845-697-250,Patent Application,no,0,0,16,16,0,C07D487/10;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P29/00;;C07D487/10,A01N43/42;;C07D491/10,,0,0,,,,DISCONTINUED
149,EP,B1,EP 1086082 B1,057-611-271-944-005,2004-08-18,2004,EP 99926152 A,1999-06-03,US 9912340 W;;US 9828598 A;;US 9813398 A,1998-06-16,ARYLSUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS,"Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5- (3-pyridyl) -4-penten-2-amine, (4E) -N-methyl-5- (5-pyrimidinyl) -4-penten-2-amine, (4E)-N-methyl-5-( 5-methoxy-3-pyridyl) -4-penten-2-amine, (4E)-N- methyl-5- (6-amino-5-methyl -3-pyridyl)-4-penten -2-amine, (2R)-(4E) -N-methyl-5-(3-pyridyl) -4-penten-2-amine, (2R)-(4E)-N- methyl-5-(5- isopropoxy-3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-bromo-3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-ethoxy-3- pyridyl)-4-penten- 2-amine, (2S)-(4E)-N- methyl-5-(3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-isopropoxy-3- pyridyl)-4- penten-2-amine and (2S)-(4E)-N-methyl -5-(5-isopropoxy -3-pyridyl) -4-penten-2-amine.",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR B;;PARK HAEIL;;WAGNER JARED MILLER;;CROOKS PETER ANTHONY;;LIPPIELLO PATRICK MICHAEL;;BENCHERIF MEROUANE,"TARGACEPT, INC. (2004-11-01)",https://lens.org/057-611-271-944-005,Granted Patent,yes,9,0,25,42,0,A61K31/44;;A61K31/4406;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26;;A61P1/04;;A61P21/00;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P43/00;;A61K31/44,A61K31/44;;A61K31/4406;;A61K31/4418;;A61K31/505;;A61P1/04;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38;;C07D213/61;;C07D213/62;;C07D213/64;;C07D213/65;;C07D213/73;;C07D239/26,,1,0,,,"THOMAS HÖGBERG ET AL.: ""Homoallylic Amines Related to Zimeldine. A Comparative study on Neuronal seroonin and Norepinephrine Reuptake based on Conformational Analysis."" J. MED. CHEM. , vol. 31, 1988, pages 913-919, XP000608983 columbus ohio",EXPIRED
150,EP,A1,EP 1086082 A1,051-818-514-269-535,2001-03-28,2001,EP 99926152 A,1999-06-03,US 9912340 W;;US 9828598 A;;US 9813398 A,1998-06-16,ARYLSUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS,"Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5- (3-pyridyl) -4-penten-2-amine, (4E) -N-methyl-5- (5-pyrimidinyl) -4-penten-2-amine, (4E)-N-methyl-5-( 5-methoxy-3-pyridyl) -4-penten-2-amine, (4E)-N- methyl-5- (6-amino-5-methyl -3-pyridyl)-4-penten -2-amine, (2R)-(4E) -N-methyl-5-(3-pyridyl) -4-penten-2-amine, (2R)-(4E)-N- methyl-5-(5- isopropoxy-3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-bromo-3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-ethoxy-3- pyridyl)-4-penten- 2-amine, (2S)-(4E)-N- methyl-5-(3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-isopropoxy-3- pyridyl)-4- penten-2-amine and (2S)-(4E)-N-methyl -5-(5-isopropoxy -3-pyridyl) -4-penten-2-amine.",REYNOLDS TOBACCO CO R,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR B;;PARK HAEIL;;WAGNER JARED MILLER;;CROOKS PETER ANTHONY;;LIPPIELLO PATRICK MICHAEL;;BENCHERIF MEROUANE,"TARGACEPT, INC. (2004-11-01)",https://lens.org/051-818-514-269-535,Patent Application,yes,0,0,25,42,0,A61K31/44;;A61K31/4406;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26;;A61P1/04;;A61P21/00;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P43/00;;A61K31/44,A61K31/44;;A61K31/4406;;A61K31/4418;;A61K31/505;;A61P1/04;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38;;C07D213/61;;C07D213/62;;C07D213/64;;C07D213/65;;C07D213/73;;C07D239/26,,0,0,,,,EXPIRED
151,AU,A,AU 1999/042307 A,028-130-679-187-31X,2000-01-05,2000,AU 1999/042307 A,1999-06-03,US 9828598 A;;US 9813398 A;;US 9912340 W,1998-06-16,Aryl substituted olefinic amines and their use as cholinergic receptors agonists,,TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR B;;PARK HAEIL;;WAGNER JARED MILLER;;CROOKS PETER ANTHONY;;LIPPIELLO PATRICK MICHAEL;;BENCHERIF MEROUANE,"TARGACEPT, INC. (2003-09-04)",https://lens.org/028-130-679-187-31X,Patent Application,no,0,0,25,42,0,A61K31/44;;A61K31/4406;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26;;A61P1/04;;A61P21/00;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P43/00;;A61K31/44,A61K31/44;;A61K31/4406;;A61K31/4418;;A61K31/505;;A61P1/04;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38;;C07D213/61;;C07D213/62;;C07D213/64;;C07D213/65;;C07D213/73;;C07D239/26,,0,0,,,,DISCONTINUED
152,CA,A1,CA 2334923 A1,193-189-201-631-281,1999-12-23,1999,CA 2334923 A,1999-06-03,US 9828598 A;;US 9813398 A;;US 9912340 W,1998-06-16,ARYL SUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS,"Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5- (3-pyridyl) -4-penten-2-amine, (4E) -N-methyl-5- (5-pyrimidinyl) -4-penten-2-amine, (4E)-N-methyl-5-( 5- methoxy-3-pyridyl) -4-penten-2-amine, (4E)-N- methyl-5- (6-amino-5-methyl -3 - pyridyl)-4-penten -2-amine, (2R)-(4E) -N-methyl-5-(3-pyridyl) -4-penten-2- amine, (2R)-(4E)-N- methyl-5-(5- isopropoxy-3-pyridyl) -4-penten-2-amine, (4 E)- N-methyl -5-(5-bromo-3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-ethox y- 3- pyridyl)-4-penten- 2-amine, (2S)-(4E)-N- methyl-5-(3-pyridyl) -4-penten-2 - amine, (4E)-N-methyl -5-(5-isopropoxy-3- pyridyl)-4- penten-2-amine and (2S) - (4E)-N-methyl -5-(5-isopropoxy -3-pyridyl) -4-penten-2-amine.",REYNOLDS TOBACCO CO R,BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR B;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;PARK HAEIL;;BENCHERIF MEROUANE;;WAGNER JARED MILLER;;CROOKS PETER ANTHONY;;LIPPIELLO PATRICK MICHAEL,,https://lens.org/193-189-201-631-281,Patent Application,no,0,0,25,42,0,A61K31/44;;A61K31/4406;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26;;A61P1/04;;A61P21/00;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P43/00;;A61K31/44,A61K31/44;;A61K31/4406;;A61K31/4418;;A61K31/505;;A61P1/04;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38;;C07D213/61;;C07D213/62;;C07D213/64;;C07D213/65;;C07D213/73;;C07D239/26,,0,0,,,,EXPIRED
153,AU,B2,AU 2003/236404 B2,067-098-484-523-51X,2005-09-01,2005,AU 2003/236404 A,2003-08-21,AU 1999/042307 A;;AU 2003/236404 A,1999-06-03,Aryl substituted olefinic amines and their use as cholinergic receptors agonists,,TARGACEPT INC,BENCHERIF MEROUANE;;LIPPIELLO PATRICK MICHAEL;;CROOKS PETER ANTHONY;;WAGNER JARED MILLER;;PARK HAEIL;;HADIMANI SRISHAILKUMAR B;;BHATTI BALWINDER SINGH;;DULL GARY MAURICE;;CALDWELL WILLIAM SCOTT,,https://lens.org/067-098-484-523-51X,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
154,CA,A1,CA 2677519 A1,183-555-940-195-705,1999-12-23,1999,CA 2677519 A,1999-06-03,US 9828598 A;;US 9813398 A;;CA 2334923 A,1998-06-16,ARYL SUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS,"Disclosed is a compound of the formula: (see formula I) or a pharmaceutically acceptable salt thereof, wherein: X is CH, CBr, or COR'; and R' is straight chain or branched alkyl. Such a compound is useful for the preparation of a medicament for the prevention or treatmen t of a central nervous system (CNS) disorder.",TARGACEPT INC,HADIMANI SRISHAILKUMAR B;;PARK HAEIL;;WAGNER JARED MILLER;;BHATTI BALWINDER SINGH;;CROOKS PETER ANTHONY;;LIPPIELLO PATRICK MICHAEL;;DULL GARY MAURICE;;CALDWELL WILLIAM SCOTT;;BENCHERIF MEROUANE,,https://lens.org/183-555-940-195-705,Patent Application,no,0,0,25,42,0,A61K31/44;;A61K31/4406;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26;;A61P1/04;;A61P21/00;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P43/00;;A61K31/44,C07D213/65;;A61K31/44;;A61K31/4406;;A61K31/4418;;A61K31/505;;A61P1/04;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38;;C07D213/61;;C07D213/62;;C07D213/64;;C07D213/73;;C07D239/26,,0,0,,,,DISCONTINUED
155,CA,A1,CA 2709735 A1,141-736-556-457-01X,1999-12-23,1999,CA 2709735 A,1999-06-03,US 9813398 A;;US 9828598 A;;CA 2677519 A,1998-06-16,ARYL SUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS,"Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5- (3-pyridyl) -4-penten-2-amine, (4E) -N-methyl-5- (5-pyrimidinyl) -4-penten-2-amine, (4E)-N-methyl-5-( 5-methoxy-3-pyridyl) -4-penten-2-amine, (4E)-N- methyl-5- (6-amino-5-methyl -3-pyridyl)-4-penten -2-amine, (2R)-(4E) -N-methyl-5-(3-pyridyl) -4-penten-2-amine, (2R)-(4E)-N- methyl-5-(5- isopropoxy-3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-bromo-3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-ethoxy-3- pyridyl)-4-penten- 2-amine, (2S)-(4E)-N- methyl-5-(3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-isopropoxy-3- pyridyl)-4- penten-2-amine and (2S)-(4E)-N-methyl -5-(5-isopropoxy -3-pyridyl) -4-penten-2-amine.",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR B;;PARK HAEIL;;WAGNER JARED MILLER;;CROOKS PETER ANTHONY;;LIPPIELLO PATRICK MICHAEL;;BENCHERIF MEROUANE,,https://lens.org/141-736-556-457-01X,Patent Application,no,0,0,25,42,0,A61K31/44;;A61K31/4406;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26;;A61P1/04;;A61P21/00;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P43/00;;A61K31/44,C07D213/65;;A61K31/44;;A61K31/4406;;A61K31/4418;;A61K31/505;;A61P1/04;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38;;C07D213/61;;C07D213/62;;C07D213/64;;C07D213/73;;C07D239/26,,0,0,,,,DISCONTINUED
156,CN,A,CN 101951773 A,121-876-245-777-373,2011-01-19,2011,CN 200980105492 A,2009-01-15,US 2009/0000242 W;;US 2119708 P,2008-01-15,"Preparation and enantiomeric separation of 7-(3-pyridinyl)-1,7-diazaspiro[4.4] nonane and novel salt forms of the racemate and enantiomers","A novel scalable synthesis for the preparation of 7-(3- pyridinyI)- 1,7- diazaspiro[4.4]nonane has been developed, and7-(3-pyridinyl)-1,7-diazaspiro[4.4]nonane salts have been formed with succinic acid and oxalic acid. Additionally, 7-(3-pyridinyl)-1,7- diazaspiro[4.4]nonane has been separated into its stereoisomers via resolution with L and D di-p-toluoyltartaric acids, giving (R)- and (S)-7-(3-pyridinyl)-1,7-diazaspiro[4.4]nonane of high enantiomeric purity. Numerous solid salts of the resulting (R)- and (S)-7-(3-pyridinyl)-1,7- diazaspiro[4.4]nonane have been prepared. Methods for the preparation of the racemic and enantiomeric salts, pharmaceutical compositions comprising such salts, and uses thereof are disclosed. The salts can be administered to patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, to treat and/or prevent such disorders.",TARGACEPT INC,JESSICA BEAVER;;SCOTT BREINING;;MAURICE DULL GARY;;GATTO GERGORY J;;JOHN GENUS;;JACOB MATHEW;;MUNOZ JULIO A;;INIGO PFEIFFER;;STEVE TOLER;;JAMES WAMSLEY;;JIANXUN XIE,,https://lens.org/121-876-245-777-373,Patent Application,no,0,2,16,16,0,C07D487/10;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P29/00;;C07D487/10,A01N43/42;;A61K31/44;;C07D491/10,,0,0,,,,DISCONTINUED
157,WO,A1,WO 2009/091561 A1,148-641-923-940-904,2009-07-23,2009,US 2009/0000242 W,2009-01-15,US 2119708 P,2008-01-15,"PREPARATION AND ENANTIOMERIC SEPARATION OF 7-(3-PYRIDINYL)-1,7-DIAZASPIRO[4.4] NONANE AND NOVEL SALT FORMS OF THE RACEMATE AND ENANTIOMERS","A novel scalable synthesis for the preparation of 7-(3- pyridinyI)- 1,7- diazaspiro[4.4)nonane has been developed, and7-(3-pyridinyl)-1,7-diazaspiro[4.4]nonane salts have been formed with succinic acid and oxalic acid. Additionally, 7-(3-pyridinyl)-1,7- diazaspiro[4.4]nonane has been separated into its stereoisomers via resolution with L and D di-p-toluoyltartaric acids, giving (R)- and (S)-7-(3-pyridinyl)-1,7-diazaspiro[4.4]nonane of high enantiomeric purity. Numerous solid salts of the resulting (R)- and (S)-7-(3-pyridinyl)-1,7- diazaspiro[4.4}nonane have been prepared. Methods for the preparation of the racemic and enantiomeric salts, pharmaceutical compositions comprising such salts, and uses thereof are disclosed. The salts can be administered to patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, to treat and/or prevent such disorders.",TARGACEPT INC;;BEAVER JESSICA;;BREINING SCOTT;;DULL GARY MAURICE;;GATTO GERGORY J;;GENUS JOHN;;MATHEW JACOB;;MUNOZ JULIO A;;PFEIFFER INIGO;;TOLER STEVE;;WAMSLEY JAMES;;XIE JIANXUN,BEAVER JESSICA;;BREINING SCOTT;;DULL GARY MAURICE;;GATTO GERGORY J;;GENUS JOHN;;MATHEW JACOB;;MUNOZ JULIO A;;PFEIFFER INIGO;;TOLER STEVE;;WAMSLEY JAMES;;XIE JIANXUN,,https://lens.org/148-641-923-940-904,Patent Application,yes,2,2,16,16,0,C07D487/10;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P29/00;;C07D487/10,A61K31/44;;A01N43/42;;C07D491/10,,1,0,,,See also references of EP 2242364A4,PENDING
158,WO,A1,WO 1999/065876 A1,030-343-936-175-637,1999-12-23,1999,US 9912340 W,1999-06-03,US 9828598 A;;US 9813398 A,1998-06-16,ARYL SUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS,"Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5- (3-pyridyl) -4-penten-2-amine, (4E) -N-methyl-5- (5-pyrimidinyl) -4-penten-2-amine, (4E)-N-methyl-5-( 5-methoxy-3-pyridyl) -4-penten-2-amine, (4E)-N- methyl-5- (6-amino-5-methyl -3-pyridyl)-4-penten -2-amine, (2R)-(4E) -N-methyl-5-(3-pyridyl) -4-penten-2-amine, (2R)-(4E)-N- methyl-5-(5- isopropoxy-3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-bromo-3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-ethoxy-3- pyridyl)-4-penten- 2-amine, (2S)-(4E)-N- methyl-5-(3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-isopropoxy-3- pyridyl)-4- penten-2-amine and (2S)-(4E)-N-methyl -5-(5-isopropoxy -3-pyridyl) -4-penten-2-amine.",REYNOLDS TOBACCO CO R;;CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR B;;PARK HAEIL;;WAGNER JARED MILLER;;CROOKS PETER ANTHONY;;LIPPIELLO PATRICK MICHAEL;;BENCHERIF MEROUANE,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR B;;PARK HAEIL;;WAGNER JARED MILLER;;CROOKS PETER ANTHONY;;LIPPIELLO PATRICK MICHAEL;;BENCHERIF MEROUANE,,https://lens.org/030-343-936-175-637,Patent Application,yes,9,44,25,42,0,A61K31/44;;A61K31/4406;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26;;A61P1/04;;A61P21/00;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P43/00;;A61K31/44,A61K31/44;;A61K31/4406;;A61K31/4418;;A61K31/505;;A61P1/04;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38;;C07D213/61;;C07D213/62;;C07D213/64;;C07D213/65;;C07D213/73;;C07D239/26,,1,1,080-173-777-134-292,10.1021/jm00400a005;;2966246,"THOMAS HÖGBERG ET AL.: ""Homoallylic Amines Related to Zimeldine. A Comparative study on Neuronal seroonin and Norepinephrine Reuptake based on Conformational Analysis."", J. MED. CHEM., vol. 31, 1988, columbus ohio, pages 913 - 919, XP000608983",PATENTED
159,AT,T1,AT E273956 T1,023-988-313-460-823,2004-09-15,2004,AT 99926152 T,1999-06-03,US 9828598 A;;US 9813398 A;;US 9912340 W,1998-06-16,ARYLSUBSTITUIERTE OLEFINISCHE AMINE UND IHRE VERWENDUNG ALS CHOLINERGISCHE REZEPTORAGONISTEN,"Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5- (3-pyridyl) -4-penten-2-amine, (4E) -N-methyl-5- (5-pyrimidinyl) -4-penten-2-amine, (4E)-N-methyl-5-( 5-methoxy-3-pyridyl) -4-penten-2-amine, (4E)-N- methyl-5- (6-amino-5-methyl -3-pyridyl)-4-penten -2-amine, (2R)-(4E) -N-methyl-5-(3-pyridyl) -4-penten-2-amine, (2R)-(4E)-N- methyl-5-(5- isopropoxy-3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-bromo-3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-ethoxy-3- pyridyl)-4-penten- 2-amine, (2S)-(4E)-N- methyl-5-(3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-isopropoxy-3- pyridyl)-4- penten-2-amine and (2S)-(4E)-N-methyl -5-(5-isopropoxy -3-pyridyl) -4-penten-2-amine.",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR B;;PARK HAEIL;;WAGNER JARED MILLER;;CROOKS PETER ANTHONY;;LIPPIELLO PATRICK MICHAEL;;BENCHERIF MEROUANE,,https://lens.org/023-988-313-460-823,Granted Patent,no,0,0,25,42,0,A61K31/44;;A61K31/4406;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26;;A61P1/04;;A61P21/00;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P43/00;;A61K31/44,A61K31/44;;A61K31/4406;;A61K31/4418;;A61K31/505;;A61P1/04;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38;;C07D213/61;;C07D213/62;;C07D213/64;;C07D213/65;;C07D213/73;;C07D239/26,,0,0,,,,PENDING
160,EP,B9,EP 1086082 B9,070-590-401-437-53X,2005-03-02,2005,EP 99926152 A,1999-06-03,US 9912340 W;;US 9828598 A;;US 9813398 A,1998-06-16,ARYLSUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS,"Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5- (3-pyridyl) -4-penten-2-amine, (4E) -N-methyl-5- (5-pyrimidinyl) -4-penten-2-amine, (4E)-N-methyl-5-( 5-methoxy-3-pyridyl) -4-penten-2-amine, (4E)-N- methyl-5- (6-amino-5-methyl -3-pyridyl)-4-penten -2-amine, (2R)-(4E) -N-methyl-5-(3-pyridyl) -4-penten-2-amine, (2R)-(4E)-N- methyl-5-(5- isopropoxy-3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-bromo-3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-ethoxy-3- pyridyl)-4-penten- 2-amine, (2S)-(4E)-N- methyl-5-(3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-isopropoxy-3- pyridyl)-4- penten-2-amine and (2S)-(4E)-N-methyl -5-(5-isopropoxy -3-pyridyl) -4-penten-2-amine.",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR B;;PARK HAEIL;;WAGNER JARED MILLER;;CROOKS PETER ANTHONY;;LIPPIELLO PATRICK MICHAEL;;BENCHERIF MEROUANE,"TARGACEPT, INC. (2004-11-01)",https://lens.org/070-590-401-437-53X,Amended Patent,yes,9,0,25,42,0,A61K31/44;;A61K31/4406;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26;;A61P1/04;;A61P21/00;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P43/00;;A61K31/44,A61K31/44;;A61K31/4406;;A61K31/4418;;A61K31/505;;A61P1/04;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38;;C07D213/61;;C07D213/62;;C07D213/64;;C07D213/65;;C07D213/73;;C07D239/26,,1,0,,,"THOMAS HÖGBERG ET AL.: ""Homoallylic Amines Related to Zimeldine. A Comparative study on Neuronal seroonin and Norepinephrine Reuptake based on Conformational Analysis."" J. MED. CHEM. , vol. 31, 1988, pages 913-919, XP000608983 columbus ohio",EXPIRED
161,EP,A4,EP 2242364 A4,014-846-049-960-764,2011-09-21,2011,EP 09701707 A,2009-01-15,US 2009/0000242 W;;US 2119708 P,2008-01-15,"PREPARATION AND ENANTIOMERIC SEPARATION OF 7-(3-PYRIDINYL)-1,7-DIAZASPIROÝ4.4¨NONANE AND NOVEL SALT FORMS OF THE RACEMATE AND ENANTIOMERS",,TARGACEPT INC,BEAVER JESSICA;;BREINING SCOTT;;DULL GARY MAURICE;;GATTO GERGORY J;;GENUS JOHN;;MATHEW JACOB;;MUNOZ JULIO A;;PFEIFFER INIGO;;TOLER STEVE;;WAMSLEY JAMES;;XIE JIANXUN,,https://lens.org/014-846-049-960-764,Search Report,no,1,0,16,16,0,C07D487/10;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P29/00;;C07D487/10,A01N43/42;;A61K31/44;;C07D491/10,,0,0,,,,DISCONTINUED
162,DK,T3,DK 1086082 T3,041-432-554-022-76X,2004-11-22,2004,DK 99926152 T,1999-06-03,EP 99926152 A;;US 9828598 A;;US 9813398 A,1998-06-16,Arylsubstituerede olefiniske aminer og deres anvendelse som cholinerge receptoragonister,"Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5- (3-pyridyl) -4-penten-2-amine, (4E) -N-methyl-5- (5-pyrimidinyl) -4-penten-2-amine, (4E)-N-methyl-5-( 5-methoxy-3-pyridyl) -4-penten-2-amine, (4E)-N- methyl-5- (6-amino-5-methyl -3-pyridyl)-4-penten -2-amine, (2R)-(4E) -N-methyl-5-(3-pyridyl) -4-penten-2-amine, (2R)-(4E)-N- methyl-5-(5- isopropoxy-3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-bromo-3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-ethoxy-3- pyridyl)-4-penten- 2-amine, (2S)-(4E)-N- methyl-5-(3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-isopropoxy-3- pyridyl)-4- penten-2-amine and (2S)-(4E)-N-methyl -5-(5-isopropoxy -3-pyridyl) -4-penten-2-amine.",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;CROOKS PETER ANTHONY;;HADIMANI SRISHAILKUMAR B;;PARK HAEIL;;WAGNER JARED MILLER;;LIPPIELLO PATRICK MICHAEL;;BENCHERIF MEROUANE,,https://lens.org/041-432-554-022-76X,Granted Patent,no,0,0,25,42,0,A61K31/44;;A61K31/4406;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26;;A61P1/04;;A61P21/00;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P43/00;;A61K31/44,A61K31/44;;A61K31/4406;;A61K31/4418;;A61K31/505;;A61P1/04;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38;;C07D213/61;;C07D213/62;;C07D213/64;;C07D213/65;;C07D213/73;;C07D239/26,,0,0,,,,EXPIRED
163,JP,A,JP 2008260774 A,111-644-999-781-832,2008-10-30,2008,JP 2008130504 A,2008-05-19,US 9828598 A;;US 9813398 A,1998-06-16,"ARYL-SUBSTITUTED OLEFINIC AMINE, AND USE OF ARYL-SUBSTITUTED OLEFINIC AMINE AS CHOLINERGIC RECEPTOR AGONIST","<P>PROBLEM TO BE SOLVED: To provide a compound activating a nicotinic cholinergic receptor and a pharmaceutical composition for treating or preventing mixed type, attention-deficit type or hyperkinetic-impulsive type attention deficit disorder. <P>SOLUTION: The compound has incorporated an aryl-substituted olefinic amine therewith. The representative compounds are (2S)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine or pharmaceutically acceptable salts thereof. The compound is a specific nicotinic receptor subtype agonist. <P>COPYRIGHT: (C)2009,JPO&INPIT",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR B;;PARK HAEIL;;WAGNER JARED MILLER;;CROOKS PETER ANTHONY;;LIPPIELLO PATRICK MICHAEL;;BENCHERIF MEROUANE,,https://lens.org/111-644-999-781-832,Patent Application,no,9,0,25,42,0,A61K31/44;;A61K31/4406;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26;;A61P1/04;;A61P21/00;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P43/00;;A61K31/44,A61K31/44;;A61K31/4406;;A61K31/4418;;A61K31/505;;A61P1/04;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D213/38;;C07D213/61;;C07D213/62;;C07D213/64;;C07D213/65;;C07D213/73;;C07D239/26,,0,0,,,,INACTIVE
164,JP,A,JP 2008255122 A,152-409-775-935-22X,2008-10-23,2008,JP 2008130502 A,2008-05-19,US 9828598 A;;US 9813398 A,1998-06-16,ARYL-SUBSTITUTED OLEFIN AMINE AND THEIR USE AS CHOLINORECEPTOR AGONIST,"<P>PROBLEM TO BE SOLVED: To provide a novel therapeutic agent for central nervous system disorder, that is a compound activating nicotinic cholinoreceptor, for example, a specifically nicotinic receptor subtype agonist. <P>SOLUTION: The compound is (4E)-N-methyl-5-(5-methoxy-3-pyridyl)-4-pentene-2-amine or its pharmaceutically acceptable salts. The therapeutic agent is for the disorders selected from the group consisting of presenile dementia (early onset type Alzheimer's disease), senile dementia (Alzheimer type dementia), Parkinson's disease, Huntington's chorea disease, tardive dyskinesia, hyperkinesia, mania, attention disturbance, anxiety, alexia, scizophrenia, and Gilles de la Tourette syndrome. <P>COPYRIGHT: (C)2009,JPO&INPIT",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR B;;PARK HAEIL;;WAGNER JARED MILLER;;CROOKS PETER ANTHONY;;LIPPIELLO PATRICK MICHAEL;;BENCHERIF MEROUANE,,https://lens.org/152-409-775-935-22X,Patent Application,no,9,0,25,42,0,A61K31/44;;A61K31/4406;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26;;A61P1/04;;A61P21/00;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P43/00;;A61K31/44,C07D213/65;;A61K31/44;;A61K31/4406;;A61K31/4418;;A61K31/505;;A61K45/00;;A61P1/04;;A61P21/00;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P43/00;;C07D213/38;;C07D213/61;;C07D213/62;;C07D213/64;;C07D213/73;;C07D239/26,,0,0,,,,INACTIVE
165,JP,A,JP 2010229149 A,039-403-109-435-879,2010-10-14,2010,JP 2010135746 A,2010-06-15,US 9828598 A;;US 9813398 A,1998-06-16,ARYL-SUBSTITUTED OLEFINIC AMINE AND USE OF ARYL-SUBSTITUTED OLEFINIC AMINE AS CHOLINERGIC RECEPTOR AGONIST,"<P>PROBLEM TO BE SOLVED: To provide a compound activating a nicotinic cholinergic receptor, for example, an agonist of a specific nicotine receptor subtype. <P>SOLUTION: The compound incorporates an aryl-substituted olefinic amine represented by the formula. <P>COPYRIGHT: (C)2011,JPO&INPIT",TARGACEPT INC,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR B;;PARK HAEIL;;WAGNER JARED MILLER;;CROOKS PETER ANTHONY;;LIPPIELLO PATRICK MICHAEL;;BENCHERIF MEROUANE,,https://lens.org/039-403-109-435-879,Patent Application,no,5,0,25,42,0,A61K31/44;;A61K31/4406;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26;;A61P1/04;;A61P21/00;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P43/00;;A61K31/44,C07D213/36;;A61K31/44;;A61K31/4406;;A61K31/4418;;A61K31/505;;A61P1/04;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38;;C07D213/61;;C07D213/62;;C07D213/64;;C07D213/65;;C07D213/73;;C07D239/26,,0,0,,,,PENDING
166,EP,A1,EP 2242364 A1,077-854-647-811-748,2010-10-27,2010,EP 09701707 A,2009-01-15,US 2009/0000242 W;;US 2119708 P,2008-01-15,"PREPARATION AND ENANTIOMERIC SEPARATION OF 7-(3-PYRIDINYL)-1,7-DIAZASPIROÝ4.4¨NONANE AND NOVEL SALT FORMS OF THE RACEMATE AND ENANTIOMERS",,TARGACEPT INC,BEAVER JESSICA;;BREINING SCOTT;;DULL GARY MAURICE;;GATTO GERGORY J;;GENUS JOHN;;MATHEW JACOB;;MUNOZ JULIO A;;PFEIFFER INIGO;;TOLER STEVE;;WAMSLEY JAMES;;XIE JIANXUN,,https://lens.org/077-854-647-811-748,Patent Application,yes,0,0,16,16,0,C07D487/10;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P29/00;;C07D487/10,A01N43/42;;A61K31/44;;C07D491/10,,0,0,,,,DISCONTINUED
167,CA,C,CA 2334923 C,197-810-454-170-493,2009-09-29,2009,CA 2334923 A,1999-06-03,US 9828598 A;;US 9813398 A;;US 9912340 W,1998-06-16,ARYL SUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS,"Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5- (3-pyridyl) -4-penten-2-amine, (4E) -N-methyl-5- (5-pyrimidinyl) -4-penten-2 - amine, (4E)-N-methyl-5-( 5-methoxy-3-pyridyl) -4-penten-2-amine, (4E)-N- methyl-5- (6-amino-5-methyl -3-pyridyl)-4-penten -2- amine, (2R)-(4E) -N-methyl-5-(3-pyridyl) -4-penten-2-amine, (2R)-(4E)-N- methyl-5-(5- isopropoxy-3-pyridyl) -4-penten -2- amine, (4E)-N-methyl -5-(5-bromo-3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-ethoxy-3- pyridyl)-4-penten- 2-amine, (2S)-(4E)-N- methyl-5-(3-pyridyl) -4-pen- ten-2-amine, (4E)-N-methyl -5-(5-isopropoxy-3- pyridyl)-4- penten-2-amine an d (2S)-(4E)-N-methyl -5-(5-isopropoxy -3-pyridyl) -4-penten-2-amine.",REYNOLDS TOBACCO CO R,WAGNER JARED MILLER;;DULL GARY MAURICE;;CALDWELL WILLIAM SCOTT;;PARK HAEIL;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR B;;CROOKS PETER ANTHONY;;BENCHERIF MEROUANE;;LIPPIELLO PATRICK MICHAEL,,https://lens.org/197-810-454-170-493,Granted Patent,no,0,0,25,42,0,A61K31/44;;A61K31/4406;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26;;A61P1/04;;A61P21/00;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P43/00;;A61K31/44,C07D213/38;;A61K31/44;;A61K31/4406;;A61K31/4418;;A61K31/505;;A61P1/04;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/61;;C07D213/62;;C07D213/64;;C07D213/65;;C07D213/73;;C07D239/26,,0,0,,,,EXPIRED
168,BR,A,BR 9911325 A,061-920-851-646-163,2001-04-03,2001,BR 9911325 A,1999-06-03,US 9828598 A;;US 9813398 A;;US 9912340 W,1998-06-16,Aminas olefìnicas substituìdas com arila e o seu uso como agonistas de receptores colinérgicos,"Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5- (3-pyridyl) -4-penten-2-amine, (4E) -N-methyl-5- (5-pyrimidinyl) -4-penten-2-amine, (4E)-N-methyl-5-( 5-methoxy-3-pyridyl) -4-penten-2-amine, (4E)-N- methyl-5- (6-amino-5-methyl -3-pyridyl)-4-penten -2-amine, (2R)-(4E) -N-methyl-5-(3-pyridyl) -4-penten-2-amine, (2R)-(4E)-N- methyl-5-(5- isopropoxy-3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-bromo-3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-ethoxy-3- pyridyl)-4-penten- 2-amine, (2S)-(4E)-N- methyl-5-(3-pyridyl) -4-penten-2-amine, (4E)-N-methyl -5-(5-isopropoxy-3- pyridyl)-4- penten-2-amine and (2S)-(4E)-N-methyl -5-(5-isopropoxy -3-pyridyl) -4-penten-2-amine.",REYNOLDS TOBACCO CO R,CALDWELL WILLIAM SCOTT;;DULL GARY MAURICE;;BHATTI BALWINDER SINGH;;HADIMANI SRISHAILKUMAR B;;PARK HAEIL;;WAGNER JARED MILLER;;CROOKS PETER ANTHONY;;LIPPIELLO PATRICK MICHAEL;;BENCHERIF MEROUANE,,https://lens.org/061-920-851-646-163,Patent Application,no,0,0,25,42,0,A61K31/44;;A61K31/4406;;A61K31/505;;C07D213/38;;C07D213/61;;C07D213/65;;C07D213/73;;C07D239/26;;A61P1/04;;A61P21/00;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P43/00;;A61K31/44,A61K31/44;;A61K31/4406;;A61K31/4418;;A61K31/505;;A61P1/04;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;C07D213/38;;C07D213/61;;C07D213/62;;C07D213/64;;C07D213/65;;C07D213/73;;C07D239/26,,0,0,,,,DISCONTINUED
169,KR,A,KR 20100118113 A,118-315-580-571-34X,2010-11-04,2010,KR 20107017920 A,2009-01-15,US 2119708 P,2008-01-15,"PREPARATION AND ENANTIOMERIC SEPARATION OF 7-(3-PYRIDINYL)-1,7-DIAZASPIRO[4.4]NONANE AND NOVEL SALT FORMS OF THE RACEMATE AND ENANTIOMERS",,TARGACEPT INC,BEAVER JESSICA;;BREINING SCOTT;;DULL GARY MAURICE;;GATTO GERGORY J;;GENUS JOHN;;MATHEW JACOB;;MUNOZ JULIO A;;PFEIFFER INIGO;;TOLER STEVE M;;WAMSLEY JAMES;;XIE JIANXUN,,https://lens.org/118-315-580-571-34X,Patent Application,no,0,3,16,16,0,C07D487/10;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P29/00;;C07D487/10,C07D487/10;;A61K31/407;;A61P25/00,,0,0,,,,DISCONTINUED
170,CA,A1,CA 2712141 A1,075-462-785-867-912,2009-07-23,2009,CA 2712141 A,2009-01-15,US 2119708 P;;US 2009/0000242 W,2008-01-15,"PREPARATION AND ENANTIOMERIC SEPARATION OF 7-(3-PYRIDINYL)-1,7-DIAZASPIRO[4.4] NONANE AND NOVEL SALT FORMS OF THE RACEMATE AND ENANTIOMERS","A novel scalable synthesis for the preparation of 7-(3- pyridinyI)- 1,7- diazaspiro[4.4)nonane has been developed, and7-(3-pyridinyl)-1,7-diazaspiro[4.4]nonane salts have been formed with succinic acid and oxalic acid. Additionally, 7-(3-pyridinyl)-1,7- diazaspiro[4.4]nonane has been separated into its stereoisomers via resolution with L and D di-p-toluoyltartaric acids, giving (R)- and (S)-7-(3-pyridinyl)-1,7-diazaspiro[4.4]nonane of high enantiomeric purity. Numerous solid salts of the resulting (R)- and (S)-7-(3-pyridinyl)-1,7- diazaspiro[4.4}nonane have been prepared. Methods for the preparation of the racemic and enantiomeric salts, pharmaceutical compositions comprising such salts, and uses thereof are disclosed. The salts can be administered to patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, to treat and/or prevent such disorders.",TARGACEPT INC,BEAVER JESSICA;;BREINING SCOTT;;DULL GARY MAURICE;;GATTO GERGORY J;;GENUS JOHN;;MATHEW JACOB;;MUNOZ JULIO A;;PFEIFFER INIGO;;TOLER STEVE M;;WAMSLEY JAMES;;XIE JIANXUN,,https://lens.org/075-462-785-867-912,Patent Application,no,0,0,16,16,0,C07D487/10;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P29/00;;C07D487/10,C07D487/10;;A61K31/4439;;A61P25/00;;A61P29/00,,0,0,,,,DISCONTINUED
171,US,A1,US 2011/0118239 A1,087-309-941-556-417,2011-05-19,2011,US 81264709 A,2009-01-15,US 81264709 A;;US 2119708 P;;US 2009/0000242 W,2008-01-15,"PREPARATION AND ENANTIOMERIC SEPARATION OF 7-(3-PYRIDINYL)-1,7-DIAZASPIRO[4.4]NONANE AND NOVEL SALT FORMS OF THE RACEMATE AND ENANTIOMERS","A novel scalable synthesis for the preparation of 7-(3-pyridinyI)-1,7-diazaspiro[4.4)nonane has been developed, and 7-(3-pyridinyl)-1,7-diazaspiro[4.4]nonane salts have been formed with succinic acid and oxalic acid. Additionally, 7-(3-pyridinyl)-1,7-diaza-spiro[4.4]nonane has been separated into its stereoisomers via resolution with L and D di-p-toluoyltartaric acids, giving (R)- and (S)-7-(3-pyridinyl)-1,7-diazaspiro[4.4]nonane of high enantiomeric purity. Numerous solid salts of the resulting (R)- and (S)-7-(3-pyridinyl)-1,7-diazaspiro[4.4}nonane have been prepared. Methods for the preparation of the racemic and enantiomeric salts, pharmaceutical compositions comprising such salts, and uses thereof are disclosed. The salts can be administered to patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, to treat and/or prevent such disorders.",TARGACEPT INC,BEAVER JESSICA;;BREINING SCOTT;;DULL GARY MAURICE;;GATTO GREGORY J;;GENUS JOHN;;MATHEW JACOB;;MUNOZ JULIO A;;PFEIFFER INIGO;;TTOLER STEVE M;;WAMSLEY JAMES;;XIE JIANXUN,,https://lens.org/087-309-941-556-417,Patent Application,yes,13,1,16,16,0,C07D487/10;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P29/00;;C07D487/10,A61K31/551;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;C07D223/32,514/221;;540/543,0,0,,,,DISCONTINUED
172,AU,A1,AU 2009/205720 A1,112-423-492-076-250,2009-07-23,2009,AU 2009/205720 A,2009-01-15,US 2119708 P;;US 2009/0000242 W,2008-01-15,"Preparation and enantiomeric separation of 7-(3-pyridinyl)-1,7-diazaspiro[4.4] nonane and novel salt forms of the racemate and enantiomers",,TARGACEPT INC,XIE JIANXUN;;WAMSLEY JAMES;;GATTO GERGORY J;;PFEIFFER INIGO;;MATHEW JACOB;;MUNOZ JULIO A;;BEAVER JESSICA;;TOLER STEVE M;;GENUS JOHN;;BREINING SCOTT;;DULL GARY MAURICE,,https://lens.org/112-423-492-076-250,Patent Application,no,0,0,16,16,0,C07D487/10;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P29/00;;C07D487/10,A01N43/42;;A61K31/44;;C07D491/10,,0,0,,,,DISCONTINUED
173,BR,A2,BR PI0907222 A2,144-834-215-280-373,2015-07-14,2015,BR PI0907222 A,2009-01-15,US 2119708 P;;US 2009/0000242 W,2008-01-15,"Preparação e separação enantiomérica de 7-(3-piridinil)-1,7-diazaspiro[4-4]nonano e novas formas salinas do racemato e enantiômeros",,TARGACEPT INC,BEAVER JESSICA;;BREINING SCOTT;;DULL GARY MAURICE;;GATTO GREGORY J;;GENUS JOHN;;MATHEW JACOB;;MUNOZ JULIO A;;PFEIFFER INIGO;;TOLER STEVE M;;WAMSLEY JAMES;;XIE JIANXUN,,https://lens.org/144-834-215-280-373,Patent Application,no,0,0,16,16,0,C07D487/10;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P29/00;;C07D487/10,A01N43/42;;A61K31/44;;C07D491/10,,0,0,,,,DISCONTINUED
174,MX,A,MX 2010007742 A,059-649-229-399-02X,2010-08-06,2010,MX 2010007742 A,2009-01-15,US 2119708 P;;US 2009/0000242 W,2008-01-15,"PREPARATION AND ENANTIOMERIC SEPARATION OF 7-(3-PYRIDINYL)-1,7-DI AZASPIRO[4.4] NONANE AND NOVEL SALT FORMS OF THE RACEMATE AND ENANTIOMERS.","A novel scalable synthesis for the preparation of 7-(3- pyridinyI)- 1,7- diazaspiro[4.4)nonane has been developed, and7-(3-pyridinyl)-1,7-diazaspiro[4.4]nonane salts have been formed with succinic acid and oxalic acid. Additionally, 7-(3-pyridinyl)-1,7- diazaspiro[4.4]nonane has been separated into its stereoisomers via resolution with L and D di-p-toluoyltartaric acids, giving (R)- and (S)-7-(3-pyridinyl)-1,7-diazaspiro[4.4]nonane of high enantiomeric purity. Numerous solid salts of the resulting (R)- and (S)-7-(3-pyridinyl)-1,7- diazaspiro[4.4}nonane have been prepared. Methods for the preparation of the racemic and enantiomeric salts, pharmaceutical compositions comprising such salts, and uses thereof are disclosed. The salts can be administered to patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, to treat and/or prevent such disorders.",TARGACEPT INC,GATTO GREGORY J;;MUNOZ JULIO A;;GENUS JOHN;;DULL GARY MAURICE;;MATHEW JACOB;;PFEIFFER INIGO;;BEAVER JESSICA;;BREINING SCOTT;;TOLER STEVE M;;WAMSLEY JAMES;;XIE JIANXUN,,https://lens.org/059-649-229-399-02X,Patent Application,no,0,0,16,16,0,C07D487/10;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P29/00;;C07D487/10,A61K31/44;;A01N43/42;;C07D491/10,,0,0,,,,PENDING
175,EC,A,EC SP10010397 A,197-171-537-370-513,2010-09-30,2010,EC SP10010397 A,2010-08-11,US 2119708 P,2008-01-15,"PREPARACION Y SEPARACION ENANTIOMERICA DE 7-(3- PIRIDINILO)-1,7-DIAZASPIRO[4.4] NONANO Y FORMAS NOVEDOSAS DE SAL DE LA MEZCLA RACEMICA Y ENANTIOMEROS","Una síntesis novedosa escalable para la preparación de 7-(3- piridinilo)- 1,7- diazaspiro[4.4)nonano ha sido desarrollado, y sales 7-(3- piridinilo)-1,7-diazaspiro[4.4]nonano han sido formadas con ácido succínico y ácido oxálico. Adicionalmente, 7-(3-piridinilo)-1,7- diazaspiro[4.4)nonano ha sido separado en sus estereoisómeros por medio de resoluciones con ácidos di-p-toluoyltartaric L y D, dando (R)- y (S)-7-(3- piridinilo)-1,7- diazaspiro[4.4)nonano de enantiómeros de alta pureza. Numerosas sales solidas de os resultantes (R)- y (S)-7 -(3-piridinilo)-1,7-diazaspiro[4.4}nonano han sido preparados. Métodos para la preparación de sales racémicas y enantioméricas, composiciones farmacéuticas que componen dichas sales, y usos de las mismas son revelados. Las sales pueden ser suministradas a pacientes susceptibles de sufrir o sufriendo de condiciones y trastornos, como trastornos del sistema nervioso central, para tratar y/o prevenir dichos trastornos.",TARGACEPT INC,DULL GARY MAURICE;;BREINING SCOTT R;;GATTO GREGORY J;;GENUS JOHN;;MUNOZ JULIO A;;PFEIFFER INIGO;;MATHEW JACOB;;BEAVER JESSICA;;TOLER STEVE M;;JAMES WAMSLEY;;JIANXUN XIE,,https://lens.org/197-171-537-370-513,Patent Application,no,0,0,16,16,0,C07D487/10;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P29/00;;C07D487/10,A01N43/42;;A61K31/44;;C07D491/10,,0,0,,,,PENDING
176,ZA,B,ZA 201005284 B,066-810-134-250-873,2011-03-30,2011,ZA 201005284 A,2010-07-23,US 2119708 P;;US 2009/0000242 W,2008-01-15,"PREPARATION AND ENANTIOMERIC SEPARATION OF 7-(3-PYRIDINYL)-1,7-DIAZASPIRO[4.4] NONANE AND NOVEL SALT FORMS OF THE RACEMATE AND ENANTIOMERS",,TARGACEPT INC,XIE JIANXUN;;WAMSLEY JAMES;;TOLER STEVEN M;;BEAVER JESSICA;;PFEIFFER INIGO;;MATHEW JACOB;;BREINING SCOTT R;;GENUS JOHN;;MUNOZ JULIO A;;GATTO GREGORY J;;DULL GARY MAURICE,,https://lens.org/066-810-134-250-873,Granted Patent,no,0,0,16,16,0,C07D487/10;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P29/00;;C07D487/10,,,0,0,,,,ACTIVE
177,EC,A,EC SP11011135 A,045-065-622-315-104,2011-07-29,2011,EC SP11011135 A,2011-06-16,US 11888508 P,2008-12-01,SÍNTESIS DE NOVEDOSAS FORMAS DE SALES DE (R)-3-((E)-2-(PIRROLIDIN-3-IL)VINIL)-5-(TETRAHIDROPIRAN-4-ILOXI) PIRIDINA,"La presente invención se refiere a compuestos que se unen a, y modulan, la actividad de receptores nicotínicos neuronales de acetilcolina, a sales novedosas de los mismos, a procesos para preparar estos compuestos, a composiciones farmacéuticas que contienen estos compuestos, y a métodos de usar estos compuestos para tratar una amplia variedad de enfermedades y trastornos, incluyendo los asociados con disfunción del sistema nervioso central (SNC).",TARGACEPT INC,DULL GARY MAURICE;;HAMMOND PHILIP S;;AKIREDDY SRINIVISA RAO;;BREINING SCOTT R;;GATTO GREGORY J;;GENUS JOHN;;CUTHBERTSON TIMOTHY J;;MITCHENER JOSEPH PIKE;;MUNOZ JULIO A;;OTTEN PIETER ALBERT,,https://lens.org/045-065-622-315-104,Patent Application,no,0,0,54,54,0,C07D405/14;;A61K31/4439;;A61P25/00;;A61P25/04;;A61P25/18;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P31/12;;A61P37/06;;C07D207/08;;C07D405/14;;A61K31/40;;C07D405/14;;A61K31/4439,C07D405/14;;A61K31/4439;;A61P25/00,,0,0,,,,PENDING
178,CO,A2,CO 6382158 A2,158-660-587-598-025,2012-02-15,2012,CO 11075843 A,2011-06-17,US 11888508 P,2008-12-01,SÍNTESIS DE NOVEDOSAS FORMAS DE SALES DE (R)-3-((E)-2-(PIRROLIDIN-3-IL)VINIL)-5-(TETRAHIDROPIRAN-4-ILOXI)PIRIDINA,"La presente invención se refiere a (R)-3-(E)-2-(pirrolidin-3-il)vinil)-5-(tetrahidropiran-4-iloxi)piridina, sus formas de sales, y a procesos para la producción a escala comercial de estos compuestos en pureza y calidad suficientes para uso en composiciones farmacéuticas. Además, la presente invención concierne al uso de este compuesto en la fabricación de un medicamento para el tratamiento de trastornos relacionados con el sistema nervioso central (SNC).",TARGACEPT INC,AKIREDDY SRINIVISA RAO;;BREINING SCOTT;;CUTHBERTSON TIMOTHY J;;DULL GARY MAURICE;;GATTO GREGORY J;;GENUS JOHN;;HAMMOND PHILIPS S;;MITCHENER JOSEPH PIKE JR;;MUNOZ JULIO A;;OTTEN PIETER ALBERT,,https://lens.org/158-660-587-598-025,Patent Application,no,0,0,54,54,0,C07D405/14;;A61K31/4439;;A61P25/00;;A61P25/04;;A61P25/18;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P31/12;;A61P37/06;;C07D207/08;;C07D405/14;;A61K31/40;;C07D405/14;;A61K31/4439,C07D405/14,,0,0,,,,ACTIVE
179,US,A1,US 2012/0015983 A1,147-864-599-777-579,2012-01-19,2012,US 200913125892 A,2009-11-30,US 200913125892 A;;US 11888508 P;;US 2009/0066092 W,2008-12-01,Synthesis and Novel Salt Forms of (R)-3-((E)-pyrrolidin-3-yl)vinyl)-5-tetrahydropyran-4-yloxy)pyridine,"The present invention relates to (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine, its salt forms, and to processes for the commercial-scale production of these compounds in sufficient purity and quality for use in pharmaceutical compositions.",AKIREDDY SRINIVASA RAO;;BREINING SCOTT R;;CUTHBERTSON TIMOTHY J;;DULL GARY MAURICE;;GATTO GREGORY J;;GENUS JOHN;;HAMMOND PHILIP S;;MITCHENER JOSEPH PIKE;;MUNOZ JULIO A;;OTTEN PIETER ALBERT;;YOHANNES DANIEL;;FEDOROV NIKOLAI;;TARGACEPT INC,AKIREDDY SRINIVASA RAO;;BREINING SCOTT R;;CUTHBERTSON TIMOTHY J;;DULL GARY MAURICE;;GATTO GREGORY J;;GENUS JOHN;;HAMMOND PHILIP S;;MITCHENER JOSEPH PIKE;;MUNOZ JULIO A;;OTTEN PIETER ALBERT;;YOHANNES DANIEL;;FEDOROV NIKOLAI,TARGACEPT INC (2010-10-21),https://lens.org/147-864-599-777-579,Patent Application,yes,0,1,54,54,0,C07D405/14;;A61K31/4439;;A61P25/00;;A61P25/04;;A61P25/18;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P31/12;;A61P37/06;;C07D207/08;;C07D405/14;;A61K31/40;;C07D405/14;;A61K31/4439,A61K31/4439;;A61P3/00;;A61P25/04;;A61P25/18;;A61P25/28;;A61P29/00;;A61P31/04;;A61P31/12;;C07D405/14,514/343;;546/276.4,3,1,001-516-175-552-397,10.1016/s0169-409x(01)00097-7;;11325474,"Guillory (in Brittain ed.), ""Polymorphism in Pharmaceutical Solids.,"" NY: Marcel Dekker, Inc., 1999, 1-2, 125-181, 183-226.;;Yu et al., ""Physical characterization of, etc.,"" PSTT, vl. 1(3), 118-127 (1998).;;Vippagunta et al., ""Crystalline Solids"", Advanced Drug Delivery Reviews 48 (2001) 3-26.",INACTIVE
180,EA,B1,EA 021054 B1,087-560-096-448-952,2015-03-31,2015,EA 201170736 A,2009-11-30,US 11888508 P;;US 2009/0066092 W,2008-12-01,SYNTHESIS AND NOVEL SALT FORMS OF (R)-3-((E)-2 (PYRR0LIDIN-3-YL)VINYL)-5-(TETRAHYDR0PYRAN-4-YLOXY)PYRIDINE,"The present invention relates to (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine, its salt forms, and also relates to the use of said compounds in the manufacture of a medicament for the treatment of CNS related disorders.",TARGACEPT INC,AKIREDDY SRINIVISA RAO;;BREINING SCOTT R;;CUTHBERTSON TIMOTHY J;;DULL GARY MAURICE;;GATTO GREGORY J;;GENUS JOHN;;HAMMOND PHILIP S;;MITCHENER JOSEPH PIKE JR;;MUNOZ JULIO A;;OTTEN PIETER ALBERT;;YOHANNES DANIEL;;FEDOROV NIKOLAI,,https://lens.org/087-560-096-448-952,Granted Patent,no,2,0,54,54,0,C07D405/14;;A61K31/4439;;A61P25/00;;A61P25/04;;A61P25/18;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P31/12;;A61P37/06;;C07D207/08;;C07D405/14;;A61K31/40;;C07D405/14;;A61K31/4439,C07D405/14;;A61K31/4439;;A61P25/00,,3,1,040-089-442-352-13X,10.1021/op000018u,"BASTIN R.J. ET AL.: ""Salt Selection and Optimisation for Pharmaceutical New Chemical Entities"" ORGANIC PROCESS RESEARCH AND DEVELOPMENT, CAMBRIDGE, GB, vol. 4, no. 5, 1 January 2000 (2000-01-01), pages 427-435, XP002228592 the whole document;;YADAV ET AL.: ""A formal total synthesis of crocacin с"" TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL LNKD-D0I:10.1016/J. TETLET. 2006. 10. 141, vol. 48, no. 1, 30 November 2006 (2006-11-30), pages 145-148, XP005785970 ISSN: 0040-4039 Scheme l, pahe 146;;THOMAS С. ET AL.: ""A Practical Ex-Chiral-Pool Synthesis of beta-Proline and Homo-beta-Proline"" SYNTHESIS, no. 10, October 1998 (1998-10), pages 1491-1496, XP002577074 DE ISSN: 0039-7881 Scheme 4, page 1492",ACTIVE
181,US,A1,US 2014/0107163 A1,146-993-301-978-007,2014-04-17,2014,US 201314107175 A,2013-12-16,US 201314107175 A;;US 201113125892 A;;US 2009/0066092 W;;US 11888508 P,2008-12-01,SYNTHESIS AND NOVEL SALT FORMS OF (R)-3-((E)-2-(PYRROLIDIN-3-YL)VINYL)-5-(TETRAHYDROPYRAN-4-YLOXY)PYRIDINE,"The present invention relates to (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine, its salt forms, and to processes for the commercial-scale production of these compounds in sufficient purity and quality for use in pharmaceutical compositions.",TARGECEPT INC,AKIREDDY SRINVASA RAO;;BREINING SCOTT R;;CUTHBERTSON TIMOTHY J;;DULL GARY MAURICE;;GATTO GREGORY J;;GENUS JOHN;;HAMMOND PHILLIP S;;MITCHENER JR JOSEPH PIKE;;MUNOZ JULIO A;;OTTEN PIETER ALBERT;;YOHANNES DANIEL;;FEDOROV NIKOLAI,,https://lens.org/146-993-301-978-007,Patent Application,yes,1,1,54,54,0,C07D405/14;;A61K31/4439;;A61P25/00;;A61P25/04;;A61P25/18;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P31/12;;A61P37/06;;C07D207/08;;C07D405/14;;A61K31/40;;C07D405/14;;A61K31/4439,A61K31/4439,514/343,1,0,,,"Lundholm, ""Reduction of , etc.,"" CA 114:39637 (1991).",DISCONTINUED
182,CN,B,CN 102232072 B,183-246-921-993-577,2014-09-24,2014,CN 200980148072 A,2009-11-30,US 2009/0066092 W;;US 11888508 P,2008-12-01,"(R)-3-(E)-2-(pyrr0lidin-3-yl) vinyl)-5-(tetrahydr0pyran-4-yl0xy) pyridine, its salts, its synthesis and its use as ligand for nicotinic acetylcholinergic receptors",,TARGACEPT INC,AKIREDDY SRINIVISA RAO;;BREINING SCOTT R;;CUTHBERTSON TIMOTHY J;;DULL GARY MAURICE;;GATTO GREGORY J;;GENUS JOHN;;HAMMOND PHILIP S;;MITCHENER JOSEPH PIKE JR;;MUNOZ JULIO A;;OTTEN PIETER ALBERT;;YOHANNES DANIEL;;FEDOROV NIKOLAI,,https://lens.org/183-246-921-993-577,Granted Patent,no,0,0,54,54,0,C07D405/14;;A61K31/4439;;A61P25/00;;A61P25/04;;A61P25/18;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P31/12;;A61P37/06;;C07D207/08;;C07D405/14;;A61K31/40;;C07D405/14;;A61K31/4439,C07D405/14;;A61K31/4439;;A61P25/00,,0,0,,,,INACTIVE
183,CN,A,CN 102232072 A,175-595-399-169-897,2011-11-02,2011,CN 200980148072 A,2009-11-30,US 2009/0066092 W;;US 11888508 P,2008-12-01,"(R)-3-(E)-2-(pyrr0lidin-3-yl) vinyl)-5-(tetrahydr0pyran-4-yl0xy) pyridine, its salts, its synthesis and its use as ligand for nicotinic acetylcholinergic receptors","The present invention relates to (R)-3-( (E)-2-(pyrrolidin-3-yl) vinyl)-5-(tetrahydropyran-4-yloxy) pyridine, its salt forms, and to processes for the commercial-scale production of these compounds in sufficient purity and quality for use in pharmaceutical compositions. The present invention relates also the use of this compound in the manufacture of a medicament for the treatment of CNS related disorders.",TARGACEPT INC,RAO AKIREDDY SRINIVISA;;BREINING SCOTT R;;CUTHBERTSON TIMOTHY J;;MAURICE DULL GARY;;GATTO GREGORY J;;JOHN GENUS;;HAMMOND PHILIP S;;PIKE MITCHENER JOSEPH JR;;MUNOZ JULIO A;;ALBERT OTTEN PIETER;;DANIEL YOHANNES;;NIKOLAI FEDOROV,,https://lens.org/175-595-399-169-897,Patent Application,no,2,0,54,54,0,C07D405/14;;A61K31/4439;;A61P25/00;;A61P25/04;;A61P25/18;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P31/12;;A61P37/06;;C07D207/08;;C07D405/14;;A61K31/40;;C07D405/14;;A61K31/4439,C07D405/14;;A61K31/4439;;A61P25/00,,3,0,,,"RICHARD J. BASTIN 等: ""“Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities”"", 《ORGANIC PROCESS RESEARCH & DEVELOPMENT》;;CHRISTOPH THOMAS 等: ""“A Practical Ex-Chiral-Pool Synthesis of beta-Proline and Homo-beta-Proline”"", 《SYNTHESIS》;;J.S.YADAV等: ""“A formal total synthesis of crocacin C”"", 《TETRAHEDRON LETTERS》",INACTIVE
184,EP,A1,EP 2896619 A1,008-451-217-631-705,2015-07-22,2015,EP 14191551 A,2009-11-30,US 11888508 P;;EP 09775410 A,2008-12-01,Salt forms of (R)-3-(E)-2-(PYRROLIDIN-3-YL)VINYL)-5-(TETRAHYDROPYRAN-4-YLOXY)PYRIDINE AND their USE,"The present invention relates to the hemi-galactarate, oxalate and di-p-toluoyl-D-tartrate salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine or hydrates or solvates thereof, compositions comprising these salt and their use for treating or preventing a NNR mediated disorder.",TARGACEPT INC,AKIREDDY SRINIVISA RAO;;BREINING SCOTT R;;CUTHBERTSON TIMOTHY J;;DULL GARY MAURICE;;GATTO GREGORY J;;GENUS JOHN;;HAMMOND PHILIP S;;MITCHENER JOSEPH PIKE JR;;MUNOZ JULIO A;;OTTEN PIETER ALBERT;;YOHANNES DANIEL;;FEDOROV NIKOLAI,,https://lens.org/008-451-217-631-705,Patent Application,yes,13,0,54,54,0,C07D405/14;;A61K31/4439;;A61P25/00;;A61P25/04;;A61P25/18;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P31/12;;A61P37/06;;C07D207/08;;C07D405/14;;A61K31/40;;C07D405/14;;A61K31/4439,C07D405/14;;A61K31/4439;;A61P25/00,,28,19,040-089-442-352-13X;;034-553-170-093-339;;184-367-294-782-70X;;073-981-318-375-830;;004-127-696-458-136;;075-115-600-469-760;;001-364-721-438-760;;010-673-210-088-258;;050-320-015-840-544;;160-102-028-768-345;;085-544-277-828-062;;047-807-682-518-619;;029-086-210-449-969;;095-719-226-739-312;;011-933-502-771-010;;150-294-822-638-894;;028-189-130-689-554;;023-814-515-002-556;;025-428-758-262-763,10.1021/op000018u;;15078187;;10.2174/1568007043482507;;8968366;;8968367;;10.1097/00000542-199911000-00038;;10551597;;9435889;;10.1021/jm970377o;;10.1126/science.279.5347.77;;9417028;;10.1038/nature01321;;12490958;;14907713;;10.1016/s0021-9258(19)52451-6;;10.1016/0006-2952(73)90196-2;;4202581;;10.1093/carcin/10.5.899;;2650908;;2571716;;2467233;;10.1016/0304-3940(89)90059-1;;10.1523/jneurosci.09-03-01082.1989;;pmc6569985;;2564429;;19912783;;10.1016/1044-7431(91)90039-q;;1646330;;2469352;;10.1016/0003-2697(88)90380-6;;8318354;;10.1007/bf02736685;;19912902;;10.1006/mcne.1993.1001;;10.1016/s0091-3057(02)00988-7;;12376170,"BASTIN R J ET AL: ""Salt Selection and Optimisation for Pharmaceutical New Chemical Entities"", ORGANIC PROCESS RESEARCH AND DEVELOPMENT, CAMBRIDGE, GB, vol. 4, no. 5, 1 January 2000 (2000-01-01), pages 427 - 435, XP002228592;;BREINING ET AL., ANN. REP. MED. CHEM., vol. 40, 2005, pages 3;;HOGG; BERTRAND, CURR. DRUG TARGETS: CNS NEUROL. DISORD., vol. 3, 2004, pages 123;;T. W. GREEN; P. G. M. WUTS: ""Protecting Groups in Organic Synthesis, 3rd ed."", 1999, JOHN WILEY & SONS;;WILLIAMS ET AL., DRUG NEWS PERSPEC., vol. 7, no. 4, 1994, pages 205;;ARNERIC ET AL., CNS DRUG REV., vol. 1, no. 1, 1995, pages 1 - 26;;ARNERIC ET AL., EXP. OPIN. INVEST. DRUGS, vol. 5, no. 1, 1996, pages 79 - 100;;BENCHERIF ET AL., J. PHARMACOL. EXP. THER., vol. 279, 1996, pages 1413;;LIPPIELLO ET AL., J. PHARMACOL. EXP. THER., vol. 279, 1996, pages 1422;;DAMAJ ET AL., J. PHARMACOL. EXP. THER., vol. 291, 1999, pages 390;;CHIARI ET AL., ANESTHESIOLOGY, vol. 91, 1999, pages 1447;;LAVAND'HOMME; EISENBACH, ANESTHESIOLOGY, vol. 91, 1999, pages 1455;;HOLLADAY ET AL., J. MED. CHEM., vol. 40, no. 28, 1997, pages 4169 - 94;;BANNON ET AL., SCIENCE, vol. 279, 1998, pages 77;;""American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision"", 2000, AMERICAN PSYCHIATRIC ASSOCIATION;;TRACEY: ""The inflammatory reflex"", NATURE, vol. 420, 2002, pages 853 - 9;;LOWRY ET AL., J. BIOL. CHEM., vol. 193, 1951, pages 265;;DAVIES ET AL., NEUROPHARMACOL., vol. 38, 1999, pages 679;;CHENG ET AL., BIOCHEM. PHARMACOL., vol. 22, 1973, pages 3099 - 3108;;STRATTON, CARCINOGEN, vol. 10, 1989, pages 899;;LUKAS, J. PHARMACOL. EXP. THER., vol. 251, 1989, pages 175;;OSWALD ET AL., NEUROSCI. LETT., vol. 96, 1989, pages 207;;LUTHER ET AL., J. NEUROSCI., vol. 9, 1989, pages 1082;;BENCHERIF ET AL., MOL. CELL. NEUROSCI., vol. 2, 1991, pages 52;;BENCHERIF ET AL., J. PHARMACOL. EXP. THER., vol. 257, 1991, pages 946;;LUKAS ET AL., ANAL. BIOCHEM., vol. 175, 1988, pages 212;;LUKAS ET AL., MOL. CELL. NEUROSCI., vol. 4, 1993, pages 1;;LUINE ET AL., PHARM. BIOCHEM. BEHAV., vol. 74, 2002, pages 213 - 220",DISCONTINUED
185,UA,C2,UA 106217 C2,015-855-981-038-83X,2014-08-11,2014,UA A201108205 A,2009-11-30,US 11888508 P;;US 2009/0066092 W,2008-12-01,SYNTHESIS OF AND SALT FORMS OF (R)-3-((E)-2-(PYRROLIDIN-3-YL)VINYL)-5-(TETRAHYDROPYRAN-4-YLOXY)PYRIDINE,"The present invention relates to (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine, its salt forms, and to processes for the commercial-scale production of these compounds in sufficient purity and quality for use in pharmaceutical compositions. The present invention relates also to the use of this compound in the manufacture of a medicament for the treatment of CNS related disorders.",TARGACEPT INC,AKIREDDY SRINIVISA RAO;;BREINING SCOTT R;;CUTHBERTSON TIMOTHY J;;DULL GARY MAURICE;;GATTO GREGORY J;;GENUS JOHN;;HAMMOND PHILIP S;;MITCHENER JOSEPH PIKE JR;;MUNOZ JULIO A;;OTTEN PIETER ALBERT;;YOHANNES DANIEL;;FEDOROV NIKOLAI,,https://lens.org/015-855-981-038-83X,Limited Patent,no,0,0,54,54,0,C07D405/14;;A61K31/4439;;A61P25/00;;A61P25/04;;A61P25/18;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P31/12;;A61P37/06;;C07D207/08;;C07D405/14;;A61K31/40;;C07D405/14;;A61K31/4439,C07D405/14;;A61K31/4439;;A61P25/00,,0,0,,,,EXPIRED
186,NZ,A,NZ 593058 A,038-567-658-109-667,2013-06-28,2013,NZ 59305809 A,2009-11-30,US 11888508 P;;US 2009/0066092 W,2008-12-01,"(R)-3-(E)-2-(PYRROLIDIN-3-YL)VINYL)-5-(TETRAHYDROPYRAN-4-YLOXY) PYRIDINE, ITS SALTS, ITS SYNTHESIS AND ITS USE AS LIGAND FOR NICOTINIC ACETYLCHOLINERGIC RECEPTORS","593058 Disclosed is (R)-3-((E)-2-(Pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine mono-L-malate or a hydrate or solvate thereof. Also disclosed is a pharmaceutical composition comprising the compound and the use of the compound in the manufacture of a medicament for the treatment of NNR mediated disorders such as CNS disorders, inflammation, inflammatory response associated with bacterial and/or viral infection, pain, metabolic syndrome, autoimmune disorders wherein the CNS disorder is selected from cognitive dysfunction in schizophrenia (CDS), Alzheimers Disease (AD), attention deficit disorder (ADD), pre-senile dementia (early onset of Alzheimer's Disease), dementia of the Alzheimer's type, mild cognitive impairment, age associated memory impairment, and attention deficit hyperactivity disorder (ADHD).",TARGACEPT INC,AKIREDDY SRINIVISA RAO;;BREINING SCOTT R;;CUTHBERTSON TIMOTHY J;;DULL GARY MAURICE;;GATTO GREGORY J;;GENUS JOHN;;HAMMOND PHILIP S;;MITCHENER JOSEPH PIKE JR;;MUNOZ JULIO A;;OTTEN PIETER ALBERT;;YOHANNES DANIEL;;FEDOROV NIKOLAI,,https://lens.org/038-567-658-109-667,Patent Application,no,0,0,54,54,0,C07D405/14;;A61K31/4439;;A61P25/00;;A61P25/04;;A61P25/18;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P31/12;;A61P37/06;;C07D207/08;;C07D405/14;;A61K31/40;;C07D405/14;;A61K31/4439,C07D405/14;;A61K31/4439;;A61P25/00,,0,0,,,,DISCONTINUED
187,ZA,B,ZA 201103497 B,097-128-953-518-127,2012-01-25,2012,ZA 201103497 A,2011-05-12,US 11888508 P;;US 2009/0066092 W,2008-12-01,"(R)-3-(E)-2-(PYRROLIDIN-3-YL)VINYL)-5-(TETRAHYDROPYRAN-4-YLOXY)PYRIDINE,ITS SALTS,ITS SYNTHESIS AND ITS USE AS LIGAND FOR NICOTINIC ACETYLCHOLINERGIC RECEPTORS",,TARGACEPT INC,AKIREDDY SRINIVISA RAO;;CUTHBERTSON TIMOTHY J;;GATTO GREGORY J;;HAMMOND PHILIP S;;MUNOZ JULIO A;;YOHANNES DANIEL;;BREINING SCOTT R;;DULL GARY MAURICE;;GENUS JOHN;;MITCHENER JOSEPH PIKE JR;;OTTEN PIETER ALBERT;;FEDOROV NIKOLAI,,https://lens.org/097-128-953-518-127,Granted Patent,no,0,0,54,54,0,C07D405/14;;A61K31/4439;;A61P25/00;;A61P25/04;;A61P25/18;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P31/12;;A61P37/06;;C07D207/08;;C07D405/14;;A61K31/40;;C07D405/14;;A61K31/4439,A61K/;;A61P/;;C07D/,,0,0,,,,ACTIVE
188,AU,A1,AU 2009/322630 A1,152-030-930-288-899,2010-06-10,2010,AU 2009/322630 A,2009-11-30,US 11888508 P;;US 2009/0066092 W,2008-12-01,"R) -3- (E) -2- (pyrrolidin-3-yl) vinyl) -5- (tetrahydropyran-4-yloxy) pyridine, its salts, its synthesis and its use as ligand for nicotinic acetylcholinergic receptors",,TARGACEPT INC,AKIREDDY SRINIVISA RAO;;BREINING SCOTT R;;CUTHBERTSON TIMOTHY J;;DULL GARY MAURICE;;GATTO GREGORY J;;GENUS JOHN;;HAMMOND PHILIP S;;MITCHENER JOSEPH PIKE JR;;MUNOZ JULIO A;;OTTEN PIETER ALBERT;;YOHANNES DANIEL;;FEDOROV NIKOLAI,,https://lens.org/152-030-930-288-899,Patent Application,no,0,0,54,54,0,C07D405/14;;A61K31/4439;;A61P25/00;;A61P25/04;;A61P25/18;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P31/12;;A61P37/06;;C07D207/08;;C07D405/14;;A61K31/40;;C07D405/14;;A61K31/4439,C07D405/14;;A61K31/4439;;A61P25/00,,0,0,,,,DISCONTINUED
189,US,B2,US 8633227 B2,053-339-926-074-392,2014-01-21,2014,US 200913125892 A,2009-11-30,US 200913125892 A;;US 11888508 P;;US 2009/0066092 W,2008-12-01,Synthesis and novel salt forms of (R)-3-((E)-pyrrolidin-3-yl)vinyl)-5-tetrahydropyran-4-yloxy)pyridine,"The present invention relates to (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine, its salt forms, and to processes for the commercial-scale production of these compounds in sufficient purity and quality for use in pharmaceutical compositions.",AKIREDDY SRINIVASA RAO;;BREINING SCOTT R;;CUTHBERTSON TIMOTHY J;;DULL GARY MAURICE;;GATTO GREGORY J;;GENUS JOHN;;HAMMOND PHILIP S;;MITCHENER JR JOESPH PIKE;;MUNOZ JULIO A;;OTTEN PIETER ALBERT;;YOHANNES DANIEL;;FEDOROV NIKOLAI;;TARGACEPT INC,AKIREDDY SRINIVASA RAO;;BREINING SCOTT R;;CUTHBERTSON TIMOTHY J;;DULL GARY MAURICE;;GATTO GREGORY J;;GENUS JOHN;;HAMMOND PHILIP S;;MITCHENER JR JOESPH PIKE;;MUNOZ JULIO A;;OTTEN PIETER ALBERT;;YOHANNES DANIEL;;FEDOROV NIKOLAI,TARGACEPT INC (2010-10-21),https://lens.org/053-339-926-074-392,Granted Patent,yes,14,1,54,54,0,C07D405/14;;A61K31/4439;;A61P25/00;;A61P25/04;;A61P25/18;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P31/12;;A61P37/06;;C07D207/08;;C07D405/14;;A61K31/40;;C07D405/14;;A61K31/4439,A61K31/4433;;C07D405/14,514/343;;546/276.4,31,26,001-516-175-552-397;;001-364-721-438-760;;040-089-442-352-13X;;150-294-822-638-894;;184-367-294-782-70X;;011-933-502-771-010;;084-618-392-852-650;;160-102-028-768-345;;004-127-696-458-136;;109-321-750-058-210;;047-794-951-805-270;;034-553-170-093-339;;075-115-600-469-760;;051-577-178-592-784;;073-981-318-375-830;;050-320-015-840-544;;025-428-758-262-763;;028-189-130-689-554;;023-814-515-002-556;;047-807-682-518-619;;095-719-226-739-312;;029-086-210-449-969;;085-544-277-828-062;;014-439-787-289-900;;026-897-727-352-991;;010-673-210-088-258,10.1016/s0169-409x(01)00097-7;;11325474;;10.1126/science.279.5347.77;;9417028;;10.1021/op000018u;;1646330;;8968366;;19912783;;10.1016/1044-7431(91)90039-q;;10.1016/s0065-7743(05)40001-9;;10.1016/0006-2952(73)90196-2;;4202581;;10.1097/00000542-199911000-00038;;10551597;;10490929;;10.1016/s0028-3908(98)00221-4;;10340305;;15078187;;10.2174/1568007043482507;;9435889;;10.1021/jm970377o;;10.1097/00000542-199911000-00039;;10551598;;8968367;;14907713;;10.1016/s0021-9258(19)52451-6;;10.1016/s0091-3057(02)00988-7;;12376170;;2469352;;10.1016/0003-2697(88)90380-6;;8318354;;10.1007/bf02736685;;19912902;;10.1006/mcne.1993.1001;;2571716;;10.1523/jneurosci.09-03-01082.1989;;pmc6569985;;2564429;;2467233;;10.1016/0304-3940(89)90059-1;;10.1093/carcin/10.5.899;;2650908;;10.1016/j.tetlet.2006.10.141;;10.1055/s-1998-2185;;10.1038/nature01321;;12490958,"Guillory (in Brittain ed.), ""Polymorphism in Pharmaceutical Solids.,"" NY: Marcel Dekker, Inc., 1999, 1-2, 125-181, 183-226.;;Yu et al., ""Physical characterization of, etc.,"" PSTT, vl. 1(3), 118-127 (1998).;;Vippagunta et al., ""Crystalline Solids"", Advanced Drug Delivery Reviews 48 (2001) 3-26.;;Arneric, S., et al., ""Preclinical Pharmacology of ABT-418: A Prototypical Cholinergic Channel Activator for the Potential Treatment of Alzheimer's Disease,"" CNS Drug Rev. 1(1): 1-26 (1995).;;Arneric, S., et al., ""Cholinergic channel modulators as a novel therapeutic strategy for Alzheimer's disease,"" Exp. Opin. Invest. Drugs 5(1): 79-100 (1996).;;Bannon, et al., ""Broad-Spectrum, Non-Opioid Analgesic Activity by Selective Modulation of Neuronal Nicotinic Acetylcholine Receptors,"" Science 279: 77-80 (1998).;;Bastin, R.J., et al., ""Salt Selection and Optimisation for Pharmaceutical New Chemical Entities,"" Organic Process Research and Dev., 4(5): 427-435 (2000).;;Bencherif, M., and R.J. Lukas, ""Ligand Binding and Functional Characterization of Muscarinic Acetylcholine Receptors on the TE671/RD Human Cell Line,"" J. Pharmacol. Exp. Ther. 257(3): 946-953 (1991).;;Bencherif, M., et al., ""RJR-2403: A Nicotinic Agonist with CNS Selectivity I: In Vitro Characterization,"" J. Pharmacol. Exper. Therapeutics 279(3): 1413-1421 (1996).;;Bencherif M. and R.J. Lukas, ""Differential Regulation of Nicotinic Acetylcholine Receptor Expression by Human TE671/RD Cells Following Second Messenger Modulation and Sodium Butyrate Treatments,"" Mol Cell Neurosci., 2(1): 52-65 (1991).;;Breining, S. et al., ""Neuronal Nicotinic Acetylcholine Receptor Modulators: Recent Advances and Therapeutic Potential,"" Annul Reports in Medicinal Chemistry, 40: 3-16 (2005).;;Cheng, Yung-Chi, and W.H. Prusoff, ""Relationship Between the Inhibition Constant (K1) and the Concentration of Inhibitor which Causes 50 Per Cent inhibition (I50) of an Enzymatic Reaction,"" Biochem. Pharmacol. 22(23): 3099-3108 (1973).;;Chiari, A., et al., ""Sex Differences in Cholinergic Analgesia I: A Supplemental Nicotinic Mechanism in Normal Females,"" Anesthesiology 91(5): 1447-1454 (1999).;;Damaj, M.I., et al., ""Antinociceptive and Pharmacological Effects of Metanicotine, a Selective Nicotinic Agonist,"" J. Pharmacol. Exp. Ther., 291(1): 390-398 (1999).;;Davies, Andrew R.L., et al., ""Characterisation of the binding of [3H]methyllycaconitine: a new radioligand for labeling alpha7-type neuronal nicotinic acetylcholine receptors,"" Neuropharmacol. 38: 679-690 (1999).;;Hogg, R.C. and D. Bertrand, ""Nicotinic Acetylcholine Receptors as Drug Targets,"" Current Drug Targets: CNS Neurol. Disord., 3: 123-130 (2004).;;Holladay, et al., ""Neuronal Nicotinic Acetylcholine Receptors as Targets for Drug Discovery,"" J. Med. Chem., 40(26): 4169-4194 (1997).;;Lavand'homme, P., and J.C. Eisenach, ""Sex Differences in Cholinergic Analgesia II: Differing Mechanisms in Two Models of Allodynia,"" Anesthesiology 91(5): 1455-1461 (1999).;;Lippiello, P.M., et al., ""RJR-2403: A Nicotinic Agonist with CNS Selectivity II. In Vivo Characterization,"" J. P. E. T. 279(3): 1422-1429 (1996).;;Lowry, et al., ""Protein Measurement with the Folin Phenol Reagent,"" J. Biol. Chem. 193: 265-275(1951).;;Luine, V.N., et al., ""Chromaproline and Chromaperidine, Nicotinie Agonists and Donepezil, Cholinesterase Inhibitor, Enhance Performance of Memory Tasks in Ovariectomized Rats,"" Pharm. Biochem. Behav. 74, 213-220 (2002).;;Lukas, R.J., and M.J. Cullen, ""An Isotopic Rubidium Ion Efflux Assay for the Functional Characterization of Nicotinic Acetylcholine Receptors on Clonal Cell Lines,"" Anal. Biochem. 175(1): 212-218 (1988).;;Lukas, R.J., et al., ""Characterization of Nicotinic Acetylcholine Receptors Expressed by Cells of the SH-SY5Y Human Neuroblastoma Clonal Line,"" Molec Cellular Neurosci 4(1): 1-12 (1993).;;Lukas, R.J., ""Pharmacological Distinctions between Functional Nicotinic Acetylcholine Receptors on the PC12 Rat Pheochromocytoma and the TE671 Human Medulloblastoma,"" J. Pharmacol. Exp. Ther. 251(1): 175-182 (1989).;;Luther, et al., ""A Muscle Acetylcholine Receptor is Expressed in the Human Cerebellar Medulloblastoma Cell Line TE671,"" J. Neurosci. 9(3): 1082-1096 (1989).;;Oswald, R.E., et al., ""Characterization of nicotinic acetylcholine receptor channels of the TE671 human medulloblastoma clonal line,"" Neurosci. Lett. 96: 207-212 (1989).;;Stratton, et al., ""Characterization of the human cell line TE671,"" Carcinogenesis 10(5): 899-905 (1989).;;Yadav et al., ""A Formal Total Synthesis of Crocacin C,"" Tetrahedron Letters 48(1): 145-148 (2006).;;Thomas, C., et al., ""A Practical Ex-Chiral-Pool Synthesis of Bets-Proline and homo-Beta-Proline,"" Synthesis, 10: 1491-1496 (1998).;;Tracey, Kevin, J., ""The Inflammatory Reflex,"" Nature 420: 853-859 (2002).;;Williams, et al., ""Neuronal Nicotinic Acetylcholine Receptors,"" Drug News Perspec. 7(4): 205-223 (1994).",INACTIVE
190,WO,A1,WO 2010/065449 A1,052-336-966-858-01X,2010-06-10,2010,US 2009/0066092 W,2009-11-30,US 11888508 P,2008-12-01,"(R) -3- (E) -2- (PYRR0LIDIN-3-YL) VINYL) -5- (TETRAHYDR0PYRAN-4-YL0XY) PYRIDINE, ITS SALTS, ITS SYNTHESIS AND ITS USE AS LIGAND FOR NICOTINIC ACETYLCHOLINERGIC RECEPTORS","The present invention relates to (R) -3- ( (E) -2- (pyrrolidin-3-yl) vinyl) -5- (tetrahydropyran-4-yloxy) pyridine, its salt forms, and to processes for the commercial-scale production of these compounds in sufficient purity and quality for use in pharmaceutical compositions. The present invention relates also the use of this compound in the manufacture of a medicament for the treatment of CNS related disorders.",TARGACEPT INC;;AKIREDDY SRINIVISA RAO;;BREINING SCOTT R;;CUTHBERTSON TIMOTHY J;;DULL GARY MAURICE;;GATTO GREGORY J;;GENUS JOHN;;HAMMOND PHILIP S;;MITCHENER JOSEPH PIKE JR;;MUNOZ JULIO A;;OTTEN PIETER ALBERT;;YOHANNES DANIEL;;FEDOROV NIKOLAI,AKIREDDY SRINIVISA RAO;;BREINING SCOTT R;;CUTHBERTSON TIMOTHY J;;DULL GARY MAURICE;;GATTO GREGORY J;;GENUS JOHN;;HAMMOND PHILIP S;;MITCHENER JOSEPH PIKE JR;;MUNOZ JULIO A;;OTTEN PIETER ALBERT;;YOHANNES DANIEL;;FEDOROV NIKOLAI,,https://lens.org/052-336-966-858-01X,Patent Application,yes,11,1,54,54,0,C07D405/14;;A61K31/4439;;A61P25/00;;A61P25/04;;A61P25/18;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P31/12;;A61P37/06;;C07D207/08;;C07D405/14;;A61K31/40;;C07D405/14;;A61K31/4439,C07D405/14;;A61K31/4439;;A61P25/00,,3,3,040-089-442-352-13X;;014-439-787-289-900;;026-897-727-352-991,10.1021/op000018u;;10.1016/j.tetlet.2006.10.141;;10.1055/s-1998-2185,"BASTIN R J ET AL: ""Salt Selection and Optimisation for Pharmaceutical New Chemical Entities"", ORGANIC PROCESS RESEARCH AND DEVELOPMENT, CAMBRIDGE, GB, vol. 4, no. 5, 1 January 2000 (2000-01-01), pages 427 - 435, XP002228592;;YADAV ET AL: ""A formal total synthesis of crocacin C"", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL LNKD- DOI:10.1016/J.TETLET.2006.10.141, vol. 48, no. 1, 30 November 2006 (2006-11-30), pages 145 - 148, XP005785970, ISSN: 0040-4039;;THOMAS C. ET AL: ""A Practical Ex-Chiral-Pool Synthesis of beta-Proline and Homo-beta-Proline"", SYNTHESIS, no. 10, October 1998 (1998-10-01), DE, pages 1491 - 1496, XP002577074, ISSN: 0039-7881",PENDING
191,KR,A,KR 20110094318 A,176-861-887-757-327,2011-08-23,2011,KR 20117014805 A,2009-11-30,US 11888508 P,2008-12-01,"(R)-3-(E)-2-(PYRROLIDIN-3-YL)VINYL)-5-(TETRAHYDROPYRAN-4-YLOXY)PYRIDINE, ITS SALTS, ITS SYNTHESIS AND ITS USE AS LIGAND FOR NICOTINIC ACETYLCHOLINERGIC RECEPTORS",,TARGACEPT INC,AKIREDDY SRINIVISA RAO;;BREINING SCOTT R;;CUTHBERTSON TIMOTHY J;;DULL GARY MAURICE;;GATTO GREGORY J;;GENUS JOHN;;HAMMOND PHILIP S;;MITCHENER JOSEPH PIKE JR;;MUNOZ JULIO A;;OTTEN PIETER ALBERT;;YOHANNES DANIEL;;FEDOROV NIKOLAI,,https://lens.org/176-861-887-757-327,Patent Application,no,0,0,54,54,0,C07D405/14;;A61K31/4439;;A61P25/00;;A61P25/04;;A61P25/18;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P31/12;;A61P37/06;;C07D207/08;;C07D405/14;;A61K31/40;;C07D405/14;;A61K31/4439,C07D405/14;;A61K31/4433;;A61K31/4439;;A61P25/28,,0,0,,,,DISCONTINUED
192,SG,A1,SG 171876 A1,185-508-089-193-191,2011-07-28,2011,SG 2011039575 A,2009-11-30,US 11888508 P;;US 2009/0066092 W,2008-12-01,"(R) -3- (E) -2- (PYRR0LIDIN-3-YL) VINYL) -5- (TETRAHYDR0PYRAN-4-YL0XY) PYRIDINE, ITS SALTS, ITS SYNTHESIS AND ITS USE AS LIGAND FOR NICOTINIC ACETYLCHOLINERGIC RECEPTORS","The present invention relates to (R) -3- ( (E) -2- (pyrrolidin-3-yl) vinyl) -5- (tetrahydropyran-4-yloxy) pyridine, its salt forms, and to processes for the commercial-scale production of these compounds in sufficient purity and quality for use in pharmaceutical compositions. The present invention relates also the use of this compound in the manufacture of a medicament for the treatment of CNS related disorders.",TARGACEPT INC,AKIREDDY SRINIVISA RAO;;BREINING SCOTT R;;CUTHBERTSON TIMOTHY J;;DULL GARY MAURICE;;GATTO GREGORY J;;GENUS JOHN;;HAMMOND PHILIP S;;MITCHENER JOSEPH PIKE JR;;MUNOZ JULIO A;;OTTEN PIETER ALBERT;;YOHANNES DANIEL;;FEDOROV NIKOLAI,,https://lens.org/185-508-089-193-191,Patent Application,no,0,0,54,54,0,C07D405/14;;A61K31/4439;;A61P25/00;;A61P25/04;;A61P25/18;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P31/12;;A61P37/06;;C07D207/08;;C07D405/14;;A61K31/40;;C07D405/14;;A61K31/4439,,,0,0,,,,PENDING
193,CA,A1,CA 2744197 A1,075-072-910-409-846,2010-06-10,2010,CA 2744197 A,2009-11-30,US 11888508 P;;US 2009/0066092 W,2008-12-01,SYNTHESIS AND NOVEL SALT FORMS OF (R)-3-((E)-2-(PYRROLIDIN-3-YL)VINYL)-5-(TETRAHYDROPYRAN-4-YLOXY)PYRIDINE,"The present invention relates to (R) -3- ( (E) -2- (pyrrolidin-3-yl) vinyl) -5- (tetrahydropyran-4-yloxy) pyridine, its salt forms, and to processes for the commercial-scale production of these compounds in sufficient purity and quality for use in pharmaceutical compositions. The present invention relates also the use of this compound in the manufacture of a medicament for the treatment of CNS related disorders.",TARGACEPT INC,AKIREDDY SRINIVISA RAO;;BREINING SCOTT R;;CUTHBERTSON TIMOTHY J;;DULL GARY MAURICE;;GATTO GREGORY J;;GENUS JOHN;;HAMMOND PHILIP S;;MITCHENER JOSEPH PIKE JR;;MUNOZ JULIO A;;OTTEN PIETER ALBERT;;YOHANNES DANIEL;;FEDOROV NIKOLAI,,https://lens.org/075-072-910-409-846,Patent Application,no,0,0,54,54,0,C07D405/14;;A61K31/4439;;A61P25/00;;A61P25/04;;A61P25/18;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P31/12;;A61P37/06;;C07D207/08;;C07D405/14;;A61K31/40;;C07D405/14;;A61K31/4439,C07D405/14;;A61K31/4439;;A61P25/00,,0,0,,,,DISCONTINUED
194,BR,A2,BR PI0922630 A2,115-903-084-493-487,2016-01-05,2016,BR PI0922630 A,2009-11-30,US 2009/0066092 W;;US 11888508 P,2008-12-01,"""(r)-3-(e)-2-(pirrolidin-33-il)vinil)-5-(tetra-hidropiran-4-ilóxi)piridina, seus sais, suas sínteses e seus usos como ligantes para receptores acetilcolinérgico nicotínicos""",,TARGACEPT INC,YOHANNES DANIEL;;DULL GARY MAURICE;;GATTO GREGORY J;;GENUS JOHN;;MITCHENER JOSEPH PIKE JR;;MUNOZ JULIO A;;FEDOROV NIKOLAI;;HAMMOND PHILIP S;;OTTEN PIETER ALBERT;;BREINING SCOTT R;;AKIREDDY SRINIVISA RAO;;CUTHBERTSON TIMOTHY J,,https://lens.org/115-903-084-493-487,Patent Application,no,0,0,54,54,0,C07D405/14;;A61K31/4439;;A61P25/00;;A61P25/04;;A61P25/18;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P31/12;;A61P37/06;;C07D207/08;;C07D405/14;;A61K31/40;;C07D405/14;;A61K31/4439,C07D405/14;;A61K31/4439;;A61P25/00,,0,0,,,,DISCONTINUED
195,EP,A1,EP 2358705 A1,017-415-622-298-019,2011-08-24,2011,EP 09775410 A,2009-11-30,US 2009/0066092 W;;US 11888508 P,2008-12-01,"(R) -3- (E) -2- (PYRR0LIDIN-3-YL) VINYL) -5- (TETRAHYDR0PYRAN-4-YL0XY) PYRIDINE, ITS SALTS, ITS SYNTHESIS AND ITS USE AS LIGAND FOR NICOTINIC ACETYLCHOLINERGIC RECEPTORS",,TARGACEPT INC,AKIREDDY SRINIVISA RAO;;BREINING SCOTT R;;CUTHBERTSON TIMOTHY J;;DULL GARY MAURICE;;GATTO GREGORY J;;GENUS JOHN;;HAMMOND PHILIP S;;MITCHENER JOSEPH PIKE JR;;MUNOZ JULIO A;;OTTEN PIETER ALBERT;;YOHANNES DANIEL;;FEDOROV NIKOLAI,"TARGACEPT, INC. (2013-04-03)",https://lens.org/017-415-622-298-019,Patent Application,yes,0,0,54,54,0,C07D405/14;;A61K31/4439;;A61P25/00;;A61P25/04;;A61P25/18;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P31/12;;A61P37/06;;C07D207/08;;C07D405/14;;A61K31/40;;C07D405/14;;A61K31/4439,C07D405/14;;A61K31/4439;;A61P25/00,,0,0,,,,DISCONTINUED
196,MX,A,MX 2011005712 A,189-695-471-298-834,2011-06-17,2011,MX 2011005712 A,2009-11-30,US 11888508 P;;US 2009/0066092 W,2008-12-01,"(R) -3- (E) -2- (PYRR0LIDIN-3-YL) VINYL) -5- (TETRAHYDR0PYRAN-4-Y L0XY) PYRIDINE, ITS SALTS, ITS SYNTHESIS AND ITS USE AS LIGAND FOR NICOTINIC ACETYLCHOLINERGIC RECEPTORS.","The present invention relates to (R) -3- ( (E) -2- (pyrrolidin-3-yl) vinyl) -5- (tetrahydropyran-4-yloxy) pyridine, its salt forms, and to processes for the commercial-scale production of these compounds in sufficient purity and quality for use in pharmaceutical compositions. The present invention relates also the use of this compound in the manufacture of a medicament for the treatment of CNS related disorders.",TARGACEPT INC,YOHANNES DANIEL;;GATTO GREGORY J;;MUNOZ JULIO A;;GENUS JOHN;;DULL GARY MAURICE;;HAMMOND PHILIP S;;AKIREDDY SRINIVISA RAO;;BREINING SCOTT R;;CUTHBERTSON TIMOTHY J;;MITCHENER JOSEPH PIKE JR;;OTTEN PIETER ALBERT;;FEDOROV NIKOLAI,,https://lens.org/189-695-471-298-834,Patent Application,no,0,0,54,54,0,C07D405/14;;A61K31/4439;;A61P25/00;;A61P25/04;;A61P25/18;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P31/12;;A61P37/06;;C07D207/08;;C07D405/14;;A61K31/40;;C07D405/14;;A61K31/4439,B01D29/00;;A61K31/4439;;A61P25/00;;B01D46/00;;C07D405/14,,0,0,,,,DISCONTINUED
197,UY,A,UY 32278 A,112-906-762-025-610,2011-06-30,2011,UY 32278 A,2009-11-30,US 11888508 P,2008-12-01,SINTESIS Y FORMAS DE SALES NOVEDOSAS DE (R) -3-((E)-2-(PYROLIDIN-3-IL)VINIL(-5-(TETRAHIDROPIRAN-4-ILOXI)PIRIDINA,"La presente invención se relaciona con ( R ) ¿3-( (E)-2-(pirrolidin-3-il)vinil)-5- (tetrahidropiran-4-iloxi)piridina, sus formas de sales y con los procesos para la producción en escala comercial de estos compuestos con pureza y calidad suficiente para su uso en composiciones farmacéuticas.",TARGACEPT INC,DANIEL YOHANNES;;BREINING SCOTT R;;MILLER CRAIG H;;RAO AKIREDDY SRINIVISA;;BALWINDER BHATTI;;PHILIP HAMMOND;;MAURICE DULL GARY;;NIKOLAI FEDOROV;;GATTO GREGORY J;;JOHN GENUS;;CUTHBERTSON TIMOTHY J;;MITCHENER JOSEPH PIKE;;MUNOS JULIO A;;OTTEN PIETER ALBERT,,https://lens.org/112-906-762-025-610,Patent Application,no,0,0,54,54,0,C07D405/14;;A61K31/4439;;A61P25/00;;A61P25/04;;A61P25/18;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P31/12;;A61P37/06;;C07D207/08;;C07D405/14;;A61K31/40;;C07D405/14;;A61K31/4439,A61P25/00;;C07D207/00;;C07D213/00;;C07D401/00;;C07D403/00,,0,0,,,,DISCONTINUED
198,TW,A,TW 201024283 A,186-661-930-546-266,2010-07-01,2010,TW 98140046 A,2009-11-25,US 11888508 P,2008-12-01,Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine,"The present invention relates to (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy) pyridine, its salt forms, and to processes for the commercial-scale production of these compounds in sufficient purity and quality for use in pharmaceutical compositions.",TARGACEPT INC,AKIREDDY SRINIVISA RAO;;BREINING SCOTT R;;BHATTI BALWINDER SINGH;;CUTHBERTSON TIMOTHY J;;DULL GARY MAURICE;;FEDOROV NIKOLAI;;GATTO GREGORY J;;GENUS JOHN;;HAMMOND PHILIP S;;MILLER CRAIG HARRISON;;MITCHENER JR;;MUNOZ JULIO A;;OTTEN PIETER ALBERT;;YOHANNES DANIEL,,https://lens.org/186-661-930-546-266,Patent of Addition,no,0,0,54,54,0,C07D405/14;;A61K31/4439;;A61P25/00;;A61P25/04;;A61P25/18;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P31/12;;A61P37/06;;C07D207/08;;C07D405/14;;A61K31/40;;C07D405/14;;A61K31/4439,C07D405/14;;A61K31/4427;;A61P25/00;;A61P25/18;;A61P25/28,,0,0,,,,PENDING
199,SA,B1,SA 109300715 B1,149-060-503-193-86X,2014-06-25,2014,SA 109300715 A,2009-12-05,US 11888508 P,2008-12-01,Manufacturing of (R)-3-((E)-2-(Pyrrolidin-3-Yl)Vinyl)-5-(Tetrahydropyran-4-Yloxy)Pyridine and Novel Salt Thereof,الملخص: يتعلق الاختراع الحالي بمركب: (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine وصور أملاح منه، وبعمليات لإنتاج هذه المركبات على نطاق تجاري بنقاء وجودة كافيين للاستخدام في تركيبات صيدلانية. شكل 1 .,TARGACEPT INC,AKIREDDY SRINIVISA RAO;;R BREINING SCOTT;;BHATTI BALWINDER SINGH;;J CUTHBERTSON TIMOTHY;;DULL GARY MAURICE;;FEDOROV NIKOLAI;;J GATTO GREGORY;;GENUS JOHN;;S HAMMOND PHILIP;;MILLER GRAIG HARRISON;;MITCHENER JOSEPH PIKE;;A MUNOZ JULIO;;OTTEN PIETER ALBERT;;YOHANNES DAIEL,,https://lens.org/149-060-503-193-86X,Granted Patent,no,0,0,54,54,0,C07D405/14;;A61K31/4439;;A61P25/00;;A61P25/04;;A61P25/18;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P31/12;;A61P37/06;;C07D207/08;;C07D405/14;;A61K31/40;;C07D405/14;;A61K31/4439,,,0,0,,,,ACTIVE
200,AR,A1,AR 074239 A1,028-677-846-683-863,2010-12-29,2010,AR P090104608 A,2009-11-30,US 11888508 P,2008-12-01,"SALES DE (R)-3-((E)-2-(PIRROLIDIN-3-IL)VINIL)-5-(TETRAHIDROXIPIRAN-4-ILOXI)PIRIDINA, SU SINTESIS E INTERMEDIARIOS DE LA MISMA, COMPOSICION FARMACEUTICA QUE LAS COM-PRENDE Y SU USO EN LA PREPARACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR NNR","(R)-3-((E)-2-(pirrolidin-3-il)vinil)-5-(tetrahidropiran-4-iloxi)piridina, sus formas de sales y con los procesos para la produccion en escala comercial de estos compuestos con pureza y calidad suficiente para su uso en composiciones farmacéuticas para el tratamiento de enfermedades mediadas por la modulacion de los receptores de acetilcolina nicotínico neuronal (NNR). Reivindicacion 1: Mono-L-malato de (R)-3-((E)-2-(pirrolidin-3-il)vinil)-5-(tetrahidropiran-4-iloxi)piridina, o un hidrato o solvato de él. Reivindicacion 2: Hemigalactarato de(R)-3-((E)-2-(pirrolidin-3-il)vinil)-5-(tetrahidropiran-4-iloxi)piridina, o un hidrato o solvato de él. Reivindicacion 3: Oxalato de (R)-3-((E)-2-(pirrolidin-3-il)vinil)-5-(tetrahidropiran-4-iloxi)piridina, o un hidrato o solvato de él. Reivindicacion 4: Di-p-toluoil-D-tartrato de (R)-3-((E)-2-(pirrolidin-3-il)vinil)-5-(tetrahidropiran-4-iloxi)piridina, o un hidrato o solvato de él. Reivindicacion 5: (R)-3-((E)-2-(pirrolidin-3-il)vinil)-5-(tetrahidropiran-4-iloxi)piridina, o una sal farmacéuticamente aceptable de ella sustancialmente libre de (S)-3-((E)-2-(pirrolidin-3-il)vinil)-5-(tetrahidropiran-4-iloxi)piridina. Reivindicacion 16: Un compuesto que se selecciona de: ( R)-2-(1-(terc-butoxicarbonil)pirrolidin-3-il)malonato de dietilo; Ácido ( R)-2-(1-(terc-butoxicarbonil)pirrolidin-3-il)malonico; (R)-3- (2-hidroxietil) pirrolidina-1-carboxilato de terc-butilo; y (R)-3-(2-yodoetil)pirrolidina-1-carboxilato de terc-butilo.",TARGACEPT INC,MILLER CRAIG HARRISON;;OTTEN PIETER ALBERT;;FEDOROV NIKOLAI;;GENUS JOHN;;BREINING SCOTT R;;AKIREDDY SRINIVISA RAO;;HAMMOND PHILIP S;;GATTO GREGORY J;;DULL GARY MAURICE;;MUNOZ JULIO A;;YOHANNES DANIEL;;CUTHBERTSON TIMOTHY J;;BHATTI BALWINDER SINGH;;MITCHENER JOSEP PIKE JR,,https://lens.org/028-677-846-683-863,Patent Application,no,0,0,54,54,0,C07D405/14;;A61K31/4439;;A61P25/00;;A61P25/04;;A61P25/18;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P31/12;;A61P37/06;;C07D207/08;;C07D405/14;;A61K31/40;;C07D405/14;;A61K31/4439,,,0,0,,,,DISCONTINUED
201,PE,A1,PE 20100467 A1,024-681-811-180-760,2010-08-03,2010,PE 2009001282 A,2009-11-30,US 11888508 P,2008-12-01,COMPUESTO MONO-L-MALATO (R)-3-((E)-2-(PIRROLIDIN-3-IL)VINIL)-5-(TETRAHIDROPIRAN-4-ILOXI)PIRIDINA Y COMPOSICIONES QUE LO CONTIENEN,"SE REFIERE AL COMPUESTO (R)-3-((E)-2-(PIRROLIDIN-3-IL)VINIL)-5-(TETRAHIDROPIRAN-4-ILOXI)PIRIDINA Y A SUS SALES MONO-L-MALATO, HEMIGALACTARATO, OXALATO Y DI-P-TOLUOIL-D-TARTRATO. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA DE DICHO COMPUESTO O DE UNA DE SUS SALES. DICHO COMPUESTO Y SUS SALES SON MODULADORES DE LOS RECEPTORES NICOTINICOS NEURONALES (NRR) SIENDO UTILES EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER, DEMENCIA PRESENIL, INFLAMACION, SINDROME METABOLICO",TARGACEPT INC,AKIREDDY SRINIVISA RAO;;CUTHBERTSON TIMOTHY J;;GATTO GREGORY J;;MILLER CRAIG HARRISON;;OTTEN PIETER ALBERT;;BREINING SCOTT R;;DULL GARY MAURICE;;GENUS JOHN;;MITCHENER JOSEPH PIKE JR;;YOHANNES DANIEL;;BHATTI BALWINDER SINGH;;FEDOROV NIKOLAI;;HAMMOND PHILIP S;;MUNOZ JULIO A,,https://lens.org/024-681-811-180-760,Patent Application,no,0,0,54,54,0,C07D405/14;;A61K31/4439;;A61P25/00;;A61P25/04;;A61P25/18;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P31/12;;A61P37/06;;C07D207/08;;C07D405/14;;A61K31/40;;C07D405/14;;A61K31/4439,C07D405/14;;A61K31/4439;;A61P25/00,,0,0,,,,ACTIVE
